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Summary 
Secondary metabolites are generally low-molecule-mass compounds, also known as natural products. 
So far, millions of natural products with remarkably structural diversity have been found in nature. 
These include, but are not limited to, polyketides, nonribosomal peptides, alkaloids, and terpenoids. 
The structural divergence of natural products begins with the formation of basic skeletons by different 
backbone enzymes using fundamental building blocks derived from primary metabolism. Following 
modifications of the pre-matured scaffolds are catalyzed by tailoring enzymes such as 
oxidoreductases and transferases, thus completing the biosynthesis of end products with vast diversity 
and complexity. Enzymes from natural product biosynthetic pathways are versatile biocatalysts due to 
the merits of high efficiency and specificity. Harnessing biocatalytic potential of enzymes through 
chemoenzymatic synthesis has proven to be a useful tool for enriching chemical libraries. In addition 
to enzymatic catalysis, the occurrence of nonenzymatic events has also been found during the post-
biosynthetic processing of natural products. These nonenzymatic reactions often occur with the 
involvement of reactive biosynthetic intermediates. Full exploitation of these intermediates for 
chemical synthesis can be used as an updated strategy to expand the chemical variety of natural 
products. 
In a cooperation project with Dr. Peter Mai, five prenyltransferases (PTs) of the dimethylallyltryptophan 
synthase (DMATS) family, i.e. FtmPT1, BrePT, CdpC2PT, CdpNPT, and CdpC3PT, were selected for 
protein engineering. These PTs catalyze a regular or reverse transfer of the dimethylallyl residue (C5) 
from dimethylallyl diphosphate (DMAPP) to the C-2 or C-3 position of indolyl residues in cyclic 
dipeptides (CDPs). To switch their prenyl donor specificity from DMAPP to geranyl diphosphate (GPP), 
protein sequence alignments of the five PTs with those of AtaPT and FgaPT2 led to the identification 
of the gatekeeping residues at Met364 in FtmPT1, Ile337 in BrePT, Thr351 in CdpC2PT, Met349 in 
CdpNPT, and Phe335 in CdpC3PT. Replacing the respective key amino acids by glycine resulted in 
the construction of FtmPT1_M364G, BrePT_I337G, CdpC2PT_T351G, CdpNPT_M349G, and 
CdpC3PT_F335G. These mutants showed clearly improved activity toward GPP but reduced activity 
toward DMAPP. As a result, 42 geranylated derivatives were obtained from the incubation mixtures of 
the generated mutants with 15 tested CDPs in the presence of GPP and their structures were 
elucidated by NMR and MS analyses. When using cyclo-L-Trp-L-Trp as the acceptor and GPP as the 
donor, the transfer of geranyl moieties to all seven possible positions of the indole nucleus can be 
achieved by the engineered enzymes. Prior to our study, only limited numbers of geranylated indole 
derivatives have been reported. This study significantly increased the structural diversity of 
geranylated products by structure-based protein engineering of available dimethylallyl transferases.  
In a cooperation study with Dr. Jie Fan, the biosynthesis of peniphenone and penilactones in 
Penicillium crustosum PRB-2 was elucidated, which revealed occurrence of both enzymatic and 
nonenzymatic reactions during their formation. The hybrid PKS-NRPS TraA from the terrestric acid 
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pathway is involved in the formation of crustosic acid, which undergoes decarboxylation by the 
nonheme FeII/2-OG-dependent oxygenase TraH and subsequent reduction by the flavin-containing 
oxidoreductase TraD to afford terrestric acid. Both acids are precursors of the -butyrolactones. The 
nonreducing PKS ClaF from the clavatol pathway is responsible for the formation of clavatol, which is 
then oxidized to hydroxyclavatol by the nonheme FeII/2-OG-dependent oxygenase ClaD. Alongside 
with spontaneous dehydration of hydroxyclavatol to the reactive intermediate ortho-quinone methide 
(QM), nonenzymatic 1,4-Michael additions were initiated by the nucleophilic attack from the -
butyrolactones to the ortho-QMs, leading to the sequential formation of peniphenone D and 
penilactone A as well as penilactones D and B. 
In addition to utilizing enzymes from the natural biosynthetic machinery, an alternative strategy was 
used for structural diversification by taking advantage of reactive intermediates from the biosynthetic 
pathway of natural products. As mentioned above, the ortho-QM involved in the formation of 
peniphenone and penilactones was proven to be highly reactive and capable of reacting with -
butyrolactones spontaneously under very mild conditions. As a following work, the reactivity of the 
ortho-QM derived from hydroxyclavatol was tested with 101 natural products or natural product-like 
compounds. These include flavonoids, hydroxynaphthalenes, coumarins, xanthones, anthraquinones, 
phloroglucinols, phenolic acids, indole derivatives, tyrosine analogues, and quinolines. LC-MS 
analysis revealed product formation in the incubation mixtures of 85 tested reactants. 32 clavatol-
containing products were isolated from 23 selected incubations and identified by NMR and MS 
analyses. The cross-coupling between the tested nucleophiles and the ortho-QM from hydroxyclavatol 
occurs preferentially via C-C bonds at the ortho- or para-position of phenolic hydroxyl groups and the 
C-2 position of the indole ring. The obtained products were also tested for their biological activities. 
This study proved the ortho-QM as an excellent Michael acceptor for a variety of substances, 
suggesting the utilization of the reactive biosynthetic intermediate for accessing chemical diversity of 
natural products. 
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Zusammenfassung 
Sekundärmetabolite sind im Allgemeinen niedermolekulare Verbindungen, die auch als Naturstoffe 
bezeichnet werden. Bisher wurden in der Natur Millionen von Naturstoffen mit bemerkenswerter 
struktureller Vielfalt gefunden. Dazu zählen unter anderem, aber nicht ausschließlich, Polyketide, 
nichtribosomale Peptide, Alkaloide und Terpenoide. Die strukturelle Divergenz von Naturstoffen 
beginnt mit der Bildung von Grundgerüsten durch verschiedene Rückgratenzyme unter Verwendung 
grundlegender Bausteine aus dem Primärstoffwechsel. Die Weiterverarbeitungen der 
Grundstrukturen werden durch modifizierende Enzyme wie Oxidoreduktasen und Transferasen 
katalysiert, wodurch die Biosynthese von Endprodukten mit großer Vielfalt und Komplexität 
abgeschlossen wird. Enzyme aus Naturstoffbiosynthesewegen sind aufgrund ihrer hohen Effizienz 
und Spezifität vielseitige Biokatalysatoren. Die Nutzung des biokatalytischen Potenzials von Enzymen 
durch chemoenzymatische Synthese hat sich als nützliches Mittel zur Erweiterung chemischer 
Bibliotheken erwiesen. Neben der enzymatischen Katalyse wurde auch das Auftreten 
nichtenzymatischer Reaktionen während des postbiosynthetischen Prozesses von Naturstoffen 
festgestellt. Solche Reaktionen treten häufig unter Beteiligung reaktiver 
Biosynthesezwischenprodukte auf. Die vollständige Nutzung dieser Zwischenprodukte für die 
chemische Synthese kann als neuartige Strategie zur Erweiterung der Variabilität von Naturstoffen 
dienen. 
In einem Kooperationsprojekt mit Dr. Peter Mai wurden fünf Prenyltransferasen (PTs) der 
Dimethylallyltryptophan-Synthase (DMATS)-Familie, FtmPT1, BrePT, CdpC2PT, CdpNPT und 
CdpC3PT, für das Protein-Engineering ausgewählt. Diese PTs katalysieren eine Übertragung 
regulärer oder reverser Prenylreste (C5) von Dimethylallyldiphosphat (DMAPP) auf die C-2- oder C-3-
Position am Indolylring der cyclischen Dipeptide (CDPs). Um ihre Prenyldonorspezifität von DMAPP 
auf Geranyldiphosphat (GPP) umzustellen, wurden Gatekeeping-Reste durch Sequenzvergleich der 
fünf PTs mit denen von AtaPT und FgaPT2 identifiziert, nämlich Met364 in FtmPT1, Ile337 in BrePT, 
Thr351 in CdpC2PT, Met349 in CdpNPT und Phe335 in CdpC3PT. Das Ersetzen dieser 
Schlüsselaminosäuren durch Glycin führte zur Erstellung von FtmPT1_M364G, BrePT_I337G, 
CdpC2PT_T351G, CdpNPT_M349G und CdpC3PT_F335G Mutanten. Diese Mutanten zeigten eine 
deutlich verbesserte Aktivität gegenüber GPP, aber eine verringerte Aktivität mit DMAPP. Daraufhin 
wurden 42 geranylierte Derivate aus den Inkubationen der erzeugten Mutanten mit 15 getesteten 
CDPs in Gegenwart von GPP erhalten und deren Strukturen wurden mittels NMR- und MS aufgeklärt. 
Bei Verwendung von cyclo-L-Trp-L-Trp als Akzeptor und GPP als Donor kann der Transfer von 
Geranylresten auf alle sieben möglichen Positionen des Indolrings durch die modifizierten Enzyme 
erreicht werden. Vor unserer Studie wurde nur über eine geringe Anzahl geranylierter Indolderivate 
berichtet. Diese Studie erhöhte signifikant die strukturelle Vielfalt geranylierter Produkte durch 
strukturbasiertes Protein-Engineering verfügbarer Dimethylallyltransferasen. 
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In einer Kooperation mit Dr. Jie Fan wurde die Biosynthese von Peniphenon und Penilactonen in 
Penicillium crustosum PRB-2 aufgeklärt, wobei das Auftreten sowohl enzymatischer als auch 
nichtenzymatischer Reaktionen während ihrer Bildung festgestellt wurde. Der PKS-NRPS-Hybrid TraA 
aus dem Terrestric acid-Gencluster ist an der Bildung von Crustosic acid beteiligt, die durch die nicht-
Häm-FeII/-KG-abhängige Oxygenase TraH decarboxyliert und anschließend durch die flavinhaltige 
Oxidoreduktase TraD zu Terrestric acid reduziert wird. Beide Säuren sind Vorstufen der -
Butyrolactone. Die nicht-reduzierende PKS ClaF aus dem Clavatolcluster ist für die Bildung von 
Clavatol verantwortlich, das dann durch die nicht-Häm-FeII/ -KG-abhängige Oxygenase ClaD zu 
Hydroxyclavatol oxidiert wird. Nach spontaner Wasserabspaltung wird Hydroxyclavatol zum reaktiven 
Intermediat ortho-Chinonmethid (QM) überführt, das durch den nukleophilen Angriff der -
Butyrolactone nichtenzymatische 1,4-Michael-Additionen initiiert. Dies führte zur 
aufeinanderfolgenden Bildung von Peniphenon D und Penilacton A sowie Penilacton D und B. 
Zusätzlich zur Verwendung von Enzymen aus natürlichen Biosynthesewegen wurde eine alternative 
Strategie zur strukturellen Diversifizierung verwendet, indem reaktive Zwischenprodukte aus dem 
Biosyntheseweg von Naturstoffen genutzt wurden. Wie oben erwähnt, erwies sich das an der Bildung 
von Peniphenonen und Penilactonen beteiligte ortho-QM als hochreaktiv und ist in der Lage, unter 
sehr milden Bedingungen spontan mit -Butyrolactonen zu reagieren. In der folgenden Arbeit wurde 
die Reaktivität des von Hydroxyclavatol abgeleiteten ortho-QM mit 101 Naturstoffen oder 
naturstoffähnlichen Verbindungen getestet. Dazu gehören Flavonoide, Hydroxynaphthaline, 
Cumarine, Xanthone, Anthrachinone, Phloroglucine, Phenolsäuren, Indolderivate, Tyrosinanaloga 
und Chinoline. Die LC-MS-Analyse ergab eine Produktbildung in den Inkubationen mit 85 getesteten 
Verbindungen. 32 Clavatol-haltige Produkte wurden aus 23 ausgewählten Inkubationen isoliert und 
mittels NMR- und MS-Analyse identifiziert. Die Verknüpfungen zwischen den getesteten Nukleophilen 
und dem ortho-QM aus Hydroxyclavatol erfolgt bevorzugt über C-C-Bindungen an der ortho- oder 
para-Position von phenolischen Hydroxylgruppen und der C-2-Positionen des Indolrings. Die 
erhaltenen Produkte wurden auch auf ihre biologischen Aktivitäten getestet. Diese Studie beweist, 
dass das ortho-QM ein ausgezeichneter Michael-Akzeptor für eine Vielzahl von Substanzen ist, was 
die Verwendung des reaktiven Biosynthesezwischenprodukts für den Zugriff zur chemischen Vielfalt 
von Naturstoffen nahelegt. 
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1 Introduction 
1.1 Natural products from filamentous fungi 
The definition of natural products could be broadly used to describe compounds derived from a natural 
source. However, it is more specific to define natural products as low-molecule-mass compounds from 
secondary metabolite pathways.1 From this point of view, natural products can also be termed as 
secondary metabolites (SMs). These compounds are not essential for the growth, development, and 
reproduction of the producing organism,2, 3 but play important roles, for example, as chemical signals 
for communication,4, 5 in defending the habitat or inhibiting the growth of competitors.6-9  
Plants and microorganisms including prokaryotic actinobacteria and eukaryotic ascomycetes are the 
most frequent producers of biologically active natural products.10-12 Among them, filamentous fungi 
serve as a representative and valuable source of fungal natural products. Aspergillus, Penicillium, 
Fusarium, and Claviceps are prominent genera of filamentous fungi growing in a polar fashion 
(extending in one direction) by elongation at the apex of the hypha, the so-called mycelium.13 The 
filamentous fungi reproduce themselves either by the formation of conidia which are borne on 
specialized stalks called conidiophores, or by the formation of ascospores which are produced in 
specialized tube- or sac-like cells termed asci.14, 15  
Driven by the discovery of penicillin and its development into an antibiotic, great progress has been 
achieved for the isolation and chemical characterization of a multitude of natural products from 
microorganisms in the last decades.16-18 Up to the year 2017, over 230,000 natural products were 
listed in the Dictionary of Natural Products.19, 20 Microbial metabolites are one of the most important 
constitution of reported natural products. Among them, approximately 45 % of microbial metabolites 
are produced by various fungi, especially filamentous fungi, underlying their importance as natural 
product sources.10  
The classical strategy for the discovery of fungal natural products is mostly based on the adjustment 
of the cultivation condition, such as different medium with various nutrition or additives, different 
incubation time or temperature, different pH values, and so on. The following work flow to explore SMs 
from fungi includes extraction of the cultures by using solvents of different polarity, fractionation of the 
crude extracts by using column chromatography, as well as structural elucidation of purified 
compounds by spectral analysis (Figure 1A). However, rapid developments in sequencing 
technologies and bioinformatic analysis have revealed that a large amount of fungal biosynthetic gene 
clusters are not expressed or only lowly expressed under laboratory culture conditions, suggesting a 
plethora of fungal natural products awaiting to be discovered and exploited.3, 21, 22 Therefore, new 
methods as shown in Figure 1B have been developed for the discovery of the hidden fungal natural 
products. These methods include epigenetic regulation,23-25 global regulator26-29 or pathway-specific 
regulator activation,30-33 and heterologous expression in other hosts.34-37 
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Figure 1. Work flow for isolation and identification of fungal natural products (A). Molecular 
strategies for activating silent biosynthetic gene clusters (B). 
The majority of so far discovered fungal natural products can be roughly classified into four categories: 
polyketides, nonribosomal peptides, terpenoids, and alkaloids. Furthermore, hybrid products of two or 
more main classes have also been found in fungi, such as hybrid polyketide-nonribosomal peptides 
and hybrid polyketide-terpenes (Figure 2).38  
Polyketides are a large group of structurally diverse and therapeutically important natural products. 
These compounds are usually biosynthesized by successive Claisen condensations between a 
malonate derivative and an acyl starter.39 Representatives of polyketide are shown in Figure 2. Among 
them, patulin is a well-studied mycotoxin produced by a variety of molds and induces immunological, 
neurological, and gastrointestinal effects.40, 41 The biosynthetic precursor of patulin is 6-methylsalicylic 
acid (6-MSA), one of the oldest known polyketides mainly found in Penicillium species.42 Orsellinic 
acid is also an acetate-derived tetraketide similar to 6-MSA but it harbors an additional hydroxyl group. 
It was proven that orsellinic acid is the biosynthetic precursor of the cathepsin K inhibitors F9775 A 
and B.43 Aflatoxin B1, with its name derived from Aspergillus flavus toxin, is synthesized from its  
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polyketide precursor norsolorinic acid via sterigmatocystin (the penultimate intermediate of aflatoxin) 
as a metabolic intermediate.44-46 Citrinin is a potent mycotoxin with nephrotoxic activities and was 
firstly isolated from a culture of Penicillium citrinum.47, 48 It is interesting that citrinin and sepedonin 
share similar biosynthetic precursors, but afterwards distinct modifications lead to the obvious 
differences in their structures.49 Lovastatin, also known as mevinolin, was isolated from Aspergillus 
terreus in 1978 and developed into a clinically used drug to treat hypercholesterolemia.50, 51 The 
structure of lovastatin is featured by the fused ring of the decalin system, which is formed by the Diels-
Alder cycloaddition of a hexaketide.52 
The second group of fungal natural products is nonribosomal peptides with large structural and 
functional diversities (Figure 2). The biosynthesis of nonribosomal peptides is similar to polyketides 
to some extent, but differs in the elongation step by C-N rather than C-C bond formation and by utilizing 
amino acids instead of acyl-CoA as building blocks.53 -Lactams are one of the most famous structural 
types among the so far identified nonribosomal peptides. Penicillin G from Penicillium fungi was a 
representative -lactam antibiotic which has been applied to the treatment of bacterial infections and 
set a start of the golden age of researches on antibiotics.54, 55 Cephalosporin C from Cephalosporium 
acremonium is another -lactam antibiotic discovered after penicillin.56 Gliotoxin from Aspergillus 
fumigatus contains a characteristic internal sulfur bridge, which is the structural motif of all 
epipolythiodioxopiperazines (ETPs).57, 58 Sirodesmin PL from Leptosphaeria maculans also harbors 
such a unique sulfur bridge.59 Furthermore, head-to-tail-cyclized peptides with large ring sizes include 
echinocandin B from Aspergillus nidulans with a linoleoyl side chain60 and the immunosuppressant 
cyclosporin A from Tolypocladium inflatum.61 The structure of cyclosporin A is featured by containing 
one D-configured alanine and two nonproteinogenic residues: L-aminobutyric acid and butenyl-methyl-
L-threonine. 
The third major group of fungal metabolites is undoubtedly terpenoids which can be typically classified 
as monoterpenes (C10), sesquiterpenes (C15), diterpenes (C20), and triterpenes (C30) (Figure 2). 
Despite the structural diversity, fungal terpenoids are biosynthetically originated from the C5 units: 
dimethylallyl diphosphate (DMAPP) and isopentenyl diphosphate (IPP).62 Head-to-tail condensation 
of DMAPP with two or three IPP moieties give farnesyl diphosphate (FPP) as the precursor of 
sesquiterpenoids and geranylgeranyl diphosphate (GGPP) as the precursor of diterpenoids. (+)-
Aristolochene from Penicillium roqueforti63 is a representative sesquiterpenoid that provides a 
biosynthetic scaffold for several mycotoxins including the sporogen-AO1,64 PR-toxin,65 and 
phomenone.66 Gibberellin A3 as a typical example of diterpenoids is one of the longest-known classes 
of plant growth hormone.67 Condensation of two FPP units in a head-to-head mode yields squalene 
as the precursor of triterpenoids. Helvolic acid isolated from Cephalosporium caerulens and 
Aspergillus fumigatus is an example of fungal triterpenoids exhibiting potent activity against gram-
positive bacteria.68, 69 
Moreover, alkaloids represent one of the largest classes of nitrogen-containing secondary metabolites 
in fungi (Figure 2). A major subgroup is dipeptidyl or tripeptidyl indole alkaloids.70 Cyclic dipeptides 
(CDPs) with a characteristic diketopiperazines core structure are formed by condensation of two amino 
acids.71 Verruculogen and its isoprenyl derivative fumitremorgin A are typical examples of 
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diketopiperazine that biosynthetically originated from brevianamide F by condensation of L-tryptophan 
and L-proline.72, 73 Unlike diketopiperazines, terrequinone A from Aspergillus nidulans is 
biosynthetically derived from indole pyruvic acid instead of L-tryptophan, leading to a non-peptidic, 
homocyclic quinone core.28, 74 Tripeptidyl indole alkaloids exemplified by ardeemin from Aspergillus 
fischeri was biosynthesized with the incorporation of anthranilic acid, L-alanine, and L-tryptophan.75 In 
addition to the peptidyl indole alkaloids, ergot alkaloids featured by a tetracyclic ergoline ring system 
are also an important group of fungal alkaloids.76, 77 Typical examples include lysergic acid derivatives 
like fumigaclavine C from Aspergillus fumigatus78 and ergotamine produced by Claviceps purpurea,79 
which is structurally assembled from D-lysergic acid with L-alanine, L-phenylalanine, and L-proline. 
Furthermore, hybrid products constructed by moieties of mixed origins have also been found in fungi 
(Figure 2). Examples of hybrid indole alkaloids include -cyclopiazonic acid as an indole-polyketide 
hybrid which is biosynthesized via a cyclo-acetoacetyl-L-tryptophan intermediate in Aspergillus 
flavus,80 as well as indole-diterpenoid hybrids comprising an indole ring and a GGPP-derived terpenoid 
moiety as exampled by paxilline from Penicillium paxilli.81 Examples of polyketide-nonribosomal 
peptide hybrid compounds include tenellin from Beauveria bassiana82 consisting of tyrosine and a 
polyketide-derived C12 unit and equisetin from Fusarium heterosporum83 harboring a polyketide-
derived decalin ring and an amino acid-derived tetramic acid ring. Further examples of polyketide-
terpene hybrid compounds (meroterpenes) include pyripyropene A from Aspergillus fumigatus which 
used nicotinic acid, malonyl-CoA, and FPP as building blocks,84, 85 as well as fumagillin from 
Aspergillus fumigatus containing an unsaturated chain as the polyketide portion and an modified 
terpenoid moiety originated from FPP.86 
Although hundreds of thousands of compounds have been isolated and identified from fungi so far, 
what we have exploited is still just the tip of the iceberg of the treasure of natural products. Continuing 
efforts made by researches of different disciplines provide greater possibilities to, i) discover new 
compounds from either new identified species or existed known species; ii) expand our knowledge of 
chemical logic and enzymatic machinery of natural product biosynthesis; iii) broaden the applications 
of natural products in pharmaceutical industry and therefore benefits human being in every aspects. 
1.2 Backbone enzymes responsible for the fundamental formation of natural 
products 
The biosynthetic genes in fungi for the formation of a given natural product are typically located 
together on the genome. Such clusters usually consist of one or more backbone gene(s) as well as 
several genes for modifications.87, 88 The backbone enzymes involved in the biosynthesis of fungal 
natural products generally include polyketide synthases (PKSs), nonribosomal peptide synthetases 
(NRPSs), terpene cyclases (TCs), and hybrid polyketide synthase-nonribosomal peptides synthetases 
(hybrid PKS-NRPSs). These enzymes usually catalyze the first step of biosynthesis to form a scaffold, 
which is afterwards modified by cluster-specific modifying enzymes in multiple biosynthetic steps to 
produce the final product. 
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1.2.1 Polyketide synthases 
The biosynthesis of polyketides is catalyzed by PKSs in a manner reminiscent of fatty acid synthesis, 
building a network between primary and secondary metabolic pathways.89 PKSs can be classified into 
three types according to their domain composition. Type I PKSs are large multifunctional proteins that 
can be further divided into iterative type I PKSs and modular type I PKSs.89, 90 In modular type I PKSs, 
domains are organized into several modules with each module catalyzing one step of condensation. 
While in iterative type I PKSs, domains are clustered in a single module which used repeatedly for 
polyketide formation (Figure 3).91 Iterative type I PKSs can be further divided into nonreducing PKSs 
(NR-PKSs), partially reducing PKSs (PR-PKSs), and highly reducing PKSs (HR-PKSs) based on the 
existence of domains that can catalyze the reduction and dehydration steps. Type II PKSs are 
dissociable multi-enzyme complexes that have sets of iteratively used individual proteins and typically 
produce polycyclic aromatic compounds (Figure 3).92 Different from type I and type II PKS relatives, 
PKSs of type III are simple homodimer ketosynthases (KS) that mainly catalyze the formation of 
pyrone- and resorcinol-type aromatic polyketides (Figure 3).93, 94 
 
Figure 3. Domain structures of modular type I PKS (A), iterative type I NR-PKS (B), type II PKS (C), 
and type III PKS (D). 
Fungal polyketides are, in most cases, products of iterative type I PKSs. The formation of polyketides 
catalyzed by PKSs commences with starter unit loading, followed by chain elongation and reduction, 
finalizing through polyketide cyclization and release. The basic domains required for polyketide 
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elongation include KS for catalyzing the decarboxylative Claisen condensation to extend the 
polyketide chain, acyltransferase (AT) for selection and recognition of the starter unit and extender 
unit, and acyl carrier protein (ACP) which shuttle growing polyketides between the active sites of the 
PKS. In addition to the minimal domain architecture of KS, AT, and ACP domains, further accessory 
domains for polyketide chain modification include ketoreductase (KR) domain for optional reduction of 
the -keto to a hydroxyl group, dehydratase (DH) domain that catalyzes dehydration to generate an 
,-unsaturated thioester, and enoylreductase (ER) domain that further reduces the double bond to a 
saturated moiety.90, 95 
The vast diversity and complexity of polyketides can be ascribed to the following strategies that are 
utilized by PKSs during the assembly process. Firstly, utilization of different starter and extender units 
by PKSs leads to the variation of polyketide skeletons. Examples of starter units are acetyl-CoA, 
propionyl-CoA, malonyl-CoA, benzoyl-CoA, and 4-coumaroyl-CoA. Extender units include malonyl-
CoA, (2S)-methylmalonyl-CoA, (2S)-ethylmalonyl-CoA and chloroethylmalonyl-CoA.95, 96 Secondly, 
PKSs employ different reduction domains to form polyketide chains with different unsaturation 
degree.97 For example, a KR domain is required to reduce the -keto group to -hydroxyl group, an 
additional DH domain can transform the -hydroxyl group to a double bond, and KR-DH-ER tridomain 
can catalyze a further reduction step to form a single bond. Thirdly, different cyclization mechanisms 
contribute to the polyketide variety, e.g. cyclization regioselectivity of the polyketide backbone 
controlled by product template (PT) domain or C-terminus thioesterase/Claisen-like-cyclase (TE/CLC) 
in fungal NR-PKSs.98 In recent years, combinatorial biosynthesis was used as a new approach to 
generate large libraries of new compounds.99 Such strategies include engineering modular PKSs by 
swapping and replacing PKS single domain or entire modules. For example, insertion of AT domains 
with altered specificity to incorporate a different starter or extender unit is proved to be an effective 
way to alter the structure of polyketides.100, 101 
1.2.2 Nonribosomal peptide synthetases 
The enzymatic machinery of NRPSs uses parallel chemical logic as PKSs to produce a wide range of 
nonribosomal peptides.1 The NRPS action can occur in linear, iterative, and nonlinear modes.53, 102 
The domains of linear NRPSs are organized into modules and each module is used only once during 
the biosynthetic cycle. Therefore, the number of modules in linear NRPSs decides the number of 
amino acids incorporated in the released products. The modular architecture of linear system is typical 
for NRPSs, while iterative and nonlinear modes have been relatively rare reported. Iterative NRPSs 
repeatedly use the entire assembly line or certain modules until the biosynthetic process is finished. 
As a further variation of the iterative mode, domain composition of nonlinear NRPSs does not have a 
straightforward correlation with the sequence of catalytic steps, it reuses a certain domain instead of 
an entire module during the nonribosomal peptide biosynthesis.102 Domain structures of apicidin 
synthetase APS1103 as a linear NRPS, beauvericin synthetase BbBEAS104 as an iterative NRPS, and 
vibriobactin synthetase VibF105 as a nonlinear NPRS are shown in Figure 4A. 
The minimal catalytic domains for peptide extension include adenylation (A), condensation (C), and 
thiolation (T) domain, which also known as peptidyl carrier protein (PCP). The A domain selects the 
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amino acid, activates it as the aminoacyl-AMP, and loads it onto the adjacent PCP domain.106 The C 
domain catalyzes peptide bond formation between PCP-bound substrates. The amine of the incoming 
downstream aminoacyl-PCP attacks the thioester carbonyl of the elongating peptidyl chain to form a 
new peptide bond (Figure 4B).107 During the elongation process, the PCP domain plays an important 
role in chain transfer from upstream to downstream and shuttling the aminoacyl-thioester 
intermediates between the A and C domains.108 In addition to the minimal A-T-C domain architecture, 
extra domains required for the biosynthesis of nonribosomal peptides include the heterocyclization 
(Cy) as a variant of the C domain that catalyzes the cyclization/dehydration to form a thiazoline or 
oxazoline structure, the epimerization (E) domain to epimerize the L-configured amino acids into their 
D-form, and the thioesterase (TE) domain that releases the completed nonribosomal peptide from the 
assembly line.109 TE domains exist commonly in bacterial NRPS, while not necessarily in fungal NRPS, 
which can alternatively use the terminal C domain to perform the cyclization.110 
 
Figure 4. Domain structures of linear, iterative, and nonlinear NRPS (A). General reaction 
mechanism of NRPSs (B). 
The structural abundance of NRPs in nature is partly due to the relaxed substrate specificity of NRPSs 
towards not only hundreds of nonproteinogenic amino acids but also fatty acids, -amino acids and -
hydroxy acids.111 Besides, on-assembly or post-assembly line modifications including epimerization, 
N-methylation, formylation, glycosylation and oxidation,102 as well as different chain release actions 
such as hydrolysis, macrocyclization, and the C-terminal reduction release, also contribute to the 
diversity of nonribosomal peptides. Furthermore, redesigning an NRPS machinery is also a promising 
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option for the construction of new nonribosomal peptides. One representative example is engineering 
of the NRPS in the daptomycin biosynthetic pathway by exchanging single and multiple modules to 
produce a library of new daptomycin analogues.112 
1.2.3 Polyketide synthase-nonribosomal peptide synthetases 
One smart strategy that nature employed to diversify natural products is the creation of hybrid 
structures by PKS–NRPS or NRPS-PKS hybrid assembly lines. As aforementioned, PKSs construct 
polyketides via C-C bond formation by using acetic acid-type acyl building blocks, while NRPSs 
catalyze the production of peptides by C-N bond formation between amino acids. Both PKSs and 
NRPSs use carrier proteins to tether the growing chain, i.e. ACP for PKSs and PCP for NRPSs, which 
facilitate the transfer of distinct biosynthetic intermediates between heterologous subunits.113 
In PKS-NRPS assembly lines, the ACP domain of PKS and the C domain of NRPS are critical for 
PKS-NRPS modular interaction. The NRPS C domain catalyzes the amide formation between the 
elongated polyketide chain attached at the upstream PKS ACP domain and the aminoacyl group 
tethered to the PCP domain of the same NRPS module.113 Representative examples of fungal PKS-
NRPS hybrid enzymes are aspyridone A synthetase ApdA incorporating L-tyrosine with the polyketide 
chain (Figure 5A)114 and -cyclopiazonic acid synthetase CpaS incorporating L-tryptophan with a 
polyketide moiety (Figure 5A),115 as well as CheA and CcsA for the formation of the cytochalasan-
type compounds chaetoglobosin A116 and cytochalasin E,117 respectively. Other examples include 
fusarin C synthetase FUSS,118 equisetin synthetase EqiS,83 tenellin synthetase TenS,119 pseurotin A 
synthetase PsoA,120 xyrrolin synthetase Pks3,121 and desmethylbassianin synthetase DMBS.122 
Carlosic acid synthetase CaaA differs from the above-mentioned hybrid enzymes by accepting L-malic 
acid instead of an amino acid as substrate.30 Sequence alignments revealed that the conserved 
aspartic acid (D235 in PheA), which is reported to stabilize the -amino group in amino acid-utilizing 
PKS-NRPS enzymes,106, 123 is replaced by an asparagine residue in CaaA.30   
In NRPS-PKS assembly lines, the PCP domain of NRPS and the KS domain of PKS play an important 
role in the interaction of NRPS and PKS module. In this case, after receiving the aminoacyl chain from 
the PCP domain of the upstream NRPS module, the KS domain of PKS module catalyzes the C-C 
bond formation between the aminoacyl chain and the malonyl-type extender unit attached to the ACP 
domain of the same PKS module.113 In contrast to PKS-NRPS hybrid enzymes, NRPS-PKS hybrid 
enzymes have been commonly reported in bacteria, but are relatively rare in fungi. TAS1 is the first 
hybrid NRPS-PKS reported from fungi catalyzing the formation of tenuazonic acid (Figure 5B).124 It 
consists of a NRPS module and a sole KS domain at C-terminus. The TAS1 KS domain was proposed 
to be responsible for the product release, which is an atypical function of a KS domain.124 Another 
newly identified NRPS-PKS enzyme is AnATPKS involved in the biosynthesis of the -pyrone-
containing compound pyrophen (Figure 5B).125 Different from TAS1, the NRPS part of AnATPKS is 
composed of A domain and PCP domain for the recognition and activation of L-phenylalanine, and the 
PKS part consists of KS-AT-ACP as minimal domain to perform two rounds of chain elongation.125 
In recent years, recombination of dissociated PKS and NRPS modules is a new fashion to create novel 
polyketide-nonribosomal peptide hybrid products. For example, both ApdA and CpaS are PKS-NRPS 
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hybrid enzymes as mentioned above. Coexpression of the PKS module of ApdA and the NRPS 
module of CpaS together with the enoylreductase ApdC in Saccharomyces cerevisiae led to the 
production of a preaspyridone analog with L-Trp instead of L-Tyr incorporation (Figure 5C).126 This 
study presented a successful example of functional recombination of heterologous PKS and NRPS 
modules. Therefore, the application of recombinant gene fragments on hybrid assembly lines provides 
more possibilities to produce hybrid scaffolds with increased diversity and complexity.  
 
Figure 5. Representatives of fungal hybrid PKS-NRPS (A) and NRPS-PKS (B). Recombination of 
ApdA PKS module with CpaS NRPS module as an example for new hybrid product formation (C). 
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1.3 Post-assembly line modifications in natural product biosynthesis 
In fungal biosynthetic gene clusters, the backbone genes are usually surrounded by several genes 
coding for modification enzymes including prenyltransferases (PTs), nonheme FeII/2-oxoglutarate 
(FeII/2-OG)-dependent oxygenases, flavin-containing oxidoreductases, cytochrome P450 
monooxygenases. Therefore, once the scaffold is synthesized by a backbone enzyme, it can be further 
diversified by subsequent oxidation, reduction, rearrangement, and transfer reactions. 
1.3.1 Prenyltransferases 
Prenylation reactions occur commonly in nature, leading to a wide range of prenylated natural products 
with various biological activities.127 PTs are responsible for the catalyzation of prenyl transfer reaction 
from different prenyl moieties (n × C5) to various acceptors including nucleic acids and proteins, as 
well as aliphatic and aromatic molecules of low-molecular-weight.128 Prenylation of small aromatic 
compounds is catalyzed by PTs generally belonging to UbiA-type, CloQ/NphB-type, and 
dimethylallyltryptophan synthase (DMATS)-type.129  
UbiA-type PTs are membrane-bound enzymes and involved in the biosynthesis of both primary 
metabolites such as ubiquinones and menaquinones and secondary metabolites such as bitter acids 
and aurachins.130 Members of this family are named after UbiA from Escherichia coli and possess a 
conserved (N/D)DXXD motif.131, 132 They require metal ions such as Mg2+ for their catalytic activity.133 
PTs of CloQ/NphB-type and DMATS-type are soluble proteins with a characteristic  folds, termed 
PT-barrel, and most of them can function ion-independently.134 The eponym for CloQ/NphB group is 
due to the first identified enzyme CloQ135 involved in the biosynthesis of clorobiocin and later NphB136 
involved in the biosynthesis of the naphterpin derivatives.  
PTs belonging to the DMATS superfamily have been intensively investigated in biochemistry, 
molecular biology, and structural biology during the past decades.134 They catalyze the prenylation of 
aromatic substrates, mainly of indole derivatives, at either the first pathway-specific step or the later 
tailoring steps.134, 137 One of the characteristics of DMATS enzyme is their substrate flexibility towards 
a broad spectrum of aromatic compounds. Conversion of indole derivatives, cyclic dipeptides, tyrosine 
derivatives, flavonoids, xanthones and hydroxynaphthalenes, to their prenylated derivatives are 
catalyzed by PTs of the DMATS type.138 The first member of the DMATS superfamily is DmaW (4-
DMATS) identified in the ergot alkaloid gene cluster in Claviceps fusiformis.139 Later, FgaPT2 was 
identified from Aspergillus fumigatus as a ortholog of DmaW.140 It catalyzes regular transfer of the 
dimethylallyl (DMA) moiety from DMAPP to the C-4 position of L-tryptophan, which is the first 
biosynthetic step of fumigaclavine C.140 Systematic investigation on FgaPT2 has been carried out after 
its discovery. One of the most important achievement is the identification of the crystal structure of 
FgaPT2, which provided a theoretical basis for structure-based protein engineering.141 After that, 
several other DMATS enzymes catalyzing prenylation of L-tryptophan have been identified from fungi. 
These include DmaW-Cs,142 MaPT,143 5-DMATS,144 6-DMATSMo,145 7-DMATS,146 and 7-DMATSNeo 
(Table 1).147 In addition to these tryptophan PTs, SirD148 from Leptosphaeria maculans and TyrPT149 
from Aspergillus niger are examples of known tyrosine O-prenyltransferases (Table 1). Another group 
of PTs of the DMATS superfamily accept tryptophan-containing CDPs as substrates. The first 
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identified PT of this group was FtmPT1 from Aspergillus fumigatus, which catalyzes C2-prenylation of 
brevianamide F (cyclo-L-Trp-L-Pro) as an early step for the biosynthesis of 
verruculogen/fumitremorgins.150 Later, more CDP PTs have been found from fungi, such as NotF,151 
BrePT,152 and CdpC2PT153 for C2-prenylation; CdpNPT,154 AnaPT,155 and CdpC3PT156 for C3-
prenylation; CdpC7PT for C7-prenylation,157 CTrpPT for both N1- and C7-prenylation (Table 1).158 
Furthermore, there are also some members of the DMATS group that transfer prenyl moieties onto 
other structural skeletons. Examples given in Table 1 include TdiB,159 PaxD,160 XptB,161 and NscD.33  
Table 1 Overview of PTs of the DMATS superfamily and their producing organism. 
enzyme organism product 
involved biosynthetic 
pathway 
reference 
tryptophan prenyltransferases 
DmaW Claviceps fusiformis 
 
ergot alkaloids 139 
FgaPT2 Aspergillus fumigatus fumigaclavine C 140 
DmaW-Cs Periglandula sp. ergot alkaloids 142, 162 
MaPT Malbranchea aurantiaca unknown 143 
5-DMATS Aspergillus clavatus 
 
unknown 144 
6-DMATSMO 
Malbranchea 
olivasterospora 
 
unknown 145 
7-DMATS Aspergillus fumigatus 
 
astechrome 146 
7-DMATSNeo Neosartorya sp. unknown 147 
     
tyrosine prenyltransferases 
SirD Leptosphaeria maculans 
 
sirodesmin PL 148 
TyrPT Aspergillus niger unknown 149 
     
cyclic dipeptide prenyltransferases 
FtmPT1 Aspergillus fumigatus 
 
verruculogen/ 
fumitremorgin 
150 
NotF  Aspergillus sp. 
 
notoamide 151 
BrePT Aspergillus versicolor brevianamide 152 
CdpC2PT Neosartorya fischeri 
 
fellutanine 153 
CdpNPT Aspergillus fumigatus 
 
unknown 154 
AnaPT Neosartorya fischeri 
 
acetylaszonalenin 155 
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CdpC3PT Neosartorya fischeri 
 
unknown 156 
CdpC7PT Aspergillus terreus 
 
unknown 157 
CTrpPT Aspergillus oryzae 
 
unknown 158 
     
DMATSs of diverse substrates 
TdiB  Aspergillus nidulans 
 
terrequinone A 159 
PaxD Penicillium paxilli 
 
diprenylated paxillin, 
paspalitrem A 
160 
XptB Aspergillus nidulans 
 
shamixanthone/ 
epishamixanthone 
161 
NscD Neosartorya fischeri 
 
neosartoricin 33 
 
Despite the extremely high abundance of prenylated products in nature, their diversity can be further 
expanded by using engineered PTs for chemoenzymatic synthesis. Since the crystal structure data of 
more and more aromatic PTs are available, it is becoming easier to recognize the gatekeeping 
residues related to the catalytic activities. For example, mutation of the Lys174 residue in FgaPT2 to 
alanine resulted in reverse C3-prenylation of L-tryptophan instead of regular C4-prenylation by the 
wild-type (Scheme 1).163 And compared to the weak activity of the wild-type and almost no activity of 
FgaPT2_K174A towards CDPs, Arg244 mutants of FgaPT2 had increased acceptance of CDPs for 
regular C4-prenylation (Scheme 1).164 Further combinational mutation on Lys174 and Arg244 yields 
FgaPT2_K174F_R244X (X = L, N, Q, Y) mutants leading to not only CDPs acceptance but also 
reverse C3-prenylation on the indole ring (Scheme 1).165 Besides, site-saturation mutagenesis of 
Met328 in FgaPT2 switched the prenyl donor preference of the mutants from DMAPP to geranyl 
diphosphate (GPP) (Scheme 1).166 Therefore, these successful engineering on FgaPT2 set examples 
for achieving extensive acceptance of aromatic substrates and shifted specificity towards prenyl 
donors, as well as alternative prenylation positions. This confirms structure-based protein engineering 
as a promising approach for producing new prenylated compounds. 
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Scheme 1. Prenylation of L-tryptophan by FgaPT2 and the shifted catalytic activities of the mutants 
 
1.3.2 Nonheme FeII/2-oxoglutarate-dependent oxygenases 
Nonheme FeII/2-OG-dependent oxygenases are tailoring enzymes that decorate the carbon skeletons 
in the late stage of a given biosynthetic pathway to attain the final framework with an array of functional 
groups.167, 168 They possess a conserved double-stranded -helix fold with a 2-His-1-carboxylate facial 
triad that coordinates to an iron atom.169 Three of the six ligands to the iron are occupied by two 
histidines and an Asp/Glu side chain carboxylate. The fourth and fifth ligands to the iron are mostly 
provided by the keto group and one of the carboxylate oxygens of 2-oxoglutarate (2-OG), the 
cosubstrate required for the catalytic activity of this enzyme family.170 The oxidation step further 
requires activation of molecular oxygen for incorporation into substrate molecules. This is achieved by 
displacing one molecule of water (the sixth ligand) to vacate a site for binding with the O2 molecule. 
During the catalytic cycle, oxidative decarboxylation of 2-OG releases a high energy FeIV=O (ferryl) 
intermediate as a strongly oxidizing agent, which is capable of performing homolysis of unactivated 
C–H bonds (Figure 6A).168 This in return makes nonheme FeII/2OG-dependent oxygenases as 
multifunctional factories to catalyze a vast diversity of oxidative transformations.168, 170 Examples as 
shown in Figure 6B include hydroxylation by AIP4H involved in the formation of trans-4-hydroxy-L-
proline,171 halogenation by AmbO5 for the formation of ambiguine A,172 oxidative decarboxylation by 
P.IsnB involved in the biosynthesis of rhabduscin,173 desaturation and spirocyclization by AusE for the 
construction of preaustinoid A3,174, 175 epimerization and desaturation by CarC for the formation of 
(5R)-carbapenem,176, 177 desaturation and epoxidation by AsqJ for the formation of cyclopepnin.178 
Since the first discovery of nonheme FeII/2OG-dependent oxygenases in the 1960s, enzymes of this 
family have grown rapidly in number and variety of chemical reactions, as well as our understanding 
of catalytic mechanisms. In fungi, the first reported enzymes of this family were those involved in the 
biosynthesis of -lactams.179 Isopenicillin N-synthase (IPNS) represented the first crystal structure for 
the nonheme iron enzyme family.180, 181 It is an atypical case that does not require 2-OG as cosubstrate.  
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Figure 6. Catalytic mechanism of hydroxylation by nonheme FeII/2-OG-dependent oxygenases (A), 
and representative structures that formed with the involvement of nonheme FeII/2-OG-dependent 
oxygenases (B). 
As shown in Figure 7A, an extra glutamine residue chelates the FeII center in addition to the common 
2-His-1-carboxylate facial triad. The mechanism of IPNS was proposed to first proceed through the 
nucleophilic attack from the deprotonated amide nitrogen to the thioaldehyde to form the four-
membered -lactam ring, followed by attacking of the valinyl radical to the coordinated sulfur atom to 
form the five-membered thiazolidine ring, thus yielding the unique 4/5 fused ring system.182 FtmOX1 
involved in the biosynthesis of verruculogen is another nonheme FeII/2OG-dependent enzyme that is 
worth mentioning. Although biosynthesis of verruculogen was long believed to be formed from 
endoperoxidation of fumitremorgin B, the mechanism of the endoperoxide formation was not clear until 
characterization of FtmOX1 in 2009.183 With the reported crystal structure, the catalytic mechanism of 
the endoperoxidation was proposed in a way that FtmOX1 probably uses the ferryl-oxo intermediate 
to first abstract the phenolic hydrogen of the tyrosine residue (Tyr224), then the generated tyrosyl 
radical abstracts a hydrogen atom from the substrate.184 However, recent reinvestigation on FtmOX1 
revealed that hydrogen donation not abstraction by another tyrosine residue (Tyr68) is involved in the 
endoperoxide installation.185 The ferryl complex directly abstracts a hydrogen-atom from C21 of the 
substrate to generate the substrate radical. After the incorporation of one molecule of O2, addition of 
the peroxyl radical to the olefin of another prenyl moiety completes the endoperoxide moiety 
installation. Following hydrogen-atom transfer from Tyr68 to C26 results in the accumulation of Tyr 
radicals, which is then quenched by inclusion of the reductant such as ascorbate (Figure 7B).185 It is 
not surprising that with improved techniques, our knowledge on catalytic mechanisms of known FeII/2-
OG enzymes is undergoing a updating process, and more FeII/2-OG enzymes with novel functions will 
be continuously discovered. 
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Figure 7. Mechanism of the fused -lactam and thiazolidine ring formation catalyzed by IPNS (A), 
and mechanism of the endoperoxide formation by FtmOx1 (B). 
By virtue of the ability to directly functionalize unactivated C–H bonds at the cost of 2-OG and O2, 
nonheme FeII/2OG-dependent oxygenases can be used as a versatile platform to synthesize plenty 
of intricate natural products.186 For example, total synthesis of tropolones is particularly challenging 
for chemists because of difficult construction of the non-benzannulated, highly substituted tropolone 
ring. However, one-pot dearomatization of 3-methylorcinaldehyde by flavin-dependent 
monooxygenase (FMO) TropB and following hydroxylation/ring-expansion by FeII/2-OG hydroxylase 
TropC led to efficient production of stipitatic aldehyde in 31 % isolated yield (54 % conversion).187 This 
two-step approach set an example for leveraging the diversity of biosynthetic catalysts and synthetic 
chemistry communities. Therefore, with broad substrate scope and reaction repertoire, nonheme 
FeII/2OG-dependent oxygenases hold great potential as useful biocatalysts for chemoenzymatic 
synthesis of bioactive natural products. 
1.3.3 Nonenzymatic events occurred in late stage of natural product biosynthesis 
Compared to the tremendous variety of chemical reactions in synthetic organic chemistry, the 
occurrence of reactions within a living organism is usually restricted to rather mild conditions that the 
living system can tolerate. Still, nature created its own efficient way to expand the chemical processes 
in life science to the current level of diversity.188, 189 One such strategy is the occurrence of 
nonenzymatic events during the post-biosynthesis of natural products. They often happen in cascade 
reactions with enzymatic reactions, because enzymatic products are, in some cases, chemically 
unstable intermediates. These intermediates can be highly reactive to undergo, e.g. condensation, 
dimerization, and lactonization, or possess electron-rich/deficient moieties that can easily be attacked 
by nucleophiles/electrophiles, thus triggering interesting chemical modifications of the pre-matured 
scaffolds.190-201 
One major group of nonenzymatic reactions is occurred via quinone methides (QMs) as highly reactive 
intermediates. Although QMs have long been used as versatile reactants in chemical synthesis,202, 203 
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they have also been increasingly found in natural product biosynthetic pathways. The biosynthesis of 
fluostatin-type dimeric polyketides sets an excellent example for a nonenzymatic strategy used in the 
formation of C–C and C–N coupled homo-/hetero-dimers.190 First spontaneous deacyloxylation of 
fluostatin D leads to a transient para-QM intermediate which is attacked by the electron-rich carbon of 
another fluostatin D to afford the dimeric products (Figure 8A).190 Nonenzymatic dimerization via 
ortho-QMs was also suggested for the biosynthesis of sporormielones.191 In addition to dimerization, 
the biosynthesis of elansolids in Chitinophaga sancti provides another example of macrolactonization 
via a para-QM intermediate. In this case, the nonenzymatic nucleophilic addition of the carboxylate 
onto a para-QM moiety of elansolid A3 yields elansolids A1/A2 (a pair of separable atropisomers) 
(Figure 8B).192 There is also a situation where enzymatic and nonenzymatic reactions occur in parallel 
at a given biosynthetic step. Taking the biosynthesis of leporin as example, the first dehydration leads 
to an E-configured ortho-QM intermediate. Following hetero-Diels–Alder (HDA) reaction occurred both 
spontaneously and enzymatically. Interestingly, S-adenosyl-L-methionine (SAM)-dependent enzyme 
LepI does not repress the spontaneous intramolecular Diels–Alder (IMDA) reaction for the byproduct 
formation, but catalyzes an additional retro-Claisen rearrangement of the byproduct to the end product, 
thus completing a “byproduct cycle” process (Figure 8C).193 
 
Figure 8. QMs as key biosynthetic intermediates involved in the formation of natural products 
In addition to QM-initiated nonenzymatic reactions, amines are also found to be multipotent for the 
nonenzymatic initiation. In the biosynthesis of the pyridine-containing rubrolones, capture of ammonia 
or anthranilic acid by an amine acceptor, the 1,5-dione intermediate, leads to the nonenzymatic 
condensation process to afford the pyridine ring in rubrolone A or the pyridine inner salt moiety in 
rubrolone B (Figure 9A).195 Similar nonenzymatic condensations between amines and carbonyl 
groups are also found in other well-studied cases. For example, discoipyrrole A is formed through a 
nonenzymatic multicomponent reaction of anthranilic acid, 4-hydroxybenzaldehyde, and 4-
hydroxysattabacin (Figure 9B).196 Another example is the construction of the jadomycin skeletons by 
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the nonenzymatic cascade reactions which starts with condensation between the amine of L-
isoleucine/L-ornithine and the carbonyl group of an intermediate from oxepinone (Figure 9C).197, 198 
 
Figure 9. Examples of nonenzymatic condensations between amines and carbonyl groups 
Except QMs and amines/imines as nonenzymatic initiation factors, formaldehyde is also reported to 
be involved in the nonenzymatic Baylis–Hillman reaction during the formation of bohemamine dimers. 
The intermediate A from bohemamine acts as the nucleophile to react with formaldehyde, leading to 
the formation of the primary alcohol intermediate B. This intermediate serves as the substrate for the 
following nucleophilic substitution of a second molecule of intermediate A to give dibohemamine A 
(Figure 10A).199 Besides, nonenzymatic involvement of benzoquinone as the Michael acceptor is also 
reported in the biosynthesis of urdamycins. Urdamycin E is a sulphur-containing angucycline that 
formed by nucleophilic attack from the methylmercaptan, which derives from enzymatic cleavage of 
methionine, onto the 5,6-double bond of the urdamycin A (Figure 10B).200 Shortly later, nonenzymatic 
condensations of urdamycin A with 4-hydroxyphenylpyruvic acid and indole-3-pyruvic acid were also 
found as the late steps in the biosynthesis of angucycline antibiotic urdamycins C and D, 
respectively.201 
With the availability of highly reactive biosynthetic intermediates as starting points, natural product-
like compounds can be easily diversified by feeding alternative precursors into the fermentation media. 
For example, 21 new elansolid derivatives were obtained by precursor-directed fermentation (Figure 
11A).204 Another impressive strategy is the combination of chemical synthesis and biosynthetic 
methods to diversify pseudo-natural products (Figure 11B). The multipotency of the biosynthetic  
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Figure 10. Examples of nonenzymatic reaction with the involvement of formaldehyde (A) or 
benzoquinone (B) 
 
Figure 11. Two strategies of diversity-oriented synthesis. Generation of elansolid derivatives by 
precursor-feeding fermentation (A), creation of pseudo-natural products with different skeletons by 
combination of heterologous expression and chemical diversification methods (B). 
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intermediate produced by a fungal NR-PKS was exploited by heterologous expression and following 
chemical diversification.205 The merit of such diversity-oriented semi-synthetic method is the 
nonlimiting expansion of polyketide frameworks. In this case, 41 pseudo-natural products with different 
carbon skeletons were rapidly and effectively generated. These include polyketide oligomers, 
azaphilone-type molecules, isoquinoline alkaloid-like compounds and indole–polyketide hybrids.205 
Since an increasing number of natural products was found to involve one or more nonenzymatic steps 
during their biosynthesis, the line between natural products and non-natural products is becoming 
unclear. Non-natural products are often workup artifacts that formed during extraction or isolation 
process due to the external stimuli such as pH or temperature changes, exposure to light or oxygen, 
and organic solvents or chromatography media.206 For example, methanol adducts are often found 
during isolation procedure as exemplified by agglomerin F30 and pestapyrone C.207 While formation of 
natural products is the results of using divergent pathways that begin with the formation of chemical 
scaffolds by backbone enzymes, and followed by multi-step enzymatic and nonenzymatic 
modifications. Further development of protein engineering, genetic manipulation, and 
chemoenzymatic synthesis provides more possibilities to enrich structural libraries for the discovery of 
novel drugs. 
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2 Aims of this thesis 
In this thesis, the following issues have been addressed: 
Geranylation of the indolyl residue in cyclic dipeptides by using engineered dimethylallyl 
transferases 
PTs of the DMATS-type are known to exhibit substrate promiscuity. However, compared to the broad 
acceptance towards aromatic compounds, they have a narrowed tolerance towards prenyl donors. 
Transfer of C5 units occurs frequently for fungal natural products, while transfer of longer prenyl donors, 
i.e. GPP (C10), FPP (C15), and GGPP (C20), is relatively rare reported. So far, there are only limited 
numbers of PTs of the DMATS family were characterized for catalyzing the geranylation, which limited 
the diversification of geranylated natural products. In this study, manipulation of available PTs was 
carried out to switch their prenyl donor specificity from DMAPP to GPP. The following experiments 
were carried out in cooperation with Dr. Peter Mai: 
➢ Sequence alignments of FtmPT1, BrePT, CdpC2PT, CdpNPT, and CdpC3PT with FgaPT2 
and AtaPT to identify the gatekeeping residue for prenyl donor selectivity 
➢ Construction of FtmPT1_M364G, BrePT_I337G, CdpC2PT_T351G, CdpNPT_M349G, 
CdpC3PT_F335G, and FgaPT2_M328G_R244Q by site-directed mutagenesis 
➢ Overproduction and purification of the recombinant histidine-tagged mutants and their 
corresponding wild-type proteins 
➢ Enzyme assays of the obtained mutants with 15 cyclic dipeptides in the presence of DMAPP 
and GPP in comparison to the enzymatic activity of the wild-type PTs 
➢ LC-MS analysis of the incubation mixtures  
➢ Isolation and structural elucidation of enzyme products by 1H NMR and HR-ESI-MS analyses 
 
Biosynthesis of peniphenone and penilactones in Penicillium crustosum requires the 
involvement of clavatol and terrestric acid from two independent pathways 
Penilactones A and B are novel natural products consisting of two clavatol moieties and one -
butyrolactone. Previous studies suggested that penilactones A and B were formed by Michael addition 
of an ortho-QM with (R)-5-methyltetronic acid or (S)-5-carboxylmethyltetronic acid, respectively. 
However, limited studies on penilactones A and B raise the question about, i) the biosynthetic origin of 
clavatol and tetronic acids, ii) the biosynthetic relationship between clavatol and the ortho-QM, and iii) 
the responsible enzyme for Michael additions. Besides, it is also interesting to investigate the 
mechanism for the conversion of the -carboxylmethyl group to the -methyl group at the C-5 position in 
the tetronate ring. To answer these questions, the following experiments were carried out in cooperation 
with Dr. Jie Fan: 
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➢ Sequencing the genome of Penicillium crustosum PRB-2 and analysis of the clavatol and 
terrestric acid biosynthetic gene clusters 
➢ Deletion of the genes in clavatol (claA-J) and terrestric acid clusters (traA-H) by using the split 
marker strategy 
➢ Heterologous expression of the NR-PKS gene claF, PKS-NRPS hybrid gene traA, and traA 
together with the enoyl reductase gene traG in Aspergillus nidulans LO8030 
➢ Large-scaled fermentation of the wild-type strain, deletion mutants, and heterologous 
expression mutants for isolation and structure elucidation of the secondary metabolites 
➢ Chemical synthesis of (5R)-methyltetronic acid and (5S)-carboxylmethyltetronic acid by Lena 
Ludwig-Radtke 
➢ Feeding biosynthetic precursors in ∆claD, ∆claF, ∆traA, and ∆traG mutants 
➢ in vitro biochemical investigation of the nonheme FeII/2OG-dependent oxygenases ClaD and 
TraH as well as the flavin-containing oxidoreductase TraD 
➢ Incubation of hydroxyclavatol in 18O-enriched water to prove the existence of ortho-QM 
➢ Incubating hydroxyclavatol with (5R)-methyltetronic acid or (5S)-carboxylmethyltetronic acid in 
H2O at room temperature to prove the nonenzymatic formation of penilactones A and B 
Expanding structural diversity of natural products by Michael addition with ortho-quinone 
methide as the acceptor  
In addition to penilactones A and B, there are numerous natural products found in fungi that also 
contain clavatol moieties in their structures. Our previous study revealed that penilactones A and B 
are formed by nonenzymatic 1,4-Michael additions via the ortho-QM derived from hydroxyclavatol. 
However, it is not clear whether other clavatol-containing compounds are also formed 
nonenzymatically in a similar way to penilactones A and B. To investigate the involvement of the ortho-
QM derived from hydroxyclavatol in their formation and to expand the structural diversity of clavatol-
containing compounds, the following experiments were carried out in cooperation with Dr. Jie Fan: 
➢ Chemical synthesis of hydroxyclavatol by Lena Ludwig-Radtke 
➢ Testing the reactivity of hydroxyclavatol with 102 different reactants and subsequent LC-MS 
analysis of the incubation mixtures 
➢ Optimization of the incubation conditions for upscaled incubations  
➢ Isolation of the reaction products by semi-preparative HPLC and structure elucidation by NMR 
and HR-ESI-MS analyses 
➢ Screening and evaluating the antibacterial activity, acetylcholinesterase, and -glucosidase 
inhibition activities for the isolated products 
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3 Results and discussion 
3.1 Geranylation of the indolyl residue in cyclic dipeptides by using engineered 
dimethylallyl transferases 
The frequent occurrence of prenylated compounds in nature makes PTs become one of the most 
important tailoring enzyme groups. PTs belonging to the DMATS superfamily catalyze the transfer 
reactions of prenyl (n x C5) moieties from different prenyl donors onto various aromatic substrates, 
especially indole derivatives.134 However, most of so far reported PTs are known for dimethylallyl (C5) 
transfer reactions and only very few of them are capable of catalyzing geranyl (C10) transfer.208-212 In 
a previous study, a single point mutation at the site of Met328 in FgaPT2 changed its prenyl donor 
preference from DMAPP to GPP.166 Following this work, we selected five CDP PTs, i.e. FtmPT1,150 
CdpC2PT,153 BrePT,152 CdpNPT154, and CdpC3PT156 for protein engineering. These enzymes catalyze 
regular or reverse prenylations at C-2 or C-3 position of the indole ring (Scheme 2). 
 
Scheme 2. The prenyl transfer reactions catalyzed by five CDP PTs with their natural or best 
accepted substrates 
Enzyme assays of the above PTs in the presence of DMAPP were carried out to confirm the activity 
of the proteins. The following 15 tryptophan-containing CDPs were used as prenyl acceptors: cyclo-L-
Trp-L-Trp (1), cyclo-L-Trp-L-Pro (2), cyclo-L-Trp-D-Pro (3), cyclo-D-Trp-L-Pro (4), cyclo-D-Trp-D-Pro (5), 
cyclo-L-Trp-L-Ala (6), cyclo-L-Trp-D-Ala (7), cyclo-D-Trp-L-Ala (8), cyclo-D-Trp-D-Ala (9), cyclo-L-Trp-L-
Leu (10), cyclo-L-Trp-L-Tyr (11), cyclo-L-Trp-L-Phe (12), cyclo-L-Trp-Gly (13), (S)-benzodiazepinedione 
(14), and (R)-benzodiazepinedione (15). Incubation mixtures of the five PTs with GPP as the prenyl 
donor were analyzed by LC-MS to evaluate their activity towards GPP. The results showed that only 
CdpC2PT exhibited clear activities toward 1, 2, 14, and 15 in the presence of GPP. CdpC3PT showed 
very low GPP acceptance toward 1, 2, 5, and 14. CdpNPT, FtmPT1, and BrePT had no activity when 
GPP was used as the prenyl donor. 
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It was reported that Gly326 in AtaPT was responsible for the enlarged pocket for prenyl donor 
binding.209 Met328 in FgaPT2 was the gatekeeping residue for the prenyl donor selectivity.166 Protein 
sequence alignments of the five aforementioned PTs with those of AtaPT and FgaPT2 showed 
corresponding residues at Met364 in FtmPT1, IIe337 in BrePT, Thr351 in CdpC2PT, Met349 in 
CdpNPT and Phe335 in CdpC3PT. Replacing the bulky amino acids by glycine led to the construction 
of the mutants FtmPT1_M364G, BrePT_I337G, CdpC2PT_T351G, CdpNPT_M349G, and 
CdpC3PT_F335G, respectively. Site-directed mutagenesis, overproduction of the recombinant 
proteins, and enzyme assays of the wild-type enzymes with DMAPP and GPP were performed by Dr. 
Peter Mai. 
This PhD candidate used the generated mutants for enzyme assays to test their activity toward GPP. 
LC-MS analysis of the incubation mixtures demonstrated improved GPP acceptance but generally 
reduced activity towards DMAPP by the mutants. In comparison to no activity of CdpNPT, FtmPT1, 
and BrePT toward GPP, CdpNPT_M349G accepted all the tested CDPs (1 − 15) with total product 
yields ranging from 13.7 % to 95.8 %. The CDPs were converted by FtmPT1_M364G with total product 
yields ranging from 9.6 % to 75.4 % except the two benzodiazepinediones (14 and 15). In addition, 
strongly increased activity of BrePT_I337G toward GPP was observed for its natural substrate 2 from 
less than 0.5 % by the wild-type to 79.8 % by I337G. For CdpC3PT_F335G, conversion of 10 in the 
presence of GPP was significantly increased in contrast to the weak activity of CdpC3PT, while only 
slight improvement was observed for other CDPs. As for CdpC2PT_T351G, comparing with wild-type 
CdpC2PT, it showed distinct product formation or different ratios of the same product toward 1 − 15 in 
the presence of GPP.  
Subsequent isolation of the enzyme products on HPLC and structural elucidation by interpretation of 
their 1H NMR spectra were also carried out by this PhD candidate. Our results revealed the relaxed 
regiospecific geranylation of the enzyme products in either reverse or regular manner (Scheme 3). 
FtmPT1_M364G catalyzes the formation of both regularly C2- and C3-prenylated, and even regularly 
N1-prenylated products. BrePT_I337G still catalyzes solely or predominantly reverse geranylation at 
the C-2 position of 2 − 4. Both CdpC2PT and its mutant CdpC2PT_T351G can catalyze geranyl 
transfer reaction, but with a distinct regioselectivity. The wild-type CdpC2PT catalyzes reverse C2-, 
regular C5- and C7-geranylation of 1, while CdpC2PT_T351G catalyzes both reverse mono- and 
digeranylation at C-2 of 1. Furthermore, reversely C3-geranylated and regularly C6-geranylated 
products were obtained from the incubation mixtures of CdpNPT_M349G with the selected substrates 
1, 5, and 14. Remarkably relaxed regioselectivity was observed for CdpC3PT_F335G in the presence 
of 10 and the structures of four products were determined as regularly N1- and C7-, reversely N1- and 
C3-geranylated compounds.  
In summary, our results proved the site-directed mutation of the gatekeeping residues as an effective 
way to turn on or improve the GPP acceptance of five PTs. Alongside with the increased activity  
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Scheme 3. Structures of enzyme products with different prenylation patterns 
towards GPP, the mutants also showed reduced regiospecificity, leading to multiple prenylated product 
formation in one incubation. This requires more efforts for product isolation, however benefits in 
creation of diverse geranylated CDPs. Taking advantage of relaxed regioselective geranylation by the 
mutants, complete decoration of N-1 and the six nonbridgehead carbons of the indole ring was 
achieved when using 1 as the acceptor and GPP as the donor. The vacancy at C4-position of 1 was 
filled by the generation of a double mutant FgaPT2_M328G_R244Q. Thus, nine products with geranyl 
moieties at all possible positions of the indole ring of 1 can be obtained by one-step chemoenzymatic 
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reactions (Scheme 4). Prior to our study, geranylated indole derivatives were relatively rare reported 
from nature.208-212 Our findings enrich the structural library of geranylated CDPs by providing 42 
compounds of this group. Furthermore, it is possible to create more geranylated CDPs by mutation of 
additional available dimethylallyl transferases in a similar way. 
 
Scheme 4. Attachment of the geranyl moieties to different positions of 1 via one-step 
chemoenzymatic reactions 
For details on this work, please see the publication (section 4.1) 
Ge Liao*, Peter Mai*, Jie Fan, Georg Zocher, Thilo Stehle and Shu-Ming Li (2018). Complete 
decoration of the indolyl residue in cyclo-L-Trp-L-Trp with geranyl moieties by using engineered 
dimethylallyl transferases. Organic Letters, 20 (22), 7201–7205, DOI: 10.1021/acs.orglett.8b03124. 
(*equal contribution) 
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3.2 Biosynthesis of peniphenone and penilactones in Penicillium crustosum 
requires the involvement of clavatol and terrestric acid from two independent 
pathways 
Penilactones A (16) and B (17) from Penicillium crustosum PRB-2 are rare natural products with novel 
structural skeletons (Figure 12).213 It was proposed that penilactones A and B as well as their putative 
precursors peniphenone D (18) and penilactone D (19) were formed by Michael addition of the ortho-
QM (20) with (5R)-methyltetronic acid (21) or (5S)-carboxylmethyltetronic acid (22), respectively.213, 
214 Although later biomimetic synthesis supported this hypothesis,215 no genetic data is available for 
the biosynthesis of 16 and 17. In this study, we proved the formation of 16 and 17 by two-step 
nonenzymatic Michael addition and the involvement of two pathways for the formation of the reaction 
substrates. 
Peniphenone and penilactones (16 – 19) were isolated from a 30 days-old rice culture, thus confirming 
their production in Penicillium crustosum PRB-2. The stereochemistry of 16 – 19 was determined by 
comparison of CD spectra with the published data213 or the chemically synthesized 21 and 22. Other 
related secondary metabolites were isolated from a 7 days-old PD culture. These include clavatol (23), 
a new derivative of clavatol named hydroxyclavatol (24), and two derivatives of 24, i.e. hydroxyclavatol 
methyl (25) and ethyl ether (26). The production of terrestric acid (27) as the predominant product in 
PRB-2 was also confirmed by isolation and structure elucidation. Meanwhile, a new compound termed 
crustosic acid (28) was identified as a carboxylated derivative of 27. The stereochemistry of 27 and 
28 were determined by comparison of the optical rotation with the published data of tetronic acids.216, 
217 The structures of these isolates are shown in Figure 12. 
 
Figure 12. Structures of compounds isolated from Penicillium crustosum PRB-2 (16 – 19 and 23 – 
28), heterologous expression mutants (29 and 30), and enzyme assay incubations (31). 
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The genome of Penicillium crustosum PRB-2 was then sequenced and 58 putative gene clusters were 
predicted by using AntiSMASH.218 Two building blocks, i.e. clavatol moieties and the -butyrolactones, 
are required for structural construction of penilactones A and B. Therefore, we focused on two gene 
clusters for detailed investigation. One of the selected gene cluster contains a NR-PKS gene (pcr3094) 
termed claF. ClaF shares 57.7 % sequence identity with CitS.48 Deletion of claF completely abolished 
the production of 16 – 19, 23, and 24, while a large amount of 27 and 28 were accumulated. Feeding 
23 to the ∆claF mutant restored the production of 16 – 19 and 24. Heterologous expression of claF in 
Aspergillus nidulans LO8030219 led to the accumulation of 23. These results proved the involvement 
of ClaF in the biosynthesis of 16 – 19 by functioning as clavatol synthase. The gene deletion, 
heterologous expression, and biochemical investigation in this project were performed by Dr. Jie Fan. 
This PhD candidate is responsible for precursor feeding, isolation and structural elucidation of the 
secondary metabolites. 
Another selected gene cluster contains a hybrid PKS-NRPS gene (pcr11009) termed traA. TraA shares 
a sequence identity of 69.6 % with CaaA in the biosynthetic pathway of carlosic acid,30 which also 
possess a -butyrolactone core. Inactivation of traA led to the abolishment of 16 – 19, 27, and 28, but 
remained the production of 23 and 24. Feeding (5R)-methyltetronic acid (21) in ∆traA mutant restored 
the production of 16 and 18, while 17 and 19 were restored when fed with (5S)-carboxylmethyltetronic 
acid (22). Further feeding experiments revealed that 16 and 18 were detected after feeding with 27, 
while production of not only 16 – 19, but also 27 were restored after feeding with 28. It can be 
concluded that TraA is involved in the biosynthesis of tetronic acids 21, 22, 27, and 28, and these 
tetronic acids are involved in the formation of peniphenone and penilactones (16 – 19). Furthermore, 
to identify the function of TraA, the traA sequence was introduced into Aspergillus nidulans LO8030. 
The product yielded by the traA expression mutant was identified to be a carboxylmethyltetronic acid 
derivative with an unsaturated acyl chain, termed carboxylcrustic acid (29). Subsequent coexpression 
of traA with the putative enoyl reductase gene traG led to the production of another metabolite, 
viridicatic acid (30). These results proved the function of TraA for synthesizing 29 and TraG for the 
side chain reduction of 29 to 30. However, the responsible enzyme for the conversion of 30 to 28 has 
not been identified yet. 
After identification of the backbone genes, we proceed to investigate the metabolism of clavatol (23). 
Isolation of hydroxyclavatol (24) gave us a clue for searching oxidase genes in the clavatol cluster. 
The nonheme FeII/2-OG-dependent oxygenase ClaD and the cytochrome P450 ClaJ were considered 
as candidate enzymes for the hydroxylation step. Deletion of claD abolished the production of 16 – 19 
and 24. Feeding 24 in the ∆claD mutant restored the production of 16 – 19. Further in vitro biochemical 
investigation of ClaD with 23 in the presence of ascorbic acid, Fe[(NH4)2(SO4)2], and 2-OG led to clear 
detection of 24 by HPLC analysis. Thus, ClaD was identified as the responsible enzyme for the 
hydroxylation of 23 to 24. 
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Alongside with the isolation of 24, two ether derivatives (25 and 26) were also obtained. The 
conversion of 24 to 25 was observed during the isolation process when dissolving 24 in methanol. 
Incubation of 24 in methanol or ethanol at 25 °C for 16 h resulted in the formation of hydroxyclavatol 
methyl (25) and ethyl ether (26), respectively (Scheme 5). The ethers (25 and 26) can convert back 
to 24 in aqueous solution. These results suggested that the spontaneous formation of the ethers is 
highly possible via the ortho-QM (20). To prove the existence of 20, compound 24 was incubated at 
25 °C for 16 h in H2O and H218O, respectively. Subsequent MS analysis of the incubation mixtures 
proved the incorporation of 18O into 24, proving the equilibration between 24 and 20 in aqueous system 
(Scheme 5). 
 
Scheme 5. The equilibration between hydroxyclavatol (24) and ortho-QM (20) in aqueous solution 
and the conversion between 20 and the ethers (25 and 26) in different alcohols. 
Having proven the function of ClaD and the existence of the ortho-QM, we speculated that the P450 
ClaJ could be responsible for catalyzing Michael addition of the two building blocks. Indeed, no 
production of 16 – 19 was detected in the claJ deletion mutant. However, when feeding the substrates 
to the claJ expression mutant, we unexpectedly observed the detection of 16 – 19 in the negative 
control. Hydroxyclavatol (24) was then incubated with the two tetronic acids 21 or 22 in water at 25 °C 
for 16 h. LC-MS analysis revealed that incubation of 24 with 21 carrying a 5-methyl group led to the 
formation of 16 and 18. Similarly, incubation of 24 with 22 carrying a 5-carboxylmethyl group resulted 
in the formation of 17 and 19. Further incubation of 24 with 18 or 19 led to the detection of 16 or 17. 
Therefore, although the function of ClaJ is not clear, it was confirmed that the formation of 16 – 19 is 
nonenzymatic events. First dehydration of 24 yielded the highly reactive intermediate 20, which served 
as the Michael acceptor attacked by the nucleophiles 21 or 22 to give 18 or 19. Subsequent addition 
of a second molecule of 20 to 18 or 19 yielded the final product 16 or 17 (Scheme 6). 
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Scheme 6. Proposed biosynthesis of peniphenone and penilactones in Penicillium crustosum PRB-2 
with the involvement of metabolites from clavatol and terrestric acid pathways 
In addition to the formation mechanism of peniphenone and penilactones, we are also interested in 
the conversion of crustosic acid (28) to terrestric acid (27). 28 carries a 5-carboxylmethyl group at 
the tetronate ring, differing from the 5-methyl group in 27. Similar situations are also found in other 
fungal tetronates. Examples are carlic acid and carlosic acid as 5 -carboxylmethyl-containing 
tetronates, carolic acid and carolinic acid as 5 -methyl-containing tetronates.30, 217, 220 As 
aforementioned, feeding 28 in the traA deletion mutant led to the formation of 27, implying 28 
undergoes decarboxylation and isomerization to 27. We took the FeII-2OG-dependent oxygenase 
TraH as the candidate enzyme for this transformation. Disruption of traH abolished 27 production, 
suggesting the role of TraH in the conversion of 28 to 27. To further verify the function of TraH, the 
purified recombinant TraH was used for the enzyme assay with 28 in the presence of ascorbic acid, 
Fe[(NH4)2(SO4)2], 2-OG, and dithiothreitol (DTT). Surprisingly, LC-MS analysis revealed an 
unexpected product peak with the molecular formula of C11H13O4, instead of C11H15O4 for 27. 
Subsequent isolation led to the identification of the enzyme product as dehydroterrestric acid (31), 
which possesses an exocyclic double bond at the C-5 position (Figure 12). This result proved the role 
of TraH in catalyzing an oxidative decarboxylation of 28 to 31. Therefore, another enzyme is required 
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for the reduction of the double bond to complete the conversion of 31 to 27. For this purpose, we took 
detailed investigation on the flavin-containing oxidoreductase TraD. After overexpression of the gene 
in Escherichia coli and purification to near homogeneity, TraD was incubated with 31 in the presence 
of NADPH. LC-MS analysis of the reaction mixtures as well as isolation and structural elucidation 
confirmed the stereospecific reduction of 31 by TraD to 27. Further coincubation of 28 with TraH and 
TraD showed sequential formation of the intermediate 31 and final product 27. To sum up, these results 
proved that the transformation of 28 to 27 required first oxidative decarboxylation by TraH to afford an 
intermediate 31, then stereospecific reduction of the double bond in 31 by TraD to install the -methyl 
group in 27 (Scheme 6). 
In conclusion, the biosynthesis of peniphenone and penilactones (16 – 19) was elucidated in this study 
as a combination of enzymatic and nonenzymatic reactions (Scheme 6). It contains enzymes 
originating from two sperate pathways to provide two building blocks for penilactone construction. The 
NR-PKS ClaF together with the nonheme FeII/2-OG-dependent oxygenase ClaD from the clavatol 
pathway are responsible for the formation of hydroxyclavatol (24). Spontaneous dehydration of 24 to 
the active intermediate ortho-QM (20) initiates the nonenzymatic Michael addition with tetronic acids 
21 or 22 to form firstly 18 or 19, then 16 or 17. Compounds 21 and 22 are metabolites of terrestric acid 
(27) and crustosic acid (28) from the terrestric acid pathway. 28 is formed via carboxylcrustic (29) and 
viridicatic acid (30) as biosynthetic precursors. Decarboxylation and isomerization of 28 to 27 was 
catalyzed by the nonheme FeII/2-OG-dependent oxygenase TraH and the flavin-containing 
oxidoreductase TraD. This study sets an example for the formation of natural products with the 
involvement of enzymes from two independent pathways and nonenzymatic reactions via ortho-QM 
as the biosynthetic intermediate. 
For details on this work, please see the publications (sections 4.2 and 4.3) 
Jie Fan*, Ge Liao*, Florian Kindinger, Lena Ludwig-Radtke, Wen-Bing Yin, and Shu-Ming Li (2019). 
Peniphenone and penilactone formation in Penicillium crustosum via 1,4-Michael additions of ortho-
quinone methide from hydroxyclavatol to -butyrolactones from crustosic acid. Journal of the American 
Chemical Society, 141 (10), 4225–4229, DOI: 10.1021/jacs.9b00110. (*equal contribution) 
Jie Fan*, Ge Liao*, Lena Ludwig-Radtke, Wen-Bing Yin, and Shu-Ming Li (2020). Formation of 
terrestric acid in Penicillium crustosum requires redox-assisted decarboxylation and 
stereoisomerization. Organic Letters, 22 (1), 88–92, DOI: 10.1021/acs.orglett.9b04002. (*equal 
contribution)  
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3.3 Expanding structural diversity of natural products by Michael addition with 
ortho-quinone methide as the acceptor 
Ortho-QMs are highly reactive intermediates that have long been used in chemical synthesis.203, 221 
Moreover, the involvement of ortho-QMs in the biosynthesis of natural products has also been reported. 
As introduced in section 1.3.3, the formation of fluostatin dimers,190 elansolids,192 and leporins193 was 
proven to require nonenzymatic reactions via QMs as the key reaction steps. Our studies on the 
biosynthesis of penilactones A and B provide another example for the ortho-QM involving 
nonenzymatic formation.222 In addition to penilactones A and B, there are several fungal natural 
products as coupling results of clavatol with -pyrone, indole, quinone, lactones, and phenols. 
Examples include erabulenol B from Penicillium sp. FO-5637223, peniphenones A – C from Penicillium 
dipodomyicola HN4-3A,224 communols A – C225 and penicophenones A and B226 from Penicillium 
commune. 
To investigate whether these clavatol-containing compounds are formed in a similar way as 
penilactones A and B, we chemically synthesized hydroxyclavatol and tested the reactivity of the ortho-
QM derived from hydroxyclavatol with 102 reactants of different structural skeletons (Table 2). These 
include flavonoids, hydroxynaphthalenes, coumarins, xanthones, anthraquinones, phloroglucinols, 
phenolic acids, indole derivatives, tyrosine analogues, and quinolines. Both hydroxyclavatol and the 
reactants at a final concentration of 0.4 mM in 50 L H2O were incubated at 25 °C for 16 h without pH 
adjustment. After adding 50 L acetonitrile and centrifuging at 13,000 rpm for 30 min, 5 L of 
supernatant were subsequently subjected to LC-MS analysis. The tests of hydroxyclavatol with a wide 
array of reactants as well as analyzing the LC-MS data of the incubation mixtures were performed by 
Dr. Jie Fan. This PhD candidate took the isolation and structural elucidation of the coupling products. 
Accordingly, coupling products with [M+H]+/[M-H]- ions being 178 Da larger than the corresponding 
reactants were detected in 86 out of 102 cases. Product formation with 10 % to 55 % conversion was 
detected for 49 reactants, product formation with 1 % to 10 % conversion was observed in 18 cases, 
and product formation in 19 incubations was only detectable by EIC of [M+H]+/[M-H]- ions. Only 16 
tested reactants showed no product formation in their incubation mixtures.  
Among the tested reactants, phloroglucinol derivatives were found to be the most favorable Michael 
donors for the ortho-QM. All eight tested phloroglucinols were converted to the coupling products with 
product yields ranging from 10 % to 55 %. Besides, flavonoids, hydroxynaphthalenes, and quinolines 
are also suitable reactants for coupling with the ortho-QM. Products were detected in incubation 
mixtures of hydroxyclavatol with 15 of 16 tested flavonoids and 9 of 11 tested hydroxynaphthalenes. 
Incubations of hydroxyclavatol with 5 of 9 tested quinolines showed UV detectable product formation. 
However, incubation mixtures of hydroxyclavatol with coumarins, xanthones, anthraquinones, and 
phenolic acids showed either very low product yields or no product formation. Further investigation on 
the reaction activity of hydroxyclavatol with indole derivatives including L-tryptophan revealed up to 
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49 % conversion. In contrast, L-tyrosine and its analogues were generally poorly converted to their 
clavatol adducts. Coincubation of hydroxyclavatol with eight tryptophan-containing CDPs showed 
product formation with 9 % to 29 % yields, while no product was detected from coincubation of 
hydroxyclavatol with two tyrosine-containing CDPs. Also 2-aminobenzyl alcohol and even 
tris(hydroxymethyl)aminomethane (Tris) prepared as Tris-HCl buffer (pH 7.5) were tested with 
hydroxyclavatol leading to a clearly coupling product detection. 
Table 2. Overview of different reactants tested with hydroxyclavatol and distribution of the reactant 
numbers for each structural group. 
reactants 
 
 
    
UV detectable (10%−55%) 7 5 1 0 0 8 
UV detectable (1%−10%) 5 4 0 5 0 0 
only detectable by EIC 3 0 2 0 2 1 
no detectable product 1 2 2 1 2 0 
total tested numbers 16 11 5 6 4 9 
reactants 
    
  
UV detectable (10%−55%) 3 9 7 0 3 4 
UV detectable (1%−10%) 1 1 1 0 0 1 
detected only by EIC 0 2 0 0 5 4 
no detectable product 6 0 0 2 0 0 
total tested numbers 10 12 8 2 8 9 
Other tested reactants 
2-aminobenzyl alcohol  
 
28 % conversion 
tris(hydroxymethyl)
aminomethane 
(Tris)  
35 % conversion 
 
To improve the product yields for subsequent isolation and structural elucidation, the reaction condition 
was optimized from 25 °C for 16 h to 95 °C for 30 min for all incubations. LC-MS results generally 
revealed two to ten-fold higher conversion of the coupling products in most of the incubations at 95 °C. 
Product formation with 30 % to 99 % yields was achieved for 58 reactants, while a few incubations 
had no significant change under the increased temperature. Consequently, upscaled reactions were 
carried out at either 25 °C or 95 °C, which led to the isolation of 32 coupling products from incubations 
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of hydroxyclavatol with 23 selected reactants. For structural elucidation, 1H NMR spectra were taken 
for 32 isolated products. In addition, 13C NMR and HMBC spectra were also measured for 19 
compounds. Biological activities, e.g. antibacterial, acetylcholinesterase and -glucosidase inhibition 
activities were tested by Dr. Jie Fan. 
The structures of coupling products originating from phenolic reactants are featured by the attachment 
of the clavatol unit to the ortho- or para-position of the hydroxyl group at the benzene ring. It was 
proposed that the ortho-QM generated from the spontaneous dehydration of hydroxyclavatol served 
as the acceptor for the nucleophilic carbon of phenols, which is due to ortho- or para-conjugation with 
the hydroxyl group (Figure 13A). As a result, a number of clavatol-phenol adducts were generated in 
this study (Figure 13B). These include clavatol-flavonoid adducts (32 – 36), clavatol-phloroglucinol  
 
Figure 13. Reaction mechanisms of nucleophilic addition from the phenolic reactants to the ortho-
QM intermediate (A) and structures of clavatol-phenol adducts (B). 
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adducts (37 – 40), and coupling products of clavatol with 1-naphthol (41 and 42), 1,3-
dihydroxynaphthalene (43), 4-hydroxycoumarin (44), 1,3-dihydroxyxanthone (45), purpurin (46), 4-
hydroxy-2-amino-quinoline (47), and 5-hydroxyquinoline (48).  
Coupling products of indole derivatives are featured by carrying clavatol moieties at the C-2 or C-3 
position. In these cases, the electron transfer within the indole ring enabled the Michael addition from 
the electron charged carbon to the electron deficient methylene group of the ortho-QM (Figure 14A). 
Accordingly, clavatol adducts with different indole derivatives (49 – 52) including tryptophan-containing 
CDPs (53 – 59) were obtained as representative structures (Figure 14B). Besides the above-
mentioned C-C linked adducts, coupling compounds via C-N bond were also obtained as exampled 
by 61 – 63 (Figure 14B). 
 
Figure 14. Reaction mechanisms of nucleophilic additions from the indole or amines to the ortho-
QM intermediate (A). Structures of clavatol-indole adducts and C-N linked clavatol adducts (B). 
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Taken together, this study as an extended work of our previous research aimed at the application of 
the ortho-QM derived from hydroxyclavatol. It was proven that the ortho-QM can be served as an 
excellent Michael acceptor for a variety of natural or natural-like products, ranging from different 
phenolic compounds to indole derivatives. 32 clavatol-containing products were isolated and identified 
from selected incubations. These structures were either formed by incorporation of a clavatol unit onto 
the ortho- or para-position of phenolic hydroxyl groups or onto the C-2 position of indole skeletons. In 
a few cases, C-N linked clavatol adducts were also obtained. In analogy, it is possible that the clavatol-
coupling natural products found from Penicillium species could also be formed by nonenzymatic 
Michael addition via the ortho-QM intermediate. Considering the high reactivity of the ortho-QM, more 
clavatol-containing compounds can be expected to be easily created artificially or naturally. 
For details on this work, please see the publication (section 4.4) 
Ge Liao*, Jie Fan*, Lena Ludwig-Radtke, Katja Backhaus, and Shu-Ming Li (2020). Increasing 
structural diversity of natural products by Michael addition with ortho-quinone methide as the acceptor. 
Journal of Organic Chemistry, 85 (2), 1298–1307, DOI:10.1021/acs.joc.9b02971 (*equal contribution) 
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4.1 Complete decoration of the indolyl residue in cyclo-L-Trp-L-Trp with geranyl 
moieties by using engineered dimethylallyl transferases 
  
Complete Decoration of the Indolyl Residue in cyclo-L‑Trp‑L‑Trp with
Geranyl Moieties by Using Engineered Dimethylallyl Transferases
Ge Liao,†,§ Peter Mai,†,§ Jie Fan,† Georg Zocher,‡ Thilo Stehle,‡ and Shu-Ming Li*,†
†Institut für Pharmazeutische Biologie und Biotechnologie, Philipps-Universitaẗ Marburg, Robert-Koch Strasse 4, Marburg 35037,
Germany
‡Interfakultar̈es Institut für Biochemie, Eberhard Karls Universitaẗ Tübingen, Tübingen 72076, Germany
*S Supporting Information
ABSTRACT: Mutation of the gatekeeping residues for
prenyl donor selectivity in six dimethylallyl transferases
significantly increased their activities toward geranyl diphos-
phate. Forty-two geranylated derivatives were obtained from
15 cyclic dipeptides by using the engineered enzymes. Taking
cyclo-L-Trp-L-Trp as an example, the geranyl moiety can be
attached to all seven possible positions of the indole nucleus.
This study demonstrates a convenient way to increase the
structural diversity of geranylated products by structure-based
engineering of the available dimethylallyl transferases.
Prenylated natural products are hybrid structures contain-ing prenyl moieties (n × C5) or derivatives thereof and are
widely distributed in plants and microorganisms.1−3 Among
them, prenylated indole alkaloids including prenylated
tryptophan-containing cyclic dipeptides (CDPs) usually exhibit
a wide range of biological and pharmacological activities and,
therefore, are important sources for drug discovery and
development.2,4,5 Representative structures such as notoa-
mides,6,7 roquefortines,8 fumitremorgins,9 and felluta-
nines10−12 are commonly derived from CDPs and often
decorated with one or more dimethylallyl (C5) moieties
(Figure 1).
The key reactions in the biosynthesis of the prenylated
natural products are connections of the prenyl moiety with its
acceptor catalyzed by prenyltransferases (PTs). PTs belonging
to the dimethylallyltryptophan synthase (DMATS) superfamily
catalyze the regiospecific Friedel−Crafts alkylation of aromatic
substrates, mainly of indole derivatives.13,14 The attachment of
the C5 unit to N1 and the six nonbridgehead carbons at the
indole ring can be achieved by the available indole PTs.13−15
However, the transfer of the C10 unit (geranyl) onto the indole
nucleus was rarely reported. Taking CDPs as examples, AnaPT
from Neosartorya fischeri catalyzes in the presence of
dimethylallyl diphosphate (DMAPP) reverse C3-prenylation
and also uses geranyl diphosphate (GPP) for their C6- and C7-
geranylation, as exemplified by cWW (1; for simplicity, one
letter codes are used for proteinogenic amino acids) in Scheme
1.16,17 AtaPT from Aspergillus terreus was reported to catalyze
the C4-geranylation of 1.18 Our recent reinvestigation on this
Received: October 1, 2018
Published: October 31, 2018
Figure 1. Representative examples of prenylated indole alkaloids
derived from cyclic dipeptides.
Scheme 1. Reverse Dimethylallyl C3-PT AnaPT from N.
fischeri Can Also Use GPP for C6- and C7-Geranylationa
aAtaPT from A. terreus attaches a geranyl moiety to C7 of 1. To
facilitate the reading flow, geranylated products are named by using
substrate number, prenylation pattern (a for regular or normal and b
for reverse prenylation), and prenylation position at the indole ring (1
to 7 for N1- to C7-alkylated products), e.g., 1a6 for C6-regularly
geranylated cWW.
Letter
pubs.acs.org/OrgLettCite This: Org. Lett. 2018, 20, 7201−7205
© 2018 American Chemical Society 7201 DOI: 10.1021/acs.orglett.8b03124
Org. Lett. 2018, 20, 7201−7205
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reaction revealed a C7- instead of a C4-geranylation (data not
shown). Other CDPs with geranyl residues have not yet been
reported. Furthermore, only a few members of PTs are able to
accept GPP as a prenyl donor and act as geranyl transferases,
e.g. TleC,19 VrtC,20 and AmbP1.21 Therefore, it is necessary to
find new geranyl transferases or to manipulate available
dimethylallyl transferases for GPP acceptance to enrich the
biocatalysis toolboxes.
Inspired by the activities of AtaPT and AnaPT toward GPP
for prenylation of CDPs, we first evaluated the GPP acceptance
of five dimethylallyl transferases, FtmPT1,22 CdpNPT,23
BrePT,24 CdpC2PT,25 and CdpC3PT,26 in the presence of
CDPs as acceptors. These enzymes catalyze regular (normal)
or reverse prenylations at C-2 or C-3 of the indole ring. The
tested CDPs include 1, cWP (2) and its stereoisomers (3−5),
cWA (6) and its stereoisomers (7−9), cWL (10), cWY (11),
cWF (12), cWG (13), (S)-(14), and (R)-benzodiazepinedin-
one (15). HPLC analysis of the incubation mixtures showed
that the five PTs well accepted their natural or best aromatic
substrates in the presence of DMAPP (Figure S1 in the
Supporting Information (SI)), confirming the presence of
active proteins. In the presence of GPP, CdpC2PT showed
clear activity toward 1, 2, 14, and 15 (Figure S2). The other
four enzymes exhibited very low (CdpC3PT toward 1, 2, 5,
and 14, Figure 2, Figure S3) or no activity (CdpNPT,
FtmPT1, and BrePT) (Figure 2, Figures S4−S6), when GPP
was used as a prenyl donor.
AtaPT was previously reported to have broad tolerance for
prenyl donors. The residue Gly326 was proven to contribute to
the enlarged pocket for donor binding.18 Mutation of Gly326
to methionine dramatically reduced the activity of G326M
toward GPP and FPP, but substantially enhanced the catalytic
activity with DMAPP. This proved that the size of the residue
at 326 controls the prenyl donor selectivity in AtaPT. Mutation
of Met328 in the tryptophan prenyltransferase FgaPT2 to
small amino acids such as cysteine, threonine, serine, glycine,
or alanine significantly increased the acceptance of GPP.27
Encouraged by these findings, structure-based protein
sequence alignments of AtaPT and FgaPT2 with the five
PTs mentioned above led to the identification of the
corresponding residues Met364 in FtmPT1, IIe337 in BrePT,
Thr351 in CdpC2PT, Met349 in CdpNPT, and Phe335 in
CdpC3PT (Figure 3, Figure S7).
Molecular modeling with the ternary crystal structures of
FtmPT1 and CdpNPT23,28 also uncovered Met364 in FtmPT1
and Met349 in CdpNPT as key residues for DMAPP
selectivity (Figure S8). The side chain of this residue seals
the active site to form a pocket for DMAPP. In the active site
of both enzymes, GPP would clash with the side chain of the
gatekeeping residue methionine. Therefore, reducing the steric
pressure in the DMAPP binding site by replacement of this
bulky residue with a small amino acid like glycine would
increase the enzymatic activity toward GPP.
To switch the prenyl donor specificity from DMAPP to GPP
for FtmPT1, BrePT, CdpNPT, and CdpC3PT and to expand
the GPP acceptance of CdpC2PT, we replaced the mentioned
amino acids of the five dimethylallyl transferases by glycine,
resulting in the mutants FtmPT1_M364G, BrePT_I337G,
C d p N P T _M 3 4 9 G , C d p C 2 P T _ T 3 5 1 G , a n d
CdpC3PT_F335G, respectively (see Table S1 for constructs
and SI for description). As expected, replacing bulky amino
acids by glycine significantly improved in most cases the CDP
consumption in the presence of GPP (Figure 2, Figures S2−
S6, S9). In comparison, the acceptance of DMAPP by the
mutants was reduced to different levels (Figure S1). In sharp
contrast to no activity in the presence of GPP by wild type
CdpNPT, FtmPT1, and BrePT, all the tested CDPs (1−15)
were accepted by CdpNPT_M349G with total product yields
from 13.7% to 95.8% (Figure 2, Figures S4 and S9). 1−13 with
a diketopiperazine ring were consumed by FtmPT1_M349G
with total product yields from 9.6% to 75.4%. The two
benzodiazepinediones 14 and 15 were not accepted (Figure 2,
Figures S5 and S9).
Figure 2. HPLC chromatograms of the incubation mixtures of six
dimethylallyl transferases and their corresponding mutants with their
natural or best accepted substrates in the presence of GPP. Regular
geranylated products are labeled in red, and reverse, in blue. The
product yields are given in parentheses after the product number. See
please Figure S1 for their behavior toward DMAPP.
Organic Letters Letter
DOI: 10.1021/acs.orglett.8b03124
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The activity of BrePT toward GPP can be strongly increased
by mutation at the gatekeeping residue Ile337, at least for its
natural substrate 2 (79.8%) and the two stereoisomers 3
(71.4%) and 4 (28.4%) (Figure 2, Figure S6). In the case of
CdpC3PT_F335G, conversion of almost all substrates was
significantly increased, especially for 10. Its conversion was
improved from 2.9% by the wild type enzyme to 51.8% by this
mutant (Figure 2, Figure S3). CdpC2PT_T351G exhibited
different behaviors toward 1−15 from CdpC2PT, with distinct
products or different ratios of the same products (Figure 2,
Figures S2 and S9). Detailed inspection of the HPLC
chromatograms of 1−15 with FtmPT1_M364G, BreP-
T_I337G, CdpNPT_M349G, CdpC2PT_T351G, and
CdpC3PT_F335G (Figures S2−S6, S9) revealed the presence
of one to four product peaks with different ratios. Most
reactions have two or three products. This shows the relaxed
regiospecific geranylation by the mutants in comparison to the
wild type enzymes in the presence of DMAPP.
For structure elucidation, 41 representative products of
selected substrates were isolated by preparative HPLC from
different incubation mixtures (Table S2) and subjected to HR-
ESI-MS and 1H NMR analyses (Tables S2−S18, Figures S10−
S54). Structure elucidation (see the SI) confirmed reverse or
regular geranylation at different positions of the indole ring
(Scheme 2).
Three of the tested PTs catalyze regular (FtmPT1) or
reverse (BrePT and CdpC2PT) C2-prenylations of CDPs in
the presence of DMAPP.22,24,25 Structure elucidation proved
that BrePT_I337G catalyzes solely or predominantly still
reverse C2-geranylation of 2− 4. In the reaction mixtures of
FtmPT1_M364G with six substrates, regularly C2-prenylated
derivatives were obtained as major products, i.e. 1a2, 2a2, 3a2,
10a2, 11a2, and 12a2. Regularly C3-prenylated derivatives
such as 1a3, 3a3, 6a3, 8a3, 10a3, 11a3, 12a3, and 13a3 were
identified in at least eight incubation mixtures. This is not
surprising, because regularly C3-prenylated CDPs were also
reported for FtmPT1 in the presence of DMAPP.29 In that
study, however, regularly C2-prenylated derivatives have been
identified as the major products. Interestingly, in the assays of
FtmPT1_M364G with GPP and 6, 8, and 13, no C2-, but
regularly N1- and C3-geranylated derivatives were obtained
(Scheme 2, Figure S5). The behavior of CdpC2PT_T351G
toward GPP also differs significantly from that of the wild type
enzyme. For example, 1 was converted by CdpC2PT to 1b2,
1a5, and 1a7, while CdpC2PT_T351G mainly catalyzes C2-
geranylation, resulting in the formation of mono- (1b2) and
digeranylated (1b2-2) derivatives (Figure 2, Figure S9).
CdpC3PT and CdpNPT both catalyze reverse C3-prenylation
of CDPs in the presence of DMAPP.23,26 Reverse C3-
geranylation was also detected for CdpNPT_M349G with
the selected substrates 1, 5, and 14. In addition, regularly C6-
geranylated products 1a6, 5a6, and 14a6 were also identified.
In the incubation mixture of CdpNPT_M349G with 15, the
product 15a6 was even the predominant peak (Figure S4).
CdpC3PT_F335G converted 10 to a mixture of at least four
products 10a1, 10b1, 10b3, and 10a7 with 10b3 as the major
one (Figure S3). These results indicate the trends of C6- and
C7-geranylation of CDPs by dimethylallyl transferases, which
catalyze C3-prenylation in the presence of DMAPP, as
observed for AnaPT (Scheme 1).16,17
In summary, our results presented in this study showed that
replacing the gatekeeping residue not only changes the
tolerance of PTs toward prenyl donor with longer chain but
Figure 3. Selected region of structure-based alignments of PTs used
in this study with AtaPT and FgaPT2. See Figure S7 for complete
alignments.
Scheme 2. Structures of Enzyme Products with Different
Prenylation Patterns and Positions (Products of 1 Are
Presented in Scheme 3)
Organic Letters Letter
DOI: 10.1021/acs.orglett.8b03124
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also breaks their regiospecificity, leading to several prenylated
products in one incubation. To some extent, this change
broadens their application in creation of structure diversity of
geranylated indole derivatives. The possible reason for the
relaxed regioselective prenylation by the mutants could be that
the enlarged pocket allows the binding of aromatic substrates
in different orientations. However, the reduced regioselectivity
requires more efforts for product isolation. Therefore, further
mutagenesis experiments are necessary in the future to increase
the desired regio- and stereoselectivity. This would require
more structural information, e.g. of the available single mutants
of the gatekeeping residues. Nevertheless, the single mutants
constructed in this study clearly showed different preferences
toward the 15 tested CDPs and converted them to geranylated
derivatives at various positions. As shown in Scheme 2,
products obtained in this study also carry the geranyl moiety at
the N1-, C2-, and C3-position of the pyrrole ring in a regular or
reverse manner.
To the best of our knowledge, known geranylations of
diverse substrates usually occur at the benzene ring of the
indole nucleus, e.g. C7-geranylation of indolactam V by TleC,
C6-geranylation of tryptophan derivatives by 6-DMATSSa, and
C6- and C7-geranylation of CDPs by AnaPT.16,19,30 As
mentioned above, the reported C4-geranylation of 1 by
AtaPT18 should be at C-7. Attachment of the geranyl moiety
has been reported at neither C-4 or C-5 nor at N-1, C-2, or C-
3 prior to this study.
The achieved relaxed regioselective geranylation by the
mutants encouraged us to decorate all nucleophilic reactive
positions (N-1 and the six nonbridgehead carbons) at the
indole ring of one CDP with the geranyl moiety. For this
purpose, 1 has been selected as the favorable CDP. HPLC
analysis of the incubation mixture of 1 and GPP with
FtmPT1_M364G, CdpNPT_M349G, CdpC2PT, and
CdpC2PT_T351G revealed the presence of two to four
product peaks each with product yields between 37.4 and
68.0% (Figure S9). Isolation and structure elucidation
confirmed geranylations at N-1 (1a1), C-2 (1a2 and 1b2),
C-3 (1a3 and 1b3), C-5 (1a5), C-6 (1a6), and C-7 (1a7) of
the indole ring (Scheme 3). To get the remaining C4-position
filled by geranylation, we applied the mutant FgaPT2_M328G,
which uses GPP for C4-geranylation of tryptophan.27 HPLC
analysis of the incubation mixture of 1 and GPP with
FgaPT2_M328G indicated product formation with a low
yield (7.2%, Figure 2). In another previous study, we
demonstrated that mutation on Arg244 of FgaPT2 significantly
increased the catalytic activity toward CDPs in the presence of
DMAPP.31 To enhance the geranylation of 1, we combined
mutations at Met328 and Arg244 and created the double
mutant FgaPT2_M328G_R244Q. As shown in Figure 2, one
peak with a product yield of 29.7% was detected. Structure
elucidation confirmed the desired geranylated product 1a4
(Scheme 3). In this way, nine products with a geranyl moiety
at all nucleophilic reactive positions of the indole ring can be
obtained from 1 by one-step chemoenzymatic reactions
(Scheme 3, Figure S9).
With the tremendously increasing availability of protein
structures, structure-based enzyme engineering becomes more
important for modification of drug-like molecules. Indolactam
geranyl transferase (TleC) can be changed to dimethylallyl
transferase by small-to-large mutation.19 MpnD and PagF were
changed from selective dimethylallyl to geranyl transferases by
large-to-small substitution.19,32 In analogy, our study provides
an excellent example for rational engineering of desirable
enzymes. Mutation of the gatekeeping residues in six PTs
turned on or improved the acceptance of GPP for geranylation
of diverse CDPs. Forty-two geranylated products were
obtained from in vitro enzymatic reactions of CDPs and
GPP. Using 1 as an acceptor and GPP as a donor, N-1 and the
six nonbridgehead carbons of the indole ring were decorated
with geranyl moieties. Derivatives of other CDPs could also be
obtained by the mutants described in this study or by mutation
of additional available dimethylallyl transferase at the
corresponding positions.
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Experimental Procedures 
Chemicals. Dimethylallyl diphosphate (DMAPP) and geranyl diphosphate (GPP) were chemically prepared according to the literature.1 
Cyclo-Trp-Pro isomers (2 − 5) and cyclo-Trp-Ala isomers (6 − 9) were synthesized according to the method published previously.2,3 
Cyclo-L-Trp-L-Pro and cyclo-L-Trp-D-Pro were synthesized from H-L-Trp-OMeꞏHCl and N-Boc-L-Pro-OH, cyclo-D-Trp-L-Pro and cyclo-
D-Trp-D-Pro from H-D-Trp-OMeꞏHCl and N-Boc-D-Pro-OH. In analogy, the two pairs H-L-Trp-OMeꞏHCl and N-Boc-L-Ala-OH as well as 
H-D-Trp-OMeꞏHCl and N-Boc-D-Ala-OH were used for the preparation of the four stereoisomers of cyclo-Trp-Ala (6 − 9). (R)-
benzodiazepinedione (14) and (S)-benzodiazepinedione (15) were synthesized by condensation of D- or L-tryptophan with isatoic 
anhydride in the presence of triethylamine according to the method described by Barrow and Sun.4 Other cyclic dipeptides (1, 10 − 13) 
were obtained from Bachem (Bubendorf, Switzerland).  
 
Strains. E. coli strains M15 [pREP4] (Qiagen, Hilden, Germany), BL21(DE3) pLysS (Invitrogen, Karlsruhe, Germany), and XL1-Blue 
MRF´ (Stratagene, Amsterdam, the Netherlands) were used for the overproduction of recombinant proteins. Luria-Bertani (LB) medium 
supplemented with 50 µg/mL carbenicillin or 50 µg/mL kanamycin was used for cultivation of recombinant E. coli strains.  
 
Site-directed mutagenesis. Plasmids harboring genes encoding recombinant PTs were used as DNA template for mutagenesis by 
PCR. To obtain specific mutations at desired gene position, (degenerated) primers were designed as described in the optimized site-
directed mutagenesis protocols and synthesized by Eurofins Genomics GmbH (Ebersberg, Germany) or Seqlab GmbH (Göttingen, 
Germany) (Table S1).5,6 Expand Long Template PCR System (Roche Diagnostics GmbH, Mannheim) was applied for PCR amplification. 
PCR reaction mixtures and thermal profiles were set as recommended by the manufacturer instructions. An annealing temperature of 
62°C and elongation time of 8 min for brePTand fgaPT2, and 4 min for ftmPT1, cdpNPT, cdpC2PT and cdpC3PT were adjusted to the 
thermal profile. The obtained plasmids were subjected to sequencing to confirm the desired mutations in the respective constructs. 
 
Protein overproduction and purification as well as enzyme assays. The recombinant histidine-tagged PTs, His8-FgaPT2, His5-
BrePT, FtmPT1-His6, CdpNPT-His6, CdpC2PT-His6, and His6-CdpC3PT as well as the corresponding engineered mutants were 
overproduced in E.coli and purified by Ni-NTA affinity chromatography (Qiagen, Hilden) according to the published procedures.7-11 The 
enzymatic reaction mixtures (50 μL) of FgaPT2, FtmPT1, and BrePT contained 50 mM Tris-HCl (pH 7.5), 10 mM CaCl2, 1 mM cyclic 
dipeptide, 2 mM DMAPP or GPP, 0.7%–6% (v/v) glycerol, up to 5% (v/v) DMSO, and 10 μg of purified protein. For determination of the 
relative activities of CdpC2PT, CdpC3PT, and CdpNPT with different cyclic dipeptides, each reaction mixture (50 µL) contained 50 mM 
Tris-HCl (pH 7.5), 2 mM DTT, 1 mM aromatic substrate, 2 mM DMAPP or GPP, 0.7%–6% (v/v) glycerol, up to 5% (v/v) DMSO, and 50 
μg purified protein for CdpC2PT and CdpC3PT and 30 μg for CdpNPT. The reaction mixtures were incubated at 37 °C for 2 h (FgaPT2, 
FtmPT1, and BrePT) or 16 h (CdpC2PT, CdpC3PT, and CdpNPT). The reaction mixtures were terminated by addition of one volume 
methanol. Before injecting to HPLC, the proteins were removed by centrifugation at 13,000 rpm for 20 min. The enzyme reactions of 
the mutated proteins were performed as for the wildtype enzymes. Product yields of the enzyme reactions were calculated from peak 
areas of prenylated products and substrates as analyzed on HPLC. Repeated enzyme assays were performed independently.  
 
HPLC conditions for analysis and isolation of enzyme products. Analysis of reaction mixtures were performed on an Agilent series 
1200 HPLC (Agilent Technologies, Böblingen, Germany) with an Agilent Eclipse XDB-C18 column (150 × 4.6 mm, 5 μm). Water (A) 
and acetonitrile (B) were used as solvents at flow rate of 0.5 mL/min. The substances were eluted with a linear gradient from 20–45 % 
B in 10 min, followed by 45–75% B in 5 min and 75–100% B in another 10 min. The column was then washed with 100 % (v/v) solvent 
B for 5 min and equilibrated with 5 % (v/v) solvent B for 5 min. Detection was carried out on a photodiode array detector and illustrated 
for aborptions at 296 nm. For isolation, the same HPLC equipment with a semipreparative Agilent ZORBAX Eclipse XDB C18 HPLC 
column (250 ×9.4 mm, 5 μm) at a fow rate of 2.5 mL/min was used. Water and acetonitrile were also used as solvents. Isocratic elution 
was performed with 75%, 80% or 85% acetonitrile/water for product isolation. 
 
LC-MS analysis of enzyme reactions. LC-MS analysis was performed on a microTOF-Q III spectrometer (Bruker, Bremen, Germany) 
with an Agilent 1260 HPLC system (Agilent Technologies, Böblingen, Germany) by using the same column and elution condition. 
Electrospray positive ionization mode was selected for determination the accuracy masses. Sodium formate was used in each run for 
mass calibration. The masses were scanned in the range of m/z 100 − 1500. The capillary voltage was set to 4.5 kV and a collision 
energy of 8.0 eV. Data were evaluated with the Compass DataAnalysis 4.2 software (Bruker Daltonik, Bremen, Germany). 
 
Preparation and identification of the reaction products. To prepare the enzyme products for structural elucidation, assays were 
carried out in large scales (10 − 20 mL) containing 2 mM GPP, 1 mM cyclic dipeptide, 10 mM CaCl2 or 2 mM DTT, 50 mM Tris-HCl (pH 
7.5), up to 5% (v/v) DMSO, and 2 − 10 mg purified recombinant protein per 10 mL mixtures. After incubation for 16 h at 37 °C, the 
reaction mixtures were extracted subsequently with double volume of ethyl acetate for three times. The organic phases were combined 
and concentrated under vacuum. The resulted residues were dissolved in MeOH and centrifuged at 13,000 rpm for 20 min. The enzyme 
products were then purified on a semi-preparative HPLC. 1H NMR spectra were recorded on a JOEL ECA-500 MHz spectrometer 
(JEOL, Tokyo, Japan). All spectra were processed with MestReNova 6.1.0 (Metrelab). Chemical shifts are referenced to those of the 
solvent signals.  
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Structure-based protein sequence alignments. Protein sequence alignments were carried out by using the sequence alignment 
function of MEGA 5.2 and visualized with ESPript 3.0 (http://espript.ibcp.fr/ESPript/ESPript/). For the secondary structure prediction, 
AtaPT (accession number 5KCG, www.rcsb.org) was taken as a reference. 
 
Molecular modeling and docking. The conformations of the mutants were calculated in silico using foldx.12,13 Substrate docking was 
done  manually  for  GPP  using  COOT14  and  DMAPP  of  FtmPT1  (pdb‐code:  3I4X)  and  CdpNPT    (pdb‐code:  3O2K)  as  templates.  The 
conformation of the prenyl donors were energetically optimized. Figure S8 was generated with pymol (The PyMOL Molecular Graphics 
System, Version 1.8 Schrödinger, LLC.). 
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Structural elucidation 
In total, 42 enzyme products were obtained in this study. LC-HR-ESI-MS data (Table S2) showed that [M+H]+ ions of 41 compounds 
are 136 Da larger than those of the respective substrates, proving the presence of a geranyl moiety each in their structures. In the case 
of 1b2-2, the [M+H]+ ion at m/z 645.4209 indicates a digeranylation. Inspection of the 1H NMR spectra revealed that 31 products 
exhibited signals of regular geranyl moieties and 11 products are reversely geranylated products.  
The different chemical shifts of the methylene group and of olefinic protons can be conveniently used to differentiate reversely or 
regularly prenylated derivatives, as exampled in Tables S3 and S4. The reverse geranyl moieties can be easily recognized by the 
presence of typical signals for three olefinic protons as two doublets around 5.0 and 5.2 ppm and one double doublets at 5.7 ppm with 
coupling constants of 17 and 10 Hz (Table S3). The chemical shifts of H-1’ of regular geranyl moieties change dependently upon the 
attached position (Table S4). If the geranyl residue attached to an aromatic carbon like C-2, C-4, C-5, C-6 or C7, H-1’ appears in the 
range of 3.3 − 3.7 ppm (CDCl3). When it connected to C-3 of the indole ring, H-1’ signal shifted upfield to 2.2 − 2.5 ppm (CDCl3, Tables 
S3 and S4). In the case of attachment of a geranyl residue to nitrogen, the signal of H-1’ will be shifted downfield to 4.6 − 4.8 ppm 
(CDCl3).  
According to the prenylation positions, the obtained products can be classified into 4 groups, i.e. N1-, C2-, and C3-geranylated products 
as well as those with geranyl moieties at C- 4 to C-7. These four groups can be easily distinguished by the signals of the protons H-2 
and H-1’ in their 1H NMR as described above (Table S4). In total, 10 products were characterized as N1-geranylated derivatives 
including one reversely geranylated product (10b1). Although structures of N1-geranylated cyclic dipeptides have not been reported, 
signals in the aromatic region of the geranylated derivatives are nearly identical to those carrying a dimethylallyl moiety. Therefore, 1a1, 
2a1, 3a1, and 11a1 were identified by comparison with the reported NMR data of N1-prenylated compounds of the respective cyclic 
dipeptides.10,15 Other five N1-geranylated products (10a1, 6a1, 8a1, 12a1, and 13a1) were characterized in comparison with their non-
substituted substrates and tryptophan part of identified N1-geranylated products. 10b1 was identified as cyclo-N1-tert-geranyl-L-Trp-L-
Leu based on the presence of typical signals for reverse geranyl moiety and N1-substitution pattern, as well as by comparison of the 
NMR data with those of cyclomarazine B.16  
Differing from signals for N1-substitution pattern, regularly C2-geranylated products exhibited chemical shifts for H-1’ at approx. 3.4 
ppm (CDCl3). 1a2, 2a2, and 10a2 were characterized by comparing with the reported NMR data of regularly C2-prenylated compounds. 
The characterization of reversely C2-geranylated products 1b2, 1b2-2, 2b2, 3b2, 4b2, and 14b2 was carried out by comparison of their 
NMR data with those of the reported reversely C2-prenylated compounds of the respective cyclic dipeptides.8,9,11 1H NMR spectra of 
3a2, 11a2, and 12a2 exhibited similar signals for their geranyl moieties and indole skeleton, which also matched with the C2-substitution 
pattern. Therefore, six regularly and six reversely C2-geranylated indole derivatives were identified in this study.  
C3-substitution pattern can be easily recognized in their 1H NMR spectra. Ring closure between H-2 and H-12 resulted in upfield shifting 
of signal for H-2 from 6.4 − 7.2 ppm to 5.3 − 5.5 ppm and disappearance of the signal for H-12. 6a3, 8a3, 11a3, and 13a3 were identified 
as regularly C3-geranylated cyclic dipeptides by comparing their NMR data with those of reported regularly C3-prenylated compounds 
of the respective cyclic dipeptides.17 1b3, 5b3, 10b3, and 14b3 were characterized as reversely C3-geranylated products by comparison 
of their NMR data with those reported for reversely C3-prenylated derivatives.15,17-19 Typical signals for regular C3-geranyaltion are 
easily observed not only for the aforementioned H-2 and H-12 protons, but also for H-1’ of the C10 unit. Differing from the N1- or C2-
susbstitution, signals of H-1’ of C3-susbtitution shifted to approx. 2.4 ppm. Thus, 1a3, 3a3, 10a3, and 12a3 were accordingly identified 
as regular C3-geranylated products. The relative configuration of geranyl and H-2 were determined according to 1H-1H vicinal coupling 
patterns of H-11 and chemical shifts of H-10syn of known anti-cis and syn-cis configured prenylated pyrroloindoline diketopiperazines 
that summarized in a previous paper.15 With the exception for 5b3, all C3-geranylated products obtained in this study have a syn-cis 
configuration. 
In addition to the products with geranyl moieties at position 1 to 3 of the pyrrole ring, seven products with geranyl substitution at the 
benzene ring were also identified. A set of characteristic signals for three protons at the benzene ring was observed in their 1H NMR 
spectra, which differs clearly from the coupling pattern consisting of four protons in the case of pyrrole ring substitution. The signals of 
the three coupling protons on the C4- and C7-geranylated benzene ring are found as doublet, triplet and doublet with coupling constants 
of approximate 7 − 8 Hz. In comparison, the signals of the three protons on the C5- and C6-geranylated benzene ring appear as two 
doublets with a coupling constant of approximate 8 Hz and one (broad) singlet. The difference between C5- and C6- as well as between 
C4- and C7-substitution in 1H NMR spectra can be distinguished by the order of the signals of the three protons, as listed in Table S5. 
One C4-geranylated product 1a4, four C6-geranylated derivatives 1a6, 5a6, 14a6, and 15a6, and two C7-geranylated compounds 1a7 
and 10a7 were identified by comparing with the reported data of known geranylated compounds of the respective cyclic dipeptides.20-
22 1a5 was identified as a C5-geranylated compound by the presence of nearly identical signals on the indole ring as those of C5-
prenylated tryptophan derivatives.23,24 
 
53
 
SUPPORTING INFORMATION          
7 
 
Table S1. List of primers and constructed plasmids used in this study.  
Mutant Plasmid Template Primer Sequence (5`→3`) Protein yield  
(mg/L culture) 
BrePT_I337G pPM81 pSY19 I337G_f 
I337G_r 
CCATCGGGTGGAACTACGAGATCAGTCCTGGG 
GTTCCACCCGATGGGCGATGGGATCTGGTC 
1.5 
FtmPT1_M364G pPM83 pAG0128 M364G_f 
M364G_r 
TATGGGGTTCCACTTCCACCTGGACGGGAGTC 
GAAGTGGAACCCCATAGGCGCCTCGAACCC 
4.3 
CdpNPT_M349G pPM85 pHL510 M349G_f 
M349G_r 
CATTGGGCTGAACTATGAGATGAAGGCCGGCCAGC 
TCATAGTTCAGCCCAATGGGCAAGAGCCCTTTCTCC 
1.6 
CdpC2PT_T351G pPM82 pKM1611 T351G_f 
T351G_r 
TTTAGGGTGGAATTACGAGCTGCAACCTGGCATTTCCCATCC 
GCTCGTAATTCCACCCTAAAGGGGGTTGAAATTTCTGCTGTGC 
1.5 
CdpC3PT_F335G pPM86 pWY257 F335G_f 
F335G_r 
GTTCGGGATGAACTACGAGATAACCCCGGGGCAGC 
CGTAGTTCATCCCGAACGGCACAATGCTCAGAGGG 
2.3 
FgaPT2_M328G_R244Q pPM46 pPM2825 R244Q_f 
R244Q_r 
CAGTCCCCAACTAGTGTCCTGTGATCTGACCAGTCCTGC 
GACACTAGTTGGGGACTGGCAGTGCTCTTGGAACCGC 
2.5 
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Table S2. LC-HR-ESI-MS data of enzyme products.  
   LC-HR-ESI-MS data [M+H]+  
Phisical 
description 
approx. 
amount 
(mg) Compund Chemical formula Isolated from Calculated Measured 
Deviation 
[ppm] 
1a1 C32H36N4O2  1 with FtmPT1_M364G 509.2911 509.2912 -0.3 colorless oil 1.1 
2a1 C26H33N3O2  2 with BrePT_I337G 420.2646  420.2660 -3.5 colorless oil 0.4 
3a1 C26H33N3O2  3 with FtmPT1_M364G 420.2646  420.2641 1.1 white powder 0.8 
6a1 C24H31N3O2 6 with FtmPT1_M364G 394.2489 394.2505 -4.0 colorless oil 0.8 
8a1 C24H31N3O2  8 with FtmPT1_M364G 394.2489 394.2488 0.4 colorless oil 1.0 
10a1 C27H37N3O2  10 with FtmPT1_M364G or CdpC3PT_F335G 436.2959 436.2963 -1.0 white powder 0.5 
11a1 C30H35N3O3  11 with FtmPT1_M364G 486.2751 486.2760 -1.8 white powder 0.6 
12a1 C30H35N3O2  12 with FtmPT1_M364G 470.2802 470.2823 -4.4 white powder 0.4 
13a1 C23H29N3O2  13 with FtmPT1_M364G 380.2333 380.2320 3.2 colorless oil 1.1 
10b1 C27H37N3O2  10 with CdpC3PT_F335G 436.2959 436.2963 -1.1 white powder 1.0 
1a2 C32H36N4O2  1 with FtmPT1_M364G 509.2911 509.2912 -0.2 colorless oil 1.0 
2a2 C26H33N3O2  2 with FtmPT1_M364G 420.2646 420.2655 -2.3 colorless oil 1.5 
3a2 C26H33N3O2  3 with FtmPT1_M364G 420.2646 420.2647 -0.3 white powder 1.1 
10a2 C27H37N3O2 10 with FtmPT1_M364G 436.2959 436.2961 -0.6 white powder 1.0 
11a2 C30H35N3O3  11 with FtmPT1_M364G 486.2751 486.2763 -2.5 colorless oil 1.0 
12a2 C30H35N3O2  12 with FtmPT1_M364G 470.2802 470.2797 1.1 white powder 0.1 
1b2 C32H36N4O2  1 with CdpC2PT or CdpC2PT_T351G  509.2911 509.2923 -2.4 white powder 1.3 
1b2-2 C42H52N4O2  1 with CdpC2PT_T351G  645.4163 645.4209 -7.1 colorless oil 0.8 
2b2 C26H33N3O2  2 with BrePT_I337G or CdpC2PT_T351G  420.2646 420.2655 -2.2 white powder 2.0 
3b2 C26H33N3O2  3 with BrePT_I337G 420.2646 420.2651 -1.4 colorless oil 1.3 
4b2 C26H33N3O2  4 with BrePT_I337G 420.2646 420.2649 -0.8 colorless oil 1.1 
14b2 C28H31N3O2  14 with CdpC2PT_T351G 442.2489 442.2487 0.5 colorless oil 1.1 
1a3 C32H36N4O2  1 with FtmPT1_M364G 509.2911 509.2901 2.1 colorless oil 0.9 
3a3 C26H33N3O2 3 with FtmPT1_M364G 420.2646 420.2654 -2.0 white powder 0.6 
6a3 C24H31N3O2 6 with FtmPT1_M364G 394.2489 394.2495 -1.5 colorless oil 0.7 
8a3 C24H31N3O2  8 with FtmPT1_M364G 394.2489 394.2508 -4.9 colorless oil 0.7 
10a3 C27H37N3O2  10 with FtmPT1_M364G 436.2959 436.2946 2.8 colorless oil 1.1 
11a3 C30H35N3O3  11 with FtmPT1_M364G 486.2751 486.2780 -6.0 white powder 0.5 
12a3 C30H35N3O2  12 with FtmPT1_M364G 470.2802 470.2820 -3.7 white powder 0.2 
13a3 C23H29N3O2  13 with FtmPT1_M364G 380.2333 380.2342 -2.5 colorless oil 0.4 
1b3 C32H36N4O2  1 with CdpNPT_M349G 509.2911 509.2931 -4.0 colorless oil 0.9 
5b3 C26H33N3O2 5 with CdpNPT_M349G 420.2646 420.2647 -0.3 colorless oil 0.8 
10b3 C27H37N3O2  10 with CdpC3PT_F335G 436.2959 436.2968 -2.2 white powder 0.5 
14b3 C28H31N3O2  14 with CdpNPT_M349G 442.2489 442.2487 0.5 colorless oil 1.1 
1a6 C32H36N4O2  1 with CdpNPT_M349G 509.2911 509.2925 -2.8 colorless oil 1.4 
5a6 C26H33N3O2  5 with CdpNPT_M349G 420.2646 420.2650 -1.0 colorless oil 1.6 
14a6 C28H31N3O2  14 with CdpNPT_M349G or CdpC2PT_T351G 442.2489 442.2482 1.5 colorless oil 0.5 
15a6 C28H31N3O2  15 with CdpNPT_M349G or CdpC2PT_T351G 442.2489 442.2493 -0.9 colorless oil 1.1 
1a4 C32H36N4O2 1 with FgaPT2_M328G_R244Q 509.2911 509.2917 -1.1 colorless oil 1.7 
1a5 C32H36N4O2  1 with CdpC2PT 509.2911 509.2891 4.0 white powder 1.2 
1a7 C32H36N4O2  1 with CdpC2PT 509.2911 509.2894 3.3 white powder 1.2 
10a7 C27H37N3O2  10 with CdpC3PT_F335G 436.2959 436.2968 -2.1 colorless oil 0.3 
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Table S3. Chemical shifts (ppm) of protons on regularly and reversely C3-substituted geranyl moiety of cyclo-L-Trp-L-Leu (CDCl3).  
 
 
C3-regular  C3-reverse 
H-1’ 2.40, dd, 14.3, 7.4, 1H 5.26, d, 10.8, 1H 
 2.44, dd, 14.3, 7.9, 1H 5.07, d, 17.4, 1H 
H-2’ 5.17, br t, 7.6, 1H 5.77, dd, 17.4, 10.8, 1H 
H-4’ 2.04, m, 2H 1.76, dd, 16.0, 7.7, 2H 
H-5’ 1.99, m, 2H  1.58, m, 1H* 
 - 1.22, ddd, 17.5, 11.5, 5.6, 1H 
H-6’ 5.06, br t, 6.6, 1H 4.98, br t, 7.3, 1H 
H-8’ 1.68, s, 3H 1.63, s, 3H  
H-9’ 1.60, s, 3H 1.10, s, 3H  
H-10’ 1.52, s, 3H 1.51, s, 3H  
[*] signal is overlapping with water. 
 
Table S4. Typical proton signals of N1-, C2-, C3-, or benzene ring-geranylated derivatives.  
 
 
 
 
 
 N1-substitution[b] C2-substitution[b] C3-substitution[c] benzene ring-substitution[b] 
H-1’ [a] 4.6 − 4.8 ppm 3.3 − 3.5 ppm 2.2 − 2.5 ppm 3.4 − 3.7 ppm 
H-1 - 7.8 − 8.0 ppm - 7.9 − 8.2 ppm 
H-2 6.4 − 7.2 ppm - 5.3 − 5.5 ppm  6.5 − 7.2 ppm 
H-12 5.6 − 5.8 ppm 5.6 − 5.8 ppm - 5.6 − 6.0 ppm 
benzene ring  AA’BB’ system AA’BB’ system AA’BB’ system ABX system 
[a] Here only referred to H-1’ of regular geranylated products. [b] chemical shifts in CDCl3. [c] chemical shifts in CD3OD. 
56
 
SUPPORTING INFORMATION          
10 
 
Table S5. Signal of protons on the substituted benzene ring of cyclo-L-Trp-L-Trp (CD3COCD3).  
     
 C4-substitution C5-substitution C6-substitution C7-substitution 
H-2 7.10, d, 2.5 6.76, d, 2.4 6.70, d, 2.4 6.63, d, 2.5 
H-4 - 7.34, d, 1.6 7.37, d, 8.1 7.33, d, 7.0 
H-5 6.76, d, 7.3 - 6.88, dd, 8.1, 1.5 6.96, dd, 7.5, 7.0 
H-6 6.94, dd, 8.0, 7.3 6.94, dd, 8.3, 1.6 - 6.93, d, 7.5 
H-7 7.14, d, 8.0 7.24, d, 8.3 7.15, d, 1.5 - 
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Table S6. 1H NMR data of N1-geranylated derivatives (1a1, 2a1, and 3a1).  
Compound 
1a1 (CDCl3)  2a1 (CD3OD)  3a1 (CDCl3) 
Position. δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
2 6.42, s, 1H 7.05, s, 1H 6.96, s, 1H 
4 7.58, d, 7.9, 1H 7.58, d, 8.0, 1H 7.60, d, 8.0, 1H 
5 7.15, dd, 8.0, 7.0, 1Ha 7.03, dd, 8.0, 7.1, 1H 7.12, dd, 8.0, 7.0, 1H 
6 7.22, dd, 8.0, 7.0, 1Hb 7.13, dd, 8.0, 7.1, 1H 7.20, dd, 8.0, 7.0, 1H 
7 7.28, d, 8.0, 1H 7.30, d, 8.3, 1H 7.30, d, 8.0, 1H 
10 3.23, dd, 14.4, 3.5, 1Hc 3.44, m, 1H 3.33, dd, 14.6, 6.8, 1H 
 2.50, dd, 14.4, 8.4, 1Hd 3.24, m, 1H 3.21, dd, 14.6, 3.4, 1H† 
11 4.18, m, 1H 3.98, ddd, 11.0, 6.3, 1.7, 1H 4.22, ddd, 6.8, 3.8, 3.4, 1H 
12 5.70, s, 1H - 5.80, d, 3.8, 1H 
14 4.18, m, 1H 4.41, br t, 5.0, 1H 3.57, ddd, 12.0, 8.7, 8.5, 1H 
15 5.72, s, 1H - - 
17 3.24, dd, 14.4, 3.7, 1Hc 3.37, m, 2H§ 3.23, m, 1H† 
 2.40, dd, 14,4, 8.6, 1Hd - 2.97, dd, 11.0, 6.3, 1H 
18 - 1.67, m, 1H 1.87, m, 1He 
 - 0.88, m, 1H 1.49, m, 1He 
19 6,57, s, 1H 1.95, m, 1H 2.12, dtd, 12.0, 7.0, 1.6, 1H 
 - 1.32, m, 1H 1.74, dtd, 12.0, 11.5, 8.1, 1He 
20 8.07, s, 1H - - 
22 7.36, d, 8.0, 1H - - 
23 7.21, dd, 8.0, 7.0, 1Hb - - 
24 7.12, dd, 8.0, 7.0, 1Ha - - 
25 7.52, d, 8.0, 1H - - 
1’ 4.59, dd, 15.6, 6.8, 1H 4.73, d, 6.6, 2H 4.67, d, 6.8, 2H 
 4.64, dd, 15.6, 6.6, 1H - - 
2’ 5.30, br t, 6.8, 1H 5.33, br t, 6.8, 1H  5.31, br t, 6.7, 1H 
4’ 2.08, m, 2H 2.06, m, 2H 2.09, m, 2H 
5’ 2.04, m, 2H 2.12, m, 2H 2.04, m, 2H 
6’ 5.04, br t, 6.6, 1H 5.06, br t, 6.9, 1H 5.05, br t, 6.6, 1H 
8’ 1.82, s, 3H 1.85, s, 3H 1.81, s, 3H 
9’ 1.65, s, 3H 1.62, s, 3H 1.66, s, 3H 
10’ 1.56, s, 3H 1.57, s, 3H 1.58, s, 3H 
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [a~e] assignments of signals with the same letter are interchangeable. [†] signals are 
overlapping with each other. [§] signals are overlapping with those of solvent. 
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Table S7. 1H NMR data of N1-geranylated derivatives (6a1, 8a1, 10a1, and 10b1).  
Compound 
 6a1 (CD3OD) 8a1 (CD3OD)  10a1 (CDCl3)  10b1 (CDCl3) 
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
2 6.99, s, 1H 6.97, s, 1H 7.00, s, 1H 7.17, s, 1H 
4 7.56, d, 8.0, 1H 7.55, d, 8.0, 1H 7.61, d, 8.2, 1H 7.59, d, 7.2, 1H 
5 6.99, dd, 8.0, 7.0, 1H 6.98, t, 8.0, 1H 7.13, dd, 8.2, 6.9, 1H 7.10, dd, 8.4, 7.2, 1H 
6 7.08, dd, 8.0, 7.0, 1H 7.08, t, 8.0, 1H 7.22, dd, 8.2, 6.9, 1H 7.13, dd, 8.4, 7.2, 1H 
7 7.26, d, 8.0, 1H 7.26, d, 8.0, 1H 7.31, d, 8.2, 1H 7.53, d, 7.2, 1H 
10 3.41, dd, 14.6, 3.7, 1H 3.40, dd, 14.5, 3.9, 1H 3.50, dd, 14.7, 3.6, 1H 3.55, dd, 14.8, 3.8, 1H 
 3.08, dd, 14.6, 4.5, 1H 3.06, dd, 14.5, 4.6, 1H 3.14, dd, 14.7, 8.8, 1H 3.09, dd, 14.8, 9.3, 1H 
11 4.23, ddd, 4.5, 3.7, 1.5, 1H 4.15, ddd, 4.6, 3.9, 1.5, 1H 4.30, br d, 8.8, 1H 4.30, br d, 9.3, 1H 
12 - - 5.80, s, 1H 5.79, s, 1H 
14 3.66, qd, 7.0, 1.2, 1H 3.29, m, 1H§ 3.90, br d, 10.2, 1H 3.93, br d, 10.1, 1H 
15 - - 5.85, s, 1H 5.88, s, 1H 
17 0.29, d, 7.0, 3H 1.04, d, 7.0, 3H 1.62, ddd, 13.8, 10.2, 3.8, 1H 1.68, ddd, 13.7, 10.1, 3.7, 1H 
 - - 1.03, ddd, 13.8, 10.2, 4.6, 1H 1.20, ddd, 13.7, 10.1, 4.5, 1H 
18 - - 1.50, m, 1H 1.59, m, 1H* 
19 - - 0.85, d, 6.6, 3Ha 0.88, d, 6.5, 3Hb 
20 - - 0.83, d, 6.6, 3Ha 0.87, d, 6.5, 3Hb 
1’ 4.69, d, 6.9, 2H 4.66, dd 15.0, 7.2, 1H 4.66, dd, 14.3, 6.5, 1H 5.29, d, 10.8, 1H 
 - 4.71, dd, 15.0, 7.1, 1H 4.70, dd, 14.3, 7.0, 1H 5.18, d, 17.6, 1H 
2’ 5.29, br t, 7.2, 1H 5.25, br t, 7.2, 1H 5.35, br t, 7.0, 1H 6.15, dd, 17.6, 10.8, 1H 
4’ 2.08, m, 2H 2.07, m, 2H 2.11, m, 2H 2.27, ddd, 14.9, 12.9, 5.8, 1H 
 - - - 1.97, ddd, 12.9, 11.4, 3.8, 1H 
5’ 2.02, m, 2H 2.01, m, 2H 2.06, m, 2H 1.91, m, 1H 
 - - - 1.50, m, 1H* 
6’ 5.02, br t, 6.9, 1H 5.01, br t, 7.2, 1H 5.06, br t, 6.7, 1H 4.99, br t, 7.2, 1H 
8’ 1.81, s, 3H 1.80, s, 3H 1.82, s, 3H 1.42, s, 3H 
9’ 1.59, s, 3H 1.57, s, 3H 1.67, s, 3H 1.61, s, 3H 
10’ 1.54, s, 3H 1.53, s, 3H 1.59, s, 3H 1.73, s, 3H 
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [a~b] assignments of signals with the same letter are interchangeable. [*] signals are 
overlapping with those of water. [§] signals are overlapping with those of solvent. 
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Table S8. 1H NMR data of N1-geranylated derivatives (11a1, 12a1, and 13a1).  
Compound 
 11a1 (CD3OD)  12a1 (CD3OD)  13a1 (CDCl3) 
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
2 7.02, s, 1H 6.98, s, 1H 7.01, s, 1H 
4 7.61, d, 8.0, 1H 7.58, d, 7.5, 1H 7.62, d, 8.0, 1H 
5 7.10, dd, 8.0, 7.0, 1H 7.06, dd, 8.0, 7.0, 1H 7.13, dd, 8.0, 7.0, 1H 
6 7.19, dd, 8.0, 7.0, 1H 7.15, dd, 8.0, 7.0, 1H 7.23, dd, 8.0, 7.0, 1H 
7 7.32, d, 8.0, 1H 7.28, d, 7.5, 1H 7.32, d, 8.0, 1H 
10 3.02, dd, 14.6, 4.0, 1H 2.97, dd, 14.7, 4.4, 1H 3.48, dd, 14.6, 3.7, 1H 
 2.90, dd, 14.6, 5.4, 1H 2.90, dd, 14.7, 5.1, 1H 3.18, dd, 14.6, 8.6, 1H 
11 4.18, ddd, 5.4, 4.0, 1.0, 1H 4.15, dd, 5.1, 4.4, 1H 4.28, br d, 8.6, 1H 
12 - - 5.67, s, 1H 
14 3.82, ddd, 9.0, 3.7, 1.1, 1H 3.83, ddd, 8.9, 3.6, 1.0, 1H 3.81, ddd, 17.3, 2.3, 1.0, 1H 
 - - 3.49, ddd, 17.3, 2.8, 1.9, 1H 
15 - - 5.87, s, 1H 
17 2.57, dd, 13.6, 3.7, 1H 2.58, dd, 13.5, 3.6, 1H - 
 1.32, dd, 13.6, 9.0, 1H 1.26, dd, 13.5, 8.9, 1H - 
19 6.34, d, 8.6, 1H 6.44, dd, 7.2, 2.0, 1H - 
20 6.58, d, 8.6, 1H 7.10, m, 1H† - 
21 - 7.10, m, 1H† - 
22 6.58, d, 8.6, 1H 7.10, m, 1H† - 
23 6.34, d, 8.6, 1H 6.44, dd, 7.2, 2.0, 1H - 
1’ 4.69, dd, 15.2, 6.8, 1H 4.68, dd, 15.2, 6.8, 1H 4.66, dd, 15.5, 7.0, 1H 
 4.73, dd, 15.2, 6.5, 1H 4.72, dd, 15.2, 6.5, 1H 4.70, dd, 15.5, 6.6, 1H 
2’ 5.31, br t, 6.8, 1H 5.27, br t, 6.8, 1H 5.34, br t, 7.0, 1H 
4’ 2.03, m, 2H 1.98, m, 2H 2.10, m, 2H 
5’ 1.99, m, 2H 1.93, m, 2H 2.05, m, 2H 
6’ 5.01, br t, 6.9, 1H 4.95, br t, 6.9, 1H 5.06, br t, 6.9, 1H 
8’ 1.84, s, 3H 1.79, s, 3H 1.82, s, 3H 
9’ 1.61, s, 3H 1.56, s, 3H 1.66, s, 3H 
10’ 1.53, s, 3H 1.47, s, 3H 1.59, s, 3H 
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [†] signals are overlapping with each other.
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Table S9. 1H NMR data of C2-geranylated derivatives (1a2, 2a2, and 3a2).  
Comound 
1a2 (CDCl3)   2a2 (CDCl3)  3a2 (CDCl3) 
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
1 7.99, s, 1Ha 7.93, s, 1H 7.89, s, 1H 
4 7.50, d, 8.0, 1H 7.47, d, 7.8, 1H 7.51, d, 7.2, 1H 
5 7.10, dd, 8.0, 7.0, 1Hb 7.09, dd, 7.8, 7.1, 1H 7.08, dd, 8.5, 7.2, 1H 
6 7.11, dd, 8.0, 7.0, 1Hc 7.15, dd, 8.1, 7.1, 1H 7.11, dd, 8.5, 7.2, 1H 
7 7.28, d, 8.0, 1Hd 7.30, d, 8.1, 1H 7.25, m, 1H§  
10 3.22, dd, 14.7, 3.8, 1H 3.67, dd, 15.1, 3.8, 1H† 3.40, dd, 14.8, 5.7, 1H 
 3.02, dd, 14.7, 7.3, 1H 2.96, dd, 15.1, 11.5, 1H 3.15, dd, 14.8, 4.3, 1H 
11 4.27, m, 1H 4.37, ddd, 11.5, 3.8, 1.3, 1H 4.25, dd, 5.7, 4.3, 1H 
12 5.63, s, 1H 5.61, br s, 1H 5.79, br s, 1H 
14 4.13, br d, 10.0, 1H 4.06, ddd, 8.4, 7.0, 1.3, 1H 3.53, ddd, 11.8, 8.8, 8.2, 1H 
15 5.76, s, 1H - - 
17 3.29, dd, 14.2, 3.2, 1H 3.71, m, 1H† 3.17, m, 1H 
 2.01, dd, 14.2, 10.0, 1H 3.59, ddd, 11.7, 8.8, 3.9, 1H 2.72, dd, 11.0, 6.4, 1H 
18 - 2.02, m, 1H†† 1.82, m, 1H 
 - 1.91, m, 1H 1.38, m, 1H 
19 6.25, s, 1H 2.33, m, 1H 2.05, dtd, 13.0, 6.7, 1.5, 1H 
 - 2.02, m, 1H†† 1.68, m, 1H 
20 7.94, s, 1Ha - - 
22 7.32, d, 8.0, 1Hd - - 
23 7.18, dd, 8.0, 7.0, 1Hc - - 
24 7.15, dd, 8.0, 7.0, 1Hb - - 
25 7.50, d, 8.0, 1H - - 
1’ 3.34, dd, 16.1, 6.3, 1H 3.46, dd, 14.4, 5.4, 1H 3.43, dd, 16.5, 7.0, 1H 
 3.38, dd, 16.1, 6.9, 1H 3.51, dd, 14.4, 5.6, 1H 3.47, dd, 16.5, 7.3, 1H 
2’ 5.31, br t, 6.9, 1H 5.32, br t, 7.3, 1H 5.31, br t, 7.3, 1H 
4’ 2.15, m, 2H‡ 2.12, m, 2H‡‡ 2.15, m, 2H 
5’ 2.15, m, 2H‡ 2.12, m, 2H‡‡ 2.13, m, 2H 
6’ 5.12, br t, 6.8, 1H 5.10, br t, 6.7, 1H 5.10, br t, 6.4, 1H 
8’ 1.75, s, 3H 1.73, s, 3H 1.73, s, 3H 
9’ 1.72, s, 3H 1.72, s, 3H 1.73, s, 3H  
10’ 1.64, s, 3H 1.62, s, 3H 1.63, s, 3H 
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [†,‡] signals are overlapping with each other. [§] signals are overlapping with those of solvent. [a-
d] assignments of signals with the same letter are interchangeable. [*] signals are overlapping with those of water. 
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Table S10. 1H NMR data of C2-geranylated derivatives (10a2, 11a2, and 12a2).  
Comound 
10a2 (CDCl3)  11a2 (DMSO-d6)  12a2 (DMSO-d6) 
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
1 7.93, s, 1H 10.61, s , 1H 10.62, s, 1H 
4 7.53, d, 8.0, 1H 7.45, d, 8.0, 1H 7.45,d, 8.0, 1H 
5 7.10, dd, 8.0, 7.0, 1H 6.93, dd, 8.0, 7.0, 1H 6.94, dd, 8.0, 7.0, 1H 
6 7.14, dd, 8.0, 7.0, 1H 7.00, dd, 8.0, 7.0, 1H 7.00, dd, 8.0, 7.0, 1H 
7 7.28, d, 8.0, 1H 7.23, d, 8.0, 1H 7.23, d, 8.0, 1H 
10 3.43, dd, 14.7, 3.9, 1H 3.44, dd, 16.3, 7.0, 1H 3.43, dd, 16.0, 7.6, 1H 
 3.19, dd, 14.7, 8.4, 1H 3.37, dd, 16.3, 7.3, 1H 3.37, dd, 16.4, 7.2, 1H 
11 4.30, br d, 8.4, 1H 3.94, m, 1H 3.96, m, 1H 
12 5.76, s, 1H 7.44, d, 3.0, 1H 7.57, d, 3.0, 1H 
14 3.89, br d, 10.1, 1H 3.64, dt, 8.0, 4.0, 1H 3.73, dt, 8.2, 4.5, 1H 
15 5.95, s, 1H 7.88, d, 2.7, 1H 7.94, d, 2.5, 1H 
17 1.59, ddd, 13.5, 10.0, 3.7, 1H* 2.35, dd, 13.0, 4.0, 1H 2.40, dd, 13.2, 4.5, 1H 
 1.00, ddd, 13.5, 10.0, 4.5, 1H 1.40, dd, 13.0, 8.0, 1H 1.50, dd, 13.6, 8.2, 1H 
18 1.50, m, 1H - - 
19 0.84, d, 6.5, 3Ha 6.33, d, 8.5, 1H 6.54, dd, 7.0, 2.7, 1H 
20 0.82, d, 6.5, 3Ha 6.50, d, 8.5, 1H 7.11, m, 1H‡ 
21 - - 7.11, m, 1H‡ 
22 - 6.50, d, 8.5, 1H 7.11, m, 1H‡ 
23 - 6.33, d, 8.5, 1H 6.54, dd, 7.0, 2.7, 1H 
24 - - - 
25 - - - 
1’ 3.49, d, 7.0, 2H 2.82, dd, 14.5, 6.5, 1H 2.81, dd, 14.8, 6.5, 1H 
 - 2.86, dd, 14.5, 5.5, 1H 2.85, dd, 14.8, 6.0, 1H 
2’ 5.33, br t, 7.0, 1H 5.34, br t, 6.5, 1H 5.33, br t, 6.5, 1H 
4’ 2.14, m, 2H† 2.09, m, 2H 2.09, m, 2H 
5’ 2.14, m, 2H† 2.01, m, 2H 2.01, m, 2H 
6’ 5.11, br t, 6.7, 1H 5.10, br t, 6.0, 1H 5.10, br t, 6.8, 1H 
8’ 1.74, s, 3H†† 1.74, s, 3H 1.74, s, 3H 
9’ 1.74, s, 3H†† 1.62, s, 3H 1.62, s, 3H 
10’ 1.63, s, 3H 1.56, s, 3H 1.56, s, 3H 
-OH - 9.06, s, 1H - 
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [a] assignments of signals with the same letter are interchangeable. [†, ‡] signals are overlapping 
with each other.
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Table S11. 1H NMR data of C2-geranylated derivatives (1b2, 1b2-2, and 2b2).  
Compound 
1b2 (CDCl3) 1b2-2 (CDCl3)  2b2 (CD3OD) 
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
1 8.03, s, 1H 8.07, s, 1H - 
4 7.40, d, 8.0, 1H 7.53, d, 8.0, 1H 7.47, d, 8.0, 1H 
5 7.05, dd, 8.0, 7.1, 1H 7.13, dd, 8.0, 7.1, 1H 7.03, dd, 8.0, 7.1, 1H 
6 7.15, dd, 8.0, 7.1, 1H 7.19, dd, 8.0, 7.1, 1H 7.10, dd, 8.0, 7.1, 1H 
7 7.18, d, 8.0, 1H 7.33, d, 8.0, 1H 7.37, d, 8.0, 1H 
10 3.58, dd, 14.6, 3.3, 1H 3.74, dd, 14.6, 3.5, 1H 3.66, dd, 15.1, 4.4, 1H 
 3.05, dd, 14.6, 9.6, 1H 3.26, dd, 14.6, 11.8, 1H 3.14, dd, 15.1, 11.2, 1H 
11 4.29, br d, 9.6, 1H 4.39, br d, 11.8, 1H 4.49, ddd, 11.2, 4.4, 1.4, 1H 
12 5.69, s, 1H 5.72, s, 1H - 
14 4.29, br d, 9.6, 1H - 4.22, ddd, 8.3, 6.4, 1.8, 1H 
15 5.85, s, 1H - - 
16 - - - 
17 3.62, dd, 14.6, 3.3, 1H - 3.61, m, 1H 
 2.88, dd, 14.6, 11.3, 1H - 3.55, ddd, 11.7, 8.6, 3.0, 1H 
18 - - 2.02, m, 1H 
 - - 1.94, m, 1H 
19 7.10, d, 2.3, 1H - 2.27, m, 1H 
 - - 1.94, m, 1H 
20 8.16, s, 1H - - 
21 - - - 
22 7.30, d, 8.0, 1H - - 
23 7.24, dd, 8.0, 7.0, 1H - - 
24 7.20, dd, 8.0, 7.0, 1H - - 
25 7.67, d, 8.0, 1H - - 
1’ 5.24, d, 10.7, 1H 5.31, d, 10.7, 1H 5.18, d, 10.3, 1H 
 5.16, d, 17.5, 1H 5.24, d, 17.5, 1H 5.15, d, 17.5, 1H 
2’ 6.11, dd, 17.5, 10.7, 1H 6.20, dd, 17.5, 10.7, 1H 6.30, dd, 17.5, 10.7, 1H 
4’ 1.81, m, 2H 1.86, m, 2H 1.84, m, 2H 
5’ 1.91, m, 2H 1.95, m, 2H 1.94, m, 2H 
6’ 5.06, m, 1H 5.09, m, 1H 5.11, m, 1H 
8’ 1.64, s, 3H 1.64, s 3H 1.62, m, 3H 
9’ 1.50, s, 3H 1.53, s 3H 1.50, m, 3H  
10’ 1.51, s, 3H 1.57, s 3H 1.55, m, 3H 
Chemical shifts (δ) are given in ppm and coupling constants in Hz.
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Table S12. 1H NMR data of C2-geranylated derivatives (3b2, 4b2, and 14b2).  
Compound 
 3b2 (CD3OD) 
 
4b2 (CD3OD)  14b2 (CDCl3) 
Position δH, multi.,J in Hz δH, multi., J in Hz δH, multi., J in Hz 
1 - - 8.04, s, 1H 
4 7.46, d, 8.0, 1H 7.46, d, 8.0, 1H 7.43, d, 8.0, 1H 
5 6.98, dd, 8.0, 7.0, 1H 6.97, dd, 8.0, 7.0, 1H 7.07, dd, 8.0, 7.4, 1H 
6 7.04, dd, 8.0, 7.0, 1H 7.04, dd, 8.0, 7.0, 1H 7.15, dd, 8.0, 7.4, 1H 
7 7.30, d, 8.0, 1H 7.30, d, 8.0, 1H 7.31, d, 8.0, 1H 
10 3.45, dd, 14.8, 5.3, 1H 3.45, dd, 14.8, 5.3, 1H 3.49, dd, 15.7, 10.0, 1H 
 3.38, dd, 14.8, 6.5, 1H 3.38, dd, 14.8, 6.5, 1H 3.40, dd, 15.7, 4.8, 1H 
11 4.18, dd, 6.5, 5.3, 1H 4.18, dd, 6.5, 5.3, 1H 4.22, td, 10.0, 4.8, 1H 
12 - - 6.04, d, 4.8, 1H 
14 3.46, m, 1H 3.46, m, 1H - 
16 - - 7.60, s, 1H 
17 3.34, m, 2H§ 3.34, m, 2H§ - 
18 1.89, m, 1H 1.90, m, 1H 6.97, d, 8.0, 1H 
 1.56, m, 1H 1.55, m, 1H - 
19 2.10, dtd, 12.3, 5.9, 1.0, 1H 2.10, dtd, 12.5, 6.5, 1.2, 1H 7.50, dd, 8.0, 7.4, 1H 
 1.74, dtd, 12.3, 10.7, 7.0, 1H 1.74, dtd, 12.5, 11.0, 7.0, 1H - 
20 - - 7.25, dd, 8.0, 7.4, 1H 
21 - - 7.84, dd, 8.0, 1H 
1’ 5.22, d, 10.6, 1H 5.22, d, 10.8, 1H 5.18, d, 10.7, 1H 
 5.19, d, 17.5, 1H 5.19, d, 17.5, 1H 5.14, d, 17.6, 1H 
2’ 6.30, dd, 17.5, 10.6, 1H 6.30, dd, 17.5, 10.8, 1H 6.12, dd, 17.6, 10.7, 1H 
4’ 1.83, m, 2H 1.83, m, 2H 1.81, m, 2H 
5’ 1.86, m, 2H 1.87, m, 2H 1.90, m, 2H 
6’ 5.09, m, 1H 5.09, m, 1H 5.03, m, 1H 
8’ 1.53, s, 3H 1.53, s, 3H 1.56, s 3H  
9’ 1.49, s, 3H  1.49, s, 3H  1.51, s 3H 
10’ 1.61, s, 3H 1.61, s, 3H 1.64, s 3H 
Chemical shifts (δ) ate given in ppm and coupling constants in Hz. [§] signals are overlapping with those of solvent.
64
 
SUPPORTING INFORMATION          
18 
 
Table S13. 1H NMR data of C3-geranylated derivatives (1a3, 3a3, 6a3, and 8a3).  
Compound 
1a3 (CDCl3) 3a3 (CDCl3) 6a3 (CD3OD) 8a3 (CD3OD)
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
2 5.67, s, 1H 5.54, s, 1H 5.28, s, 1H 5.35, s, 1H 
4 7.08, d, 7.5, 1H 7.10, d, 7.4, 1H 7.11, d, 7.4, 1H 7.10, d, 7.4, 1H 
5 6.77, t, 7.5, 1H 6.76, t, 7.4, 1H 6.69, t, 7.4, 1H 6.69, t, 7.4, 1H 
6 7.10, m, 1H† 7.07, t, 7.4, 1H 7.00, t, 7.4, 1H 7.01, t, 7.4, 1H 
7 6.66, br s, 1H 6.58, d, 7.4, 1H 6.57, d, 7.4, 1H 6.58, d, 7.4, 1H 
10syn 2.61, dd, 12.6, 6.0, 1H 2.64, dd, 12.0, 5.0, 1H 2.57, dd, 12.6, 6.2, 1H 2.58, dd, 12.5, 5.9, 1H 
10anti 2.22, dd, 12.6, 11,3, 1H 2.13, t, 12.0, 1H 2.22, dd, 12.6, 11.3, 1H 2.19, dd, 12.5, 11.5, 1H 
11 3.98, ddd, 11.3, 6.0, 1.2, 1H 4.04, m, 1H†† 4.02, dd, 11.3, 6.2, 1H 4.00, dd, 11.5, 5.9, 1H 
14 4.33, br d, 11.0, 1H 4.04, m, 1H†† 4.10, qd, 6.8, 2.0, 1H 3.87, qd, 7.1, 0.7, 1H 
15 5.35, s, 1H - - - 
17 3.73, dd, 15.0, 3.7, 1H 3.92,ddd, 12.4, 7.3, 3.3, 1H 1.34, d, 6.8, 3H 1.34, d, 7.1, 3H 
 2.97, dd, 15.0, 11.0, 1H 3.28,ddd, 12.4, 10.1, 4.1, 1H - - 
18 - 1.98, m, 1H‡ - - 
 - 1.89, m, 1H - - 
19 7.10, s, 1H† 2.41, m, 1H - - 
 - 1.76, dtd, 12.0, 11.2, 9.1, 1H - - 
20 8.14, s, 1H - - - 
22 7.39, d, 8.0, 1H - - - 
23 7.22, d, 8.0, 7.0, 1H - - - 
24 7.12, d, 8.0, 7.0, 1H - - - 
25 7.55, d, 8.0, 1H - - - 
1’ 2.38, dd, 14.3, 7.3, 1H 2.45, dd, 14.0, 7.1, 1H 2.41, d, 7.8, 2H 2.42, d, 7.8, 2H 
 2.42, dd, 14.3, 7.7, 1H 2.49, dd, 14.0, 7.8, 1H - - 
2’ 5.16, br t, 7.7, 1H 5.11, br t, 7.8, 1H 5.15, br t, 7.8, 1H 5.13, br t, 7.8, 1H 
4’ 1.99, m, 2H 2.02, m, 2H 2.02, m, 2H 2.00, m, 2H 
5’ 2.05, m, 2H 1.98, m, 2H‡ 1.96, m, 2H 1.95, m, 2H 
6’ 5.06, br t, 6.6, 1H 5.04, br t, 6.6, 1H 5.03, br t, 6.8, 1H 5.02, br t, 6.7, 1H 
8’ 1.69, s, 3H 1.68, s, 3H 1.63, s, 3H 1.63, s, 3H 
9’ 1.60, s, 3H  1.59, s, 3H 1.56, s, 3H 1.55, s, 3H 
10’ 1.52, s, 3H 1.55, s, 3H 1.51, s, 3H 1.50, s, 3H 
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [a, b] assignments of signals with the same letter are interchangeable. [†, ‡] signals are overlapping 
with each other. H-10syn has a cis- and H-10anti a trans-configuration to H-11. 
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Table S14. 1H NMR data of C3-geranylated derivatives (10a3, 11a3, 12a3, and 13a3).  
Compound 
10a3 (CDCl3) 11a3 (CD3OD) 12a3 (CD3OD) 13a3 (CD3OD) 
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
2 5.29, s, 1H 5.15, s, 1H 5.15, s, 1H 5.32, s, 1H 
4 7.10, d, 7.6, 1H 6.98, d, 7.4, 1H 6.97, d, 7.4, 1H† 7.10, d, 7.5, 1H 
5 6.77, t, 7.6, 1H 6.62, t, 7.4, 1H 6.62, t, 7.4, 1H 6.69, t, 7.5, 1H 
6 7.09, t, 7.6, 1H 6.95, t, 7.4, 1H 6.96, t, 7.4, 1H† 7.00, t, 7.5, 1H 
7 6.61, d, 7.6, 1H 6.51, d, 7.4, 1H 6.51, d, 7.4, 1H 6.57, d, 7.5, 1H 
10syn 2.65, dd, 12.8, 6.1, 1H 2.23, dd, 12.0, 5.3, 1H 2.23, dd, 12.0, 5.4, 1H†† 2.57, dd, 12.5, 5.9, 1H 
10anti 2.32, dd, 12.8, 11.2, 1H 1.11, t, 12.0, 1H 1.10, t, 12.0, 1H 2.21, dd, 12.5, 11.4, 1H 
11 4.02, dd, 11.2, 6.1, 1H 3.76, ddd, 12.0, 5.3, 1.9, 1H 3.77, ddd, 12.0, 5.4, 2.0, 1H 4.00, dd, 11.4, 5.9, 1H 
14 3.96, dd, 10.5, 3.2, 1H 4.32, td, 4.4, 2.0, 1H 4.39, td, 4.4, 2.0, 1H 4.05, dd, 16.6, 2.3, 1H 
 - - - 3.70, d, 16.6, 1H 
15 5.64, s, 1H - - - 
17 2.00, m, 1H† 3.15, dd, 13.9, 4.4, 1H 3.28, m, 1H§ - 
 1.55, m, 1H 2.90, dd, 13.9, 4,4, 1H 3.02, dd, 13.8, 4.4, 1H - 
18 1.67, m, 1H - - - 
19 0.99, d, 6.6, 3Ha 7.00, d, 8.7, 1H 7.19, dd, 8.0, 1.4, 1H - 
20 0.92, d, 6.6, 3Ha 6.71, d, 8.7, 1H 7.29, m, 1H‡ - 
21 - - 7.25, m, 1H‡ - 
22 - 6.71, d, 8.7, 1H 7.29, m, 1H‡ - 
23 - 7.00, d, 8.7, 1H 7.19, dd, 8.0, 1.4, 1H - 
1’ 2.40, dd, 14.3, 7.4, 1H 2.18, dd, 14.2, 8.0, 1H 2.14, dd, 14.0, 8.4, 1H 2.42, d, 7.6, 2H 
 2.44, dd, 14.3, 7.9, 1H 2.27, dd, 14.2, 6.6, 1H 2.21, dd, 14.0, 6.0, 1H†† - 
2’ 5.17, br t, 7.6, 1H 4.91, br t, 8.0, 1H 4.99, br t, 8.4, 1H 5.15, br t, 7.6, 1H 
4’ 2.04, m, 2H 1.91, m, 2H 1.97, m, 2H※ 2.01, m, 2H 
5’ 1.99, m, 2H† 1.97, m, 2H 1.90, m, 2H 1.95, m, 2H 
6’ 5.06, br t, 6.6, 1H 5.00, br t, 6.7, 1H 4.90, m, 1H* 5.03, br t, 6.4, 1H 
8’ 1.68, s, 3H 1.63, s, 3H 1.63, s, 3H 1.63, s, 3H 
9’ 1.60, s, 3H 1.54, s, 3H  1.54, s, 3H 1.56, s, 3H 
10’ 1.52, s, 3H 1.49, s, 3H 1.48, s, 3H 1.51, s, 3H 
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [§] signals are overlapping with those of solvent. [*] signals are overlapping with those of water. 
[†, ‡] signals are overlapping with each other. [a] assignments of signals with the same letter are interchangeable. [※] signals are overlapping with impurities. H-
10syn has a cis- and H-10anti a trans-configuration to H-11.
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Table S15. 1H NMR data of C3-geranylated derivatives (1b3, 5b3, 10b3, and 14b3).  
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [†] signals are overlapping with each other. [§] signals are overlapping with those of solvent. [a, b] 
assignments of signals with the same letter are interchangeable. [*] signals are overlapping with those of water. H-10syn has a cis- and H-10anti a trans-
configuration to H-11. 
Compund 
 1b3 (CDCl3)  5b3 (CDCl3) 10b3 (CDCl3)  14b3 (CDCl3) 
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
2 5.63, s, 1H 5.49, s, 1H 5.57, s, 1H 5.64, s, 1H 
4 7.13, d, 7.5, 1Ha 7.16, d, 7.5, 1H 7.15, d, 7.5, 1H 7.14, d, 7.5, 1H 
5 6.75, t, 7.5, 1H 6.72, t, 7.5, 1H 6.75, t, 7.5, 1H 6.71, t, 7.5, 1H 
6 7.10, t, 7.5, 1Ha 7.06, t, 7.5, 1H 7.10, t, 7.5, 1H 7.07, t, 7.5, 1H 
7 6.61, d, 7.5, 1H 6.53, d, 7.5, 1H 6.58, d, 7.5, 1H 6.61, d, 7.5, 1H 
10syn 2.50, dd, 12.6, 6.4, 1H 2.80, dd, 13.8, 9.0, 1H 2.53, dd, 11.8, 6.0, 1H 3.48, dd, 13.8, 8.0, 1H 
10anti 2.45, dd, 12.6, 11.0, 1H 2.52, dd, 13.8, 8.9, 1H 2.49, dd, 11.8, 10.0, 1H 2.41, dd, 13.8, 8.7, 1H 
11 3.90, ddd, 11.0, 6.4, 1.5, 1H 4.14, t, 8.9, 1H 3.95, m, 1H† 3.96, dd, 8.7, 8.0, 1H 
14 4.31, ddd, 11.0, 3.5, 1.8, 1H 4.09, t, 8.0, 1H 3.95, m, 1H† - 
15 5.65, s, 1H - 5.64, s, 1H - 
16 - - - 7.66, s, 1H 
17 3.75, dd, 15.0, 3.6, 1H 3.45, m, 1H 2.02, ddd, 13.7, 10.0, 3.6, 1H - 
 2.97, dd, 15.0, 11.1, 1H 3.41, m, 1H 1.58, m, 1H* - 
18 - 2.04, m, 1H 1.68, m, 1H 6.88, d, 8.0, 1H 
 - 1.87, m, 1H - - 
19 7.10, d,1.2, 1H 2.32, dtd, 9.0, 6.6, 2.3, 1H 0.99, d, 6.6, 1Hb 7.43, dd, 8.0,7.5, 1H 
 - 1.97, ddd, 10.6, 6.3, 3.1, 1H -  
20 8.13, s, 1H - 0.91, d, 6.6, 1Hb 7.21, dd, 7.9, 7.5, 1H§ 
21 - - - 7.83, d, 7.9, 1H 
22 7.39, d, 8.0, 1H - - - 
23 7.23, dd, 8.0, 7.1, 1H - - - 
24 7.13, dd, 8.0, 7.1, 1Ha - - - 
25 7.55, d, 8.0, 1H - - - 
1’ 5.27, dd, 10.8, 1H 5.28, d, 10.9, 1H 5.26, d, 10.8, 1H 5.29, dd, 10.8, 1.0, 1H 
 5.07, dd, 17.4, 1H 5.12, d, 17.6, 1H 5.07, d, 17.4, 1H 5.10, dd, 17.4, 1,0, 1H 
2’ 5.76, dd, 17.4, 10.8, 1H 5.78, dd, 17.6, 10.9, 1H 5.77, dd, 17.4, 10.8, 1H 5.82, dd, 17.4, 10.8 , 1H 
4’ 1.77, dd, 16.0, 8.0, 2H 1.76, m, 2H 1.76, dd, 16.0, 7.7, 2H 1.72, m, 1H 
5’ 1.59, ddd, 17.6, 12.7, 5.9, 1H* 1.56, m, 1H * 1.58, m, 1H* 1.78, m, 2H 
 1.24, ddd, 17.6, 12.3, 7.6, 1H 1.20, m, 1H 1.22, ddd, 17.5, 11.5, 5.6, 1H 1.25, m, 1H  
6’ 5.00, br t, 7.1, 1H 4.99, br t, 7.0, 1H 4.98, br t, 7.3, 1H 5.01, br t, 6.8, 1H 
8’ 1.64, s, 3H  1.63, s, 3H  1.63, s, 3H  1.64, s, 3H 
9’ 1.09, s, 3H  1.13, s, 3H  1.10, s, 3H  1.12, s, 3H 
10’ 1.53, s, 3H  1.52, s, 3H  1.51, s, 3H  1.53, s, 3H 
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Table S16. 1H NMR data of 1a4 and 1a5.  
Compound 
 1a4   1a5 
Position δH, multi., J in Hz (CDCl3) δH, multi., J in Hz (CD3COCD3) δH, multi., J in Hz (CD3COCD3) 
1 8.18, s, 1H 9.98, s, 1Ha 9.94, s, 1Hc 
2 7.05, d, 2.3, 1H 7.10, d, 2.5, 1H 6.76, d, 2.4, 1Hd 
4 - - 7.34, d, 1.6, 1H† 
5 6.90, d, 7.2, 1H 6.76, d, 7.3, 1H - 
6 7.09, dd, 8.2, 7.2, 1H 6.94, dd, 8.0, 7.3, 1H 6.94, dd, 8.3, 1.6, 1H 
7 7.17, d, 8.2, 1H 7.14, d, 8.0, 1H 7.24, d, 8.3, 1H 
10 3.54, dd, 14.8, 2.9, 1H 3.24, dd, 14.4, 3.0, 1H 3.00, dd, 14.5, 3.8, 1H 
 1.84, dd, 14.8, 11.0, 1H 2.08, m, 1H§ 2.17, dd, 14.5, 7.5, 1H 
11 4.03, br d, 11.0, 1H 3.91, ddd, 4.9, 3.0, 2.7, 1H 4.03, ddd, 7.5, 3.8, 0.9, 1H 
12 5.87, s, 1H 7.08, br s, 1Hb 6.71, s, 1He 
14 4.32, m, 1H 4.23, ddd, 4.7, 2.5, 0.7, 1H 4.08, ddd, 7.0, 4.1, 1.2, 1H 
15 5.63, s, 1H 6.49, s, 1Hb 6.79, s, 1He 
17 3.31, dd, 14.7, 4.3, 1H 3.17, dd, 14.1, 4.8, 1H 3.05, dd, 14.2, 3.8, 1H 
 3.26, dd, 14.7, 6.8, 1H 3.14, dd, 14.1, 4.5, 1H 2.45, dd, 14.2, 7.0, 1H 
19 6.06, d, 2.2, 1H 6.00, d, 2.3, 1H 6.55, d, 2.4, 1Hd 
20 7.99, s, 1H 10.20, s, 1Ha 10.10, s, 1Hc 
22 7.39, d, 8.0, 1H 7.37, d, 8.0, 1H 7.34, d, 8.0, 1H† 
23 7.20, dd, 8.0, 7.0, 1H 7.06, dd, 8.0, 7.0, 1H 7.08, dd, 8.0, 7.0, 1H 
24 7.25, dd, 8.0, 7.0, 1H 7.11, dd, 8.0, 7.0, 1H 7.01, dd, 8.0, 7.0, 1H 
25 7.70, d, 8.0, 1H 7.65, d, 8.0, 1H 7.49, d, 8.0, 1H 
1’ 3.72, dd, 16.0, 6.7, 1H 3.69, d, 6.8, 2H 3.45, dd, 15.7, 6.7, 1H 
 3.66, dd, 16.0, 6.7, 1H - 3.41, dd, 15.7, 7.2, 1H 
2’ 5.29, br t, 6.6, 1H 5.30, br t, 6.8, 1H 5.41, br t, 7.2, 1H 
4’ 2.10, m, 2H 2.10, m, 2H 2.11, m, 2H 
5’ 2.04, m, 2H 2.02, m, 2H§ 2.07, m, 2H§ 
6’ 5.10, br t, 6.8 5.12, br t, 7.0, 1H 5.12, br t, 6.9, 1H 
8’ 1.71, s, 3H 1.72, s, 3H 1.76, s, 3H 
9’ 1.67, s, 3H 1.65, s, 3H 1.63, s, 3H 
10’ 1.58, s, 3H 1.58, s, 3H 1.57, s, 3H 
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [†] signals are overlapping with each other. [§] signals are overlapping with those of solvent. [a~e] 
assignments of signals with the same letter are interchangeable. 
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Table S17. 1H NMR data of 5a6, 14a6, and 15a6, 10a7.  
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [†] signals are overlapping with each other. [§] signals are overlapping with those of solvent. [a, b] 
assignments of signals with the same letter are interchangeable. [*] signals are overlapping with those of water. 
Compound 
5a6 (CDCl3) 14a6 (CDCl3) 15a6 (CDCl3)  10a7 (CDCl3) 
Position δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz δH, multi., J in Hz 
1 8.00, s, 1H, 1H 7.98, s, 1H 7.99, s, 1H 8.15, s, 1H 
2 7.20, s, 1H 7.12, d, 2.3, 1H 7.12, d, 2.3, 1H 7.08, d, 2.6, 1H 
4 7.48, d, 8.1, 1H 7.42, d, 8.1, 1H 7.42, d, 8.1, 1H 7.49, d, 8.0, 1H 
5 7.00, dd, 8.1, 1.5, 1H 6.95, dd, 8.1, 1.0, 1H 6.95, dd, 8.1, 1.1, 1H†† 7.09, dd, 8.0, 7.3, 1H 
6 - - - 7.04, d, 7.3, 1H 
7 7.06, d, 1.5, 1H 7.17, d, 1.0, 1H 7.17, d, 1.1, 1H - 
10 3.75, dd, 15.0, 3.7, 1H 3.50, dd, 15.1, 5.7, 1H 3.50, dd, 15.2, 5.6, 1H 3.51, dd, 15.0, 3.8, 1H 
 2.92, dd, 15.0, 11.1, 1H 3.20, dd, 15.1, 8.4, 1H 3.20, dd, 15.2, 8.1, 1H 3.16, dd, 15.0, 8.9, 1H 
11 4.36, dd, 11.1, 3.7, 1H 4.13, ddd, 8.4, 5.6, 4.9, 1H 4.13, ddd, 8.4, 5.6, 4.9, 1H 4.31, br d, 9.0, 1H 
12 5.71, s, 1H 6.02, d, 4.9, 1H 6.05, d, 4.7, 1H 5.85, s, 1Ha 
14 4.07, t, 8.1, 1H - - 3.90, br d, 10.4, 1H 
15 - - - 5.79, s, 1Ha 
16 - 7.63, s, 1H 7.67, s, 1H - 
17 3.66, ddd, 11.5, 7.4, 7.4, 1H - - 1.58, m, 1H* 
 3.59, ddd, 11.5, 8.7, 3.1, 1H - - 1.04, ddd, 14.6, 10.2, 4.4, 1H 
18 2.01, m, 1H† 6.95, d, 8.0, 1H 6.96, d, 8.0, 1H†† 1.51, m, 1H 
 1.91, m, 1H - - - 
19 2.33, m, 1H 7.50, dd, 8.0, 7.4, 1H 7.50, dd, 8.0,7.4, 1H 0.85, d, 6.5, 3Hb 
 2.01, m, 1H† - - - 
20 - 7.26, dd, 7.9, 7.4, 1H§ 7.26, dd, 7.9, 7.4, 1H§ 0.84, d, 6.5, 3Hb 
21 - 7.91, d, 7.9, 1H 7.91, d, 7.9, 1H - 
1’ 3.41, d, 7.2, 1H 3.44, d, 7.3, 2H 3.44, d, 7.4, 2H 3.57, d, 7.7, 2H 
2’ 5.39, br t, 7.4, 1H 5.37, br t, 7.3, 1H 5.37, br t, 8.0, 1H 5.42, br t, 7.5, 1H 
4’ 2.12, m, 2H 2.11, dd, 15.1, 7.3, 2H 2.12, dd, 14.7, 7.6, 2H 2.15, m, 2H 
5’ 2.06, m, 2H 2.04, m, 2H 2.04, m, 2H 2.11, m, 2H 
6’ 5.12, br t, 6.9, 1H 5.10, br t, 6.9, 1H 5.10, br t, 6.9, 1H 5.10, br t, 6.9, 1H 
8’ 1.74, s, 3H 1.72, s, 3H 1.72, s, 3H 1.81, s, 3H 
9’ 1.69, s, 3H 1.67, s, 3H 1.67, s, 3H 1.69, s, 3H 
10’ 1.60, s, 3H 1.59, s, 3H 1.59, s, 3H 1.61, s, 3H 
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Table S18. 1H NMR data of 1a6, and 1a7.  
Chemical shifts (δ) are given in ppm and coupling constants in Hz. [§] signals are overlapping with those of solvent. [a~j] assignments of signals with the same 
letter are interchangeable. [*] signals are overlapping with those of water.
Compound 
 1a6  1a7 
Position δH, multi., J in Hz (CDCl3) δH, multi., J in Hz (CD3COCD3) δH, multi., J in Hz (CDCl3) 
δH, multi., J in Hz 
(CD3COCD3) 
1 8.05, s, 1H 9.93, s, 1H 8.06, s, 1H  9.93, s, 1H 
2 6.51, d, 2.3, 1Ha 6.70, d, 2.4, 1Hb 6.54, d, 2.3, 1Hd 6.63, d, 2.5, 1Hf 
4 7.56, d, 8.0, 1H 7.37, d, 8.1, 1H 7.41, d, 7.5, 1H 7.33, d, 7.0, 1H 
5 7.00, dd, 8.0, 1.3, 1H 6.88, dd, 8.1, 1.5, 1H 7.08, dd, 7.5, 7.2, 1H 6.96, dd, 7.5, 7.0, 1H 
6 - - 7.03, d, 7.2, 1H 6.93, d, 7.5, 1H 
7 7.15, d, 1.3, 1H 7.15, d, 1.5, 1H - - 
10 3.22, dd, 14.5, 3.5, 1H 2.99, dd, 14.3, 3.9, 1H 3.24, br d, 14.4, 1H 3.02, ddd, 14.0, 4.0, 3.5, 1H 
 2.44, dd, 14.5, 8.5, 1H 2.26, dd, 14.3, 7.5, 1H 2.39, dd, 14.4, 8.8, 1H 2.19, ddd, 14.0, 7.0, 4.0, 1H 
11 4.17, m, 1H 4.04, m, 1H 4.19, br t, 10.4, 1H 4.05, m, 1H 
12 5.69, s, 1H 6.75, s, 1Hc 5.73, s, 1He 6.74, s, 1H 
14 4.18, m, 1H 4.04, m, 1H 4.19, br t, 10.4, 1H 4.05, m, 1H 
15 5.69, s, 1H 6.78, s, 1Hc 5.70, s, 1He 6.74, s, 1H 
17 3.24, dd, 14.5, 3.5, 1H 3.03, dd, 14.4, 4.0, 1H 3.24, br d, 14.4, 1H 3.02, ddd, 14.0, 4.0, 3.5, 1H 
 2.47, dd, 14.5, 8.5, 1H 2.34, dd, 14.3, 7.4, 1H 2.51, dd, 14,4, 8.3, 1H 2.19, ddd, 14.0, 7.0, 4.0, 1H 
19 6.55, d, 2.2, 1Ha 6.59, d, 2.4, 1Hb 6.59, d, 2.3, 1Hd 6.65, d, 2,2, 1Hf 
20 7.94, s, 1H 10.09, s, 1H 8.08, s, 1H  10.07, s, 1H 
22 7.35, d, 8.0, 1H 7.34, d, 8.1, 1H 7.36, d, 8.0, 1H 7.33, d, 8.0, 1H 
23 7.22, dd, 8.0, 7.0, 1H 7.08, dd, 8.1, 7.0, 1H 7.22, d, 8.0, 7.0, 1H 7.08, dd, 8.0, 7.0, 1H 
24 7.14, dd, 8.0, 7.0, 1H 7.00, dd, 8.1, 7.0, 1H 7.15, d, 8.0, 7.0, 1H 7.00, dd, 8.0, 7.0, 1H 
25 7.46, d, 8.0, 1H 7.46, d, 8.1, 1H 7.57, d, 8.0, 1H 7.46, d, 8.0, 1H 
1’ 3.45, d, 7.2, 2H 3.43, d, 7.3, 2H 3.50, d, 7.3, 2H 3.54, d, 7.0, 2H 
2’ 5.38, br t, 7.4, 1H 5.39, br t, 7.8, 1H 5.33, br t, 6.9, 1H 5.38, br t, 7.2, 1H 
4’ 2.13, m, 1H 2.10, m, 2H 2.07, m, 2H 2.07, m, 2H§ 
5’ 2.06, m, 1H 2.03, m, 2H§ 2.02, m, 2H 1.96, m, 2H 
6’ 5.11, br t, 7.0, 1H 5.11, br t, 6.9, 1H 5.05, br t, 6.6, 1H 5.04, br t, 6.9, 1H 
8’ 1.73, s, 3H 1.73, s, 3H 1.76, s, 3H 1.69, s, 3H 
9’ 1.68, s, 3H 1.63, s, 3H 1.68, s, 3H 1.63, s, 3H 
10’ 1.59, s, 3H 1.57, s, 3H 1.58, s, 3H 1.53, s, 3H 
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Figure S1 HPLC chromatograms of the incubation mixtures of cyclic dieptide PTs and their corresponding mutants with their natural or best substrates in the 
presence of DMAPP. The assays (50 μL) contained 50 mM Tris-HCl (pH 7.5), 10 mM CaCl2, 1 mM cyclic dipeptide, 2 mM DMAPP, 0.7–6% (v/v) glycerol, up to 5% 
(v/v) DMSO, and 10 μg purified protein for FtmPT1 and BrePT, or 20 μg for CdpNPT, CdpC2PT, and CdpC3PT. The reaction mixtures were incubated at 37 °C for 
2 h for FtmPT1 and BrePT, and 4h for CdpNPT, CdpC2PT and CdpC3PT. Detection was carried out with a photodiode array detector and illustrated for absorption 
at 296 nm. According to previous results,7-9,11,18 P1 should be tryprostatin B, P2 deoxybrevianamide E, P5 cyclo-3β-prenyl-L-Trp-L-Leu, P6 (2S, 3R, 11S)-aszonalenin, 
and P7 (S)-2-tert-prenyl-benzodiazepinedione. The structures of P1, P2, and P6 have also been confirmed by NMR after isolation friom the incubation mixtures with 
the mutants. 
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Figure S2 HPLC chromatograms of the incubation mixtures of CdpC2PT and CdpC2PT _T351G with 15 cyclic dipeptides in the presence of GPP. The assays (50 
μL) contained 50 mM Tris-HCl (pH 7.5), 2 mM DTT, 1 mM cyclic dipeptide, 2 mM GPP, 5% (v/v) glycerol, up to 5% (v/v) DMSO, and 50 μg purified protein. The 
reaction mixtures were incubated at 37 °C for 16 h. Detection were carried out with a photodiode array detector and illustrated for absorption at 296 nm. The product 
yields (%) are given in average of two replicate. 
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Figure S3 HPLC chromatograms of the incubation mixtures of CdpC3PT and CdpC3PT _F335G with 15 cyclic dipeptides in the presence of GPP. The assays (50 
μL) contained 50 mM Tris-HCl (pH 7.5), 2 mM DTT, 1 mM cyclic dipeptide, 2 mM GPP, 3.3% (v/v) glycerol, up to 5% (v/v) DMSO, and 50 μg purified protein. The 
reaction mixtures were incubated at 37 °C for 16 h. Detection were carried out with a photodiode array detector and illustrated for absorption at 296 nm. The product 
yields (%) are given in average of two replicate. 
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Figure S4 HPLC chromatograms of the incubation mixtures of CdpNPT and CdpNPT _M349G with 15 cyclic dipeptides in the presence of GPP. The assays (50 
μL) contained 50 mM Tris-HCl (pH 7.5), 2 mM DTT, 1 mM cyclic dipeptide, 2 mM GPP, 5% (v/v) glycerol, up to 5% (v/v) DMSO, and 30 μg purified protein. The 
reaction mixtures were incubated at 37 °C for 16 h. Detection were carried out with a photodiode array detector and illustrated for absorption at 296 nm. The product 
yields (%) are given in average of two replicate. 
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Figure S5 HPLC chromatograms of the incubation mixtures of FtmPT1 and FtmPT1_M364G with 15 cyclic dipeptides in the presence of GPP. The assays (50 μL) 
contained 50 mM Tris-HCl (pH 7.5), 10 mM CaCl2, 1 mM cyclic dipeptide, 2 mM GPP, 0.7 % (v/v) glycerol, up to 5% (v/v) DMSO, and 10 μg purified protein. The 
reaction mixtures were incubated at 37 °C for 2 h. Detection were carried out with a photodiode array detector and illustrated for absorption at 296 nm. The product 
yields (%) are given in average of two replicate. 
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Figure S6 HPLC chromatograms of the incubation mixtures of BrePT and BrePT_I337G with 15 cyclic dipeptides in the presence of GPP. The assays (50 μL) 
contained 50 mM Tris-HCl (pH 7.5), 10 mM CaCl2, 1 mM cyclic dipeptide, 2 mM GPP, 2% (v/v) glycerol, up to 5% (v/v) DMSO, and 10 μg purified protein. The 
reaction mixtures were incubated at 37 °C for 2 h. Detection were carried out with a photodiode array detector and illustrated for absorption at 296 nm. The product 
yields (%) are given in average of two replicate. 
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Figure S7 Protein alignments of AtaPT with PTs used in this study. AtaPT (PDB code: 5KCG), FgaPT2 (PDB code: 3I4Z), FtmPT1 (PDB code: 3O24), BrePT 
(GenBank: I4AY86.1), CdpC2PT (GenBank: AGR03830.1), CdpC3PT (GenBank: EAW17508.1), and CdpNPT (PDB code: 4E0T). 
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Figure S8: Models of catalysis for PTs. DMAPP (orange) and GPP (green) were modelled into the crystal structures of FtmPT1 (A) (pdb-code: 3I4X) with 2 (blue) 
and of CdpNPT (B) (pdb-code: 3O2K) with 14 (blue) as acceptor. The GPP molecule was modelled into the active site on the basis of the DMAPP binding of both 
enzymes. The pyrophosphate of the prenyl donor was kept as fixed anchor and the geranyl entity was placed into the DMAPP binding pocket by avoiding clashes 
with the active site residues of the enzyme variant where the gatekeeper residue was in silico mutated to glycine. In the native state, the gatekeeper residue (pink) 
would clash with the GPP molecule. This clash is emphasized by transparent spheres (pink).  
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Figure S9 HPLC analysis of enzyme assays of FtmPT1_M364G, CdpNPT_M349G, CdpC2PT, and CdpC2PT_T351G with GPP and cyclo-L-Trp-L-Trp (1). The 
assay (50 μL) for FtmPT1_M364G contained 50 mM Tris-HCl (pH 7.5), 10 mM CaCl2, 1 mM cyclo-L-Trp-L-Trp, 2 mM GPP, 0.7% (v/v) glycerol, 5% (v/v) DMSO, and 
10 μg purified protein. The assay (50 μL) for CdpNPT_M349G contained 50 mM Tris-HCl (pH 7.5), 2 mM DTT, 1 mM cyclo-L-Trp-L-Trp, 2 mM GPP, 5% (v/v) glycerol, 
5% (v/v) DMSO, and 30 μg purified protein. The assays for CdpC2PT and CdpC2PT_T351G contained 50 mM Tris-HCl (pH 7.5), 2 mM DTT, 1 mM cyclo-L-Trp-L-
Trp, 2 mM GPP, 0.7-6% (v/v) glycerol, 5% (v/v) DMSO, and 50 μg purified protein. The reaction mixtures were incubated at 37 °C for 2 h for FtmPT1, and 16 h for 
CdpNPT_M349G, CdpC2PT and CdpC2PT_T351G. Detection were carried out with a photodiode array detector and illustrated for absorption at 296 nm. Product 
yields are given in parenthesis after compound numbers.  
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Figure S10 1H NMR spectrum of 1a1 in CDCl3 (500MHz). 
 
Figure S11 1H NMR spectrum of 2a1 in CD3OD (500MHz). 
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Figure S12 1H NMR spectrum of 3a1 in CDCl3 (500MHz). 
 
Figure S13 1H NMR spectrum of 6a1 in CD3OD (500MHz). 
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Figure S14 1H NMR spectrum of 8a1 in CD3OD (500MHz). 
 
Figure S15 1H NMR spectrum of 10a1 in CDCl3 (500MHz). 
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Figure S16 1H NMR spectrum of 11a1 in CD3OD (500MHz). 
 
Figure S17 1H NMR spectrum of 12a1 in CD3OD (500MHz). 
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Figure S18 1H NMR spectrum of 13a1 in CDCl3 (500MHz). 
 
Figure S19 1H NMR spectrum of 10b1 in CDCl3 (500MHz). 
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Figure S20 1H NMR spectrum of 1a2 in CDCl3 (500MHz). 
 
Figure S21 1H NMR spectrum of 2a2 in CDCl3 (500MHz). 
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Figure S22 1H NMR spectrum of 3a2 in CDCl3 (500MHz). 
 
Figure S23 1H NMR spectrum of 10a2 in CDCl3 (500MHz). 
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Figure S24 1H NMR spectrum of 11a2 in DMSO-d6 (500MHz). 
 
Figure S25 1H NMR spectrum of 12a2 in DMSO-d6 (500MHz). 
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Figure S26 1H NMR spectrum of 1b2 in CDCl3 (500MHz). 
 
Figure S27 1H NMR spectrum of 1b2-2 in CDCl3 (500MHz). 
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Figure S28 1H NMR spectrum of 2b2 in CD3OD (500MHz). 
 
Figure S29 1H NMR spectrum of 3b2 in CD3OD (500MHz). 
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Figure S30 1H NMR spectrum of 4b2 in CD3OD (500MHz). 
 
Figure S31 1H NMR spectrum of 14b2 in CDCl3 (500MHz). 
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Figure S32 1H NMR spectrum of 1a3 in CDCl3 (500MHz). 
 
Figure S33 1H NMR spectrum of 3a3 in CDCl3 (500MHz). 
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Figure S34 1H NMR spectrum of 6a3 in CD3OD (500MHz). 
 
Figure S35 1H NMR spectrum of 8a3 in CD3OD (500MHz). 
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Figure S36 1H NMR spectrum of 10a3 in CDCl3 (500MHz). 
 
Figure S37 1H NMR spectrum of 11a3 in CD3OD (500MHz). 
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Figure S38 1H NMR spectrum of 12a3 in CD3OD (500MHz). 
 
Figure S39 1H NMR spectrum of 13a3 in CD3OD (500MHz). 
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Figure S40 1H NMR spectrum of 1b3 in CDCl3 (500MHz). 
 
Figure S41 1H NMR spectrum of 5b3 in CDCl3 (500MHz). 
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Figure S42 1H NMR spectrum of 10b3 in CDCl3 (500MHz). 
 
Figure S43 1H NMR spectrum of 14b3 in CDCl3 (500MHz). 
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Figure S44 1H NMR spectrum of 1a4 in CDCl3 (500MHz). 
 
Figure S45 1H NMR spectrum of 1a4 in CD3COCD3 (500MHz). 
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Figure S46 1H NMR spectrum of 1a5 in CD3COCD3 (500MHz). 
 
Figure S47 1H NMR spectrum of 1a6 in CD3COCD3 (500MHz). 
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Figure S48 1H NMR spectrum of 1a6 in CDCl3 (500MHz). 
 
Figure S49 1H NMR spectrum of 5a6 in CDCl3 (500MHz). 
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Figure S50 1H NMR spectrum of 14a6 in CDCl3 (500MHz). 
 
Figure S51 1H NMR spectrum of 15a6 in CDCl3 (500MHz). 
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Figure S52 1H NMR spectrum of 1a7 in CDCl3 (500MHz). 
 
Figure S53 1H NMR spectrum of 1a7 in CD3COCD3 (500MHz). 
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Figure S54 1H NMR spectrum of 10a7 in CDCl3 (500MHz). 
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ABSTRACT: Penilactones A and B consist of a γ-
butyrolactone and two clavatol moieties. We identified
two separate gene clusters for the biosynthesis of these
key building blocks in Penicillium crustosum. Gene
deletion, feeding experiments, and biochemical inves-
tigations proved that a nonreducing PKS ClaF is
responsible for the formation of clavatol and the PKS-
NRPS hybrid TraA is involved in the formation of
crustosic acid, which undergoes decarboxylation and
isomerization to the predominant terrestric acid. Both
acids are proposed to be converted to γ-butyrolactones
with involvement of a cytochrome P450 ClaJ. Oxidation of
clavatol to hydroxyclavatol by a nonheme FeII/2-
oxoglutarate-dependent oxygenase ClaD and its sponta-
neous dehydration to an ortho-quinone methide initiate
the two nonenzymatic 1,4-Michael addition steps.
Spontaneous addition of the methide to the γ-
butyrolactones led to peniphenone D and penilactone
D, which undergo again stereospecific attacking by
methide to give penilactones A/B.
Penilactones A (1) and B (2) (Figure 1A) are rare fungalmetabolites and were first isolated from Penicillium
crustosum PRB-2.1 Together with their putative precursors
peniphenone D (3) and penilactone D (4) (Figure 1A), they
were also identified in other Penicillium species.2−4 Feeding
experiments suggested that 1 and 2 are derived from acetyl-CoA
and L-malic acid (Figure 1B).1 It was proposed that 1 and 2 are
formed by 1,4-Michael additions of two clavatol (5) molecules
in its active form ortho-quinone methide (6) with a γ-
butyrolactone (tetronic acid), i.e. (R)-5-methyl (7) or (S)-5-
carboxylmethyltetronic acid (8).1,2 This hypothesis was
confirmed by a biomimetic synthesis.5−7 Acetate of hydrox-
yclavatol (9) instead of 5 was used at 110 °C for the synthesis.
Hydroxyclavatol methyl ether (10) was also isolated from P.
crustosum.3
5 can be considered as a polyketide synthase (PKS) product.
However, the responsible enzyme is unknown before. Neither
the direct precursor nor the biosynthesis of 7 and 8 has been
reported. Michael addition as a thermodynamically controlled
1,4-addition of active methylenes to activated olefins such as
α,β-unsaturated carbonyl derivatives8 are widely used in the
chemical synthesis9−12 and also involved in the biosynthesis of
natural products.13 However, the substrates, enzymes and
conditions for Michael addition involved in the formation of
1−4 in nature have not been reported yet.
For secondary metabolite (SM) production in PRB-2, several
culture conditions were tested and the extracts were analyzed on
HPLC (Figure S1 in the Supplement Information (SI)). Three
dominant peaks were detected in a 7 days-old PD culture
(Figure S1), which were identified as 9, 10,14 and terrestric acid
(11)15 after isolation and structure elucidation (see SI for
details, NMR data and spectra are given in Tables S6−S10 and
Figures S28−S45). The stereochemistry of 11 was confirmed by
determination of its optical rotation and comparison with the
published data.15 9 has not been described before and therefore
Received: January 10, 2019
Published: February 27, 2019
Figure 1. Metabolites from PRB-2 (A) and proposed biosynthetic
routes to 1 and 2 (B).1
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was confirmed by X-ray analysis (Table S11). Two additional
minor peaks were proven to be 5 and hydroxyclavatol ethyl ether
(12) (Figures 1A and S1).14
However, peniphenones and penilactones could only be
detected in extracted ion chromatograms (EICs, data not
shown). To increase their productivity, PRB-2 was cultivated in
PD surface culture for 14 days. LC-MS analysis revealed clear
accumulation of 1−4 (Figures 2, S1, and S2). A 30 days-old rice
culture also accumulated 1−4 and was therefore used for
isolation and structure elucidation by MS, NMR (Tables S6−S7
and Figures S28−S31), optical rotation, and CD spectra
(Figures S46−S49).1,3 The CD spectra of 1 and 2 (Figures
S46 and S47) correspond very well to those reported
previously.1 The stereochemistry of 3 and 4 was determined
by chemical synthesis from 7 and 8 with known configuration at
C-5 (Figure S21, see below for the formation of 3 from 7 and 4
from 8). Under these conditions, the production of 9 and 10was
strongly reduced. In comparison, 11 was detected as the
predominant peak. Furthermore, a new peak was identified as
carboxylated derivative of 11, termed crustosic acid (13)
hereafter (Figures 1A, S44, and S45). 13 has an [α]D
20 value of
−164.1, while that of 11 at +37.1. The configuration of 13 was
assigned by comparison with the optical rotation data of 5-
methyl- and 5-carboxylmethyltetronic acids.16
For biosynthetic studies on 1 and 2, the genome of PRB-2 was
sequenced and the draft genome sequence was used for
prediction of putative gene clusters by using AntiSMASH.17
For gene inactivation, we established a gene replacement
protocol using the split marker strategy and hygromycin B as
selection marker, which significantly enhances the homologous
recombination events at the target gene (Figure S3).18
Based on its aromatic character, 5 is expected to be assembled
by a nonreducing PKS (NR-PKS).19 One of the six NR-PKS
genes pcr3094 within a 36.2 kbp large cluster (Figure 2A and
Table S4) has a SAT-KS-AT-PT-ACP-MeT-TE domain
structure (Abbreviations for PKS and NRPS domains as given
before19,20). It shares a sequence identity of 57.7% with CitS
from Monascus ruber21 and 64.4% with EAW12049.1 from
Aspergillus clavatus (Table S4). Deletion of pcr3094, termed claF
(from the clavatol cluster) hereafter, completely abolished the
production of 1−5, 9, and 10 (see SI for manipulation). The two
tetronic acids 11 and 13 accumulated with much higher yields in
the ΔclaF mutant than in PRB-2 (Figures 2B, S4, and S6).
Feeding 5 to the mutant restored the production of 1−4 and 9
(Figure S15).
To provide more evidence for the function of ClaF as a
clavatol synthase, pcr3094 was cloned into pYH-wA-pyrG and
expressed in A. nidulans.22−24 The formation of 5 in the
transformant JF11 was confirmed by LC-MS (Figure S20) and
1HNMR analyses after isolation. These results proved that ClaF
is responsible for 5 formation in the biosynthesis of 1−4
(Scheme 1).
To identify the genetic potential for 7 and 8, we focused on
PKS-NRPS hybrid enzymes, because tetronic acids like carlosic
acid are usually assembled by such enzymes.25 Analysis of the
draft sequence revealed the presence of a candidate gene
pcr11009, termed traA (from the terrestric acid cluster), within a
33.6 kbp large cluster. TraA with a domain structure KS-AT-
DH-MeT-KR-ACP-C-A-PCP (Figure 2A) shares a sequence
identity of 69.6% with CaaA in the carlosic acid biosynthesis
(Table S5).25 Deletion of traA completely abolished the
production of 1−4, indicating its involvement in the biosyn-
thesis. As expected, 5, 9, and 10 were accumulated in the ΔtraA
Figure 2. Schematic representation of clavatol and terrestric acid
clusters in PRB-2 (A) and LC-MS results of deletionmutants (B andC)
as well as ofΔtraAmutant fed with putative precursors (D). EICs refer
[M + H]+ ions of 1−6 and 11, 13 or [M + Na]+ of 9 and 10 with
tolerance ranges of ±0.005.
Journal of the American Chemical Society Communication
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mutant (Figures 2C and S8). Surprisingly, the production of 11
and 13 were also totally blocked. To restore the production of
1−4, we chemically synthesized 7 and 8 (Figure S21)5,7,26,27 and
fed them to the ΔtraA mutant. LC-MS analysis revealed that
feeding 7 restored the production of 1 and 3, but not 2 and 4. In
contrast, 2 and 4, but not 1 and 3 were detected in the culture of
ΔtraA mutant fed with 8 (Figures 2C, S16, and S17). This
proved that TraA is involved in the formation of 7 and 8, which
cannot be converted to each other (Scheme 1).
For understanding the role of 11 and 13 for 1−4, they were
isolated fromΔclaFmutant and fed intoΔtraAmutant. Feeding
11 only restored 1 and 3 production, while 1−4 were detected
after feeding with 13 (Figures 2C, S18, and S19). More
interestingly, 11 was also restored after feeding with 13, but not
vice versa (Figure 2D). This proved that 13 is the precursor of
both 8 and 11. 11 serves then as a precursor of 7 (Scheme 1).
It can be concluded that 13 is the product of TraA with or
without other enzymes and mainly converted to the
predominant product 11 in PRB-2. Only small amounts of 11
and 13 undergo degradation to 7 and 8 for the formation of 1−4
(Figure 2D and Scheme 1).
Having the both backbone genes/enzymes identified, we
intended to investigate the conversion of 13 to 8 and 11, 11 to 7,
and the metabolism of 5. Inactivation of the oxygenase gene
traH abolished the production of 1, 3, and 11, confirming its
involvement in the decarboxylation and isomerization of 13 to
11 (Figures 2C and S13). In the deletion mutants of the
cytochrome P450 traB and the dehydrogenase traD, no
accumulation of 11, 13, or 1−4 was detected (Figures S9 and
S10), proving their roles in the 13 formation (Scheme 1).
Deletion of traE and traF did not result in significant changes in
SM production (Figures S11 and S12).
Regarding Michael addition, we presumed a more active
intermediate than 5 for the formation of 6. Detailed inspection
of the cla cluster (Figure 2A, Table S4) revealed the presence of
genes coding for an oxygenase (claD) and a cytochrome P450
(claJ). ClaD comprises 338 amino acids and shares a sequence
identity of 53.8% with CitB in the citrinin biosynthesis.21 It also
contains the typical conserved 2-His-1-Asp ion-binding triad
(His184, His202 and Asp187) of nonheme Fe
II/2-oxoglutarate-
dependent oxygenases (Figure S22). Deletion of claD abolished
the production of 1−4 and 9, whereas 5was clearly accumulated
(Figures 2B and S5). Feeding 9 in the ΔclaD mutant restored
the production of 1−4 (Figure S14), proving its role in the
conversion of 5 to 9.
For biochemical characterization, claD was amplified and
cloned into pET28a (+). The purified ClaD (Figure S23) was
used for incubation with 5 in the presence of ascorbate (AA),
Fe[(NH4)2(SO4)2], and 2-oxoglutarate (2OG).
28,29 HPLC
analysis confirmed the oxidation of 5 to 9 with a conversion
yield of 22.5% after incubation with 2 μg protein at 37 °C for 30
min (Figure 3A). Nearly no consumption of 5 was detected in
the assays without ascorbate or 2-oxoglutarate. Replacing
ascorbate by dithiothreitol (DTT) or without additional FeII
reduced the activity significantly. These results proved that ClaD
acts as a nonheme FeII/2-oxoglutarate-dependent oxygenase
and oxidizes 5 to yield 9. Determination of kinetic parameters
Scheme 1. Proposed Biosynthetic Pathways of Penilactones and Peniphenones in P. crustosum
Figure 3. Functional proof of ClaD as a nonheme FeII/2-oxoglutarate-
dependent clavatol oxidase (A and B) and determination of the
equilibration between 9 and 6 (C).
Journal of the American Chemical Society Communication
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gave a KM of 0.30 mM toward 5 and a turnover number (kcat) of
0.26 s−1 (Figure 3B).
To prove the conversion between 9 and 6, 9 was incubated in
H2O and H2
18O at 25 °C for 16 h. MS data in positive and
negative modes confirmed the incorporation of 18O into 9 and
therefore the equilibration (Figures 3C and S24).
ClaJ shares clear sequence homology with fungal cytochrome
P450 enzymes, e.g. 42.0% identity with BAJ04372.1 from
Aspergillus oryzae.30 Deletion of claJ resulted in the abolishment
of 1−4 (Figures 2B and S7), but still retained the production of
5, 9, 11, and 13. This indicates its role in the C−C double bond
cleavage of 11 and 13 (Scheme 1). However, ClaJ could also
catalyze the connection of the two building blocks via Michael
addition.
For preparing feeding experiments in ΔclaJ, we carried out
control incubations of 7 with 9 and 8 with 9 in water at 25 °C,
which delivered surprising results, i.e. the nonenzymaticMichael
addition under these mild conditions (Figure 4A). In the first
combination, 3 was detected as the major and 1 as a minor
product, while 4 as the major and 2 as a minor product in the
case of 8 with 9. When 3 and 4 were incubated with 9, 1 and 2
were detected (Figure 4A). Formation of 3 and 4 is time- and
pH-dependent (Figures S25 and S26). 3 and 4 are formed under
neutral or acidic conditions. When pH values were higher than
5.0, diclavatol3 was also detected (Figure S26). It is obvious that
the active intermediate 6 can be easily formed from 9 in aqueous
system and initiates the Michael additions (Figure 4B), which
was confirmed by incubation of 9, 10, and 12 in different
solvents. They are stable in acetonitrile. Alcohols determined the
end products of 6 (Figure S27, Scheme 1). All these results
indicate that ClaJ is likely not involved in the Michael addition,
probably in the conversion of 11 to 7 and 13 to 8 (Scheme 1).
Taken together, 1−4 are formed by enzymes from
independent pathways of two separate gene clusters (Scheme
1). The tra cluster assembles 13, which is converted to 11. Both
acids deliver the two γ-butyrolactones 7 and 8. The cla cluster
provides the highly active 6 by a spontaneous dehydration of 9.
This initiates the two step nonenzymatic Michael additions by
the intermolecular nucleophile attacking of 6 to 7 or 8 and
subsequent reaction with 3 and 4. Thus, this study provides an
excellent example for SMs with complex structures that are
formed by enzymes from different pathways and by combination
of enzymatic and nonenzymatic reactions.
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Experiment Procedures 
1. Strains, media and growth conditions 
The fungal strains used in this study are summarized in Table S1. Penicillium crustosum strain 
PRB-2 was isolated from a deep-sea sediment collected in Prydz Bay at a depth of -526 m.1 
For detection of secondary metabolites (SMs), the strain PRB-2 was cultivated in PD medium 
(potato dextrose broth, Sigma) at 25°C. Aspergillus nidulans strains were grown at 37°C on 
GMM medium (1.0% glucose, 50 mL/L salt solution, 1 mL/L trace element solution, 1.6% agar) 
for sporulation and transformation with appropriate nutrition as required.2-4 The salt solution 
comprises (w/v) 12% NaNO3, 1.04% KCl, 1.04% MgSO4∙7H2O, and 3.04% KH2PO4. The trace 
element solution contains (w/v) 2.2% ZnSO4∙7H2O, 1.1% H3BO3, 0.5% MnCl2∙4H2O, 0.16% 
FeSO4∙7H2O, 0.16% CoCl2∙5H2O, 0.16% CuSO4∙5H2O, 0.11% (NH4)6Mo7O24∙4H2O, and 5% 
Na4EDTA. Escherichia coli DH5α and BL21(DE3) were grown in LB medium (1% NaCl, 1% 
tryptone, and 0.5% yeast extract) for standard DNA manipulation. 50 µg/mL carbenicillin or 
kanamycin were supplemented for cultivation of recombinant E. coli strains.  
2. Genomic DNA isolation 
The mycelia of P. crustosum and A. nidulans were collected in 2 mL Eppendorf tubes by 
centrifugation (13,000 rpm, 10 min). Four glass beads (2.85 mm in diameter) and 400 μL of 
LETS buffer (10 mM Tris-HCl pH 8.0, 20 mM EDTA pH 8.0, 0.5% SDS, and 0.1 M LiCl) were 
added to the tubes. After vigorous mixing for 4 min, 300 μL LETS buffer was added, and then 
the solution was treated with 700 μL phenol: chloroform: isoamyl alcohol (25: 24: 1). The 
genomic DNA was precipitated by addition of 900 μL absolute ethanol. After centrifugation at 
13,000 rpm for 30 min and washing with 70% ethanol, the obtained DNA was dissolved in 50 
μL distillated H2O. 
3. RNA isolation and cDNA synthesis 
For isolation of RNA from P. crustosum PRB-2, the fungus was cultivated in liquid PD medium 
for 7 d and the cells were collected by centrifugation. RNA extraction was performed by using 
Fungal RNA Mini kit (VWR OMEGA bio-tek E.Z.N.A) according to the manufacturer´s 
instruction. The ProtoScript II First Strand cDNA Synthesis kit (BioLabs) was used for cDNA 
synthesis with Oligo-dT primers. 
4. Genome sequencing and sequence analysis  
The genome of P. crustosum PRB-2 was sequenced by BerryGenomics (Beijing, China) using 
Nova-seq6000/X-ten (Illumina). Initial prediction and analysis of the clavatol and terrestric acid 
biosynthetic gene clusters were carried out by using antiSMASH 
(http://antismash.secondarymetabolites.org/). Prediction of the open reading frames (ORFs) 
was performed with the online BLAST approaches (http://blast.ncbi.nlm.nih.gov). Detailed 
prediction for domain structures of PKS and PKS-NRPS hybrid enzymes was performed with 
the PKS/NRPS analysis tool (http://nrps.igs.umaryland.edu/). The genes in clavatol and 
terrestric acid clusters were named as claA-J and traA-H, respectively (Figure 2A, Tables S4 
and S5). The genomic DNA sequences of the clavatol and terrestric acid clusters from P. 
crustosum PRB-2 reported in this study are available at GenBank under accession numbers 
MK360918 and MK360919, respectively. 
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5. PCR amplification, gene cloning and plasmid construction 
Plasmids used in this study are listed in Table S2. The oligonucleotide sequences for PCR 
primers are given in Table S3. Primers were designed as described for gene deletion strategy 
(Figure S3) and synthesized by Seqlab GmbH (Göttingen, Germany). PCR amplification was 
carried out by using Phusion® High-Fidelity DNA polymerase from New England Biolabs (NEB) 
on a T100TM Thermal cycler from Bio-Rad. PCR reaction mixtures and thermal profiles were 
set as recommended by the manufacturer´s instruction.  
To identify the clavatol and terrestric acid biosynthetic gene clusters, we deleted genes of 
interest by using split-marker approach, which significantly enhances the homologous 
recombination events at the target genes.5 In this approach, two DNA fragments are 
constructed. One fragment comprises the upstream DNA region of the target gene and the 
two-third of the sequence of the selection marker at its 5´-end, e.g. the hygromycin B 
resistance gene in this study. The second fragment consists of two-third at the 3´-end of the 
selection marker and the downstream region of the target gene (Figure S3). 1.0–1.5 kbp 
upstream and downstream fragments of claD, claF, claJ, traA, traB, traD, traE, traF and traH 
were amplified from P. crustosum genomic DNA using the designed primers listed in Table S3. 
To construct the plasmid for heterologous expression of claF in A. nidulans, an assembly 
approach based on the homologous recombination in E. coli was used.6 claF including its 
terminator of 480 bp was amplified from genomic DNA of P. crustosum by using primers 
A.n-claF-For/Rev (Table S3) and inserted into the corresponding sites of pYH-wA-pyrG with 
homologous flanking sequences of the wA gene.4 To construct the plasmid for expressing claD 
in E. coli, the coding region of claD was amplified by PCR from cDNA with the primers 
ClaD-28-For/Rev (Table S3). The DNA fragment was digested with BamHI and EcoRI and 
ligated into the same site of the expression vector pET-28a (+), yielding the expression plasmid 
pJF37, which was confirmed by sequencing (Seqlab GmbH). 
6. Genetic manipulation in P. crustosum and cultivation of deletion mutants 
Fresh spores of P. crustosum were inoculated into 30 mL LMM medium (1.0% glucose, 50 
mL/L salt solution, 1 mL/L trace element solution, and 0.5% yeast extract) in 100 mL flask and 
incubated at 25°C and 230 rpm for germination. Mycelia were harvested after 11 h by 
centrifugation at 5,000 rpm for 10 min, and washed with distillated H2O. The mycelia were then 
transferred into a 50 mL flask with 10 mL of osmotic buffer (1.2 M MgSO4 in 10 mM sodium 
phosphate, pH 5.8) containing 50 mg lysing enzyme from Trichoderma harzianum (Sigma) and 
20 mg yatalase from Corynebacterium sp. OZ-21 (OZEKI Co., Ltd.). After shaking at 30°C and 
100 rpm for 2.5 h, the cells were transferred into a 50 mL falcon tube and overlaid gently with 
10 mL of trapping buffer (0.6 M sorbitol in 0.1 M Tris-HCI, pH 7.0). After centrifugation at 4°C 
and 5,000 rpm for 10 min, the protoplasts were collected from the interface of the two buffer 
systems. The protoplasts were then transferred to a sterile 15 mL falcon tube and resuspended 
in 200 μL of STC buffer (1.2 M sorbitol, 10 mM CaCl2, and 10 mM Tris-HCI, pH 7.5) for 
transformation. 
The via PCR constructed gene deletion cassettes mentioned above were transformed into P. 
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crustosum by polyethylene glycol (PEG) mediated protoplast transformation. The DNA 
fragments were incubated with 100 μL of the protoplasts for 50 min on ice. 1.25 mL of PEG 
solution (60% PEG 4000, 50 mM CaCl2, 50 mM Tris-HCI, pH 7.5) was then added and gently 
mixed. After incubation at room temperature for 30 min, the mixture was transferred in 5 mL 
STC buffer and spread on plates with SMM bottom medium (1.0% glucose, 50 mL/L salt 
solution, 1 mL/L trace element solution, 1.2 M sorbitol, and 1.6% agar) containing 200 µg/mL 
hygromycin B. SMM top medium (1.0% glucose, 50 mL/L salt solution, 1 mL/L trace element 
solution, 1.2 M sorbitol, and 0.8% agar) containing 100 µg/mL hygromycin B was overlaid softly 
on the plates. Three days later, the transformants were transferred onto fresh PDA plates (PD 
medium with 1.6% agar) containing 200 µg/mL hygromycin B for second selection. The 
obtained transformants were inoculated in PD medium for isolation of genomic DNA to verify 
the integrity, which was carried out by PCR amplification (Figure S4). After cultivation in PD 
liquid medium at 25°C for 14 days, the secondary metabolites of the deletion mutants were 
extracted with ethyl acetate, dissolved in MeOH and analyzed on LC-MS.  
7. Heterologous expression of claF in A. nidulans 
A. nidulans strain LO8030 was used as the recipient host.3 Fungal protoplast preparation and 
transformation were performed according to the method described previously.3 pJF18 
containing the PKS gene claF was transformed into A. nidulans strain LO8030 to create the 
claF expression strain JF11. Potential transformants were verified by PCR using the primers 
claF-F/R (Table S3). Rice medium was used to cultivate the transformants (25°C, 7d) for 
LC-MS analysis of the secondary metabolite production. 
8. Precursor feeding in ∆claD, ∆claF, and ∆traA–mutants 
For feeding experiments, the precursors were dissolved in DMSO to give 1 M stock solutions. 
Adequate volumes of such solutions were then added to 10 mL of liquid PD cultures of 
respective deletion mutant, △claF, △claD or △traA, leading to final concentrations of 0.5 mM 
for clavatol (5) and hydroxyclavatol (9), 0.2 mM for terrestric acid (11), crustosic acid (13), 
(R)-5-methyltetronic acid (7), and (S)-5-carboxylmethyltetronic acid (8). After further cultivation 
at 25°C for 14 d, the secondary metabolites were extracted with ethyl acetate, dissolved in 
MeOH and analyzed on LC-MS. 
9. Chemical synthesis of tetronic acids 7 and 8 
For feeding experiments in deletion mutants, two tetronic acids (R)-5-methyltetronic acid (7) 
and (S)-5-carboxylmethyltetronic acid (8) were synthesized chemically according to the 
published methods (Figure S21). 7 was synthesized in two steps from (R)-ethyl lactate7 and 8 
in three steps from L-malic acid.8,9 
10. Overproduction and purification of ClaD 
The expression plasmid pJF37 was constructed for claD expression in E. coli as mentioned 
above. The recombinant E. coli BL21(DE3) strain was cultivated in Terrific Broth medium (TB 
medium, with 2.4% yeast extract, 2.0% tryptone, 0.4% glycerol, 0.1 M phosphate buffer, pH 7.4) 
and claD expression was induced with 0.5 mM IPTG at 30°C for 6 h. The recombinant 
histidine-tagged ClaD was purified on Ni-NTA agaroses (Qiagen, Hilden) and proven on 
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SDS-PAGE (Figure S23). 
11. In vitro assays of ClaD 
To determine the enzyme activity toward clavatol (5), the enzyme assays (50 μL) contained 
phosphate buffer (20 mM, pH 7.4), ascorbic acid (1 mM), clavatol (1 mM), Fe[(NH4)2(SO4)2] (1 
mM), 2-oxoglutarate (1 mM), glycerol (0.5−5%), DMSO (5%), and the purified recombinant 
ClaD (2 µg). The enzyme assays were incubated at 37 °C for 30 min and terminated with one 
volume of acetonitrile. The reaction mixtures were centrifuged at 13,000 rpm for 30 min before 
further analysis on HPLC.  
12. Proof of the existence of ortho-quinone methide  
In order to provide evidence for the existence of ortho-quinone methide (6), hydroxyclavatol (9) 
isolated from the fungal culture was dissolved in both H2O and in 18O-enriched H218O. After 
incubation at room temperature for 16 h, the samples were analyzed by MS on positive and 
negative modes.  
To prove their conversion via 6, hydroxyclavatol (9), hydroxyclavatol methyl ether (10), and 
hydroxyclavatol ethyl ether (12) were incubated in different solvents such as H2O, acetonitrile, 
MeOH and EtOH at room temperature for 12 h. The mixtures were analyzed on HPLC by using 
method B. 
13. Non-enzymatic formation of penilactones and peniphenones 
To determine the non-enzymatic formation, hydroxyclavatol (9) was incubated with 
(R)-5-methyltetronic acid (7) or (S)-5-carboxylmethyltetronic acid (8) in H2O at room 
temperature for 16 h. The dependence of the product formation on time (0, 5, 15, 30, 60, 120 
min, and 24 h) was monitored on HPLC (method A) (Figure S25). pH dependence of the 
product formation was carried out by incubation in phosphate buffer saline (PBS, pH 3−10) for 
12 h (Figure S26). 
14. Large-scale fermentation, extraction and isolation of secondary metabolites 
To isolate 5, 9, and 10–12, P. crustosum PRB-2 spores were inoculated into 60x 250-mL flask 
containing 100 mL PD liquid medium each and incubated on a rotary shaker at 220 rpm and 
25 °C for 7 d. The supernatant and mycelia were separated by filtration. The supernatant was 
extracted with equal volume of ethyl acetate for three times, and the mycelia were extracted 
with acetone. The acetone extract was concentrated under reduced pressure to afford an 
aqueous solution, and then extracted with ethyl acetate. The two ethyl acetate extracts were 
combined and evaporated under reduced pressure to give a crude extract (1.8 g). The crude 
extract was subjected to silica gel column chromatography by using stepwise gradient elution 
with the mixtures of CH2Cl2/MeOH (100:1 to 20:1, v/v) to give eleven fractions (1–11). Fraction 
3 eluted with CH2Cl2/MeOH (80:1) was further purified on semi-preparative HPLC (ACN/H2O 
(70:30)) to yield clavatol (5) (15 mg), hydroxyclavatol methyl ether (10) (7 mg) and 
hydroxyclavatol ethyl ether (12) (4 mg). Hydroxyclavatol (9) (17 mg) was obtained from fraction 
7, which was eluted with CH2Cl2/MeOH (40:1), by semi-preparative HPLC (ACN/H2O (60:40)). 
Fraction 8 eluted with CH2Cl2/MeOH (20:1) was chromatographed over Sephadex LH-20 
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column and eluted with MeOH, resulting in terrestric acid (11) (40 mg).  
To isolate 1–4, P. crustosum PRB-2 was cultivated in 300x 250-mL flasks each containing 20 g 
rice, 30 mL H2O, and 0.75 g soy flour at 25 °C for 30 days. The rice cultures were extracted 
with 15 L ethyl acetate and concentrated under reduced pressure to obtain a crude extract (35 
g). The crude extract was applied to silica gel column chromatography and eluted with a 
stepwise gradient CH2Cl2/acetone (100:1, 50:1, 25:1, 19:1, and 1:1), yielding eight fractions (1–
8). Subsequent elution with methanol gave 10 additional fractions (9−18). Fraction 4 was 
separated by repeated silica gel column chromatography with CH2Cl2/MeOH (50:1) and 
petroleum ether/EtOAc (1:1 and 1:6) as solvents to afford pure peniphenone D (3) (12 mg). 
Penilactone A (1) (7 mg) was obtained from fraction 7 by silica gel and Sephadex LH-20 
column chromatography as well as by final purification on a semi-preparative HPLC 
(MeOH/H2O (70:30) with 0.1% trifluoroacetic acid). In analogy, penilactone B (2) (5 mg) and 
penilactone D (4) (6 mg) were purified from fractions 12 and 18, respectively. 
To isolate 13, the △claF-mutant was cultivated in PD medium at 25°C for 14 d. The culture was 
extracted with ethyl acetate using the same procedure as mentioned above. 1.0 g crude extract 
was obtained from 4 L culture, and subjected to silica gel column chromatography by using 
petroleum ether/EtOAc (10:1, 3:1, 1:1, 1:3, 1:6) as elution solvents, giving 5 fractions (1−5). 
Pure 13 (20 mg) was obtained from fraction 5 after purification on Sephadex LH-20 column 
using MeOH as eluent. 
15. HPLC and LC-MS analysis of secondary metabolites 
Analysis of secondary metabolites was performed on an Agilent series 1200 HPLC (Agilent 
Technologies, Böblingen, Germany) with an Agilent Eclipse XDB-C18 column (150 × 4.6 mm, 5 
μm). Water (A) and acetonitrile (B), both with 0.1% (v/v) formic acid, were used as solvents at 
flow rate of 0.5 mL/min. The substances were eluted with a linear gradient from 5–100% B in 
15 min, then washed with 100% (v/v) solvent B for 5 min and equilibrated with 5% (v/v) solvent 
B for 5 min (method A) or with a linear gradient from 5–100% B in 40 min, then washed with 
100% (v/v) solvent B for 5 min and equilibrated with 5% (v/v) solvent B for 10 min (method B). 
Absorptions at UV 280 nm were illustrated. Semi-preparative HPLC was performed on the 
same equipment with an Agilent Eclipse XDB-C18 column (9.4 × 250 mm, 5 μm) column and a 
flow rate of 2.5 mL/min. 
LC-MS analysis was performed on an Agilent 1260 HPLC system equipped with a microTOF-Q 
III spectrometer (Bruker, Bremen, Germany) by using Multospher 120 RP18-5µ column (250 × 
2 mm, 5 μm) (CS-Chromatographie Service GmbH) and method B for separation at flow rate of 
0.25 mL/min. Electrospray positive or negative ionization mode was selected for determination 
of the exact masses. The capillary voltage was set to 4.5 kV and a collision energy of 8.0 eV. 
Sodium formate was used in each run for mass calibration. The masses were scanned in the 
range of m/z 100–1500. Data were evaluated with the Compass DataAnalysis 4.2 software 
(Bruker Daltonik, Bremen, Germany). 
16. NMR analysis  
NMR spectra were recorded on a JOEL ECA-500 MHz spectrometer (JEOL, Tokyo, Japan). All 
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spectra were processed with MestReNova 6.1.0 (Metrelab). Chemical shifts are referenced to 
those of the solvent signals. NMR data are given in Tables S6–S10 and spectra in Figures 
S28–S45. 
17. Measurement of optical rotations 
The optical rotation was measured with the polarimeter Jasco DIP-370 at 20°C using the D-line 
of the sodium lamp at λ=589.3 nm. Prior to the measurement, the polarimeter was calibrated 
with methanol as solvent. 
18. Circular dichroism (CD) spectroscopic analysis 
CD spectra were taken on a J-815 CD spectrometer (Jasco Deutschland GmbH, Pfungstadt, 
Germany). The samples were dissolved in methanol and measured in the range of 200–400 
nm by using a 1 mm path length quartz cuvette (Hellma Analytics, Müllheim, Germany). The 
CD spectra are given in Figures S46–S52. 
19. X-ray crystallographic analysis 
Colorless crystals of hydroxyclavatol (9) were obtained in CH2Cl2/MeOH. Crystallographic data 
for 9 (Cu Ka radiation) has been deposited in the Cambridge Crystallographic Data Centre with 
the deposition number CCDC 1883090 (Table S11). These data can be obtained free of charge 
via www.ccdc.cam.ac.uk/data_request/cif. 
20. Physiochemical properties of the compounds described in this study 
Penilactone A (1): Colorless solid; [α]20 D  = -14.8 (c 0.25, MeOH); CD (MeOH) λ max (∆ε) 333 
(-13.1), 295 (+28.2), 271 (-25.0), 240 (+17.2), 226 (-27.4) nm; HRMS (m/z): (ESI/[M + H]+) 
calcd. for C25H27O9, 471.1650, found 471.1652. 
Penilactone B (2): Colorless solid; [α]20 D  = +12.6 (c 0.25, MeOH); CD (MeOH) λ max (∆ε) 335 
(+9.6), 292 (-28.7), 270 (+18.9), 240 (-10.5), 227 (+11.4) nm; HRMS (m/z): (ESI/[M + H]+) calcd. 
for C26H27O11, 515.1548, found 515.1570. 
Peniphenone D (3): Colorless solid; [α]20 D  = +10.6 (c 0.25, MeOH); CD (MeOH) λ max (∆ε) 254 
(+2.4), 232 (-2.1), 200 (-3.0) nm; HRMS (m/z): (ESI/[M + H]+) calcd. for C15H17O6, 293.1020, 
found 293.1040.  
Penilactone D (4): Colorless solid; [α]20 D  = -15.9 (c 0.20, MeOH); CD (MeOH) λ max (∆ε) 280 
(-1.2), 242 (-3.0), 211 (+4.9) nm; HRMS (m/z): (ESI/[M + H]+) calcd. for C16H17O8, 337.0918, 
found 337.0932. 
Clavatol (5): Colorless solid; HRMS (m/z): (ESI/[M + H]+) calcd. for C10H13O3, 181.0859, found 
181.0860. 
(R)-5-Methyltetronic acid (7): Yellow solid; 1H NMR (400 MHz, DMSO-d6) δ 12.60 (s, 1H, 
4-OH), 4.87 (s, 1H, H-3), 4.85 (q, J = 6.7 Hz, 1H, H-5), 1.33 (d, J = 6.7 Hz, 3H, H-6); [α]20 D  = 
-22.8 (c 0.5, H2O); CD (H2O) λ max (∆ε) 309 (-9.3), 247 (+19.4) nm; HRMS (m/z): (ESI/[M + H]+) 
calcd. for C5H7O3, 115.0390, found 115.0369. 
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(S)-5-carboxylmethyltetronic acid (8): Yellow solid; 1H NMR (500 MHz, CD3OD) δ 5.18 (dd, J = 
8.8, 3.6 Hz, 1H, H-5), 2.94 (dd, J = 16.5, 3.6 Hz, 1H, H-6a), 2.53 (dd, J = 16.5, 8.8 Hz, 1H, 
H-6b); [α]20 D  = -0.8 (c 1.4, MeOH). HRMS (m/z): (ESI/[M + H]+) calcd. for C6H7O5, 159.0288, 
found 159.0272. 
Hydroxyclavatol (9): Colorless crystal; HRMS (m/z): (ESI/[M + Na]+) calcd. for C10H12NaO4, 
219.0628, found 219.0626. Crystallographic data for 9 (Cu Ka radiation) has been deposited in 
the Cambridge Crystallographic Data Centre with the deposition number CCDC 1883090.  
Hydroxyclavatol methyl ether (10): Colorless solid; HRMS (m/z): (ESI/[M + Na]+) calcd. for 
C11H14NaO4, 233.0784, found 233.0778. 
Terrestric acid (11): Yellow oil; [α]20 D  = +37.1 (c 0.80, MeOH); CD (MeOH) λ max (∆ε) 282 (+1.0), 
234 (+2.8), 212 (+8.2) nm; HRMS (m/z): (ESI/[M + H]+) calcd. for C11H15O4, 211.0965, found 
211.1003. 
Hydroxyclavatol ethyl ether (12): Colorless solid; HRMS (m/z): (ESI/[M + Na]+) calcd. for 
C12H16NaO4, 247.0941, found 247.0959. 
Crustosic acid (13): Yellow oil; [α]20 D  = -164.1 (c 0.50, MeOH); CD (MeOH) λ max (∆ε) 272 (-11.2), 
207 (-12.4) nm; HRMS (m/z): (ESI/[M + H]+) calcd. for C12H15O6, 255.0863, found 255.0876. 
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Supplementary Tables 
Table S1. Strains used in this study 
Strains Genotype 
Wild type Penicillium crustosum PRB-2 
ΔclaD ΔclaD::hph in P. crustosum PRB-2 
ΔclaF ΔclaF::hph in P. crustosum PRB-2 
ΔclaJ ΔclaJ::hph in P. crustosum PRB-2 
ΔtraA ΔtraA::hph in P. crustosum PRB-2 
ΔtraB ΔtraB::hph in P. crustosum PRB-2 
ΔtraD ΔtraD::hph in P. crustosum PRB-2 
ΔtraE ΔtraE::hph in P. crustosum PRB-2 
ΔtraF ΔtraF::hph in P. crustosum PRB-2 
ΔtraH ΔtraH::hph in P. crustosum PRB-2 
Aspergillus nidulans 
LO80302,3 
pyroA4, riboB2, pyrG89, nkuA::argB,  
sterigmatocystin cluster (AN7804-AN7825)Δ, 
emericellamide cluster (AN2545-AN2549)Δ, 
asperfuranone cluster (AN1039-AN1029)Δ, 
monodictyphenone cluster (AN10023-AN10021)Δ, 
terrequinone cluster (AN8512-AN8520)Δ, 
austinol cluster part 1 (AN8379-AN8384)Δ, 
austinol cluster part 2 (AN9246-AN9259)Δ, 
F9775 cluster (AN7906-AN7915)Δ,  
asperthecin cluster (AN6000-AN6002)Δ 
JF10 pYH- wA -pyrG in A. nidulans LO8030 
JF11 gpdA::claF::AfpyrG in A. nidulans LO8030 
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Table S2. Plasmids used and constructed in this study 
Plasmids Description 
pESC-URA Saccharomyces cerevisiae shuttle vector. 
pUChph vector with hygromycin B (hph) resistance originate. 
pET28a(+) vector with T7 promoter, 6xHis tag, T7 terminator, kanamycin resistance.  
p5HY Two-third of the hph resistance gene at the 5´-end, originated from the pUChph and inserted into 
pESC-URA. For gene replacement using hph as selection marker. 
p3YG Two-third of the hph resistance gene at the 3´-end, originated from the pUChph and inserted into 
pESC-URA. For gene replacement using hph as selection marker. 
pJF19 (p5HY-claD) a 1012 bp US PCR fragment of claD from genomic DNA of P. crustosum PRB-2 inserted in p5HY. 
pJF20 (p3YG-claD) a 1008 bp DS PCR fragment of claD from genomic DNA of P. crustosum PRB-2 inserted in p3YG. 
pJF40 (p5HY-claF) a 1560 bp US PCR fragment of claF from genomic DNA of P. crustosum PRB-2 inserted in p5HY. 
pJF41 (p3YG-claF) a 1426 bp DS PCR fragment of claF from genomic DNA of P. crustosum PRB-2 inserted in p3YG. 
pJF21 (p5HY-claJ) a 1367 bp US PCR fragment of claJ from genomic DNA of P. crustosum PRB-2 inserted in p5HY. 
pJF22 (p3YG-claJ) a 1259 bp DS PCR fragment of claJ from genomic DNA of P. crustosum PRB-2 inserted in p3YG. 
pJF38 (p5HY-traA) a 1500 bp US PCR fragment of traA from genomic DNA of P. crustosum PRB-2 inserted in p5HY. 
pJF39 (p3YG-traA) a 1496 bp DS PCR fragment of traA from genomic DNA of P. crustosum PRB-2 inserted in p3YG. 
pJF56 (p5HY-traB) a 1388 bp US PCR fragment of traB from genomic DNA of P. crustosum PRB-2 inserted in p5HY. 
pJF57 (p3YG-traB) a 1067 bp DS PCR fragment of traB from genomic DNA of P. crustosum PRB-2 inserted in p3YG. 
pJF54 (p5HY-traD) a 1170 bp US PCR fragment of traD from genomic DNA of P. crustosum PRB-2 inserted in p5HY. 
pJF55 (p3YG-traD) a 1139 bp DS PCR fragment of traD from genomic DNA of P. crustosum PRB-2 inserted in p3YG. 
pJF52 (p5HY-traE) a 1130 bp US PCR fragment of traE from genomic DNA of P. crustosum PRB-2 inserted in p5HY. 
pJF53 (p3YG-traE) a 1027 bp DS PCR fragment of traE from genomic DNA of P. crustosum PRB-2 inserted in p3YG. 
pJF50 (p5HY-traF) a 977 bp US PCR fragment of traF from genomic DNA of P. crustosum PRB-2 inserted in p5HY. 
pJF51 (p3YG-traF) a 1031 bp DS PCR fragment of traF from genomic DNA of P. crustosum PRB-2 inserted in p3YG. 
pJF48 (p5HY-traH) a 1101 bp US PCR fragment of traH from genomic DNA of P. crustosum PRB-2 inserted in p5HY. 
pJF49 (p3YG-traH) a 1114 bp DS PCR fragment of traH from genomic DNA of P. crustosum PRB-2 inserted in p3YG. 
pYH-wA-pyrG URA3, wA flanking, AfpyrG, Amp 
pJF18 pYH-wA-claF; a 8119 bp fragment of claF with its terminator from genomic DNA of P. crustosum 
PRB-2 inserted in pYH-wA 
pJF37 pET-28a(+)-claD; a 1017 bp fragment of claD from cDNA of P. crustosum PRB-2 inserted in 
pET28a(+) 
US: upstream; DS: downstream 
  
122
S14 
 
Table S3. Primers used in this study 
Primers Sequence 5’-3’ Targeted amplification 
P5HY-1 TGCGGCCGCCCTTTAGTGAGGGTTGAATTAGCTCTCCAAAGGGCG Two-third of the hph resistance 
gene at the 5´-end from pUChph to 
construct p5HY 
P5HY-2 CCTATAGTGAGTCGTATTACGGATCCAAGACCAATGCGGAGCATATAC 
P3YG-1 TGCGGCCGCCCTTTAGTGAGGGTTGAATTGATTCCGGAAGTGCTTGAC Two-third of the hph resistance 
gene at the 3´-end from pUChph to 
construct p3YG 
P3YG-2 CCTATAGTGAGTCGTATTACGGATCTCGCGTGGAGCCAAG 
5F-R GCTGAAGTCGATTTGAGTCCAC US of hph to verify 5F of P. 
crustosum mutant 
3F-F GCATTAATGCATTGGACCTCGC DS of hph to verify 3F of P. 
crustosum mutant 
claD-up-F AAGAATTGTTAATTAAGAGCTCAGATCTGTAGAGCAGGCTGGCGGATAC 1012 bp US fragment of claD to 
construct pJF19 claD-up-R AACCCTCACTAAAGGGCGGCCGCACTAGTGTCTTTCGCGGATGATAAAC 
claD-down-F ATACGACTCACTATAGGGCCCGGGCGTCGACCTGGAAGGGGGAGCCTTG 1008 bp DS fragment of claD to 
construct pJF20 claD-down-R GCTAGCCGCGGTACCAAGCTTACTCGAGCGGTGCTGGTGGTACCTATC 
claD-F ATGCCTGTTCTAAGCAATCC 1017 bp partial fragment of claD 
claD-R TTAAATGGCATAACTCGCCGTC 
claD-5F-F CTCGCAATCCATGGACGTG US of hph to verify △claD mutant 
claD-3F-R GCGCTTTGGTTATTGCGAG DS of hph to verify △claD mutant 
claF-up-F AAGAATTGTTAATTAAGAGCTCAGATCAGAGAACTGAGCTTTAGATTGG 1560 bp US fragment of claF to 
construct pJF40 claF-up-R CCTCACTAAAGGGCGGCCGCACTAGCGATTGCAGCTATACCCG 
claF-down-F ACTCACTATAGGGCCCGGGCGTCGAGCCTGATGGCCTATTGTAC 1426 bp DS of claF to construct 
pJF41 claF-down-R TAGCCGCGGTACCAAGCTTACTCGAGATGCAGGATATACGTTTCCAC 
claF-F GCGAATGACTGATGCAGTG 1845 bp partial fragment of claF 
claF-R GAAGTTCACTCGGCAGAGC 
claF-5F-F CATCGCTATAGATGTCTGGTCC US of hph to verify △claF mutant 
claF-3F-R CAACCCACAACTGGATCG DS of hph to verify △claF mutant 
claJ-up-F GAATTGTTAATTAAGAGCTCAGATCTCTTGTGTAATGCCCAAATGCC 1367 bp US fragment of claJ to 
construct pJF21 claJ-up-R CCCTCACTAAAGGGCGGCCGCACTAGTCCGTCATAGTTGAAGCGCAG 
claJ-down-F CTCACTATAGGGCCCGGGCGTCGACATATTAAATTTCAGGTAGCACGAG 1259 bp DS fragment of claJ to 
construct pJF22 claJ-down-R CTAGCCGCGGTACCAAGCTTACTCGAGGCTATTGCTAGGATGTCACGC 
claJ--F ATGAAAGGTCCAATTGTCCGC 
867 bp partial fragment of claJ 
claJ-R AAGGTATGGAAGCTTCTGGGC 
claJ-5F-F CTAGTTAGCAGCACTCGTC  US of hph to verify △claJ mutant 
claJ-3F-R CTATAGCAGTGGTCTCAACGGC DS of hph to verify △claJ mutant 
traA-up-F AAGAATTGTTAATTAAGAGCTCAGATCTTCGTGGTTTGTAACAACTGC 1500 bp US fragment of traA to 
construct pJF38 traA-up-R CCTCACTAAAGGGCGGCCGCACTAGATCTTTTGAGGGTTATCTTACAGC 
traA-down-F ACTCACTATAGGGCCCGGGCGTCGAGTTAGTTGTAGTAGCACTACTGC 1496 bp DS fragment of traA to 
construct pJF39 traA-down-R TAGCCGCGGTACCAAGCTTACTCGACCACGTACCGTAAATATCTGG 
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Table S3. Primers used in this study (continued) 
traA-F TGCATCTTGTAGAGCTCGC 
1819 bp partial fragment of traA 
traA-R GAGGGCGGTTTTAGAATCAATTG 
traA-5F-F GGACACACAGTTAAATGCAG US of hph to verify △traA mutant 
traA-3F-R CCTAGGCCATGTTAGATTGC DS of hph to verify △traA mutant 
traB-up-F GAATTGTTAATTAAGAGCTCAGATCTCTGACGAATGAGGCATTCAATG 1388 bp US fragment of traB to 
construct pJF56 traB-up-R ACCCTCACTAAAGGGCGGCCGCACTAGCATGGCTTGACAGCGCTCTC 
traB-down-F GACTCACTATAGGGCCCGGGCGTCGACGGGCCTCCCCTTGTCTATTC 1067 bp DS fragment of traB to 
construct pJF57 traB-down-R CTAGCCGCGGTACCAAGCTTACTCGAGCGTCCGACGATCATGATCCC 
traB-F GAATGCGTATTGCACTAGTATG 
1037 bp partial fragment of traB 
traB-R CCAGTTATACCACGACACC 
traB-5F-F CCTGCTGTACCTTCTGTATGC US of hph to verify △traB mutant 
traB-3F-R GTGGCTACGGTTACCACTG DS of hph to verify △traB mutant 
traD-up-F GAATTGTTAATTAAGAGCTCAGATCTGGCTCAGATCTTCCAGTGAAC 1170 bp US fragment of traD to 
construct pJF54 traD-up-R CAACCCTCACTAAAGGGCGGCCGCACTAGGTTGCAGCTAGGTGGGTG 
traD-down-F CTCACTATAGGGCCCGGGCGTCGACCTACCATACCTGCCTTTTCTGAC 1139 bp DS fragment of traD to 
construct pJF55 traD-down-R GCTAGCCGCGGTACCAAGCTTACTCGAGGGACCGCTCTGCTCTCATAC 
traD--F ATGAAAGTTTTGATTATTTTTGCCCACC 
942 bp partial fragment of traD 
traD-R TCACGCTTCTTTGACGTCGG 
traD-5F-F GGTAGAGCAGCGCGGTCTA US of hph to verify △traD mutant 
traD-3F-R CAAAGGCTGAGCCAGAGACTC DS of hph to verify △traD mutant 
traE-up-F GAATTGTTAATTAAGAGCTCAGATCTCCGCATATGCTTCAGCTGAC 1030 bp US fragment of traE to 
construct pJF52 
traE-up-R CCCTCACTAAAGGGCGGCCGCACTAGCAAATTATGCAGTGGTGCACG 
traE-down-F CTCACTATAGGGCCCGGGCGTCGACGATAGTATGAGAGCAGAGCGGTC 1027 bp DS fragment of traE to 
construct pJF53 traE-down-R GCTAGCCGCGGTACCAAGCTTACTCGAGGGCAGTATTCTGATGCCTGC 
traE-F ATGGCCGCACCAGCACTTC 
471 bp partial fragment of traE 
traE-R CTATTTGCCGAAAACTGCCCAG 
traE-5F-F CAATGTTCCTTCTCCGTATCGGTC US of hph to verify △traE mutant 
traE-3F-R CTGTTGACGCTGTACATGGG DS of hph to verify △traE mutant 
traF-up-F GAAGAATTGTTAATTAAGAGCTCAGATCTCAACCGCATATCGCCAAG 977 bp US fragment of traF to 
construct pJF50 traF-up-R CCCTCACTAAAGGGCGGCCGCACTAGCACGACAGCCTTTGTCCG 
traF-down-F GACTCACTATAGGGCCCGGGCGTCGACAGCAATCGTCGATTTTGCAAAC 1031 bp DS of traF to construct 
pJF51 traF-down-R CTAGCCGCGGTACCAAGCTTACTCGAGCGTATTCGGCCCCATTGAAAC 
traF-F ATGACCTCCGGCACTGAG 
1795 bp partial fragment of traF 
traF-R CTAATGCGCTGTAAACTTGCTC 
traF-5F-F CAGCCAATCGAAGATCCTTGC US of hph to verify △traF mutant 
traF-3F-R CATGTTTGCCTTGGAGCAGG DS of hph to verify △traF mutant 
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Table S3. Primers used in this study (continued) 
traH-up-F GAATTGTTAATTAAGAGCTCAGATCTCCCATCCATGGTCCGATTGAG 1101 bp US fragment of traH to 
construct pJF48 traH-up-R CCTCACTAAAGGGCGGCCGCACTAGGATTGCTTATGTGACGTGCTTTTG 
traH-down-F CTCACTATAGGGCCCGGGCGTCGACCGTTACAGCCAAGACATTGATG 1114 bp DS fragment of traH to 
construct pJF49 traH-down-R CTAGCCGCGGTACCAAGCTTACTCGAGCGCAGGACTCGACATGGATC 
traH-F GCGAAGGTCATTGAGCAAGTG 
1097 bp partial fragment of traH 
traH-R CACTACATACTGTGAATGCTATCACC 
traH-5F-F GCGGTGGAGTTGACGGTAAG US of hph to verify △traH mutant 
traH-3F-R GTCTCTCTCGCCCACCAC DS of hph to verify △traH mutant 
A.n-claF-For TATTCATCTTCCCATCCAAGAACCTTTAATCATGCCGTCTGAGTCTTAC DNA of claF with its 480 bp 
terminator from P. crustosum to 
construct pJF18 
A.n-claF-Rev CATATTTCGTCAGACACAGAATAACTCTCCATGTTATTAGGGACCATGG 
ClaD-28-For GTGGACAGCAAATGGGTCGCGGATCCATGCCTGTTCTAAGCAATCCATC 1017 bp fragment of claD to 
construct pJF37 ClaD-28-Rev CAAGCTTGTCGACGGAGCTCGAATTCTTAAATGGCATAACTCGCCGTCA 
US: upstream; DS: downstream 
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Table S4. Putative functions of the genes from clavatol gene cluster 
 
Protein No. in 
genome 
Size 
(AA) 
Homologous known protein  Identity 
(%) 
Putative function 
ClaA Pcr3099 476 C6 transcription factor (ANF07281) from 
Byssochlamys fulva 10 
53.1 transcription activator 
ClaB Pcr3098 214 hypothetical protein AUD_9432 (GAO90472) from 
Aspergillus udagawae 11 
38.8 hypothetical protein 
ClaC Pcr3097 878 enoyl-CoA hydratase/isomerase family protein  
(OCK96737) from Cenococcum geophilum 12 
53.6 enoyl-CoA 
hydratase/isomerase 
ClaD Pcr3096 338 FeII/2-oxoglutarate-dependent oxygenase CitB 
(ALI92653) from Monascus ruber M7 13 
53.8 clavatol oxidase 
ClaE Pcr3095 265 citrinin biosynthesis protein CitA (ALI92654) from 
Monascus ruber M7 13 
64.8 hypothetical protein 
ClaF Pcr3094 2587 citrinin polyketide synthase CitS (ALI92655) from 
Monascus ruber M7 13 
57.7 clavatol synthase 
ClaG Pcr3093 743 hypothetical protein (XP_020058556.1) from 
Aspergillus aculeatus ATCC 16872 
47.0 hypothetical protein 
ClaH Pcr3092 308 thiohydrolase in the brefeldin A biosynthesis 
(A0A068ACU9.1) from Penicillium brefeldianum 14 
44.0 hydrolase 
ClaI Pcr3091 2346 polyketide synthase (AFP89392) from 
Cladosporium phlei 15 
42.8 polyketide synthase 
ClaJ Pcr3089 438 cytochrome P450 monooxygenase (BAJ04372.1) 
from Aspergillus oryzae 
42.0 cytochrome P450 
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Table S5. Putative functions of the genes from terrestric acid gene cluster 
 
Protein No. in 
genome 
Size 
(AA) 
homologous known protein  Identity 
(%) 
Putative Function 
TraA Pcr11009 3856 NRPS/PKS hybrid enzyme 
(XP_001392496) from Aspergillus niger 
CBS 513.88 16 
69.6 PKS-NRPS hybrid enzyme  
TraB Pcr11010 509 cytochrome P450 monooxygenase 
(XP_001392495) in toxin biosynthesis in 
Aspergillus niger CBS 513.88 16 
65.5 cytochrome P450 
TraC Pcr11011 417 hypothetical protein (OQD61093) from 
Penicillium polonicum 
81.0 hypothetical protein 
TraD Pcr11012 267 NAD(P)H dehydrogenase (AEO48230) 
from Rhodospirillum rubrum F11 17 
63.4 flavodoxin family protein 
TraE Pcr11013 156 hypothetical protein (XP_001392493) from 
Aspergillus niger CBS 513.88 16 
49.0 hypothetical protein 
TraF Pcr11014 482 MFS multidrug transporter 
(XP_001392492) from Aspergillus niger 
CBS 513.88 16 
68.9 transporter 
TraG Pcr11015 364 enoyl reductase (XP_001392491) from 
Aspergillus niger CBS 513.88 16 
68.9 enoyl reductase 
TraH Pcr11016 327 2-oxoglutarate-dependent oxygenase 
(XP_001392490) from Aspergillus niger 
CBS 513.88 16 
66.0 2-oxoglutarate-dependent 
oxygenase 
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Table S6. 1H NMR data of compounds 1 and 2 
Compound 
 
Penilactone A (1, DMSO-d6) 
 
Penilactone B (2, DMSO-d6) 
Position δH, multi., J in Hz δH, multi., J in Hz 
5 5.00, q, 6.4, 1H 5.22, dd, 9.6, 2.1, 1H 
6 1.51, d, 6.4, 3H 3.18, t, 9.6, 1H 
 - 2.66, dd, 16.9, 9.6, 1H 
6´ 7.57, s, 1H 7.59, s, 1H 
8´ 2.55, s, 3H 2.56, s, 3H 
9´ 2.97, d, 17.0, 1H 2.96, d, 17.4, 1H 
 2.79, d, 17.0, 1H 2.82, d, 17.4, 1H 
10´ 2.13, s, 3H 2.13, s, 3H 
6´´ 7.61, s, 1H 7.62, s, 1H 
8´´ 2.52, s, 3H 2.53, s, 3H 
9´´ 3.25, d, 12.3, 1H 3.25, d, 13.8, 1H 
 3.13, d, 12.3, 1H 3.17, d, 13.8, 1H 
10´´ 2.16, s, 3H 2.16, s, 3H 
4-OH 8.15, s, 1H 8.32, s, 1H 
2´-OH 12.82, s, 1H 12.81, s, 1H 
2´´-OH 13.01, s, 1H 13.03, s, 1H 
4´´-OH 9.78, s, 1H 9.84, s, 1H 
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Table S7. 1H NMR data of compounds 3 and 4 
Compound 
 
Peniphenone D (3, CDCl3) 
 
Penilactone D (4, DMSO-d6) 
Position δH, multi., J in Hz δH, multi., J in Hz 
5 4.83, q, 6.8, 1H 4.96, dd, 9.6, 3.0, 1H 
6 1.46, d, 6.8, 3H 2.89, dd, 16.2, 3.0, 1H 
 - 2.25, dd, 16.2, 9.6, 1H 
6´ 7.40, s, 1H 7.53, s, 1H 
8´ 2.56, s, 3H 2.52, s, 3H 
9´ 3.47, d, 15.1, 1H 3.41, d, 14.5, 1H 
 3.42, d, 15.1, 1H 3.37, d, 14.5, 1H 
10´ 2.20, s, 3H 2.13, s, 3H 
2´-OH 13.98, s, 1H 12.94, s, 1H 
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Table S8. 1H NMR data of compounds 5, 10 and 12 
Compound 
 
Clavatol (5) 
 
 
Hydroxyclavatol methyl 
ether (10, CDCl3) 
 
Hydroxyclavatol ethyl ether 
(12, CDCl3) 
Position 
δH, multi., J in Hz  
(CDCl3) 
δH, multi., J in Hz  
(DMSO-d6) 
δH, multi., J in Hz δH, multi., J in Hz 
1 2.56, s, 3H 2.56, s, 3H 2.54, s, 3H 2.54, s, 3H 
6´ 7.37, s, 1H 7.56, s, 1H 7.41, s, 1H 7.41, s, 1H 
7´ 2.14, s, 3H 2.05, s, 3H 2.16, s, 3H 2.16, s, 3H 
8´ 2.21, s, 3H 2.18, s, 3H 4.84, s, 2H 4.88, s, 2H 
9´ - - 3.50, s, 3H 3.67, q, 7.1, 2H 
10´ - - - 1.31, t, 7.1, 3H 
2´-OH 12.89, s, 1H 12.94, s, 1H 12.95, s, 1H 12.95, s, 1H 
4´-OH - 9.48, s, 1H 9.15, s, 1H 9.44, s, 1H 
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Table S9. NMR data of compound 9 
Compound 
 
Hydroxyclavatol (9) 
 
Position 
δH, multi., J in Hz 
(CDCl3) 
δH, multi., J in Hz 
(DMSO-d6) 
δC (CDCl3) Key HMBC correlations 
1 2.53, s, 3H 2.53, s, 3H 26.4 C-2 
2 - - 203.0  
1´ - - 112.6  
2´ - - 159.8  
3´ - - 110.3  
4´ - - 162.4  
5´ - - 117.2  
6´ 7.40, s, 1H 7.61, s, 1H 131.9 C-2, C-2´, C-4´ 
7´ 2.17, s, 3H 2.11, s, 3H 15.5 C-4´, C-5´, C-6´ 
8´ 5.07, s, 2H 4.70, s, 2H 58.9 C-3´ 
2´-OH 12.93, s, 1H 12.98, s, 1H - C-1´, C-2´ 
4´-OH 9.13, s, 1H 10.23, s, 1H - C-4´ 
8´-OH - 5.75, s, 1H -  
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Table S10. NMR data of 11 and 13 
Compound 
 
Terrestric acid (11, CDCl3) 
 
Crustosic acid (13, CDCl3) 
Position δH, multi., J in Hz δH, multi., J in Hz δC 
2 - - 167.5/170.7 
3 - - 95.2/95.6 
4 - - 197.4/193.8 
5 4.61, q, 7.0, 1H 4.81, dd, 6.4, 4.0, 1H 78.6/78.3 
6 1.46, d, 7.0, 3H 3.00, ddd, 17.2, 9.3, 4.0, 1H 35.8/35.7 
 - 2.82, td, 17.2, 6.4, 1H - 
7 - - 173.8/173.6 
2´ - - 187.6/187.0 
3´ 3.60, ddd, 20.1, 9.3, 1.5, 1H 3.58, ddd, 19.9, 9.3, 4.1, 1H 33.9/34.2 
 3.27, ddd, 20.1, 9.7, 8.5, 1H 3.26, ddd, 19.9, 9.6, 9.0, 1H - 
4´ 2.36, m, 1H 2.37, m, 1H 27.7/27.7 
 1.87, m, 1H 1.86, m, 1H - 
5´ 4.93, m, 1H 4.94, m, 1H 93.0/93.6 
6´ 1.96, m, 1H 1.94, m, 1H 26.5/26.4 
 1.79, m, 1H 1.77, m, 1H - 
7´ 1.06, t, 7.5, 3H 1.04, t, 7.4, 3H 9.6/9.5 
7-OH - 8.59, s, 1H - 
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Table S11. Crystal data and structure refinement of 9 
 
Perspective drawing of the X-ray structure of 9 
Name Hydroxyclavatol  
Identification code CCDC 1883090  
Empirical formula C10H12O4  
Formula weight 196.20  
Temperature 113(2) K  
Wavelength 1.54178 Å  
Crystal system Triclinic  
Space group P -1  
Unit cell dimensions a = 7.7553(9) Å = 77.750(5)°. 
 b = 8.2119(10) Å = 69.610(4)°. 
 c = 8.3575(10) Å = 66.847(5)°. 
Volume 456.97(10) Å3  
Z 2  
Density (calculated) 1.426 mg/m3  
Absorption coefficient 0.929 mm-1  
F(000) 208  
Crystal size 0.900 x 0.500 x 0.200 mm3  
Theta range for data collection 5.669 to 64.115°.  
Index ranges -8<=h<=9, -9<=k<=9, -9<=l<=9  
Reflections collected 3969  
Independent reflections 1409 [R(int) = 0.0585]  
Completeness to theta = 64.115° 92.6%  
Refinement method Full-matrix least-squares on F2  
Data / restraints / parameters 1409 / 8 / 134  
Goodness-of-fit on F2 1.589  
Final R indices [I>2sigma(I)] R1 = 0.0535, wR2 = 0.1801  
R indices (all data) R1 = 0.0542, wR2 = 0.1834  
Extinction coefficient 0.044(8)  
Largest diff. peak and hole 0.391 and -0.328 e.Å-3  
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Supplementary Figures 
 
Figure S1. HPLC analysis of secondary metabolite profiles of P. crustosum 
(A) in 7 days-old PD liquid shaking culture at 230 rpm. (B) in 14 days-old PD liquid surface 
culture. Absorptions at 280 nm are illustrated. 
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Figure S2. LC-MS analysis of secondary metabolites from a 14 days-old liquid PD surface 
culture of P. crustosum 
EICs of 1–5, 9, 10, 11, and 13 are selected with a tolerance range of ± 0.005. UV spectra are 
shown in blue. 
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Figure S3. Schematic representation of the gene deletion strategy in P. crustosum 
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Figure S4. PCR verification of deletion mutants of P. crustosum 
PCR amplification for three different fragments from genomic DNA of WT and deletion mutants 
was used to prove the presence/absence of the gene of interest and its site specific integration 
with the help of up- and downstream regions. The PCR primers are given in Table S3. 
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Figure S5. LC-MS analysis of the metabolite profile of the △claD-mutant  
Absorptions at 280 nm are illustrated in black (A). EICs in dark green (B) refer total [M+H]+ ions 
of 1–6, 11, and 13 with a tolerance range of ± 0.005, and in other colors refer [M+H]+ ions of 1–
6, 11, and 13 (C−J), respectively.  
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Figure S6. LC-MS analysis of the metabolite profile of the △claF-mutant  
Absorptions at 280 nm are illustrated in black (A). EICs in dark green (B) refer total [M+H]+ ions 
of 1–6, 11, and 13 with a tolerance range of ± 0.005, and in other colors refer [M+H]+ ions of 1–
6, 11, and 13 (C-J), respectively.  
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Figure S7. LC-MS analysis of the metabolite profile of the △claJ-mutant  
Absorptions at 280 nm are illustrated in black (A). EICs in dark green (B) refer total [M+H]+ ions 
of 1–6, 11, and 13 with a tolerance range of ± 0.005, and in other colors refer [M+H]+ ions of 1–
6, 11, and 13 (C-J), respectively. The peak at 29.3 min, which is very likely derived from the 
cyclodipeptide of tyrosine and glycine (cYG), was isolated and identified as the enantiomer of 
cis-Bis(methylthio)silvatin18 (data not shown). The peak at 33.5 min was also detected in the 
control chromatogram with methanol as a sample. 
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Figure S8. LC-MS analysis of the metabolite profile of the △traA-mutant  
Absorptions at 280 nm are illustrated in black (A). EICs in dark green (B) refer total [M+H]+ ions 
of 1–6, 11, and 13 with a tolerance range of ± 0.005, and in other colors refer [M+H]+ ions of 1–
6, 11, and 13 (C−J), respectively. 
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Figure S9. LC-MS analysis of the metabolite profile of the △traB-mutant  
Absorptions at 280 nm are illustrated in black (A). EICs in dark green (B) refer total [M+H]+ ions 
of 1–6, 11, and 13 with a tolerance range of ± 0.005, and in other colors refer [M+H]+ ions of 1–
6, 11, and 13 (C−J), respectively. 
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Figure S10. LC-MS analysis of the metabolite profile of the △traD-mutant  
Absorptions at 280 nm are illustrated in black (A). EICs in dark green (B) refer total [M+H]+ ions 
of 1–6, 11, and 13 with a tolerance range of ± 0.005, and in other colors refer [M+H]+ ions of 1–
6, 11, and 13 (C−J), respectively.  
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Figure S11. LC-MS analysis of the metabolite profile of the △traE-mutant  
Absorptions at 280 nm are illustrated in black (A). EICs in dark green (B) refer total [M+H]+ ions 
of 1–6, 11, and 13 with a tolerance range of ± 0.005, and in other colors refer [M+H]+ ions of 1–
6, 11, and 13 (C−J), respectively. 
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Figure S12. LC-MS analysis of the metabolite profile of the △traF-mutant  
Absorptions at 280 nm are illustrated in black (A). EICs in dark green (B) refer total [M+H]+ ions 
of 1–6, 11, and 13 with a tolerance range of ± 0.005, and in other colors refer [M+H]+ ions of 1–
6, 11, and 13 (C−J), respectively. 
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Figure S13. LC-MS analysis of the metabolite profile of the △traH-mutant  
Absorptions at 280 nm are illustrated in black (A). EICs in dark green (B) refer total [M+H]+ ions 
of 1–6, 11, and 13 with a tolerance range of ± 0.005, and in other colors refer [M+H]+ ions of 1–
6, 11, and 13 (C−J), respectively. 
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Figure S14. LC-MS analysis of the metabolite profile of the △claD-mutant with and without 
feeding with 9  
Absorptions at 280 nm are illustrated in black (A and C). EICs in dark green (B and D) refer 
total [M+H]+ ions of 1–6, 11, and 13 with a tolerance range of ± 0.005, and in other colors refer 
[M+H]+ ions of 1–4 and 6 (E−I), respectively. 
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Figure S15. LC-MS analysis of the metabolite profile of the △claF-mutant with and without 
feeding with 5  
Absorptions at 280 nm are illustrated in black (A and C). EICs in dark green (B and D) refer 
total [M+H]+ ions of 1–6, 11, and 13 with a tolerance range of ± 0.005, and in other colors refer 
[M+H]+ ions of 1–5 (E−I ) or [M+Na]+ ion of 9 (J).  
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Figure S16. LC-MS analysis of the metabolite profile of the △traA-mutant with and without 
feeding with 7 
Absorptions at 280 nm are illustrated in black (A and C). EICs in dark green (B and D) refer 
total [M+H]+ ions of 1–6, 11, and 13 with a tolerance range of ± 0.005, in other colors refer 
[M+H]+ ions of 1–4, 11, and 13 (E–J), respectively. 
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Figure S17. LC-MS analysis of the metabolite profile of the △traA-mutant with and without 
feeding with 8  
Absorptions at 280 nm are illustrated in black (A and C). EICs in dark green refer [M+H]+ ions of 
1–6, 11, and 13 (B and D) with a tolerance range of ± 0.005, and in other colors refer [M+H]+ 
ions of 1 –4, 11, and 13 (E–J), respectively. 
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Figure S18. LC-MS analysis of the metabolite profile of the △traA-mutant with and without 
feeding with 11  
Absorptions at 280 nm are illustrated in black (A and C). EICs in dark green refer [M+H]+ ions of 
1–6, 11, and 13 (B and D with a tolerance range of ± 0.005, and in other different colors refer 
[M+H]+ ions of 1 –4, 11, and 13 (E–J), respectively. 
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Figure S19. LC-MS analysis of the metabolite profile of the △traA-mutant with and without 
feeding with 13  
Absorptions at 280 nm are illustrated in black (A and C). EICs in dark green refer [M+H]+ ions of 
1– 6, 11, and 13 (B and D) with a tolerance range of ± 0.005, and in other different colors refer 
[M+H]+ ions of 1–4, 11, and 13 (E–J), respectively. 
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Figure S20. LC-MS analysis of the metabolite profile of different A. nidulans strains  
Absorptions at 280 nm and [M+H]+ of (5) m/z 181.0859 are illustrated. JF11 carries the 
expression construct for claF in A. nidulans LO8030 and JF10 the empty vector pYH-wA-pyrG. 
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Figure S21. Chemical synthesis of the tetronic acids 7 and 8 
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Figure S22. Sequence alignments of 2-OG-dependent oxygenases  
CitB (ALI92653), CtnA (BAE95338), and KGO36755 are from Monascus ruber M7, Monascus 
purpureus, and Penicillium expansum and share sequence identities of 53.8, 53.8, and 53.6% 
with ClaD, respectively. ClaD also contains the typical conserved 2-His-1-Asp ion-binding triad 
of non-heme FeII/2-oxoglutarate-dependent oxygenases (His184, His202 and Asp187) (marked 
with *).13 Protein sequence alignments were carried out by using the sequence alignment 
function of MEGA 5.2 and visualized with ESPript 3.0 (http://espript.ibcp.fr/ESPript/ESPript/). 
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Figure S23. Analysis of ClaD on SDS PAGE 
(A) claD was inserted into pET28a(+) with 6xHis at its N-terminal. (B) The recombinant 
histidine-tagged ClaD was purified and separated on a 12% gel after induction with 0.5 mM 
IPTG at 30℃ for 6 h in TB medium. 
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Figure S24. MS analysis of 9 after incubation in H2O and in 18O-enriched H218O 
Hydroxyclavatol (9) was dissolved in H2O and 18O-enriched H218O and incubated at room 
temperature for 16 h. MS data of two samples were collected in both positive and negative 
modes. 
S48 
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Figure S25. Time dependence of Michael addition reaction of 9 with 7 (A) or 8 (B) 
The incubations were carried out at room temperature in distillated H2O. Absorptions at 254 
nm are illustrated. 
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Figure S26. pH dependence on Michael addition reactions forming 3 and 4 
HPLC analysis of mixtures of 9 with 7 (A), 8 (B) or alone (C) in phosphate saline buffer with 
different pH values at room temperature for 12 h. Absorptions at 254 nm are illustrated. 
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Figure S27. HPLC analysis of 9, 10, and 12 after incubation in different solvents 
Incubation of hydroxyclavatol (9), hydroxyclavatol methyl ether (10), and hydroxyclavatol ethyl 
ether (12) in H2O, acetonitrile, MeOH and EtOH at room temperature for 12 h. Absorptions at 
280 nm are illustrated.  
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Figure S28. 1H NMR spectrum of compound 1 in DMSO-d6 (500 MHz) 
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Figure S29. 1H NMR spectrum of compound 2 in DMSO-d6 (500 MHz) 
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Figure S30. 1H NMR spectrum of compound 3 in CDCl3 (500 MHz) 
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Figure S31. 1H NMR spectrum of compound 4 in DMSO-d6 (500 MHz) 
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Figure S32. 1H NMR spectrum of compound 5 in CDCl3 (500MHz) 
165
S57 
 
 
Figure S33. 1H NMR spectrum of compound 5 in DMSO-d6 (500MHz)  
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Figure S34. 1H NMR spectrum of compound 7 in DMSO-d6 (400MHz) 
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Figure S35. 1H NMR spectrum of compound 8 in CD3OD (500MHz) 
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Figure S36. 1H NMR spectrum of compound 9 in CDCl3 (500MHz) 
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Figure S37. 1H NMR spectrum of compound 9 in DMSO-d6 (500MHz) 
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Figure S38. 13C NMR spectrum of compound 9 in CDCl3 (125MHz) 
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Figure S39. HMQC spectrum of compound 9 in CDCl3 
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Figure S40. HMBC spectrum of compound 9 in CDCl3 
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Figure S41. 1H NMR spectrum of compound 10 in CDCl3 (500MHz) 
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Figure S42. 1H NMR spectrum of compound 11 in CDCl3 (500 MHz) 
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Figure S43. 1H NMR spectrum of compound 12 in CDCl3 (500 MHz) 
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Figure S44. 1H NMR spectrum of compound 13 in CDCl3 (500MHz) 
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Figure S45. 13C NMR spectrum of compound 13 in CDCl3 (125MHz) 
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Figure S46. CD spectrum of penilactone A (1) 
 
 
Figure S47. CD spectrum of penilactone B (2) 
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Figure S48. CD spectrum of peniphenone D (3) 
 
 
Figure S49. CD spectrum of penilactone D (4) 
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Figure S50. CD spectrum of (R)-5-methyltetronic acid (7) 
 
Figure S51. CD spectrum of terrestric acid (11) 
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Figure S52. CD spectrum of crustosic acid (13)  
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4.3 Formation of terrestric acid in Penicillium crustosum requires redox-assisted 
decarboxylation and stereoisomerization 
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ABSTRACT: Crustosic acid (1) differs from terrestric acid (2) by
a 5β-carboxylmethyl at the tetronate ring instead of a 5α-methyl
group in Penicillium crustosum. The formation of 1 via carbox-
ylcrustic and viridicatic acid was confirmed by gene deletion and
heterologous expression. The conversion of 1 to 2 requires a
decarboxylation-mediated olefination by TraH and subsequent
reduction by TraD. The redox-assisted decarboxylation and
stereoisomerization proved the biosynthetic relationships of fungal
acyltetronates with different stereochemistry.
Natural products of the tetronate family with over 100members contain a characteristic γ-butyrolactone ring
and are mainly found in Actinomycetes.1,2 Fungus-originated
tetronates carry different acyl moieties at C3 and differ from
each other often in substituents at C5. Representatives are
crustosic acid (1), carlic acid, and carlosic acid with a 5β-
carboxylmethyl moiety, terrestric acid (2), carolic acid, and
carolinic acid with a 5α-methyl group, as well as
dehydroterrestric acid (3), dehydrocarolic acid, and agglom-
erin F with an olefinic methylene group at the corresponding
position (Figure 1A).3−9 Despite the interesting structural
features of these fungal tetronates, no detailed investigation on
their biosynthesis was reported prior to this study. The
biosynthesis of agglomerin F in Aspergillus niger was proposed
after a regulator activation and product isolation (Figure 1B).7
In this pathway, the hybrid polyketide synthase−nonribosomal
peptide synthetase (PKS−NRPS) CaaA should be responsible
for the formation of carlosic acid and the P450 oxygenase
CaaC for the oxidative decarboxylation to install the exocyclic
double bond. The nonheme FeII/2-oxoglutarate (FeII-2OG)-
dependent oxygenase CaaD was speculated for the oxidation of
the terminal methyl group at the acyl chain. However, no
genetic and biochemical data support the hypothesis.
We recently identified the terrestric acid biosynthetic gene
cluster (traA-H, pcr11009-pcr11016) in Penicillium crustosum
PRB-2 and proved the involvement of the hybrid PKS−NRPS
TraA in the formation of 1. The nonheme FeII-2OG-
dependent oxygenase TraH was proposed for the conversion
of 1 to 2 (Figure S1, see Supporting Information (SI)).9 In this
study, we report the functions of TraA and the enoyl reductase
TraG to give precursors of 1. Biochemical investigations
proved that the conversion of 1 to 2 was achieved via an
oxidative decarboxylation catalyzed by TraH and a subsequent
stereospecific reduction with the flavin-containing oxidoreduc-
tase TraD.
To identify its function, the genomic sequence of traA was
introduced into Aspergillus nidulans LO8030 by PEG-mediated
protoplast transformation (Tables S1−S3 and Figure S2).10−12
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Figure 1. Representatives of acyltetronic acids in fungi (A) and
proposed biosynthetic pathway of agglomerin F in A. niger (B).
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A transformant JF15 harboring traA was cultivated as a PD
surface culture for 7 days. LC-MS analysis of the EtOAc extract
revealed the presence of two new product peaks 4 and 4* with
[M + H]+ ions at m/z 253.071 ± 0.005 and almost the same
UV spectra (Figures 2A and S3). Both peaks were
interchangeable, which was observed during the isolation
procedure. Isolation and structure elucidation (Table S5 and
Figures S23−S26) proved 4 as the stable form in CD3OD and
identified to be a carboxylmethyltetronic acid derivative with
an unsaturated acyl chain, termed carboxylcrustic acid. We
proposed 4* as a tautomer of 4 (Figures 2A and S3).
Therefore, TraA, sharing 59.5% sequence identity with CaaA
on the amino acid level, functions alone as a tetronate synthase
and differs from other known PKS−NRPS enzymes, requiring
a trans-acting enoyl reductase (ER) for product releasing.13,14
Subsequently, coexpression of traA and the putative ER traG
in LO8030 led to accumulation of a predominant peak 5 with
an [M + H]+ ion at m/z 257.1038 in the obtained transformant
JF45, together with the PKS−NRPS product 4 as a minor
product (Figures 2A and S3). Isolation and NMR analysis
proved 5 to be viridicatic acid, which was also identified in the
wild-type PRB-2 (Table S6 and Figures S5 and S27−S31).15
Obviously, TraG, with sequence identity of 68.9% with CaaB,
acts as an enoyl reductase for the reduction of the two double
bonds at the acyl chain. This was further confirmed by
replacing traG with a hygromycin B cassette in PRB-2 (Figures
2B, S4, and S7).9,16 In comparison to PRB-2, the production of
1, 2, and 5 was completely abolished in the ΔtraG mutant,
whereas 4 as the putative substrate of TraG was accumulated
and confirmed by 1H NMR analysis. One additional minor
peak with an [M + H]+ ion at m/z 209.0827 was identified as a
decarboxylated stereoisomer of 4, termed crustic acid (6), by
comparing their optical rotation values and CD spectra (Table
S7 and Figures S32−S34 and S38). Detection of 6 as a minor
metabolite indicates that the enzyme(s) for the conversion of 1
to 2 can also use 4 as substrate, but with low activity.
To identify their metabolism in the biosynthesis, 4 and 5
were fed in the available ΔtraA and ΔtraG mutants,
respectively (Figures S6−S9). LC-MS analysis revealed that
4 was metabolized to 2 and 6 in the ΔtraA mutant. Feeding 5
also restored the accumulation of 2 as the predominant
product in both ΔtraA and ΔtraG mutants, suggesting their
involvement in the biosynthesis of 2.
Structural comparison revealed that 1 is an anhydrous form
of a hydroxylated derivative of 5. Existence of the open form of
1 was confirmed by LC-MS analysis after incubation in D2O
(Figure S10). The equilibrium between the open and closed
forms explains well the presence of broad peaks in the LC-MS
chromatograms of 1 and 2 (Figures 2B and S5). The
responsible enzyme for the hydroxylation of 5 has not been
identified yet. It cannot be excluded that the responsible
structure gene is located outside the tra cluster.
Having identified the formation of 1 with 4 and 5 as
precursors, we proceeded to investigate its conversion to 2. In
our previous study, the involvement of the putative FeII-2OG-
dependent oxygenase TraH in the conversion of 1 to 2 was
proved by the accumulation of 1 in a ΔtraH mutant.9 TraH
comprises 327 amino acids and shares a sequence identity of
66% with the aforementioned CaaD (Figure 1B). Sequence
alignments showed the typical conserved 2-His-1-Asp ion-
binding triad (His198, His211, and Asp112) in TraH (Figure
S11).17,18 For biochemical characterization, the coding
sequence of traH was amplified from cDNA and cloned into
pET28a (+) for overexpression in Escherichia coli.19,20 The
recombinant N-terminally His6-tagged protein was purified to
near homogeneity as confirmed on SDS-PAGE, yielding 4.5
mg of purified TraH per liter of bacterial culture (Figure S12).
TraH (5.4 μM) was then incubated with 0.5 mM of 1 in the
presence of ascorbic acid (AA), Fe[(NH4)2(SO4)2] (Fe
II), 2-
oxoglutarate (2OG), and dithiothreitol (DTT) at 37 °C for 30
min.21 Surprisingly, LC-MS analysis of the full assay showed a
product peak with an [M + H]+ ion at m/z 209.0806,
corresponding to the molecular formula of C11H13O4, but not
the expected C11H15O4 for 2 (Figures 3A and S13).
Subsequent incubation of TraH with 1 in a large scale enabled
us to identify this product as dehydroterrestric acid (3) with an
exocyclic double bond at the C5-position, which had been
identified in Aspergillus hancockii (Table S4 and Figure S22).8
Detailed investigations demonstrated that the activity of TraH
is strictly dependent on the presence of 2OG and can be
enhanced by externally added FeII (Figure S14). A KM value at
0.49 mM and a turnover number (kcat) at 0.02 s
−1 were
determined for TraH reaction with 1 (Figure S13). These
results proved that TraH catalyzes an oxidative decarboxylation
of 1 to yield 3 instead of 2 (Scheme 1A).
Differing slightly from the previous hypothesis, conversion
of 1 to 3 by TraH implies one additional enzyme required for
the reduction of 3 to 2. We took the flavin-containing
oxidoreductase TraD as a top candidate for the reduction of
the double bond of 3 to the α-methyl group of 2. TraD
comprises 267 amino acids with a well-known conserved FAD-
Figure 2. LC-MS analysis of extracts from A. nidulans (A) and P.
crustosum (B). UV absorptions at 280 nm are illustrated. Extracted ion
chromatograms (EICs) for [M + H]+ ions of 1−6 are given with a
tolerance range of ± 0.005.
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binding motif (GXXXGXG).22−24 To verify its function in
vitro, TraD was successfully overproduced in E. coli BL21-
(DE3) in a similar way to TraH. With the aid of Ni-NTA resin,
TraD was obtained in a yellow color with a yield of 10.6 mg
per liter of bacterial culture (Figure S12). The enzyme assay
with 0.6 μM of TraD and 0.5 mM of 3 was carried out in the
presence of NADPH at 30 °C. LC-MS analysis revealed that 3
was completely converted to 2 in 10 min (Figure 3A). The
high efficiency of the TraD reaction was confirmed by
incubation of 3 with different protein amounts. An amount
of 23% of a 0.5 mM solution of 3 was consumed by 6 nM of
TraD in 10 min (Figure S15). This proved that the reduction
of the exocyclic double bond at the C5-position by TraD was
much more efficient than the oxidative decarboxylation of 1 by
TraH, which was also confirmed by coincubation of 1 with
TraH and TraD.
Incubations of 0.5 mM of 1 with TraH and TraD at different
ratios in the presence of AA, FeII, 2OG, and NADPH at 30 °C
for 30 min showed sequential formation of the intermediate 3
and final product 2 (Figures 3A and S16). The integrity of 2
from the enzyme assay was confirmed by isolation and
comparison of its 1H NMR and CD spectra with those of 2
from PRB-2 (Table S4 and Figures S17 and S21).9 Therefore,
it can be concluded that the flavin-containing oxidoreductase
TraD is responsible for the stereospecific reduction of 3 to
yield 2 with a 5α-methyl group. The product yields of 2 and 3
in different assays confirmed the high efficiency of TraD
toward 3, which was only detected at very low TraD
concentration. This proved that the conversion of 1 to 2 was
controlled by the TraH-catalyzed oxidative decarboxylation of
1 and provides evidence for the absence of 3 in the wild-type
PRB-2.
Incubation of 4 with TraH and TraD led to the detection of
a very weak peak with the same retention time and
fragmentation pattern as those of 6. The proposed
intermediate dehydrocrustic acid with an [M + H]+ at m/z
Figure 3. LC-MS analysis of enzyme assays of TraH without or
together with TraD with 1, TraD with 1 or 3 (A), TraH with 7, and
TraD with 8 (B). UV absorptions at 280 nm are illustrated. EICs refer
to [M + H]+ of 7 at m/z 269.102 and [M + Na]+ of 8 at m/z 289.068
with a tolerance range of ± 0.005.
Scheme 1. Proposed Terrestric Acid Biosynthetic Pathway in P. crusotusm PRB-2 (A) and Mechanisms of TraH-Catalyzed
Olefination (B)
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207.0662 was also detected in the TraH assay with 4 (Figure
S18). These results proved that TraH and TraD can also
convert 4 to 6, but only with very low efficiency, as observed in
the ΔtraG mutant (Scheme 1A).
Taken together, our results proved that the conversion of 1
to 2 required sequential two-step reactions, i.e., oxidative
decarboxylation by the nonheme FeII-2OG-dependent oxygen-
ase TraH and double-bond reduction by the flavin-containing
oxidoreductase TraD (Scheme 1A). Oxidative decarboxyla-
tions have been reported for enzymes from different families,
e.g., the cytochrome P450 OleT,25 the FAD-dependent
decarboxylase CndG,26 and the radical S-adenosyl-L-methio-
nine (SAM) enzyme HemN,27 as well as the nonheme iron
oxidase UndA28,29 and the nonheme FeII-2OG-dependent
oxygenases IsnB, AmbI3, and ScoE.30−33 Differing from IsnB,
AmbI3, and ScoE with indole vinyl isonitriles as final products,
TraH provides a transient intermediate for further reduction,
which accomplishes decarboxylation and stereoisomerization
in the biosynthesis of fungal acyltetronates with different
stereochemistry. In analogy to IsnB, the oxidative decarbox-
ylation by TraH would very likely undergo the abstraction of a
hydrogen atom from the β-position of COOH by FeIV-oxo
species to generate the substrate radical. Subsequent radical-
mediated electron transfer and C−C bond scission eventually
install the exocyclic double bond in 3 accompanied by CO2
elimination (Scheme 1B).
To probe whether the decarboxylation is required for the
olefination by TraH, crustosic acid methyl ester (7) was
prepared by spontaneous methylation of 1 in methanol (Table
S8 and Figures S19, S35, and S36). The enzyme assay of 7 with
TraH was carried out in a similar way as 1 with TraH. LC-MS
analysis revealed the presence of an enzyme product with
almost the same retention time as 7 (Figures 3B and S20).
Subsequent isolation and structure elucidation by comparison
of its 1H NMR data with that of 7 (Tables S8 and S9 and
Figures S35 and S37)) led to the unequivocal identification of
dehydrocrustosic acid methyl ester (8) as the enzyme product,
although no 13C NMR data of 8 could be obtained due to low
conversion. In comparison to the reported oxidative decar-
boxylations catalyzed by nonheme FeII-2OG-dependent oxy-
genases,30−32 methylation of 1 redirected the TraH reaction
from oxidative decarboxylation of 1 to the sole olefination of 7.
Conversion of 7 to the dehydrogenated product 8 by TraH
seems to proceed via a second hydrogen abstraction from the
α-position of COOCH3 by Fe
III−OH species. In total, two
consecutive cleavages of the C−H bond with H2O elimination
completed the olefin installation (Scheme 1B). 7 with a KM at
0.11 mM and kcat at 0.03 s
−1 seem to be even a better substrate
for TraH than 1 (Figure S20). However, neither 7 nor 8 was
detected in P. crustosum PRB-2. Further incubation of TraD
with 8 showed no product formation, indicating the necessity
of the terminal double bond for the reduction by TraD.
In summary, our study provides new insights into the
biosynthesis of fungal acyltetronic acids, especially the
formation of the skeleton and the relationships between
different stereoisomers. Heterologous expression and feeding
experiments suggested that 4 and 5, as the products of TraA
and TraG, respectively, serve as precursors of 1, carrying a 5β-
carboxylmethyl group. Chemically, the conversion of 1 to 2 is a
decarboxylation with epimerization. We demonstrated that 1
was first converted by the nonheme FeII-2OG-dependent
oxygenase TraH, via an oxidative decarboxylation, to a
transient intermediate 3 carrying an exocyclic double bond.
Subsequent stereospecific reduction by the flavin-containing
oxidoreductase TraD led to the formation of the final product
2 bearing a 5α-methyl group. Among the two-step conversion,
the oxidative decarboxylation seems to be the rate-controlling
reaction, and its product 3 was immediately consumed by
TraD with high efficiency. Differing from other nonheme FeII-
2OG-dependent oxygenases being responsible for decarbox-
ylation-assisted olefination,30−32 TraH is capable of catalyzing
dehydrogenation with or without simultaneous decarboxyla-
tion, as demonstrated with 1 and 7 as substrates. It can be
speculated that other fungal stereospecific acyltetronic acids
mentioned in Figure 1A are very likely biosynthesized in a
similar way.
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Experiment Procedures 
1. Computer-assisted sequence analysis 
Sequence analysis of terrestric acid gene cluster was carried out by antiSMASH 
(http://antismash.secondarymetabolites.org/) and by comparison with known entries in database. 
The genomic DNA sequence of the terrestric acid cluster from P. crustosum PRB-2 reported in 
this study is available at GenBank under the accession number MK360919. Multiple sequence 
alignments for TraH and analogues were carried out with the program ClustalW and visualized 
with ESPript 3.2 (http://espript.ibcp.fr/ESPript/cgi-bin/ESPript.cgi) to identify strictly conserved 
amino acid residues. 
2. Strains, media and growth conditions 
The fungal strains used in this study are summarized in Table S1. Penicillium crustosum strain 
PRB-2 was isolated from a deep-sea sediment collected in Prydz Bay at a depth of -526 m.1 The 
wild type strain PRB-2 and deletion mutants ∆traA and ∆traG were cultivated on PDA plates 
(potato dextrose broth, Sigma) with 1.6% agar at 25°C for sporulation and in PD surface culture 
at 25°C for 7 days for detection of secondary metabolites (SMs).  
Aspergillus nidulans strains were grown at 37°C on GMM medium (1.0% glucose, 50 mL/L salt 
solution, 1 mL/L trace element solution, 1.6% agar) for sporulation and transformation with 
appropriate nutrition as required, and incubated at 25°C in PD medium for 7 days for SM 
detection.2-4 The salt solution contains (w/v) 12% NaNO3, 1.04% KCl, 1.04% MgSO4∙7H2O, and 
3.04% KH2PO4. The trace element solution comprises (w/v) 2.2% ZnSO4∙7H2O, 1.1% H3BO3, 
0.5% MnCl2∙4H2O, 0.16% FeSO4∙7H2O, 0.16% CoCl2∙5H2O, 0.16% CuSO4∙5H2O, 0.11% 
(NH4)6Mo7O24∙4H2O, and 5% Na4EDTA. 
Escherichia coli DH5α and BL21(DE3) were grown in liquid or on solid Luria-Bertani (LB) 
medium (1% NaCl, 1% tryptone, and 0.5% yeast extract) for standard DNA manipulation. 50 
g/mL carbenicillin or 25 g/mL kanamycin were supplemented for cultivation of recombinant E. 
coli strains.  
3. Genomic DNA isolation 
The mycelia of P. crustosum and A. nidulans were collected on sterilized filter paper and then 
suspended in 400 L of LETS buffer (10 mM Tris-HCl pH 8.0, 20 mM EDTA pH 8.0, 0.5% SDS, 
and 0.1 M LiCl) in 2 mL Eppendorf tubes and vigorous vortexed with four glass beads (2.85 mm 
in diameter). 300 L LETS buffer were added in the solution, which was subsequently treated 
with 700 μL phenol: chloroform: isoamylol (25:24:1). The genomic DNA (gDNA) was precipitated 
by addition of 900 L absolute ethanol and centrifugation at 17,000 x g for 30 min. After washing 
with 70% ethanol and drying, the obtained DNA was dissolved in 50 L distillated H2O. 
4. RNA isolation and cDNA synthesis 
For isolation of RNA from P. crustosum PRB-2, the fungus was cultivated in liquid PD medium 
shaking at 230 rpm for 7 days and the cells were collected by centrifugation. RNA extraction was 
performed by using Fungal RNA Mini kit (VWR OMEGA bio-tek E.Z.N.A) according to the 
standard manufacturer´s instruction. The ProtoScript II First Strand cDNA Synthesis kit (BioLabs) 
was used for cDNA synthesis with Oligo-dT primers. 
195
SUPPORTING INFORMATION 
S5 
 
5. PCR amplification, gene cloning and plasmid construction 
Plasmids used in this study are listed in Table S2. The oligonucleotide sequences for PCR 
amplification are given in Table S3. Genetic manipulation in E. coli was carried out according to 
the protocol by Sambrook and Russell.5 All primers were synthesized by Seqlab GmbH 
(Göttingen, Germany). PCR amplification was carried out by using Phusion® High-Fidelity DNA 
polymerase from New England Biolabs (NEB) on a T100TM Thermal cycler from Bio-Rad. PCR 
reaction mixtures and thermal profiles were set as recommended by the manufacturer´s 
instruction. 
To construct pJF80 and pJF81 for traG deletion, primers were designed with split-marker 
strategy by using p5HY and p3YG vectors (Figure S4).6,7 To construct the plasmids for 
heterologous expression of traA and traAG in A. nidulans, an assembly approach based on the 
homologous recombination in E. coli was used (Figure S2).8 Full length of traA including its 
terminator of 497 bp was amplified from gDNA of P. crustosum PRB-2 as the template by PCR 
with primer pairs A.n-traA-1F-For/1F-Rev and A.n-traA-2F-For/2F-Rev (Table S3) and inserted 
into the corresponding sites of pYH-wA-pyrG with homologous flanking sequences of the wA 
gene to create pJF27.4 For co-expression of traA and traG, traA including gpdA promoter and its 
terminator of 497 bp from pJF27, and traG with its 778 bp promoter and 568 bp terminator from 
P. crustosum PRB-2 were cloned into pYWB2 by homologous recombination with flanking 
sequences of the wA gene to create pJF91.9 Herein, primers A.n-traAG-1F-For/traA-1F-Rev, 
A.n-traA-2F-For/traAG-1F-Rev and A.n-traAG-2F-For/2F-Rev (Table S3) were used for PCR 
amplification.  
To construct the plasmid for expressing traD and traH in E. coli, the coding region of traD and 
traH were amplified by PCR from cDNA with the primer pairs TraD-28-For/Rev and 
TraH-28-For/Rev (Table S3). The expression vector pET-28a (+) was digested with BamHI and 
EcoRI, and ligated with DNA fragments by homologous recombination yielding the expression 
plasmid pJF72 for TraD and pJF74 for TraH, which were confirmed by sequencing (Seqlab 
GmbH). 
6. Deletion of traG in P. crustosum and cultivation of deletion mutants. 
Fresh conidia from 7-day PDA culture of P. crustosum PRB-2 were inoculated into 30 mL LMM 
medium (1.0% glucose, 50 mL/L salt solution, 1 mL/L trace element solution, and 0.5% yeast 
extract) in 100 mL flask and incubated at 25°C and 230 rpm for germination. Mycelia were 
harvested after 11 h by centrifugation at 2,800 x g for 10 min, and washed with distillated H2O. 
The mycelia were then transferred into a 50 mL flask with 10 mL of osmotic buffer (1.2 M MgSO4 
in 10 mM sodium phosphate, pH 5.8) containing 50 mg lysing enzyme from Trichoderma 
harzianum (Sigma) and 20 mg yatalase from Corynebacterium sp. OZ-21 (OZEKI Co., Ltd.). 
After shaking at 30°C and 100 rpm for 2.5 h, the cells were transferred into a 50 mL falcon tube 
and overlaid gently with 10 mL of trapping buffer (0.6 M sorbitol in 0.1 M Tris-HCI, pH 7.0). After 
centrifugation at 4°C and 2,800 x g for 10 min, the protoplasts were collected from the interface 
of the two buffer systems. The protoplasts were then transferred to a sterile 15 mL falcon tube 
and resuspended in 200 L of STC buffer (1.2 M sorbitol, 10 mM CaCl2, and 10 mM Tris-HCI, pH 
7.5) for transformation.  
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The via PCR constructed gene deletion cassettes mentioned above were transformed into P. 
crustosum by polyethylene glycol (PEG) mediated protoplast transformation. The DNA 
fragments (2 g) were incubated with 100 L of the protoplasts for 50 min on ice. 1.25 mL of 
PEG solution (60% PEG 4000, 50 mM CaCl2, 50 mM Tris-HCI, pH 7.5) was then added and 
gently mixed. After incubation at room temperature for 30 min, the mixture was transferred in 5 
mL STC buffer and spread on plates with SMM bottom medium (1.0% glucose, 50 mL/L salt 
solution, 1 mL/L trace element solution, 1.2 M sorbitol, and 1.6% agar) containing 200 g/mL 
hygromycin B. SMM top medium (1.0% glucose, 50 mL/L salt solution, 1 mL/L trace element 
solution, 1.2 M sorbitol, and 0.8% agar) containing 100 g/mL hygromycin B was overlaid softly 
on the plates. Three days later, the transformants were transferred onto fresh PDA plates 
containing 200 g/mL hygromycin B for second round selection. The obtained transformants 
were inoculated in PD medium for isolation of genomic DNA to verify the integrity, which was 
carried out by PCR amplification (Figure S4). The obtained ∆traG mutant was cultivated in PD 
liquid medium at 25 °C for 7 days, together with ∆traA mutant in a previous study.6 For SM 
detection of the deletion mutants, cultures were extracted with ethyl acetate, dissolved in a 
mixture of MeOH and H2O (8 : 2) and analyzed on LC-MS by method B (see below for methods 
of HPLC and LC-MS analysis).  
7. Heterologous expression of traA and traG in A. nidulans 
A. nidulans strain LO8030 was used as the recipient host.3 Fungal protoplast preparation and 
transformation were performed according to the method described previously.3 pJF27 containing 
the PKS-NRPS gene traA was transformed into LO8030 to create the traA expression strain 
JF15. pJF91 containing both traA and traG was transformed into LO8030 to create the traAG 
expression strain JF45. Potential transformants were verified by PCR using the primers traA-F/R 
or traG-F/R (Table S3). Differing from P. crustosum, germination condition was at 37°C with 
appropriate nutrition as supplements (0.75 M riboflavin and 0.5 M pyridoxine for JF15, 5% 
uracil, 6% uridine and 0.5 M pyridoxine for JF45) for 6 h. Protoplastation condition was at 37°C 
for 2.5 h. A. nidulans strains were cultivated in PD liquid medium at 25°C for 7 days for LC-MS 
analysis (method B) of the SM production. 
8. Precursor feeding in P. crustosum deletion mutants 
For feeding experiments, the precursors (5S)-carboxylcrustic acid (4) and (5S)-viridicatic acid (5) 
were dissolved in DMSO to give 1 M stock solution, and added to 10 mL of PD cultures of 
respective deletion mutants, 4 to ∆traA mutant, and 5 to ∆traA and ∆traG, leading to final 
concentrations of 0.4 mM. After further cultivation at 25°C for 7 d in PD medium, the secondary 
metabolites were extracted with ethyl acetate, dissolved in a mixture of MeOH and H2O (8 : 2) 
and analyzed on LC-MS by method B (see below for methods of HPLC and LC-MS analysis). 
9. Overproduction and purification of TraD and TraH 
The expression plasmids pJF72 and pJF74 were constructed for TraD and TraH expression in E. 
coli as mentioned above. The recombinant E. coli BL21(DE3) strains were cultivated in Terrific 
Broth (TB) medium (2.4% yeast extract, 2.0% tryptone, 0.4% glycerol, 0.1 M phosphate buffer, 
pH 7.4). TraH expression was induced with 0.5 mM IPTG at 20°C for 16 h and TraD at 16°C for 
16 h. The recombinant His6-tagged protein were purified on Ni-NTA affinity chromatography 
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(Qiagen, Hilden) using the published procedures.10,11 The purity for TraH and TraD were 
confirmed on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 
S12). The protein concentration was determined on Nanodrop 2000c spectrophotometer 
(Thermo Scientific, Braunschweig, Germany). 4.5 mg/L of protein can be obtained for TraH, 10.6 
mg/L of protein can be obtained for TraD from the bacterial culture. 
10. In vitro assays of TraD and TraH 
To determine the enzyme activity of TraH toward (5S, 5'S)-crustosic acid (1) or (5S, 
5'S)-crustosic acid methyl ester (7), the enzyme assays (50 L) contained phosphate buffer (20 
mM, pH 7.4), ascorbic acid (1 mM), (5S, 5'S)-crustosic acid (1, 0.5 mM) or (5S, 5'S)-crustosic 
acid methyl ester (7, 0.5 mM), DTT (1 mM), Fe[(NH4)2(SO4)2] (1 mM), 2-oxoglutarate (1 mM), 
glycerol (0.5 − 5%), DMSO (5%), and the purified recombinant TraH (5.4 M). The enzyme 
assays were carried out at 37 °C for 30 min and terminated with one volume of acetonitrile. The 
reaction mixtures were centrifuged at 17,000 x g for 30 min before further analysis on HPLC and 
LC-MS by method A (see below for methods of HPLC and LC-MS analysis). 
To determine the enzyme activity of TraD toward dehydroterrestric acid (3), the enzyme assays 
(50 L) contained phosphate buffer (20 mM, pH 7.4), NAD(P)H (2 mM), glycerol (0.5 − 5%), 
DMSO (5%), dehydroterrestric acid (3, 0.5 mM), and the purified recombinant TraD (0.6 M). 
The enzyme assays were incubated at 30 °C for 10 min and terminated with one volume of 
acetonitrile. The reaction mixtures were centrifuged at 17,000 x g for 30 min before further 
analysis on HPLC and LC-MS by method A. The same reaction condition was used for the 
enzyme assay of TraD with (5'S)-dehydrocrustosic acid methyl ester (8). 
To prove the conversion of (5S, 5'S)-crustosic acid (1) by TraH and TraD, the enzyme assays 
(50 L) contained phosphate buffer (20 mM, pH 7.4), ascorbic acid (1 mM), (5S, 5'S)-crustosic 
acid (1, 0.5 mM), Fe[(NH4)2(SO4)2] (1 mM), 2-oxoglutarate (1 mM), NADPH (2 mM), glycerol (0.5 
− 5%), DMSO (5%), and the purified recombinant TraH (5.4 M) and TraD (0.6 M). The 
enzyme assays were incubated at 30 °C for 30 min and terminated with one volume of 
acetonitrile. The reaction mixtures were centrifuged at 17,000 x g for 30 min before further 
analysis on HPLC and LC-MS by method A. 
To prove the conversion of (5S)-carboxylcrustic acid (4) to (5R)-crustic acid (6) by TraH and 
TraD, the enzyme assays (50 L) containing phosphate buffer (20 mM, pH 7.4), ascorbic acid (1 
mM), (5S)-carboxylcrustic acid (4, 0.5 mM), DTT (1 mM), Fe[(NH4)2(SO4)2] (1 mM), 
2-oxoglutarate (1 mM), NAD(P)H (2 mM), glycerol (0.5 − 5%), DMSO (5%), and the purified 
recombinant TraH (12 M) and TraD (6 M) were incubated at 30°C for 16 h and terminated with 
one volume of acetonitrile. The reaction mixtures were centrifuged at 17,000 x g for 30 min 
before further analysis on HPLC and LC-MS by method A. In addition, (5S)-carboxylcrustic acid 
(4, 0.5 mM) was incubated with TraH (12 M) in the presence of ascorbic acid (1 mM), DTT (1 
mM), Fe[(NH4)2(SO4)2] (1 mM), 2-oxoglutarate (1 mM) at 37°C for 16 h. After terminated with 
acetonitrile and centrifugation, the enzyme assay was further analyzed on HPLC and LC-MS by 
method A. 
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11. Large-scale fermentation, extraction and isolation of secondary metabolites 
To isolate 4 from A. nidulans carrying traA, the transformant JF15 was cultivated in 60 x 250 mL 
flasks each containing 50 mL PD liquid medium with appropriate nutrition as supplement at 25°C 
for 7 days. The supernatant and mycelia were separated, and extracted with ethyl acetate and 
acetone, separately. The acetone extract was concentrated under reduced pressure to afford an 
aqueous solution, and then extracted with ethyl acetate. The two ethyl acetate extracts were 
combined and evaporated under reduced pressure to give a crude extract (0.8 g). The crude 
extract was applied to Sephadex LH-20 column eluted with methanol, yielding twenty fractions 
(1 – 20). Fraction 8 was purified on a semi-preparative HPLC (acetonitrile / H2O (40 : 60) with 
0.1% trifluoroacetic acid) yielding compound 4 (8 mg). 
To isolate 5 from A. nidulans carrying traA and traG, the transformant JF45 was cultivated in 10 
x 1 L flasks each containing 100 g rice and 150 mL H2O (with appropriate nutrition as 
supplement) at 25°C for 7 days. After extracting with 15 L ethyl acetate and concentrated under 
reduced pressure, the crude extract (2.5 g) obtained from JF45 cultivation was applied to silica 
gel column chromatography by using petroleum ether / EtOAc (1 : 1, 1 : 3, and 1 : 5, v/v) as 
elution solvents, giving fractions 1 − 10. 5 (15 mg) was obtained from fraction 3 after purification 
on Sephadex LH-20 column using MeOH as eluent. 
To isolate 5 from P. crustosum PRB-2, spores were inoculated in 4 L PD liquid medium and 
cultivated at 25°C for 14 days. 1.0 g crude extract was obtained after extraction, and subjected 
to silica gel column chromatography by using petroleum ether / EtOAc (10 : 1, 3 : 1, 1 : 1, 1 : 3, 
1 : 6, v/v) as elution solvents, giving fractions 1 − 5. 5 (3 mg) was obtained from fraction 3 by 
applying to Sephadex LH-20 column using MeOH as eluent. 
To isolate the accumulated products 4 and 6 from ∆traG mutant, the strain was cultivated in 6 L 
PD liquid medium at 25°C for 14 days and extracted as mentioned above. The resulted crude 
extract (2.5 g) was subjected to silica gel column chromatography by using stepwise gradient 
elution with the mixtures of petroleum ether / EtOAc (10 : 1, 5 : 1, 3 : 1, and 1 : 1, v/v) to give 25 
fractions. Subsequent purification on semi-preparative HPLC with isocratic elution using 
acetonitrile / H2O (40 : 60) supplied with 0.1% trifluoroacetic acid yielded 3 mg of 4, using 
acetonitrile / H2O (70 : 30) with 0.1% trifluoroacetic acid yielded 5 mg of 6.  
To prepare the enzyme products for structural elucidation, assays were carried out in large 
scales (10 − 20 mL) using the reaction conditions mentioned above. The reaction mixtures were 
extracted with double volume of ethyl acetate for three times. The organic phases were 
combined and concentrated under vacuum. The resulted residues were dissolved in acetonitrile 
and centrifuged at 17,000 x g for 20 min. After isolation on semi-preparative HPLC eluted with 
40% acetonitrile containing 0.1% trifluoroacetic acid, compound 2 from the incubation mixture of 
TraH, TraD and 1, compound 3 from TraH and 1, and 5 from TraH and 4, were obtained. 
12. Determination of kinetic parameters 
For determination of kinetic parameters of TraH toward 1 or 7, the enzyme assays were carried 
out in a similar way as mentioned above, excepting that substrates at final concentrations of 
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0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 2, 5 mM, respectively. The enzyme assays were incubated at 
37°C for 30 min and terminated with one volume of acetonitrile. The supernatants were 
subjected to HPLC analysis by method A after centrifuging at 17,000 x g for 30 min. The KM and 
kcat values were obtained by analysis with GraphPad Prism 8. 
13. HPLC and LC-MS analysis of secondary metabolites 
Analysis of SMs was performed on an Agilent series 1200 HPLC (Agilent Technologies, 
Böblingen, Germany) with an Agilent Eclipse XDB-C18 column (150 × 4.6 mm, 5 m). Water (A) 
and acetonitrile (B), both with 0.1% (v/v) formic acid, were used as solvents at flow rate of 0.5 
mL/min. The substances were eluted with a linear gradient from 5 – 100% B in 15 min, then 
washed with 100% (v/v) solvent B for 5 min and equilibrated with 5% (v/v) solvent B for 5 min 
(method A) or with a linear gradient from 5 – 100% B in 40 min, then washed with 100% (v/v) 
solvent B for 5 min and equilibrated with 5% (v/v) solvent B for 10 min (method B). UV 
absorptions at 280 nm were illustrated in this study. Semi-preparative HPLC was performed on 
the same equipment with an Agilent Eclipse XDB-C18 column (9.4 × 250 mm, 5 m) column and 
a flow rate of 2 mL/min. 
LC-MS analysis was performed on an Agilent 1260 HPLC system equipped with a microTOF-Q 
III spectrometer (Bruker, Bremen, Germany) by using Multospher 120 RP18-5 column (250 × 2 
mm, 5 m) (CS-Chromatographie Service GmbH) and method A or method B for separation at 
flow rate of 0.25 mL/min. Electrospray positive or negative ionization mode was selected for 
determination of the exact masses. The capillary voltage was set to 4.5 kV and a collision 
energy of 8.0 eV. Sodium formate was used in each run for mass calibration. The masses were 
scanned in the range of m/z 100 – 1500. Data were evaluated with the Compass DataAnalysis 
4.2 software (Bruker Daltonik, Bremen, Germany). 
14. NMR analysis  
NMR spectra were recorded on a JEOL ECA-500 MHz spectrometer (JEOL, Tokyo, Japan). The 
spectra were processed with MestReNova 6.1.0 (Metrelab) or Delta 5.0.4 (JEOL). Chemical 
shifts are referenced to those of the solvent signals. NMR data are given in Tables S4 – S8 and 
spectra in Figures S21 – S35. 
15. Circular dichroism (CD) spectroscopic analysis 
CD spectra were taken on a J-815 CD spectrometer (Jasco Deutschland GmbH, Pfungstadt, 
Germany). The samples were dissolved in methanol and measured in the range of 200–400 nm 
by using a 1 mm path length quartz cuvette (Hellma Analytics, Müllheim, Germany). The CD 
spectra are given in Figures S36. 
16. Measurement of optical rotations 
The optical rotation was measured with the polarimeter Jasco DIP-370 at 20°C using the D-line 
of the sodium lamp at =589.3 nm. Prior to the measurement, the polarimeter was calibrated 
with methanol or ethanol as solvent. 
17. Physiochemical properties of the compounds described in this study 
(5R, 5'S)-terrestric acid (2): Yellow oil; CD (MeOH): max () 282 (+0.9) nm, 228 (+2.8), 212 
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(+7.5); HRMS (m/z): (ESI/[M+H]+) calcd. for C11H15O4, 211.0965, found 211.0963. 
(5'S)-dehydroterrestric acid (3): White powder; HRMS (m/z): (ESI/[M+H]+) calcd. for C11H13O4, 
209.0808, found 209.0806. 
(5S)-carboxylcrustic acid (4): Yellow oil; [α]20 D  = -46.5 (c 0.40, MeOH); HRMS (m/z): (ESI/[M+H]+) 
calcd. for C12H13O6, 253.0707, found 253.0719 
CD spectrum (MeOH) of sample isolated from a A. nidulans strain JF15 harboring traA: max () 
332 (-1.9), 268 (-1.7), 228 (-4.1) nm . 
CD spectrum (MeOH) of sample isolated from ∆traG mutant of P. crustosum: max () 346 (-2.8), 
279 (-3.9), 223 (-6.0) nm. 
(5S)-viridicatic acid (5): Yellow oil; [α]20 D  = -73.6 (c 1.0, EtOH); HRMS (m/z): (ESI/[M+H]+) calcd. 
for C12H17O6, 257.1020, found 257.1038. 
CD spectrum (MeOH) of sample isolated from a A. nidulans strain JF45 harboring traA and traG: 
max () 258 (-11.4), 230 (-11.3) nm. 
CD spectrum (MeOH) of sample isolated from P. crustosum PRB-2: max () 259 (-7.0), 230 
(-7.6) nm. 
(5R)-crustic acid (6): Yellow oil; [α]20 D  = +19.1 (c 0.25, MeOH); CD (MeOH) max () 317 (+0.2), 
258 (+2.1), 228 (+5.2) nm; HRMS (m/z): (ESI/[M+H]+) calcd. for C11H13O4, 209.0808, found 
209.0827. 
(5S, 5'S)-custosic acid methyl ester (7): Yellow oil; HRMS (m/z): (ESI/[M+H]+) calcd. for 
C13H17O6, 269.1020, found 269.1037. 
(5'S)-dehydrocrustosic acid methyl ester (8): White powder; HRMS (m/z): (ESI/[M+Na]+) calcd. 
for C13H14NaO6, 289.0683, found 289.0700. 
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Supplementary Tables 
Table S1. Strains used in this study 
Strains Genotype Source/Ref. 
Penicillium crustosum   
 PRB-2 Wild type 1 
 ΔtraA ΔtraA::hph in P. crustosum PRB-2 6 
 ΔtraG ΔtraG::hph in P. crustosum PRB-2 This study 
Aspergillus nidulans   
 LO8030 pyroA4, riboB2, pyrG89, nkuA::argB,  
sterigmatocystin cluster (AN7804-AN7825), 
emericellamide cluster (AN2545-AN2549), 
asperfuranone cluster (AN1039-AN1029), 
monodictyphenone cluster (AN10023-AN10021), 
terrequinone cluster (AN8512-AN8520), 
austinol cluster part 1 (AN8379-AN8384), 
austinol cluster part 2 (AN9246-AN9259), 
F9775 cluster (AN7906-AN7915),  
asperthecin cluster (AN6000-AN6002) 
2,3 
 JF15 gpdA::traA::AfpyrG in A. nidulans LO8030 This study 
 JF45 gpdA::traA::traG::Ribo in A. nidulans LO8030 This study 
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Table S2. Plasmids used and constructed in this study 
Plasmids Description Source/Ref. 
p5HY Two-third of the hph resistance gene at the 5´-end, originated from the 
pUChph and inserted into pESC-URA. For gene replacement using hph 
as selection marker. 
6 
p3YG Two-third of the hph resistance gene at the 3´-end, originated from the 
pUChph and inserted into pESC-URA. For gene replacement using hph 
as selection marker. 
6 
pJF80 A 1054 bp US PCR fragment of traG from genomic DNA of P. 
crustosum PRB-2 inserted in p5HY. 
This study 
pJF81 A 939 bp DS PCR fragment of traG from genomic DNA of P. crustosum 
PRB-2 inserted in p3YG. 
This study 
pYH-wA-pyrG URA3, wA flanking, AfpyrG, Amp 4  
pYWB2 URA3, wA flanking, Afribo, Amp 9 
pJF27 pYH-wA-traA; a 12068 bp fragment of traA with its terminator from 
genomic DNA of P. crustosum PRB-2 inserted in pYH-wA-gpdA 
This study 
pJF91 pYH-wA-traAG; a 12788 bp fragment of traA with gpdA promoter and 
its terminator from pJF27, and a 2528 bp fragment of traG with its 
promoter and terminator from genomic DNA of P. crustosum PRB-2 
inserted in pYWB2 
This study 
pJF72 pET-28a(+)-traD; a 804 bp fragment of traD from cDNA of P. crustosum 
PRB-2 with BamHI and EcoRI inserted in pET28a(+) 
This study 
pJF74 pET-28a(+)-traH; a 984 bp fragment of traH from cDNA of P. crustosum 
PRB-2 with BamHI and EcoRI inserted in pET28a(+) 
This study 
US: upstream; DS: downstream 
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Table S3. Primers used in this study 
Primers Sequence 5’-3’ Targeted amplification 
5F-R GCTGAAGTCGATTTGAGTCCAC 
US of hph to verify 5F of P. crustosum 
mutant 
3F-F GCATTAATGCATTGGACCTCGC 
DS of hph to verify 3F of P. crustosum 
mutant 
traA-F TGCATCTTGTAGAGCTCGC 
1819 bp partial fragment of traA 
traA-R GAGGGCGGTTTTAGAATCAATTG 
traG-up-F GAATTGTTAATTAAGAGCTCAGATCTCTAGCAGGACTCATCACAGACG 1054 bp upstream fragment of traG to 
construct pJF80 traG-up-R CAACCCTCACTAAAGGGCGGCCGCACTAGCCGGGCTTCAGGGAAATTC 
traG-down-F CGACTCACTATAGGGCCCGGGCGTCGACCCATGGTCCGATTGAGCTGG 939 bp downstream fragment of traG to 
construct pJF81 traG-down-R CTAGCCGCGGTACCAAGCTTACTCGAGGCATGATTTGCCTCTAGACCCC 
traG-F CAACACAATGTCACGGTACC 
1071 bp partial fragment of traG 
traG-R CAGACATGGCCTGGGTACG 
traG-5F-F CCGACAGACGAATATGGTGGC US of hph to verify ∆traG mutant 
traG-3F-R CAGACATGCTTTCCGCAC DS of hph to verify ∆traG mutant 
A.n-traA-1F-For CATCTTCCCATCCAAGAACCTTTAATCATGGTTCTACCCCAGCCC DNA of 1st traA fragment 5442 bp from P. 
crustosum to construct pJF27 A.n-traA-1F-Rev CTCATCAAGCCCGTGGACGAGCAAATGACTGTGAGCAACCACCATAG 
A.n-traA-2F-For CTATGGTGGTTGCTCACAGTCATTTGCTCGTCCACGGGCTTGATGAG DNA of 2nd traA fragment 6176 bp with 
its 497 bp terminator from P. crustosum 
to construct pJF27 
A.n-traA-2F-Rev GACACAGAATAACTCTCGCTAGCGTAGCTGGCAAATATAGTTACCT 
A.n-traAG-1F-For CTTGACTCTCCTTCTCCTGATCGGATCCCATGCGGAGAGACGGACG 
DNA of 6190 bp from pJF27 with 
A.n-traA-1F-Rev to construct pJF91 
A.n-traAG-1R-Rev TTAGTTTGCAAAATCGACGATTGCTGTAGCTGGCAAATATAGTTACCTA 
DNA of 6673 bp from pJF27 with 
A.n-traA-2F-For to construct pJF91 
A.n-traAG-2F-For GATAGGTAACTATATTTGCCAGCTACAGCAATCGTCGATTTTGCAAAC DNA of traG with its 788 bp promoter and 
568 bp terminator from P. crustosum to 
construct pJF91 
A.n-traAG-2R-Rev CAACACCATATTTTAATCCCATGTGCATGGATACTCAGGTGGTATAATT 
TraD-28-For GTGGACAGCAAATGGGTCGCGGATCCATGAAAGTTTTGATTATTTTTGC 804 bp fragment of traD to construct 
pJF72 TraD-28-Rev GCAAGCTTGTCGACGGAGCTCGAATTCTCACGCTTCTTTGACGTCG 
TraH-28-For CTGGTGGACAGCAAATGGGTCGCGGATCCATGTCTGTCGATGCGGCC 984 bp fragment of traH to construct 
pJF74 TraH-28-Rev CAAGCTTGTCGACGGAGCTCGAATTCCTACAATGAAGTATCATCCGTCA 
US: upstream; DS: downstream 
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Table S4. 1H NMR data of compounds 2 and 3 
Compound 
 
(5R, 5'S)-terrestric acid (2, CDCl3)12 
 
(5'S)-dehydroterrestric acid (3, DMSO-d6)13 
Position δH, multi., J in Hz δH, multi., J in Hz 
5 4.62, q, 7.0, 1H  - 
6 1.48, d, 7.0, 3H 5.18, d, 2.5, 1H 
 - 5.01, d, 2.5, 1H 
3´ 3.60, ddd, 20.0, 9.6, 4.5, 1H 3.56, ddd, 19.9, 9.4, 4.2, 1Ha 
 3.27, ddd, 20.0, 9.6, 5.1, 1H 3.48, ddd, 19.9, 9.4, 4.2, 1Ha 
4´ 2.36, m, 1H 2.33, m, 1H 
 1.87, m, 1H 1.84, m, 1H 
5´ 4.93, m, 1H 5.02, m, 1H 
6´ 1.97, m, 1H 1.81, m, 1H 
 1.79, m, 1H 1.74, m, 1H 
7´ 1.07, t, 7.5, 3H  0.97, t, 7.4, 3H 
Note: Due to the Z/E isomerization, there were two sets of signals in a ratio of 1:1 showed in the 1H NMR spectra. 
The corresponding signals are overlapping in most cases with each other. Therefore, only one set of the NMR 
data was listed in the table. The Z/E isomerization was proved by deuterium incorporation after incubation of (5S, 
5'S)-crustosic acid (1) in D2O-enriched milieu (Figure S10). 
a signals overlapped with those of water. 
Compounds 3 and 2 were isolated from incubation mixtures of 1 with TraH alone and with TraH and TraD, 
respectively. Their NMR data correspond very well to those reported previously.12,13 
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Table S5. NMR data of compound 4 
Compound 
 
(5S)-carboxylcrustic acid (4, CD3OD) 
 
Position δH, multi., J in Hz δC Key HMBC correlations 
2 - 167.8a  
3 - n.d.b  
4 - n.d.b  
5 4.95, dd, 5.9, 4.1, 1H 80.2 C-2, C-13 
6 - 178.5  
7 7.10, d, 15.3, 1H 119.0 C-6, C-9 
8 7.68, dd, 15.3, 9.9, 1H 149.5 C-6, C-10 
9 6.50, m, 1H 132.2 C-8, C-11 
10 6.50, m, 1H 146.5 C-8, C-11 
11 1.96, d, 5.5, 3H 19.3 C-9, C-10 
12 2.99, dd, 17.4, 4.1, 1H 35.8 C-5, C-13 
 2.88, dd, 17.4, 5.9, 1H -  
13 - 172.2  
Note: a Signals acquired from HMBC correlations.  
b Signals not detected in neither 13C NMR nor HMBC spectrum. 
Compound 4 was isolated from A. nidulans JF15 harboring pJF27 with traA. 
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Table S6. NMR data of compound 5 
Compound 
 
(5S)-viridicatic acid (5, DMSO-d6) 
 
Position δH, multi., J in Hz δC Key HMBC correlations 
2 - 174.2  
3 - 94.2  
4 - 171.8  
5 4.37, dd, 9.3, 3.5, 1H 75.7 C-2, C-4, C-13 
6 - 194.2  
7 2.61, dd, 8.5, 6.9, 2H 40.1a C-6, C-8, C-9 
8 1.45, m, 2H 24.2 C-6, C-9, C-10 
9 1.25, m, 2H 31.3 C-10 
10 1.25, m, 2H 22.0 C-9 
11 0.85, t, 7.0, 3H 13.9 C-9, C-10 
12 2.69, dd, 16.0, 3.5, 1H 37.6 C-5, C-13 
 2.20, dd, 16.0, 9.3, 1H -  
13 - 193.7  
13-OH 12.44, s, 1H -  
Note: a signals overlapped with those of solvents. 
Compound 5 was isolated from A. nidulans JF45 harboring pJF91 with traA and traG. 
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Table S7. NMR data of compound 6 
Compound 
 
(5R)-crustic acid (6, CD3OD) 
 
Position δH, multi., J in Hz δC Key HMBC correlations 
2 - 173.7  
3 - 96.8  
4 - 201.4a  
5 4.79, q, 7.0, 1H 80.8 C-2, C-4 
6 - 179.4  
7 7.11, d, 15.2, 1H 119.0 C-6, C-9 
8 7.69, dd, 15.2, 9.9, 1H 149.9 C-6, C-10 
9 6.50, m, 1H 132.2 C-7, C-11 
10 6.50, m, 1H 146.9 C-8, C-11 
11 1.96, d, 5.6, 3H 19.4 C-9, C-10 
12 1.45, d, 7.0, 3H 17.0 C-4, C-5 
Note: a Signal acquired from HMBC correlations.  
Compound 6 was isolated from a traG-mutant. 
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Table S8. NMR data of compound 7 
Compound 
 
(5S, 5'S)-crustosic acid methyl ester (7, CDCl3) 
Position δH, multi., J in Hz δC 
2 - 170.6/167.2 
3 - 95.8/95.3 
4 - 197.5/193.7 
5 4.83, dd, 6.9, 4.1, 1H 78.8/78.6 
6 3.00, dd, 9.0, 4.1, 1H 35.9/35.9 
 2.85, dd, 9.0, 6.9, 1H - 
7 - 169.8/169.8 
8 3.70, s, 3H 52.3/52.3 
9 - - 
10 - - 
11 - - 
12 - - 
2´ - 187.0/186.3 
3´ 3.61, ddd, 14.0, 8.7, 4.2, 1H 34.1/33.8 
 3.28, ddd, 14.0, 9.5, 8.6, 1H - 
4´ 2.37, m, 1H 27.9/27.8 
 1.87, m, 1H - 
5´ 4.93, m, 1H 93.3/92.8 
6´ 1.98, m, 1H 26.6/26.6 
 1.79, m, 1H - 
7´ 1.06, t, 7.5, 3H 9.7/9.5 
Note: due to the Z/E isomerization, there were two sets of signals in a ratio of 1:1 showed in the 1H NMR spectra. 
The corresponding signals are overlapping in most cases with each other. Therefore, only one set of the NMR 
data was listed in the table. 
Compound 7 was isolated from a methanol solution of 1. 
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Table S9. 1H NMR data of compound 8 
Compound 
(5'S)-dehydrocrustosic acid methyl ester (8, CDCl3) 
Position δH, multi., J in Hz 
6 5.91, s, 1H 
8 3.81, s, 3H 
3´ 3.68, ddd, 20.3, 9.4, 4.0, 1H 
 3.35, m, 1H 
4´ 2.43, m, 1H 
 2.01, m, 1Ha 
5´ 5.02, m, 1H 
6´ 1.93, m, 1Ha 
 1.83, m, 1H 
7´ 1.08, t, 7.4, 3H 
Note: due to the Z/E isomerization, there were two sets of signals in a ratio of 1:1 showed in the 1H NMR spectra. 
The corresponding signals are overlapping in most cases with each other. Therefore, only one set of the NMR 
data was listed in the table. 
a signals overlapped with those of water. 
Compound 8 was isolated from incubation mixture of 7 with TraH. 
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Supplementary Figures 
 
Protein Putative function 
TraA carboxylcrustic acid synthase  
KS-AT-DH-MeT-KR-ACP-C-A-PCP 
TraB cytochrome P450 
TraC hypothetical protein 
TraD flavin containing dehydroterrestric acid hydrogenase 
TraE hypothetical protein 
TraF transporter 
TraG crustic acid reductase 
TraH 2-oxoglutarate-dependent crustosic acid decarboxylase 
The domain organization of TraA was deduced as ketosynthase (KS), acyltransferase (AT), 
dehydratase (DH), methyltransferase (MeT), ketoreductase (KR), and acyl carrier protein (ACP) 
domains of PKS, and the condensation (C), adenylation (A), peptidyl carrier protein (PCP) domains 
of NRPS.14,15 
 
Figure S1. Deduced functions of ORFs in terrestric acid gene cluster of P. crustosum PRB-26 
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Figure S2. Constructs used for heterologous expression of traA and traAG in A. nidulans 
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Figure S3. LC-MS analysis of the metabolite profile of different A. nidulans strains  
LO8030 as an expression host in (A), JF15 carrying the expression construct for traA (B), JF45 
for co-expression of traA and traG (C) were cultivated in PD medium at 25 °C for 7 days. UV 
absorptions at 280 nm, [M+H]+ of 4 at m/z 253.071 ± 0.005 and [M+H]+ of 5 at m/z 257.102 ± 
0.005 are illustrated. Structures, mass, and UV spectra of 4, 4* and 5 are shown in (D). 
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Figure S4. Verification of ∆traG-mutant from P. crustosum PRB-2 
Gene deletion strategy in P. crustosum was schematically represented in (A). PCR amplification 
for three different fragments from genomic DNA of WT and traG-mutant was used to prove the 
presence/absence of traG and its site specific integration with the help of up- and downstream 
regions (B). The PCR primers are given in Table S3. 
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Figure S5. LC-MS detection of secondary metabolites from a 7 days-old liquid PD surface 
culture of P. crustosum PRB-2 
UV absorptions at 280 nm are illustrated in (A). EICs in dark green refer total [M+H]+ ions of 1 –
6 with a tolerance range of ± 0.005 (B), and in black refer [M+H]+ ions of 1 – 6 (C – G), 
respectively. Standards of 1, 2, 4 – 6 are shown in H – L. 
  
215
SUPPORTING INFORMATION 
S25 
 
 
Figure S6. LC-MS detection of the metabolites in the terrestric acid biosynthesis in ∆traA-mutant 
obtained from a previous study6 
UV absorptions at 280 nm are illustrated in (A). EICs in dark green refer total [M+H]+ ions of 1 –
6 with a tolerance range of ± 0.005 (B), and in black refer [M+H]+ ions of 1 – 6 (C − G), 
respectively.  
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Figure S7. LC-MS detection of the metabolites in the terrestric acid biosynthesis in ∆traG-mutant  
UV absorptions at 280 nm are illustrated in (A). EICs in dark green refer total [M+H]+ ions of 1 –
6 with a tolerance range of ± 0.005 (B), and in black refer [M+H]+ ions of 1 – 6 (C−G), 
respectively. 
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Figure S8. LC-MS detection of the metabolite profile of traA mutant after feeding with 4 
traA culture were fed with 4 and maintained for 7 days (A) and 14 days (B). UV absorptions at 
280 nm are illustrated. EICs refer [M+H]+ ions of 1, 2, 4, 5 and 6 with a tolerance range of ± 
0.005. 
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Figure S9. LC-MS detection of the metabolite profile of traA and traG mutants after feeding 
with 5 
traA (A) and traG (B) cultures were fed with 5 and maintained for 7 days. UV absorptions at 
280 nm are illustrated. EICs refer [M+H]+ ions of 1, 2 and 5 with a tolerance range of ± 0.005. 
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Figure S10. Incorporation of deuterium in 1 via E/Z-isomerization in D2O-enriched milieu 
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Figure S11. Sequence alignments of non-heme FeII-2OG-dependent decarboxylases  
CaaD (XP_001392490), IsnB (CEK22194.1), and AmbI3 (AIJ28554.1) are from Aspergillus 
niger, Xenorhabdus nematophila, and Fischerella ambigua, respectively.16-18 TraH also contains 
the typical conserved 2-His-1-Asp ion-binding triad of non-heme FeII/2-oxoglutarate-dependent 
enzyme (His198, His211 and Asp112) (marked with *). Protein sequence alignments were carried 
out by using the sequence alignment function of ClustalW and visualized with ESPript 3.0 
(http://espript.ibcp.fr/ESPript/ESPript/). 
  
221
SUPPORTING INFORMATION 
S31 
 
 
 
Figure S12. Analysis of recombinant TraD and TraH on SDS-PAGE 
TraD and traH were separately inserted into pET28a(+) with 6xHis-tag at its N-terminal (A). The 
purified recombinant histidine-tagged TraD and TraH were separated on a 12% SDS-PAGE (B). 
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Figure S13. Oxidative decarboxylation of 1 catalyzed by TraH 
LC-MS analysis of incubation mixture of 1 with TraH (A), determination of kinetic parameter of 
the TraH toward 1 (B). 
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Figure S14. HPLC analysis of the incubation mixtures of 1 with TraH 
5.4 µM TraH in the full assay with ascorbic acid (AA), dithiothreitol (DTT), Fe[(NH4)2(SO4)2] (FeII) 
and 2-oxoglutarate (2OG) (A); full assay without AA (B); full assay without DTT (C); full assay 
without AA and DTT (D); full assay without exogenous FeII (E); full assay without 2OG (F), 
standards of 1 (G) and 3 (H). UV absorptions at 280 nm are illustrated. 
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Figure S15. HPLC analysis of incubation mixtures of 3 with TraD at different concentrations 
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Figure S16. HPLC analysis of sequential reaction products in enzyme assays of TraH and TraD 
with 1  
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Figure S17. Comparison of CD spectra of two terrestric acid samples 
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Figure S18. LC-MS analysis of enzyme assays of 4 with TraH without or together with TraD 
Incubation mixtures of 4 with TraH (A), 4 with denat TraH (B) at 37℃ for 16 h, 4 with TraH and 
TraD (C), and 4 with denat TraH and TraD (D) at 30℃ for 16 h. EICs refer [M+H]+ ions of 4, 6 
and dehydrocrustic acid with a tolerance range of ± 0.005.  
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Figure S19. LC-MS analysis of spontaneous ester formation of 1 with different alcohols 
0.4 mM solutions of crustosic acid (1) in ACN, MeOH, EtOH or n-propanol were kept at 25℃ for 
24 h and subjected directly to LC-MS analysis. UV absorptions at 280 nm are illustrated. EIC at 
m/z 255.086 ± 0.005 refer [M+H]+ ion of (5S, 5'S)-crustosic acid (1), EICs at m/z 291.084 ± 
0.005, 305.010 ± 0.005, 319.115 ± 0.005 refer [M+Na]+ ion of its methyl ester (7), ethyl ester, 
propyl ester, respectively. 
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Figure S20. Conversion of 7 to 8 catalyzed by TraH 
LC-MS analysis of incubation mixture of 7 with TraH (A), determination of kinetic parameter of 
the TraH toward 7 (B). 
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Figure S21. 1H NMR spectrum of compound 2 isolated from an incubation mixture of 1 with TraH and TraD in CDCl3 (500MHz) 
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Figure S22. 1H NMR spectrum of compound 3 in DMSO-d6 (500MHz) 
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Figure S23. 1H NMR spectrum of compound 4 isolated from A. nidulans JF15 harboring traA in CD3OD (500MHz) 
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Figure S24. 1H NMR spectrum of compound 4 isolated from ∆traG-mutant in CD3OD (500MHz)  
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Figure S25. 13C NMR spectrum of compound 4 isolated from A. nidulans JF15 harboring traA in CD3OD (125MHz)  
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Figure S26. HMBC spectrum of compound 4 isolated from A. nidulans JF15 harboring traA in CD3OD 
 
  
X : parts per Million : 1H
8.0 7.0 6.0 5.0 4.0 3.0 2.0
Y
 : 
pa
rts
 p
er
 M
ill
io
n 
: 1
3C
21
0.
0
19
0.
0
17
0.
0
15
0.
0
13
0.
0
11
0.
0
90
.0
70
.0
50
.0
30
.0
10
.0
abundance
0.1 0.2
ab
un
da
nc
e
0.
1
0.
3
0.
5
236
SUPPORTING INFORMATION 
S46 
 
 
Figure S27. 1H NMR spectrum of compound 5 isolated from P. crustosum PRB-2 in DMSO-d6 (500MHz) 
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Figure S28. 1H NMR spectrum of compound 5 isolated from A. nidulans JF45 harboring traAG in DMSO-d6 (500MHz) 
  
238
SUPPORTING INFORMATION 
S48 
 
 
Figure S29. 13C NMR spectrum of compound 5 isolated from A. nidulans JF45 harboring traAG in DMSO-d6 (125MHz) 
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Figure S30. HMBC spectrum of compound 5 isolated from A. nidulans JF45 harboring traAG in DMSO-d6 
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Figure S31. 1H-1H COSY spectrum of compound 5 isolated from A. nidulans JF45 harboring traAG in DMSO-d6 
  
241
SUPPORTING INFORMATION 
S51 
 
 
Figure S32. 1H NMR spectrum of compound 6 in CD3OD (500MHz) 
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Figure S33. 13C NMR spectrum of compound 6 in CD3OD (125MHz) 
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Figure S34. HMBC spectrum of compound 6 in CD3OD  
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Figure S35. 1H NMR spectrum of compound 7 in CDCl3 (500MHz) 
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Figure S36. 13C NMR spectrum of compound 7 in CDCl3 (125MHz) 
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Figure S37. 1H NMR spectrum of compound 8 in CDCl3 (500MHz) 
  
247
SUPPORTING INFORMATION 
S57 
 
 
Figure S38. CD spectra of compounds 4 – 6 
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ABSTRACT: The active form of clavatol, ortho-quinone
methide, can be generated from hydroxyclavatol in an aqueous
system and used as a highly reactive intermediate for coupling
with diverse natural products under very mild conditions. These
include flavonoids, hydroxynaphthalenes, coumarins, xanthones,
anthraquinones, phloroglucinols, phenolic acids, indole deriva-
tives, tyrosine analogues, and quinolines. The clavatol moiety
was mainly attached via C−C bonds to the ortho- or para-
positions of phenolic hydroxyl/amino groups and the C2-
position of the indole ring.
Ortho-quinone methides (o-QMs), as transient intermediates
with remarkable reactivity, have been utilized as useful
reactants in chemical synthesis.1−5 A wide range of strategies,
e.g., thermally driven,6,7 photolytically induced tautomeriza-
tion,8,9 and benzylic oxidation,10,11 were developed to generate
o-QMs. However, o-QMs can also be formed by spontaneous
elimination of a stable molecule with concomitant dearoma-
tization.12,13
Recently, we reported the formation of penilactones A and B
by two-step nonenzymatic Michael additions between a γ-
butyrolactone and two o-QM molecules. The key precursor
hydroxyclavatol was the oxidation product of clavatol by the
nonheme FeII/2-oxoglutarate dependent oxygenase ClaD and
undergoes spontaneous water elimination, resulting in the
active o-QM intermediate (Figure 1i).12
In addition to penilactones A and B from Penicillium
crustosum,14 a number of natural products containing a clavatol
unit are found in fungi, especially in Penicillium species.14−20
These include a clavatol−flavanone adduct from Penicillium
griseoroseum16 as well as coupling products of clavatol with α-
pyrone (communol A) and indole (communol B) from
Penicillium commune17 (Figure 1ii). More coupling products
of clavatol with diverse lactones, phenols, and quinones are
listed in Figure S1 (see Supporting Information (SI)).
The occurrence of these natural products implies the
involvement of clavatol, very likely via the o-QM intermediate,
in their formation. Inspired by the postbiosynthetic non-
enzymatic event in the formation of penilactones A and B, we
wondered whether these clavatol-containing compounds are
also pseudonatural products.
This hypothesis triggered our interest to prove the reactivity
of the o-QM intermediate derived from hydroxyclavatol with
diverse natural products. Encouraged by accumulation of the
clavatol−flavanone adduct in P. griseoroseum,16 we synthesized
hydroxyclavatol chemically (Scheme S1)6,21 and screened its
reactivity with 16 flavonoids including catechin (1a−16a)
Received: November 1, 2019
Published: December 20, 2019
Figure 1. Formation of hydroxyclavatol and its equilibration with the
o-QM intermediate (i). Representative examples of clavatol-
containing natural products (ii). See Figure S1 for more examples.
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under mild conditions (Figures S2−S4). Both hydroxyclavatol
and reactants at a final concentration of 0.4 mM in 50 μL of
H2O were incubated at 25 °C for 16 h without pH adjustment.
LC−MS analysis of the incubation mixtures showed that, with
the exception for 10a, [M + H]+ ions being 178 Da larger than
the corresponding reactants were detected. These proved the
formation of the coupling products of flavonoids with clavatol.
Masses of products harboring two clavatol units were also
detected when using 4a, 5a, 8a, 9a, and 12a−15a as reactants.
Subsequent assays of hydroxyclavatol with other phenolic
substances, including hydroxynaphthalenes (17a−27a), cou-
marins (28a−32a), xanthones (33a−38a), anthraquinones
(39a−42a), phloroglucinol derivatives (43a−51a), and
phenolic acids (52a−60a) were carried out in a similar way
as mentioned above. Products were detected in incubation
mixtures of hydroxyclavatol with 9 of 11 tested hydroxynaph-
thalenes. This proved hydroxynaphthalenes as suitable
reactants for coupling with the o-QM (Figures S2−S4).
Coumarins with 29a as an exception, xanthones, and
anthraquinones were relatively poor reaction partners for the
o-QM and gave no product or only trace amount of products
in their reaction mixtures (Figures S2−S5). Among all the
tested phenolic substances, phloroglucinol derivatives were
found to be the most favorable Michael donors for the o-QM
intermediate, with 10 to 55% conversion (Figures S2 and S6).
In addition, coupling products of benzoic acids (52a−54a)
were also observed by LC−MS analysis, while products from
hydroxyphenyl acetic acid (55a), propionic acids (56a and
57a), and acrylic acids (58a − 60a) were not detectable
(Figures S2−S4).
We speculated that the formation of the clavatol−indole
adduct communol B from P. commune17 was also a non-
enzymatic event and therefore investigated the reaction activity
of hydroxyclavatol with indole derivatives (61a−72a). The
incubation mixture of L-tryptophan (61a) with hydroxyclavatol
showed a coupling product with a conversion of 20%, while
replacement of the nitrogen of the indole ring by sulfur (62a)
and methylation at the N1 position (63a) significantly reduced
the activity. Other indole derivatives carrying different side
chains at C3 coupled with clavatol with up to 49% conversion
(Figures S2, S3, and S7).
Subsequently, cyclic dipeptides (73a−82a) were tested by
coincubation with hydroxyclavatol. All tryptophan-containing
cyclic dipeptides (73a−80a) showed UV detectable product
formation with 9 to 29% conversion. No product formation
was detected for the incubation mixtures of cyclo-L-Tyr−L-Tyr
(81a) and cyclo-L-Ser−L-Tyr (82a) (Figures S2−4, S7, and
S8). In contrast to the easy coupling of L-tryptophan with the
o-QM, L-tyrosine and its analogues (83a − 87a) were generally
poorly converted to their clavatol adducts. 88a−90a with an
amino group at the benzene ring showed UV detectable
product formation (Figures S2 and S3). All selected quinolines
(91a−99a) served as Michael donors to couple with the o-
QM, especially 92a, 94a, 95a, and 98a with obvious product
peaks in UV chromatograms (Figures S2, S3, and S8).
In addition, clear product formation was also detected for
the o-QM with other nitrogen-containing reactants, including
2-aminobenzyl alcohol (100a), 2-aminobenzoic acid (101a),
and even tris(hydroxymethyl)aminomethane (Tris, 102a)
prepared as Tris−HCl buffer (pH 7.5) (Figures S2 and S8).
In summary, we demonstrated in a previous study that
Michael additions between the o-QM and γ-butyrolactones
took place easily under neutral or acidic conditions.12
Therefore, hydroxyclavatol was incubated in this study with
101 natural products or natural-product-like compounds at 25
°C and a nearly neutral pH value, which led to the detection of
coupling products in 85 cases. Product formation with 10 to
55% conversion was detected for 49 reactants (Schemes 1 and
2 and Figures S5−S10). To facilitate the isolation of the
Scheme 1. Reactions of Hydroxyclavatol with Nitrogen-Free
Reactants
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products for structural elucidation, we changed the reaction
temperature for all the incubations to 95 °C for 30 min to
improve the product yields. As shown in Figures S5−S10, the
majority of the reactions was promoted by increased
temperature, leading to generally 2 to 10-fold higher
accumulation of the coupling products. Taking purpurin
(41a) as an example, its coupling with clavatol was improved
dramatically from a trace amount to 86%. In total, product
formation with 30 to 99% conversion was achieved for 58
reactants at 95 °C for 30 min. However, in a few cases, no
significant change was observed for reactions performed at 25
and 95 °C (Figures S5−S10). Therefore, large scaled reactions
of hydroxyclavatol with 23 reactants of different structural
skeletons were carried out at either 25 or 95 °C, resulting in
the isolation of 32 products, which were further subjected to
HR-ESI-MS and NMR analyses (Figures S12−S86).
Structural elucidation of the coupling products of phenolic
reactants confirmed the attachment of the clavatol unit to the
ortho- or para-positions of the hydroxyl group at the benzene
ring. Herein, the o-QM formed from hydroxyclavatol in an
aqueous system was proposed to act as the Michael acceptor
for the phenolic substances (Figure S11i,ii). The formation of
17b and 98b represents examples for the attachment of a
clavatol moiety onto the para-position of the hydroxyl group
(Schemes 1 and 2 and Figures S5 and S8). For flavan
derivatives with a 5,7-dihydroxyl feature (2a, 6a, and 14a), C8-
adducts (2b, 6b, and 14b) were identified as main products,
and the C6-adduct (14c) was identified as a byproduct
(Scheme 1 and Figure S5). The clavatol-containing flavanone
from P. griseoroseum (Figure 1) was identified by feeding
5,7,3′,4′,5′-pentamethoxyflavanone into the culture.16 The
incorporation of the clavatol unit into the exogenous flavanone
might be also a nonenzymatic product. In analogy, 18b and
35b were identified as products of hydroxyclavatol with 1,3-
dihydroxynaphthalene (18a) and 1,3-dihydroxyxanthone
(35a) (Scheme 1 and Figures S5 and S6). Additionally,
formation of 29b by the linkage between the clavatol unit and
the α-pyrone moiety of 29a suggests that communol A from P.
commune could be formed in a similar way (Scheme 1 and
Figure S5). Phloroglucinol derivatives harboring three hydroxyl
groups at the benzene ring conjugated with a clavatol also via
C−C bonds (44b, 45b, 47b, and 50b) (Scheme 1 and Figure
S6).
The indole ring in the tryptophanyl moiety contributes
greatly to structural complexity by enzymatic modifications
and spontaneous rearrangement.22,23 Communol B mentioned
above represents a coupling example of a clavatol moiety with
an indole skeleton.17 Accordingly, incubation of L-tryptophan
(61a) with hydroxyclavatol enabled us to obtain the product
(61b) with a similar structure to communol B (Scheme 2 and
Figure S7). Subsequent isolation of clavatol adducts with
different indole derivatives ((±)-65b and 72b) confirmed the
spontaneous addition of the indole moiety via C2 to the o-QM
(Scheme 2 and Figure S7). Furthermore, a number of coupling
products of clavatol with tryptophan-containing cyclic
dipeptides were also identified. Among them, C2-adducts
were obtained as main products (76b, 77b, 79b, and 80b), and
C3-adducts (79c and 80c) were obtained as byproducts
(Scheme 2 and Figures S7 and S8). In addition, a cyclo-L-Trp−
L-Trp derivative carrying two clavatol units (79d) was also
identified (Scheme 2 and Figure S7). The conjugation between
the clavatol unit and indole skeleton indicates that the electron
transfer in the indole ring enabled the Michael addition from
C2 to the electrophilic methylene group of the o-QM (Figure
S11iii).
Steinmetz et al.24 reported C−N coupling compounds as
Michael addition products of different nucleophiles via their
amino groups to the p-quinone methide, i.e., elansolid A3.
However, only a few coupling products were obtained via C−
N bond formation in this study. Examples are (±)-65c as a
byproduct from the incubation of hydroxyclavatol with N-
acetyl-DL-tryptophan ((±)-65a), 101c, and 101d from 2-
aminobenzoic acid (101a) and 102b from Tris (102a)
(Scheme 2 and Figures S7, S8, and S11iv). It can be concluded
Scheme 2. Reactions of Hydroxyclavatol with Nitrogen-
Containing Reactants
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that the cross-coupling between the nucleophiles tested above
and the o-QM from hydroxyclavatol occurs preferentially via
C−C bond formation. In addition, the C−N bond in 101d
seems unstable and can be easily hydrolyzed, which was
observed by inspection of the 1H NMR spectrum of 101d
(Figure S83) and comparison of the impurity signals with
those of 101b (Figure S79).
After structure elucidation, the obtained clavatol-containing
products were screened for their antibacterial, acetylcholines-
terase, and α-glucosidase inhibition activities. Detailed
evaluation of the α-glucosidase inhibitory activity revealed
the clavatol-coupling products 2b, 17b, 18b, 35b, 72b, and
95b showed clear inhibition with IC50 values ranging from 43.8
± 1.0 to 231.0 ± 7.5 μM, while their precursors showed no
activity. These concentrations are significantly lower than that
of the control substance acarbose with an IC50 at 766.2 ± 37.8
μM (Table 1), indicating that conjugation of low-molecular-
weight compounds with clavatol has the potential to increase
the biological activity.
In summary, our extended study on the utility of
hydroxyclavatol proved that the o-QM generated from
hydroxyclavatol can be considered as an excellent Michael
acceptor for a variety of substances. The coupling reactions
occurred under very mild conditions, i.e., overnight incubation
at 25 °C in water. Increasing the reaction temperature can
accelerate the reaction rate and promote the product
accumulation. Diverse clavatol-containing products were
identified in this study by incorporation of a clavatol unit
onto the ortho- or para-positions of the hydroxyl group of
different phenolic compounds as well as connection between
the methylene group of the clavatol unit and the C2 of indole
skeletons. Additional C−N bond formation of clavatol-
coupling products was also observed in a few cases.
Despite of the wide application of QMs in chemical
synthesis,1−5 QMs have also been reported to be involved in
the assembly of natural products in recent years. For example,
elansolid A3 acts as a key intermediate in the biosynthesis of
elansolids.25,26 Spontaneous Diels−Alder addition via an o-QM
intermediate was suggested for the formation of leprins.27
Another QM-like intermediate is likely responsible for the
dimerization of benzofluorene-containing angucyclines.13 In
analogy, it is plausible that the clavatol-containing natural
products listed in Figures 1 and S1 are formed by
nonenzymatic Michael addition with involvement of the o-
QM derived from hydroxyclavatol. Furthermore, it can be
expected that more clavatol-coupling natural products will be
discovered in the near future.
■ EXPERIMENTAL SECTION
Chemicals. 35a−38a, 46a−48a, 73a, 75a, 79a, and 80a were
chemically synthesized as previously reported.28−34 Other chemicals
used in this study were purchased from Bachem (Bubendorf,
Switzerland), ABCR (Karlsruhe, Germany), TCI Europe (Zwijn-
drecht, Belgium), Alfa Aesar (Kandel, Germany), Carl Roth
(Karlsruhe, Germany), Sigma-Aldrich (St. Louis, USA), or Acros
(Merelbeke, Belgium).
Reaction Conditions of Hydroxyclavatol with the Tested
Aromatic Compounds. Stock solutions of the tested compounds
were prepared at 20 mM in DMSO or DMSO/H2O (v/v, 1:1).
Reactions were initiated by adding hydroxyclavatol (0.4 mM) and
reactants (0.4 mM) into 50 μL of distilled H2O without pH
adjustment. As a result, the reactions generally took place in the pH
environment of 5.0−7.5. After incubation at 25 °C for 16 h, 50 μL of
ACN was added into the reaction mixture. A 5 μL aliquot of
supernatant was injected into LC−MS for analysis after centrifugation
at 13 000 rpm for 30 min. Conversions were calculated from peak
areas of products and reactants with UV detection. Two independent
experiments were performed. In addition, reactions of all reactants
were also carried out at 95 °C for 30 min.
LC−MS Analysis of Reaction Mixtures. LC−MS analysis was
performed on a microTOF-Q III spectrometer (Bruker, Bremen,
Germany) with an Agilent 1260 HPLC system (Agilent Technologies,
Böblingen, Germany), using the Multospher 120 RP18-5μ column
(250 × 2 mm, 5 μm) (CS-Chromatographie Service GmbH). H2O
(A) and ACN (B), both with 0.1% (v/v) HCOOH, were used as
solvents at flow rate of 0.25 mL/min. The substances were eluted with
a linear gradient from 5−100% (v/v) B in 15 min. The column was
then washed with 100% (v/v) solvent B for 5 min and equilibrated
with 5% (v/v) solvent B for 5 min. Detection was carried out on a
photodiode array detector, and UV absorptions at 280 nm are
illustrated in this study. Electrospray ionization in positive or negative
mode was set for the determination of the accuracy masses.
HCOONa was used in each run for mass calibration. The capillary
voltage was set to 4.5 kV, and collision energy was set to 8.0 eV. Data
were evaluated with the Compass DataAnalysis 4.2 software (Bruker
Daltonik, Bremen, Germany). The masses were scanned in the range
of m/z 100−1500.
Isolation and Identification of the Reaction Products. To
isolate the reaction products for structural elucidation, reactions were
carried out in large scaled incubations (40 or 200 mL) containing
hydroxyclavatol (0.4 mM), different reactants (0.4−0.8 mM), and up
to 2% (v/v) DMSO. After incubation at 25 °C for 16 h or heating at
95 °C for 30 min, the reaction mixtures were extracted with a double
volume of EtOAc three times. The organic phases were combined and
concentrated under vacuum. The resulted residues were dissolved in
MeOH and centrifuged at 13 000 rpm for 20 min. The products were
then purified by silica gel column chromatography with a stepwise
gradient of petroleum ether/EtOAc or on a Sephadex LH20 column
with MeOH as elution solvent. A semipreparative HPLC equipped
with an Agilent ZORBAX Eclipse XDB-C18 HPLC column (250 ×
9.4 mm, 5 μm) was also applied for purification by using isocratic
elution with H2O and ACN containing 0.1% trifluoroacetic acid
(TFA). NMR spectra were recorded on a JEOL ECA-500 MHz
spectrometer (JEOL, Tokyo, Japan). The spectra were processed with
MestReNova 6.1.0 (Metrelab). Chemical shifts are referenced to
those of the solvent signals.
Structural Elucidation. Characteristic signals of the clavatol
moiety were observed in 1H NMR spectra of all the isolated products
as a set of signals for an aromatic proton at approximately 7.5 ppm, a
singlet between 12−14 ppm, a methylene group mostly between 3−4
ppm, and two methyl groups at around 2.5 and 2.1 ppm. The clavatol-
coupling products generally belong to two major groups. The majority
is with the clavatol unit attached to the ortho- or para-position of a
phenolic hydroxyl group at the benzene ring and other products
carrying clavatol moieties attached to C2 or C3 of the indole skeleton.
In the cases of 17b and 98b, the linkage between the methylene
group of the clavatol unit and the para-position of the hydroxy group
Table 1. Inhibitory Effects of the Selected Compounds
against α-Glucosidase
reactants IC50 (μM) products IC50 (μM)
2a n.i. 2b 60.1 ± 0.6
17a n.i. 17b 167.8 ± 2.3
18a n.i. 18b 231.0 ± 7.5
35a n.i. 35b 43.8 ± 1.0
72a n.i. 72b 140.1 ± 1.3
95a n.i. 95b 52.0 ± 2.4
acarbosea 766.2 ± 37.8
aPositive control. n.i.: no inhibition. The IC50 data with standard
deviation are mean values of three independent experiments.
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was proven by HMBC correlations (Figures S27−S30 and S76−S78).
In analogy, correlations of the methylene group to different aromatic
carbons in the HMBC spectra supported the linkage between the
clavatol part and meta-dihydroxylated benzene ring, such as 2b
(Figures S12−S14), 6b (Figures S15−S17), 6c (Figures S18−S20),
14b (Figures S21−S25), 18b (Figures S32−S34), 35b (Figures S38−
S40), and 41b (Figures S41−S43). 14c obtained as the byproduct
from the reaction mixture of (+)-catechin (14a) with hydroxyclavatol
is an analogue of isopilosanols A−C. Its structure was confirmed by
comparison of 1H NMR spectra with those of reported data (Figure
S26).35,36 Since 44b, 45b, 47b, and 50b are formed via coupling of
clavatol unit with phloroglucinol derivatives, the attachment of
clavatol to the phloroglucinol moiety in 44b and 47b was proven by
HMBC correlations as examples (Figures S44−S46 and S48−S50).
The structures of 45b and 50b are deduced according to their
molecular weight and 1H NMR data (Figures S47 and S51). 29b and
95b showed two sets of signals in their 1H NMR, one set for the
clavatol subunit and one set of four coupling aromatic protons for the
ortho-disubstituted benzene ring, suggesting the attachment of the
clavatol unit to the α-pyrone ring in 29b (Figures S35−S37) and to
the pyridine ring in 95b (Figures S73−S75).
61b, (±)-65b, and 72b are indole derivatives with the clavatol unit
linked at C2-position and differ only at the side chain of the C3-
position. Therefore, their structures were determined by comparison
of the NMR data (Figures S52−S54 and S60) with the known
compound communol B.17 (±)-65c is an example of C−N bond
formation between the clavatol moiety and the indole skeleton, which
was confirmed by HMBC correlations (Figures S55−S59). 76b, 77b,
79b, 79c, 79d, 80b, and 80c are coupling products of clavatol with
tryptophan-containing cyclic dipeptides (Figures S61−S72). The
structures of 79b and 80b were unequivocally confirmed by 1H and
13C NMR data as well as HMBC correlations (Figures S63−S66 and
S69−S71). Other products are analogues of 79b, and their structures
were determined according to the C2- and C3-substitution patterns of
the indole ring as reported before.37
In the cases of 101b−101d obtained from 2-aminobenzoic acid
(101a), detailed inspection of the 1H NMR revealed that 101b and
101c are products with one clavatol moiety, and 101d is a product
harboring two clavatol units. The presence of one set of characteristic
signals for an ABX system in the 1H NMR spectrum of 101b revealed
a para-substitution of the amino group at the benzene ring. The
structure of 101b was further confirmed by 13C NMR and HMBC
analyses (Figures S79−S81). In the 1H NMR spectrum of 101c, the
coupling pattern consisting of four protons at the benzene ring, and a
downfield shift of the methylene group from 3.95 to 4.51 ppm (Figure
S82) indicated clavatol attachment to the amino group of 101a.
Similarly, one clavatol at the para-position of the amino group and
one at the amino group can be concluded for the structure of 101d
(Figure S83). 102b is another clavatol-coupling derivative via a C−N
linkage, which was supported by the slightly downfield shifts of the
methylene group at 4.49 ppm in the 1H NMR spectrum and
confirmed by HMBC correlations (Figure S84−S86).
Characterization Data. 8-(3-Acetyl-2,6-dihydroxy-5-methyl-
benzyl)-5,7-dihydroxy-2-phenyl-4H-chromen-4-one (2b). The title
compound was prepared using 2a (0.106 mmol, 32.0 mg) and
hydroxyclavatol (0.102 mmol, 20.0 mg) as reactants. The product was
isolated in 39% yield (17.3 mg) as yellow amorphous solid. Eluent:
petroleum ether/EtOAc (5:1, v/v). 1H NMR (500 MHz, DMSO-d6)
δ 13.00 (s, 1H), 8.00 (dd, J = 8.4, 1.5 Hz, 2H), 7.59 (tt, J = 7.5, 1.5
Hz, 1H), 7.54−7.49 (m, 2H), 7.52 (s, 1H), 6.91 (s, 1H), 6.25 (s, 1H),
4.10 (s, 2H), 2.49 (s, 3H), 2.11 (s, 3H). 13C{1H} NMR (125 MHz,
DMSO-d6) δ 203.2, 182.2, 163.4, 162.2, 160.9, 160.9, 159.1, 155.0,
131.8, 131.1, 130.8, 128.9, 128.9, 126.5, 126.5, 115.8, 113.1, 112.1,
105.5, 104.8, 103.8, 98.4, 26.1, 16.6, 16.2. HRMS (ESI-TOF) m/z:
[M + H]+ Calcd for C25H21O7 433.1282; Found 433.1272.
8-(3-Acetyl-2,6-dihydroxy-5-methylbenzyl)-2-(2,4-dihydroxy-
phenyl)-3,5,7-trihydroxy-4H-chromen-4-one (6b). The title com-
pound was prepared using 6a (0.108 mmol, 32.9 mg) and
hydroxyclavatol (0.066 mmol, 12.9 mg) as reactants. The product
was isolated in 17% yield (5.5 mg) as yellow amorphous solid. Eluent:
ACN/H2O (55:45, v/v) supplied with 0.1% TFA.
1H NMR (500
MHz, DMSO-d6) δ 12.82 (s, 1H), 12.64 (s, 1H), 9.74 (s, 1H), 7.48
(s, 1H), 7.09 (d, J = 8.5 Hz, 1H), 6.37 (d, J = 2.3 Hz, 1H), 6.30 (dd, J
= 8.5, 2.3 Hz, 1H), 6.20 (s, 1H), 3.95 (s, 2H), 2.49 (s, 3H), 2.07 (s,
3H). 13C{1H} NMR (125 MHz, DMSO-d6) δ 202.8, 176.3, 160.9,
160.9, 160.4, 160.4, 158.4, 156.5, 154.5, 148.7, 135.4, 131.1, 130.5,
115.6, 113.1, 112.0, 109.5, 107.0, 104.7, 103.4, 102.9, 97.5, 26.1, 16.2,
16.2. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C25H21O10
481.1129; Found 481.1151.
2-(5-(3-Acetyl-2,6-dihydroxy-5-methylbenzyl)-2,4-dihydroxy-
phenyl)-3,5,7-trihydroxy-4H-chromen-4-one (6c). The title com-
pound was prepared using 6a (0.108 mmol, 32.9 mg) and
hydroxyclavatol (0.066 mmol, 12.9 mg) as reactants. The product
was isolated in 21% yield (6.7 mg) as yellow amorphous solid. Eluent:
ACN/H2O (55:45, v/v) supplied with 0.1% TFA.
1H NMR (500
MHz, DMSO-d6) δ 12.95 (s, 1H), 10.66 (s, 1H), 7.58 (s, 1H), 6.79
(s, 1H), 6.50 (s, 1H), 6.18 (d, J = 2.2 Hz, 1H), 6.14 (d, J = 2.2 Hz,
1H), 3.78 (s, 2H), 2.52 (s, 3H), 2.15 (s, 3H). 13C{1H} NMR (125
MHz, DMSO-d6) δ 203.2, 176.0, 163.6, 160.9, 160.7, 160.6, 157.4,
156.7, 154.4, 148.9, 136.0, 131.1, 129.9, 117.6, 116.0, 113.2, 112.3,
109.0, 103.4, 102.6, 98.0, 93.1, 26.1, 21.1, 16.1. HRMS (ESI-TOF)
m/z: [M + H]+ Calcd for C25H21O10 481.1129; Found 481.1147.
1-(3-(((2R,3S)-2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxychro-
man-8-yl)methyl)-2,4-dihydroxy-5-methylphenyl)ethan-1-one
(14b). The title compound was prepared using 14a (0.106 mmol, 30.8
mg) and hydroxyclavatol (0.066 mmol, 12.9 mg) as reactants. The
product was isolated in 28% yield (8.6 mg) as brown oil. Eluent:
ACN/H2O (55:45, v/v) supplied with 0.1% TFA.
1H NMR (500
MHz, acetone-d6) δ 14.26 (s, 1H), 7.59 (s, 1H), 6.99 (d, J = 1.2 Hz,
1H), 6.86 (s, 1H), 6.86 (s, 1H), 6.11 (s, 1H), 4.81 (d, J = 7.8 Hz,
1H), 4.15 (ddd, J = 8.5, 7.8, 5.5 Hz, 1H), 3.81 (d, J = 15.6 Hz, 1H),
3.77 (d, J = 15.6 Hz, 1H), 2.97 (dd, J = 16.3, 5.5 Hz, 1H), 2.61 (dd, J
= 16.3, 8.5 Hz, 1H), 2.53 (s, 3H), 2.09 (s, 3H). 1H NMR (500 MHz,
pyridine-d6) δ 7.62 (d, J = 2.1 Hz, 1H), 7.47 (s, 1H), 7.30 (d, J = 8.1
Hz, 1H), 7.25 (dd, J = 8.1, 2.1 Hz, 1H), 6.67 (s, 1H), 5.31 (d, J = 7.7
Hz, 1H), 4.57 (ddd, J = 8.4, 7.7, 5.4 Hz, 1H), 4.47 (d, J = 15.1 Hz,
1H), 4.35 (d, J = 15.1 Hz, 1H), 3.63 (dd, J = 16.1, 5.4 Hz, 1H), 3.31
(dd, J = 16.1, 8.4 Hz, 1H), 2.46 (s, 3H), 2.20 (s, 3H). 1H NMR (500
MHz, DMSO-d6) δ 12.90 (s, 1H), 9.67 (s, 1H), 9.11 (s, 1H), 8.95 (s,
1H), 7.48 (s, 1H), 6.66 (d, J = 2.0 Hz, 1H), 6.60 (d, J = 8.1 Hz, 1H),
6.46 (dd, J = 8.1, 2.0 Hz, 1H), 6.03 (s, 1H), 4.54 (d, J = 7.1 Hz, 1H),
3.82−3.78 (m, 1H), 3.76 (d, J = 14.8 Hz, 1H), 3.68 (d, J = 14.8 Hz,
1H), 2.62 (dd, J = 16.2, 5.3 Hz, 1H), 2.49 (s, 3H), 2.37 (dd, J = 16.2,
7.7 Hz, 1H), 2.04 (s, 3H). 13C{1H} NMR (125 MHz, DMSO-d6) δ
202.6, 160.6, 160.4, 154.0, 153.0, 152.8, 144.6, 144.5, 130.3, 130.2,
117.9, 115.6, 114.9, 114.4, 113.5, 112.2, 103.2, 99.8, 94.8, 81.2, 66.0,
30.6, 27.7, 26.2, 15.8. [α]D
20 = +25 (c 0.1, MeOH); HRMS (ESI-
TOF) m/z: [M + H]+ Calcd for C25H25O9 469.1493; Found
469.1493.
1-(3-(((2R,3S)-2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxychro-
man-6-yl)methyl)-2,4-dihydroxy-5-methylphenyl)ethan-1-one
(14c). The title compound was prepared using 14a (0.106 mmol, 30.8
mg) and hydroxyclavatol (0.066 mmol, 12.9 mg) as reactants. The
product was isolated in 6% yield (1.8 mg) as brown oil. Eluent: ACN/
H2O (55:45, v/v) supplied with 0.1% TFA.
1H NMR (500 MHz,
acetone-d6) δ 14.5 (s, 1H), 7.67 (s, 1H), 6.85 (d, J = 2.0 Hz, 1H),
6.77 (d, J = 8.1 Hz, 1H), 6.71 (dd, J = 8.1, 2.0 Hz, 1H), 6.10 (s, 1H),
4.57 (d, J = 7.5 Hz, 1H), 3.98 (ddd, J = 8.5, 7.5, 5.3 Hz, 1H), 3.86 (s,
2H), 2.87 (dd, J = 16.2, 5.3 Hz, 1H), 2.60 (s, 3H), 2.54 (dd, J = 16.2,
8.5 Hz, 1H), 2.15 (s, 3H). [α]D
20 = +23 (c 0.1, MeOH); HRMS (ESI-
TOF) m/z: [M + H]+ Calcd for C25H25O9 469.1493; Found
469.1496.
1-(2,4-Dihydroxy-3-((4-hydroxynaphthalen-1-yl)methyl)-5-
methylphenyl)ethan-1-one (17b). The title compound was prepared
using 17a (0.179 mmol, 25.9 mg) and hydroxyclavatol (0.076 mmol,
14.9 mg) as reactants. The product was isolated in 21% yield (5.0 mg)
as yellow amorphous solid. Eluent: ACN/H2O (70:30, v/v).
1H NMR
(500 MHz, acetone-d6) δ 13.09 (s, 1H), 8.28 (dd, J = 8.6, 1.5, Hz,
1H), 8.23 (dd, J = 8.6, 1.5, Hz, 1H), 7.71 (s, 1H), 7.56 (ddd, J = 8.6,
7.0, 1.5 Hz, 1H), 7.48 (ddd, J = 8.6, 7.0, 1.5 Hz, 1H), 6.71 (s, 2H),
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4.38 (s, 2H), 2.60 (s, 3H), 2.25 (s, 3H). 1H NMR (500 MHz, DMSO-
d6) δ 12.95 (s, 1H), 9.78 (s, 1H), 9.54 (s, 1H), 8.22 (d, J = 8.5 Hz,
1H), 8.16 (d, J = 8.5 Hz, 1H), 7.66 (s, 1H), 7.55 (dd, J = 8.5, 6.8 Hz,
1H), 7.46 (dd, J = 8.5, 6.8 Hz, 1H), 6.67 (d, J = 8.0 Hz, 1H), 6.63 (d,
J = 8.0 Hz, 1H), 4.26 (s, 2H), 2.57 (s, 3H), 2.19 (s, 3H). 13C{1H}
NMR (125 MHz, DMSO-d6) δ 203.2, 161.1, 160.9, 151.4, 132.8,
131.3, 125.8, 125.6, 124.8, 124.1, 124.0, 123.6, 122.4, 116.0, 113.1,
112.3, 107.3, 26.2, 24.3, 16.2. HRMS (ESI-TOF) m/z: [M − H]−
Calcd for C20H17O4 321.1132; Found 321.1159.
1,1′-(((4-Hydroxynaphthalene-1,3-diyl)bis(methylene))bis(2,4-di-
hydroxy-5-methyl-3,1-phenylene))bis(ethan-1-one) (17c). The title
compound was prepared using 17a (0.179 mmol, 25.9 mg) and
hydroxyclavatol (0.076 mmol, 14.9 mg) as reactants. The product was
isolated in 6% yield (1.5 mg) as yellow amorphous solid. Eluent:
ACN/H2O (70:30, v/v).
1H NMR (500 MHz, acetone-d6) δ 13.11 (s,
1H), 13.00 (s, 1H), 8.27 (d, J = 8.4 Hz, 1H), 8.16 (d, J = 8.4 Hz, 1H),
7.69 (s, 1H), 7.54 (s, 1H), 7.50 (dd, J = 8.4, 6.8 Hz, 1H), 7.47 (dd, J
= 8.4, 6.8 Hz, 1H), 7.00 (s, 1H), 4.30 (s, 2H), 3.98 (s, 2H), 2.63 (s,
3H), 2.55 (s, 3H), 2.24 (s, 3H), 2.15 (s, 3H). HRMS (ESI-TOF) m/
z: [M − H]− Calcd for C30H27O7 499.1762; Found 499.1773.
1-(3-((2,4-Dihydroxynaphthalen-1-yl)methyl)-2,4-dihydroxy-5-
methylphenyl)ethan-1-one (18b). The title compound was prepared
using 18a (0.161 mmol, 25.9 mg) and hydroxyclavatol (0.089 mmol,
17.4 mg) as reactants. The product was isolated in 24% yield (7.3 mg)
as white amorphous solid. Eluent: ACN/H2O (65:35, v/v) supplied
with 0.1% TFA. 1H NMR (500 MHz, DMSO-d6) δ 13.66 (s, 1H),
10.11 (s, 1H), 8.32 (d, J = 8.9 Hz, 1H), 8.00 (d, J = 8.9 Hz, 1H), 7.55
(s, 1H), 7.37 (dd, J = 8.9, 6.7 Hz, 1H), 7.19 (dd, J = 8.9, 6.7 Hz, 1H),
6.71 (s, 1H), 4.18 (s, 2H), 2.54 (s, 3H), 2.04 (s, 3H). 13C{1H} NMR
(125 MHz, DMSO-d6) δ 203.4, 160.9, 159.9, 153.1, 150.9, 134.1,
131.0, 126.6, 123.5, 122.2, 121.5, 120.8, 116.1, 113.3, 112.1, 107.9,
99.6, 26.2, 17.1, 15.7. HRMS (ESI-TOF) m/z: [M − H]− Calcd for
C20H17O5 337.1081; Found 337.1097.
3-(3-Acetyl-2,6-dihydroxy-5-methylbenzyl)-4-hydroxy-2H-chro-
men-2-one (29b). The title compound was prepared using 29a
(0.173 mmol, 28.1 mg) and hydroxyclavatol (0.076 mmol, 14.9 mg)
as reactants. The product was isolated in 43% yield (11.2 mg) as
white amorphous solid. Eluent: ACN/H2O (90:10, v/v) supplied with
0.1% TFA. 1H NMR (500 MHz, CDCl3) δ 14.70 (s, 1H), 10.28 (s,
1H), 10.23 (s, 1H), 7.93 (dd, J = 8.5, 1.6 Hz, 1H), 7.56 (ddd, J = 8.5,
7.0, 1.6 Hz, 1H), 7.43 (s, 1H), 7.35 (dd, J = 8.5, 1.6 Hz, 1H), 7.33
(ddd, J = 8.5, 7.0, 1.6 Hz, 1H), 3.87 (s, 2H), 2.58 (s, 3H), 2.21 (s,
3H). 13C{1H} NMR (125 MHz, CDCl3) δ 203.6, 168.4, 163.4, 162.0,
158.9, 152.3, 132.6, 131.1, 124.8, 123.9, 119.8, 116.7, 116.3, 112.6,
112.3, 103.5, 26.0, 18.2, 16.2. HRMS (ESI-TOF) m/z: [M + H]+
Calcd for C19H17O6 341.1020; Found 341.1013.
4-(3-Acetyl-2,6-dihydroxy-5-methylbenzyl)-1,3-dihydroxy-9H-
xanthen-9-one (35b). The title compound was prepared using 35a
(0.122 mmol, 27.9 mg) and hydroxyclavatol (0.071 mmol, 13.9 mg)
as reactants. The product was isolated in 31% yield (9.1 mg) as white
amorphous solid. Eluent: ACN/H2O (80:20, v/v) supplied with 0.1%
TFA. 1H NMR (500 MHz, DMSO-d6) δ 13.04 (s, 1H), 12.76 (s, 1H),
8.08 (dd, J = 8.0, 1.6 Hz, 1H), 7.83 (ddd, J = 8.0, 7.2, 1.6 Hz, 1H),
7.52 (s, 1H), 7.42 (ddd, J = 8.0, 7.2, 1.6 Hz, 1H), 7.39 (dd, J = 8.0, 1.6
Hz, 1H), 6.28 (s, 1H), 4.06 (s, 2H), 2.50 (s, 3H), 2.16 (s, 3H).
13C{1H} NMR (125 MHz, DMSO-d6) δ 203.1, 179.9, 161.0, 161.0,
160.3, 160.3, 155.3, 154.8, 135.5, 130.7, 125.1, 124.1, 119.4, 117.3,
115.7, 113.4, 112.0, 105.5, 102.1, 97.5, 26.1, 16.3, 16.2. HRMS (ESI-
TOF) m/z: [M + H]+ Calcd for C23H19O7 407.1125; Found
407.1116.
2-(3-Acetyl-2,6-dihydroxy-5-methylbenzyl)-1,3,4-trihydroxyan-
thracene-9,10-dione (41b). The title compound was prepared using
41a (0.094 mmol, 24.1 mg) and hydroxyclavatol (0.058 mmol, 11.4
mg) as reactants. The product was isolated in 33% yield (8.3 mg) as
red amorphous solid. Eluent: ACN/H2O (75:25, v/v) supplied with
0.1% TFA. 1H NMR (500 MHz, DMSO-d6) δ 14.24 (s, 1H), 13.46 (s,
1H), 12.95 (s, 1H), 8.27 (dd, J = 7.6, 1.3 Hz, 1H), 8.26 (dd, J = 7.6,
1.3 Hz, 1H), 7.93 (td, J = 7.6, 1.3 Hz, 1H), 7.89 (td, J = 7.6, 1.3 Hz,
1H), 7.51 (s, 1H), 3.99 (s, 2H), 2.50 (s, 3H), 2.11 (s, 3H). 13C{1H}
NMR (125 MHz, DMSO-d6) δ 202.9, 184.8, 181.8, 161.2, 160.9,
160.9, 155.8, 134.7, 133.7, 133.6, 132.4, 130.7, 126.3, 126.2, 123.2,
115.8, 112.5, 112.2, 112.0, 109.8, 26.2, 17.5, 16.2. HRMS (ESI-TOF)
m/z: [M + H]+ Calcd for C24H19O8 435.1074; Found 435.1069.
1-(2,4-Dihydroxy-5-methyl-3-((2,3′,4,5′,6-pentahydroxy-[1,1′-bi-
phenyl]-3-yl)methyl)phenyl)ethan-1-one (44b). The title compound
was prepared using 44a (0.128 mmol, 30.0 mg) and hydroxyclavatol
(0.076 mmol, 14.9 mg) as reactants. The product was isolated in 28%
yield (8.9 mg) as brown oil. Eluent: ACN/H2O (60:40, v/v) supplied
with 0.1% TFA. 1H NMR (500 MHz, DMSO-d6) δ 13.96 (s, 1H),
8.90 (s, 1H), 8.87 (s, 1H), 7.64 (s, 1H), 6.10 (s, 1H), 6.06−6.04 (m,
3H), 3.73 (s, 2H), 2.56 (s, 3H), 2.12 (s, 3H). 13C{1H} NMR (125
MHz, DMSO-d6) δ 203.8, 160.6, 158.7, 157.4, 157.4, 154.2, 152.9,
152.8, 136.3, 131.1, 117.2, 113.2, 112.2, 110.1, 109.4, 109.4, 103.4,
100.5, 94.9, 48.6, 26.1, 15.7. HRMS (ESI-TOF) m/z: [M + H]+ Calcd
for C22H21O8 413.1231; Found 413.1242.
3-(3-Acetyl-2,6-dihydroxy-5-methylbenzyl)-2,4,6-trihydroxyben-
zoic acid (45b). The title compound was prepared using 45a (0.024
mmol, 4.2 mg) and hydroxyclavatol (0.016 mmol, 3.1 mg) as
reactants. The product was isolated in 44% yield (2.5 mg) as white
amorphous solid. Eluent: ACN/H2O (60:40, v/v) supplied with 0.1%
TFA. 1H NMR (500 MHz, acetone-d6) δ 14.42 (s, 1H), 7.64 (s, 1H),
6.04 (s, 1H), 3.82 (s, 2H), 2.59 (s, 3H), 2.13 (s, 3H). HRMS (ESI-
TOF) m/z: [M + H]+ Calcd for C17H17O8 349.0918; Found
349.0925.
1-(3-(3-Acetyl-2,6-dihydroxy-5-methylbenzyl)-2,4,6-trihydroxy-
phenyl)-3-methylbutan-1-one (47b). The title compound was
prepared using 29a (0.142 mmol, 30.0 mg) and hydroxyclavatol
(0.076 mmol, 14.9 mg) as reactants. The product was isolated in 31%
yield (9.1 mg) as yellow amorphous solid. Eluent: ACN/H2O (90:10,
v/v) supplied with 0.1% TFA. 1H NMR (500 MHz, DMSO-d6) δ
13.09 (s, 1H), 10.69 (s, 1H), 7.51 (s, 1H), 5.96 (s, 1H), 3.74 (s, 2H),
2.87 (d, J = 6.7 Hz, 1H), 2.51 (s, 3H), 2.14 (m, 1H), 2.08 (s, 3H),
0.90 (d, J = 6.7 Hz, 3H), 0.90 (d, J = 6.7 Hz, 3H). 13C{1H} NMR
(125 MHz, DMSO-d6) δ 205.1, 203.0, 163.4, 162.3, 160.8, 160.7,
160.3, 130.4, 115.7, 113.3, 112.0, 104.4, 103.7, 94.4, 51.8, 48.6, 26.1,
24.8, 22.6, 22.6, 15.9. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for
C21H25O7 389.1595; Found 389.1597.
1-(3-(3-Acetyl-2,6-dihydroxy-5-methylbenzyl)-2,4,6-trihydroxy-
phenyl)-3-(4-hydroxyphenyl)propan-1-one (50b). The title com-
pound was prepared using 50a (0.028 mmol, 7.9 mg) and
hydroxyclavatol (0.024 mmol, 4.7 mg) as reactants. The product
was isolated in 19% yield (2.0 mg) as white amorphous solid. Eluent:
ACN/H2O (80:20, v/v) supplied with 0.1% TFA.
1H NMR (500
MHz, acetone-d6) δ 14.53 (s, 1H), 7.66 (s, 1H), 7.10 (d, J = 8.6 Hz,
2H), 6.75 (d, J = 8.6 Hz, 2H), 6.08 (s, 1H), 3.85 (s, 2H), 3.39 (t, J =
7.5 Hz, 2H), 2.90 (t, J = 7.5 Hz, 2H), 2.59 (s, 3H), 2.14 (s, 3H).
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C25H25O8 453.1544;
Found 453.1561.
(S)-3-(2-(3-Acetyl-2,6-dihydroxy-5-methylbenzyl)-1H-indol-3-yl)-
2-aminopropanoic acid (61b). The title compound was prepared
using 61a (0.160 mmol, 44.0 mg) and hydroxyclavatol (0.102 mmol,
20.0 mg) as reactants. The product was isolated in 27% yield (10.4
mg) as yellow amorphous solid. Eluent: CH2Cl2.
1H NMR (500 MHz,
DMSO-d6) δ 10.19 (s, 1H), 7.56 (s, 1H), 7.51 (d, J = 8.0 Hz, 1H),
7.26 (d, J = 8.0 Hz, 1H), 6.94 (dd, J = 8.0, 6.8 Hz, 1H), 6.90 (dd, J =
8.0, 6.8 Hz, 1H), 4.14 (d, J = 15.2 Hz, 1H), 4.07 (d, J = 15.2 Hz, 1H),
3.41 (dd, J = 6.8, 5.8, 1H), 3.18 (dd, J = 14.7, 5.8 Hz, 1H), 3.03 (dd, J
= 14.7, 6.8 Hz, 1H), 2.52 (s, 3H), 2.11 (s, 3H). 13C{1H} NMR (125
MHz, DMSO-d6) δ 202.1, 171.2, 161.5, 136.1, 134.9, 130.8, 128.4,
119.8, 118.2, 118.0, 117.2, 111.9, 111.4, 110.9, 105.1, 55.0, 26.1, 25.9,
20.0, 16.5. [α]D
20 = −6 (c 0.2, acetone); HRMS (ESI-TOF) m/z: [M
+ H]+ Calcd for C21H23N2O5 383.1601; Found 383.1609.
2-Acetamido-3-(2-(3-acetyl-2,6-dihydroxy-5-methylbenzyl)-1H-
indol-3-yl)propanoic acid ((±)-65b). The title compound was
prepared using (±)-65a (0.178 mmol, 44.0 mg) and hydroxyclavatol
(0.069 mmol, 13.5 mg) as reactants. The product was isolated in 29%
yield (8.6 mg) as brown oil. Eluent: ACN/H2O (55:45, v/v) supplied
with 0.1% TFA. 1H NMR (500 MHz, acetone-d6) δ 13.26 (s, 1H),
7.66 (s, 1H), 7.53 (d, J = 7.4 Hz, 1H), 7.23 (d, J = 7.4 Hz, 1H), 6.96
(t, J = 7.4 Hz, 1H), 6.92 (t, J = 7.4 Hz, 1H), 4.81 (ddd, J = 8.2, 7.7,
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6.0 Hz, 1H), 4.21 (d, J = 15.0 Hz, 1H), 4.18 (d, J = 15.0 Hz, 1H),
3.45 (dd, J = 14.7, 6.0 Hz, 1H), 3.33 (dd, J = 14.7, 7.7 Hz, 1H), 2.57
(s, 3H), 2.26 (s, 3H), 1.85 (s, 3H). HRMS (ESI-TOF) m/z: [M +
H]+ Calcd for C23H25N2O6 425.1707; Found 425.1713.
Na-Acetyl-1-(3-acetyl-2,6-dihydroxy-5-methylbenzyl)tryptophan
((±)-65c). The title compound was prepared using (±)-65a (0.178
mmol, 44.0 mg) and hydroxyclavatol (0.069 mmol, 13.5 mg) as
reactants. The product was isolated in 14% yield (4.3 mg) as brown
oil. Eluent: ACN/H2O (55:45, v/v) supplied with 0.1% TFA.
1H
NMR (500 MHz, acetone-d6) δ 13.31 (s, 1H), 7.71 (s, 1H), 7.70 (d, J
= 8.2 Hz, 1H), 7.51 (d, J = 8.2 Hz, 1H), 7.29 (s, 1H), 7.09 (dd, J =
8.2, 7.0 Hz, 1H), 6.97 (dd, J = 8.2, 7.0 Hz, 1H), 5.33 (s, 2H), 4.68
(ddd, J = 8.2, 7.5, 5.6 Hz, 1H), 3.27 (dd, J = 14.7, 5.6 Hz, 1H), 3.10
(dd, J = 14.7, 7.5 Hz, 3H), 2.56 (s, 3H), 2.27 (s, 3H), 1.83 (s, 3H).
1H NMR (500 MHz, DMSO-d6) δ 13.19 (s, 1H), 8.06 (d, J = 8.4 Hz,
1H), 7.69 (s, 1H), 7.65 (d, J = 8.2 Hz, 1H), 7.48 (d, J = 8.2 Hz, 1H),
7.15 (s, 1H), 7.10 (dd, J = 8.2, 7.0 Hz, 1H), 6.98 (dd, J = 8.2, 7.0 Hz,
1H), 5.25 (s, 2H), 4.38 (td, J = 9.2, 5.1 Hz, 1H), 3.11 (dd, J = 15.0,
5.1 Hz, 1H), 2.90 (dd, J = 15.0, 9.2 Hz, 1H), 2.54 (s, 3H), 2.17 (s,
3H), 1.75 (s, 3H). 13C{1H} NMR (125 MHz, DMSO-d6) δ 203.4,
173.4, 169.0, 161.0, 161.0, 136.0, 133.1, 127.3, 127.2, 120.8, 118.3,
118.1, 116.1, 112.4, 111.1, 110.2, 109.1, 52.8, 37.5, 26.9, 26.2, 22.2,
16.2. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C23H25N2O6
425.1707; Found 425.1708.
4-(2-(3-Acetyl-2,6-dihydroxy-5-methylbenzyl)-1H-indol-3-yl)-
butanoic acid (72b). The title compound was prepared using 72a
(0.008 mmol, 1.6 mg) and hydroxyclavatol (0.008 mmol, 1.6 mg) as
reactants. The product was isolated in 46% yield (1.4 mg) as brown
oil. Eluent: ACN/H2O (65:35, v/v) supplied with 0.1% TFA.
1H
NMR (500 MHz, CDCl3) δ 13.30 (s, 1H), 8.57 (s, 1H), 7.49 (d, J =
8.0 Hz, 1H), 7.40 (s, 1H), 7.24 (d, J = 8.0 Hz, 1H), 7.08 (dd, J = 8.0,
7.0 Hz, 1H), 7.03 (dd, J = 8.0, 7.0 Hz, 1H), 4.14 (s, 2H), 2.95 (t, J =
7.0 Hz, 2H), 2.57 (s, 3H), 2.50 (t, J = 7.0 Hz, 2H), 2.18 (s, 3H),
2.07−2.01 (m, 2H). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for
C22H24NO5 382.1649; Found 382.1662.
(3S,6S)-3-((2-(3-Acetyl-2,6-dihydroxy-5-methylbenzyl)-1H-indol-
3-yl)methyl)-6-isobutylpiperazine-2,5-dione (76b). The title com-
pound was prepared using 76a (0.016 mmol, 4.8 mg) and
hydroxyclavatol (0.016 mmol, 3.2 mg) as reactants. The product
was isolated in 13% yield (1.0 mg) as white amorphous solid. Eluent:
ACN/H2O (60:40, v/v).
1H NMR (500 MHz, CDCl3) δ 13.40 (s,
1H), 8.77 (s, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.46 (s, 1H), 7.25 (d, J =
8.0 Hz, 1H), 7.12 (dd, J = 8.0, 7.1 Hz, 1H), 7.07 (dd, J = 8.0, 7.1 Hz,
1H), 6.39 (s, 1H), 5.99 (s, 1H), 4.40 (d, J = 8.9 Hz, 1H), 4.16 (d, J =
15.0 Hz, 1H), 4.13 (d, J = 15.0 Hz, 1H), 3.94 (d, J = 10.0 Hz, 1H),
3.65 (dd, J = 14.8, 3.2 Hz, 1H), 3.28 (dd, J = 14.8, 8.9 Hz, 1H), 2.60
(s, 3H), 2.23 (s, 3H), 1.68−1.60 (m, 1H), 1.61−1.56 (m, 1H), 1.17
(ddd, 13.7, 10.0, 4.5 Hz, 1H), 0.86 (d, J = 6.2 Hz, 1H), 0.85 (d, J =
6.2 Hz, 1H). [α]D
20 = −41 (c 0.1, CHCl3); HRMS (ESI-TOF) m/z:
[M + H]+ Calcd for C27H32N3O5 478.2336; Found 478.2339.
(3S,6S)-3-((2-(3-Acetyl-2,6-dihydroxy-5-methylbenzyl)-1H-indol-
3-yl)methyl)-6-benzylpiperazine-2,5-dione (77b). The title com-
pound was prepared using 77a (0.032 mmol, 10.7 mg) and
hydroxyclavatol (0.016 mmol, 3.1 mg) as reactants. The product
was isolated in 24% yield (2.0 mg) as white amorphous solid. Eluent:
ACN/H2O (55:45, v/v).
1H NMR (500 MHz, DMSO-d6) δ 13.04 (s,
1H), 9.96 (s, 1H), 9.63 (s, 1H), 7.94 (d, J = 3.0 Hz, 1H), 7.64 (d, J =
3.3 Hz, 1H), 7.62 (s, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.22 (d, J = 7.6
Hz, 1H), 7.16−7.10 (m, 3H), 6.95 (dd, J = 7.6, 6.5 Hz, 1H), 6.92 (dd,
J = 7.6, 6.5 Hz, 1H), 6.62 (dd, J = 7.5, 2.3 Hz, 2H), 4.05 (d, J = 15.7
Hz, 1H), 4.07−4.04 (m, 1H), 4.01 (d, J = 15.7 Hz, 1H), 3.80−3.76
(m, 1H), 3.05 (dd, J = 14.7, 4.7 Hz, 1H), 2.98 (dd, J = 14.7, 5.4 Hz,
1H), 2.55 (s, 3H), 2.47 (m, 1H), 2.18 (s, 3H), 1.61 (dd, J = 13.7, 7.9
Hz, 1H). [α]D
20 = −49 (c 0.2, MeOH); HRMS (ESI-TOF) m/z: [M
+ H]+ Calcd for C30H30N3O5 512.2180; Found 512.2200.
3-((1H-Indol-3-yl)methyl)-6-((2-(3-acetyl-2,6-dihydroxy-5-meth-
ylbenzyl)-1H-indol-3-yl)methyl)piperazine-2,5-dione (79b). The
title compound was prepared using 79a (0.040 mmol, 14.9 mg)
and hydroxyclavatol (0.033 mmol, 6.5 mg) as reactants. The product
was isolated in 30% yield (5.4 mg) as white amorphous solid. Eluent:
ACN/H2O (65:35, v/v).
1H NMR (500 MHz, CDCl3) δ 13.40 (s,
1H), 8.74 (s, 1H), 8.01 (s, 1H), 7.48 (s, 1H), 7.47 (d, J = 8.0, 1H),
7.46 (d, J = 8.2, 1H), 7.34 (d, J = 8.2 Hz, 1H), 7.24 (d, J = 8.0 Hz,
1H), 7.17 (dd, J = 8.2, 7.2 Hz, 1H), 7.11 (dd, J = 8.2, 7.2 Hz, 1H),
7.08 (dd, J = 8.0, 7.1 Hz, 1H), 7.05 (dd, J = 8.0, 7.1 Hz, 1H), 6.58 (s,
1H), 6.48 (s, 1H), 5.84 (s, 1H), 4.36 (d, J = 7.7 Hz, 1H), 4.20 (d, J =
10.1 Hz, 1H), 4.08 (d, J = 15.1 Hz, 1H), 4.04 (d, J = 15.1 Hz, 1H),
3.45 (dd, J = 14.7, 3.2 Hz, 1H), 3.30 (dd, J = 14.5, 3.2 Hz, 1H), 3.08
(dd, J = 14.5, 7.7 Hz, 1H), 2.61 (s, 3H), 2.27−2.24 (m, 1H), 2.23 (s,
3H). 1H NMR (500 MHz, DMSO-d6) δ 13.04 (s, 1H), 10.75 (d, J =
1.9 Hz, 1H), 9.92 (s, 1H), 9.61 (s, 1H), 7.85 (d, J = 2.5 Hz, 1H), 7.62
(s, 1H), 7.60 (d, J = 2.7 Hz, 1H), 7.30 (d, J = 8.0 Hz, 1H), 7.27 (d, J =
8.2 Hz, 1H), 7.25 (d, J = 8.2 Hz, 1H), 7.21 (d, J = 8.0 Hz, 1H), 6.98
(dd, J = 8.0, 7.0 Hz, 1H), 6.93 (dd, J = 8.0, 7.0 Hz, 1H), 6.90 (dd, J =
8.0, 7.0 Hz, 1H), 6.88 (dd, J = 8.0, 7.0 Hz, 1H), 6.37 (d, J = 2.1 Hz,
1H), 4.02 (dd, J = 8.1, 3.8 Hz, 1H), 3.97 (d, J = 15.4 Hz, 1H), 3.91
(d, J = 15.4 Hz, 1H), 3.81−3.76 (m, 1H), 2.99 (dd, J = 14.4, 4.6 Hz,
1H), 2.88 (dd, J = 14.4, 5.4 Hz, 1H), 2.71 (dd, J = 14.4, 3.8 Hz, 1H),
2.55 (s, 3H), 2.17 (s, 3H), 1.85 (dd, J = 14.4, 8.1 Hz, 1H). 13C{1H}
NMR (125 MHz, DMSO-d6) δ 203.1, 167.0, 166.5, 160.7, 160.6,
136.1, 136.1, 135.2, 131.4, 128.4, 127.0, 124.2, 120.7, 119.8, 119.4,
118.2, 118.1, 118.0, 115.9, 112.5, 112.5, 111.1, 110.8, 108.8, 104.9,
55.9, 55.3, 30.6, 30.6, 26.2, 19.3, 16.2. [α]D
20 = −38 (c 0.1, CHCl3);
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C32H31N4O5 551.2289;
Found 551.2313.
(3S,5aS,10bS,11aS)-3-((1H-Indol-3-yl)methyl)-10b-(3-acetyl-2,6-
dihydroxy-5-methylbenzyl)-2,3,6,10b,11,11a-hexahydro-4H-
pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4(5aH)-dione (79c). The
title compound was prepared using 79a (0.040 mmol, 14.9 mg)
and hydroxyclavatol (0.033 mmol, 6.5 mg) as reactants. The product
was isolated in 3% yield (0.6 mg) as white amorphous solid. Eluent:
ACN/H2O (65:35, v/v).
1H NMR (500 MHz, CDCl3) δ 13.01 (s,
1H), 8.11 (s, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.44 (s, 1H), 7.38 (d, J =
8.0 Hz, 1H), 7.21 (dd, J = 8.0, 7.0 Hz, 1H), 7.15 (dd, J = 8.0, 7.0 Hz,
1H), 7.11 (d, J = 8.0 Hz, 1H), 7.10 (dd, J = 8.0, 7.0 Hz, 1H), 7.06 (s,
1H), 6.82 (dd, J = 8.0, 7.0 Hz, 1H), 6.72 (d, J = 8.0 Hz, 1H), 5.60 (s,
1H), 5.47 (s, 1H), 4.29 (d, J = 11.0 Hz, 1H), 3.92 (dd, J = 11.3, 5.8
Hz, 1H), 3.69 (dd, J = 15.0, 3.5 Hz, 1H), 3.21 (d, J = 14.0 Hz, 1H),
2.97 (d, J = 14.0 Hz, 1H), 2.90 (dd, J = 15.0, 11.0 Hz, 1H), 2.74 (dd, J
= 13.2, 5.8 Hz, 1H), 2.57 (s, 3H), 2.37 (dd, J = 13.2, 11.3 Hz, 1H),
2.18 (s, 3H). [α]D
20 = −58 (c 0.06, CHCl3); HRMS (ESI-TOF) m/z:
[M + H]+ Calcd for C32H31N4O5 551.2289; Found 551.2314.
(3S,5aS,10bS,11aS)-10b-(3-Acetyl-2,6-dihydroxy-5-methylben-
zyl)-3-((2-(3-acetyl-2,6-dihydroxy-5-methylbenzyl)-1H-indol-3-yl)-
methyl)-2,3,6,10b,11,11a-hexahydro-4H-pyrazino[1′,2′:1,5]pyrrolo-
[2,3-b]indole-1,4(5aH)-dione (79d). The title compound was
prepared using 79a (0.040 mmol, 14.9 mg) and hydroxyclavatol
(0.033 mmol, 6.5 mg) as reactants. The product was isolated in 4%
yield (1.0 mg) as white amorphous solid. Eluent: ACN/H2O (65:35,
v/v). 1H NMR (500 MHz, CDCl3) δ 12.98 (s, 1H), 12.92 (s, 1H),
8.18 (s, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.42 (s, 1H), 7.40 (d, J = 8.0
Hz, 1H), 7.24−7.21 (m, 1H), 7.19 (t, J = 7.5, 1H), 7.12 (dd, J = 8.0,
7.0 Hz, 1H) 7.12 (s, 1H), 6.89 (d, J = 7.5 Hz, 1H), 6.79 (d, J = 7.5
Hz, 1H), 6.71 (t, J = 7.5 Hz, 1H), 5.69 (s, 1H), 5.52 (s, 1H), 4.76 (d,
J = 15.2 Hz, 1H), 4.54 (d, J = 15.2 Hz, 1H), 4.46 (dd, J = 10.0, 3.4
Hz, 1H), 3.99 (dd, J = 11.9, 5.5 Hz, 1H), 3.70 (dd, J = 15.0, 3.4 Hz,
1H), 3.12 (dd, J = 15.0, 10.0 Hz, 1H), 2.78 (s, 2H), 2.69 (dd, J = 13.0,
5.5 Hz, 1H), 2.55 (s, 3H), 2.51 (s, 3H), 2.28 (s, 3H), 2.04 (dd, J =
13.0, 11.9 Hz, 1H), 1.99 (s, 3H). [α]D
20 = −63 (c 0.1, CHCl3);
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C42H41N4O8 729.2919;
Found 729.2932.
(R)-3-((2-(3-Acetyl-2,6-dihydroxy-5-methylbenzyl)-1H-indol-3-
yl)methyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione (80b).
The title compound was prepared using 80a (0.080 mmol, 24.5 mg)
and hydroxyclavatol (0.051 mmol, 10.0 mg) as reactants. The product
was isolated in 21% yield (5.3 mg) as white amorphous solid. Eluent:
ACN/H2O (55:45, v/v).
1H NMR (500 MHz, acetone-d6) δ 13.30 (s,
1H), 9.71 (s, 1H), 9.52 (s, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.62 (s,
1H), 7.52 (dd, J = 8.0, 7.2 Hz, 1H), 7.45 (d, J = 8.0 Hz, 1H), 7.23 (d,
J = 8.0 Hz, 1H), 7.21 (d, J = 8.0 Hz, 1H), 7.20 (dd, J = 8.0, 7.2 Hz,
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1H), 6.93 (dd, J = 8.0, 7.0 Hz, 1H), 6.84 (dd, J = 8.0, 7.0 Hz, 1H),
4.28 (d, J = 15.0 Hz, 1H), 4.25 (dd, J = 9.0, 5.9 Hz, 1H), 4.22 (d, J =
15.0 Hz, 1H), 3.51 (dd, J = 15.0, 5.9 Hz, 1H), 3.34 (dd, J = 15.0, 9.0
Hz, 1H), 2.56 (s, 3H), 2.24 (s, 3H). 13C{1H} NMR (125 MHz,
acetone-d6) δ 203.9, 172.7, 168.5, 161.4, 161.4, 137.5, 136.6, 136.5,
133.3, 132.4, 131.8, 128.9, 127.1, 125.1, 121.9, 121.6, 119.5, 118.5,
117.0, 114.2, 113.8, 111.7, 106.3, 53.2, 26.4, 24.4, 20.2, 16.3. [α]D
20 =
−52 (c 0.1, acetone); HRMS (ESI-TOF) m/z: [M + H]+ Calcd for
C28H26N3O5 484.1867; Found 484.1870.
(5aS,13aR,14aS)-14a-(3-Acetyl-2,6-dihydroxy-5-methylbenzyl)-
5a,13a,14,14a-tetrahydrobenzo[5′,6′][1,4]diazepino[1′,2′:1,5]-
pyrrolo[2,3-b]indole-7,13(5H,12H)-dione (80c). The title compound
was prepared using 80a (0.080 mmol, 24.5 mg) and hydroxyclavatol
(0.051 mmol, 10.0 mg) as reactants. The product was isolated in 4%
yield (1.0 mg) as white amorphous solid. Eluent: ACN/H2O (55:45,
v/v). 1H NMR (500 MHz, acetone-d6) δ 13.14 (s, 1H), 9.54 (s, 1H),
8.63 (s, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.64 (s, 1H), 7.48 (dd, J = 8.0,
7.3 Hz, 1H), 7.20 (dd, J = 8.0, 7.3 Hz, 1H), 7.16 (dd, J = 8.2 Hz, 1H),
7.12 (d, J = 8.0 Hz, 1H), 6.97 (dd, J = 8.2, 7.7 Hz, 1H), 6.67 (d, J =
8.2 Hz, 1H), 6.61 (dd, J = 8.2, 7.7 Hz, 1H), 6.31 (s, 1H), 5.65 (s,
1H), 4.01 (dd, J = 8.2, 7.0 Hz, 1H), 3.22 (d, J = 14.0 Hz, 1H), 3.17
(d, J = 14.0 Hz, 1H), 3.17 (dd, J = 14.0, 7.0 Hz, 1H), 2.56 (s, 3H),
2.47 (dd, J = 14.0, 8.2 Hz, 1H), 2.25 (s, 1H). [α]D
20 = −47 (c 0.1,
acetone); HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C28H26N3O5
484.1867; Found 484.1874.
1-(3-((2-Amino-4-hydroxyquinolin-3-yl)methyl)-2,4-dihydroxy-5-
methylphenyl)ethan-1-one (95b). The title compound was prepared
using 95a (0.128 mmol, 20.6 mg) and hydroxyclavatol (0.058 mmol,
11.3 mg) as reactants. The product was isolated in 46% yield (9.0 mg)
as brown amorphous solid. Eluent: ACN/H2O (75:25, v/v) supplied
with 0.1% TFA. 1H NMR (500 MHz, DMSO-d6) δ 13.93 (s, 1H),
11.52 (s, 1H), 8.05 (d, J = 8.2 Hz, 1H), 7.56 (s, 1H), 7.55 (dd, J = 8.2,
7.1, 1H), 7.36 (d, J = 8.2 Hz, 1H), 7.25 (dd, J = 8.2, 7.1 Hz, 1H), 6.67
(s, 2H), 3.70 (s, 2H), 2.53 (s, 3H), 2.08 (s, 3H). 13C{1H} NMR (125
MHz, DMSO-d6) δ 202.9, 174.0, 164.1, 159.4, 153.0, 136.9, 130.9,
130.8, 124.4, 122.3, 120.6, 117.7, 116.3, 113.1, 111.0, 101.0, 25.8,
17.6, 15.9. HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C19H19N2O4
339.1339; Found 339.1357.
1-(2,4-Dihydroxy-3-((5-hydroxyquinolin-8-yl)methyl)-5-methyl
phenyl)ethan-1-one (98b). The title compound was prepared using
98a (0.157 mmol, 22.9 mg) and hydroxyclavatol (0.059 mmol, 11.5
mg) as reactants. The product was isolated in 38% yield (7.1 mg) as
yellow amorphous solid. Eluent: ACN/H2O (80:20, v/v) supplied
with 0.1% TFA. 1H NMR (500 MHz, DMSO-d6) δ 13.19 (s, 1H),
10.59 (s, 1H), 9.01 (dd, J = 4.5, 1.7 Hz, 1H), 8.69 (dd, J = 8.4, 1.7 Hz,
1H), 7.75 (d, J = 8.0 Hz, 1H), 7.63 (dd, J = 8.4, 4.5 Hz, 1H), 7.55 (s,
1H), 6.96 (d, J = 8.0 Hz, 1H), 4.23 (s, 2H), 2.51 (s, 3H), 2.12 (s,
3H). 13C{1H} NMR (125 MHz, DMSO-d6) δ 203.1, 161.2, 160.9,
152.0, 148.6, 144.4, 133.7, 132.1, 130.7, 126.9, 120.2, 120.1, 117.3,
114.1, 112.0, 109.0, 26.1, 24.5, 15.9. HRMS (ESI-TOF) m/z: [M +
H]+ Calcd for C19H18NO4 324.1230; Found 324.1235.
5-(3-Acetyl-2,6-dihydroxy-5-methylbenzyl)-2-aminobenzoic acid
(101b). The title compound was prepared using 101a (0.167 mmol,
23.0 mg) and hydroxyclavatol (0.066 mmol, 12.9 mg) as reactants.
The product was isolated in 23% yield (4.7 mg) as brown amorphous
solid. Eluent: ACN/H2O (65:35, v/v) supplied with 0.1% TFA.
1H
NMR (500 MHz, acetone-d6) δ 13.08 (s, 1H), 7.72 (d, J = 2.1 Hz,
1H), 7.62 (s, 1H), 7.37 (dd, J = 8.4, 2.1 Hz, 1H), 6.68 (d, J = 8.4 Hz,
1H), 3.95 (s, 2H), 2.56 (s, 3H), 2.24 (s, 3H). 13C{1H} NMR (125
MHz, acetone-d6) δ 204.0, 163.7, 162.0, 161.6, 146.0, 136.8, 132.2,
132.1, 129.8, 116.4, 115.5, 114.0, 114.0, 112.6, 27.9, 26.4, 16.3.
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C17H18NO5 316.1179;
Found 316.1169.
2-((3-Acetyl-2,6-dihydroxy-5-methylbenzyl)amino)benzoic acid
(101c). The title compound was prepared using 101a (0.167 mmol,
23.0 mg) and hydroxyclavatol (0.066 mmol, 12.9 mg) as reactants.
The product was isolated in 6% yield (1.2 mg) as brown amorphous
solid. Eluent: ACN/H2O (65:35, v/v) supplied with 0.1% TFA.
1H
NMR (500 MHz, acetone-d6) δ 13.23 (s, 1H), 7.89 (d, J = 8.0 Hz,
1H), 7.68 (s, 1H), 7.37 (dd, J = 8.0, 7.1 Hz, 1H), 7.05 (d, J = 8.0 Hz,
1H), 6.59 (dd, J = 8.0, 7.1 Hz, 1H), 4.51 (s, 2H), 2.56 (s, 3H), 2.21
(s, 3H). HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C17H18NO5
316.1179; Found 316.1181.
5-(3-Acetyl-2,6-dihydroxy-5-methylbenzyl)-2-((3-acetyl-2,6-dihy-
droxy-5-methylbenzyl)amino)benzoic acid (101d). The title com-
pound was prepared using 101a (0.167 mmol, 23.0 mg) and
hydroxyclavatol (0.066 mmol, 12.9 mg) as reactants. The product was
isolated in 3% yield (0.9 mg) as yellow amorphous solid. Eluent:
ACN/H2O (65:35, v/v) supplied with 0.1% TFA.
1H NMR (500
MHz, acetone-d6) δ 13.21 (s, 1H), 13.06 (s, 1H), 7.89 (d, J = 2.1 Hz,
1H), 7.64 (s, 1H), 7.59 (s, 1H), 7.32 (dd, J = 8.6, 2.1 Hz, 1H), 6.92
(d, J = 8.6 Hz, 1H), 4.49 (s, 2H), 3.91 (s, 2H), 2.55 (s, 3H), 2.54 (s,
3H), 2.22 (s, 3H), 2.17 (s, 3H). HRMS (ESI-TOF) m/z: [M + H]+
Calcd for C27H28NO8 494.1809; Found 494.1823.
1-(3-(((1,3-Dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)-
methyl)-2,4-dihydroxy-5-methylphenyl)ethan-1-one (102b). The
title compound was prepared by using 102a (1.0 mmol, 122.0 mg,
prepared as Tris−HCl buffer, pH 7.5) and hydroxyclavatol (0.066
mmol, 12.9 mg) as reactants. The product was isolated in 16% yield
(3.2 mg) as brown oil. Eluent: ACN/H2O (70:30, v/v) supplied with
0.1% TFA. 1H NMR (500 MHz, CD3OD) δ 7.72 (s, 1H), 4.49 (s,
2H), 3.82 (s, 6H), 2.56 (s, 3H), 2.22 (s, 3H). 13C{1H} NMR (125
MHz, CD3OD) δ 204.9, 162.5, 162.4, 135.5, 117.3, 114.4, 107.3, 67.5,
59.7, 59.7, 59.7, 36.5, 26.3, 16.1. HRMS (ESI-TOF) m/z: [M + H]+
Calcd for C14H22NO6 300.1442; Found 300.1445.
α-Glucosidase Inhibition Assay. The α-glucosidase inhibition
activity was evaluated by modified procedures reported previ-
ously.38,39 The assays contained 100 mM phosphate buffer (pH
6.8), α-glucosidase (1.3 U/mL) (Sigma-Aldrich, St. Louis, USA), and
10 μL of a 2 mM DMSO solution of compounds to be tested. After
preincubation at 37 °C for 15 min, the assays were initiated by
addition of 40 μL of 2.5 mM p-nitrophenyl-α-D-glucopyranoside
solution (Sigma-Aldrich, St. Louis, USA) to a final volume of 150 μL.
After incubation at 37 °C for a further 15 min, the absorbance at 405
nm was recorded on a microplate reader (BMG Labtech, Offenburg,
Germany). DMSO was used as a negative control, and acarbose (TCI
Europe, Zwijndrecht, Belgium) was used as positive control. All assays
were performed in triplicate. The IC50 value was determined by
regression analysis.40,41
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acs.joc.9b02971.
Chemical synthesis of hydroxyclavatol, structural over-
view of all reactants, LC−MS chromatograms of selected
reactions, NMR spectra of coupling products (PDF)
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: shuming.li@staff.uni-marburg.de.
ORCID
Shu-Ming Li: 0000-0003-4583-2655
Author Contributions
†G.L. and J.F. contributed equally to this work.
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
We thank Rixa Kraut and Stefan Newel (University of
Marburg) for taking MS and NMR spectra, respectively. S.-
M.L. acknowledges the DFG for funding the Bruker microTOF
QIII mass spectrometer (INST 160/620-1). G.L.
(201607565014) and J.F. (201507565006) are scholarship
recipients from the China Scholarship Council.
The Journal of Organic Chemistry Note
DOI: 10.1021/acs.joc.9b02971
J. Org. Chem. 2020, 85, 1298−1307
1305
260
■ REFERENCES
(1) Van De Water, R. W.; Pettus, T. R. R. o-Quinone methides:
intermediates underdeveloped and underutilized in organic synthesis.
Tetrahedron 2002, 58 (27), 5367−5406.
(2) Bai, W. J.; David, J. G.; Feng, Z. G.; Weaver, M. G.; Wu, K. L.;
Pettus, T. R. R. The domestication of ortho-quinone methides. Acc.
Chem. Res. 2014, 47 (12), 3655−3664.
(3) Nielsen, C. D. T.; Abas, H.; Spivey, A. C. Stereoselective
reactions of ortho-quinone methide and ortho-quinone methide imines
and their utility in natural product synthesis. Synthesis 2018, 50 (20),
4008−4018.
(4) Pathak, T. P.; Sigman, M. S. Applications of ortho-quinone
methide intermediates in catalysis and asymmetric synthesis. J. Org.
Chem. 2011, 76 (22), 9210−9215.
(5) Willis, N. J.; Bray, C. D. ortho-Quinone methides in natural
product synthesis. Chem. - Eur. J. 2012, 18 (30), 9160−9173.
(6) Spence, J. T.; George, J. H. Biomimetic total synthesis of ent-
penilactone A and penilactone B. Org. Lett. 2013, 15 (15), 3891−
3893.
(7) Spence, J. T.; George, J. H. Total synthesis of peniphenones A-D
via biomimetic reactions of a common o-quinone methide
intermediate. Org. Lett. 2015, 17 (24), 5970−5973.
(8) Forest, K.; Wan, P.; Preston, C. M. Catechin and
hydroxybenzhydrols as models for the environmental photochemistry
of tannins and lignins. Photochem. Photobiol. Sci. 2004, 3 (5), 463−
472.
(9) Chen, Y.; Steinmetz, M. G. Photoactivation of amino-substituted
1,4-benzoquinones for release of carboxylate and phenolate leaving
groups using visible light. J. Org. Chem. 2006, 71 (16), 6053−6060.
(10) Bishop, L. M.; Winkler, M.; Houk, K. N.; Bergman, R. G.;
Trauner, D. Mechanistic investigations of the acid-catalyzed
cyclization of a vinyl ortho-quinone methide. Chem. - Eur. J. 2008,
14 (18), 5405−5408.
(11) Patel, A.; Netscher, T.; Rosenau, T. Stabilization of ortho-
quinone methides by a bis (sulfonium ylide) derived from 2, 5-
dihydroxy-[1, 4] benzoquinone. Tetrahedron Lett. 2008, 49 (15),
2442−2445.
(12) Fan, J.; Liao, G.; Kindinger, F.; Ludwig-Radtke, L.; Yin, W.-B.;
Li, S.-M. Peniphenone and penilactone formation in Penicillium
crustosum via 1,4-Michael additions of ortho-quinone methide from
hydroxyclavatol to γ-butyrolactones from crustosic acid. J. Am. Chem.
Soc. 2019, 141, 4225−4229.
(13) Huang, C.; Yang, C.; Zhang, W.; Zhang, L.; De, B. C.; Zhu, Y.;
Jiang, X.; Fang, C.; Zhang, Q.; Yuan, C. S.; Liu, H. W.; Zhang, C.
Molecular basis of dimer formation during the biosynthesis of
benzofluorene-containing atypical angucyclines. Nat. Commun. 2018,
9 (1), 2088.
(14) Wu, G.; Ma, H.; Zhu, T.; Li, J.; Gu, Q.; Li, D. Penilactones A
and B, two novel polyketides from Antarctic deep-sea derived fungus
Penicillium crustosum PRB-2. Tetrahedron 2012, 68, 9745−9749.
(15) Tomoda, H.; Tabata, N.; Masuma, R.; Si, S. Y.; Omura, S.
Erabulenols, inhibitors of cholesteryl ester transfer protein produced
by Penicillium sp. FO-5637. I. Production, isolation and biological
properties. J. Antibiot. 1998, 51 (7), 618−623.
(16) da Silva, B. F.; Rodrigues-Fo, E. Production of a benzylated
flavonoid from 5,7,3′,4’,5′-pentamethoxyflavanone by Penicillium
griseoroseum. J. Mol. Catal. B: Enzym. 2010, 67 (3−4), 184−188.
(17) Wang, J.; Liu, P.; Wang, Y.; Wang, H.; Li, J.; Zhuang, Y.; Zhu,
W. Antimicrobial aromatic polyketides from Gorgonian-associated
fungus, Penicillium commune 518. Chin. J. Chem. 2012, 30, 1236−
1242.
(18) Li, H.; Jiang, J.; Liu, Z.; Lin, S.; Xia, G.; Xia, X.; Ding, B.; He,
L.; Lu, Y.; She, Z. Peniphenones A-D from the mangrove fungus
Penicillium dipodomyicola HN4−3A as inhibitors of Mycobacterium
tuberculosis phosphatase MptpB. J. Nat. Prod. 2014, 77 (4), 800−806.
(19) Sun, W.; Chen, X.; Tong, Q.; Zhu, H.; He, Y.; Lei, L.; Xue, Y.;
Yao, G.; Luo, Z.; Wang, J.; Li, H.; Zhang, Y. Novel small molecule
11beta-HSD1 inhibitor from the endophytic fungus Penicillium
commune. Sci. Rep. 2016, 6, 26418.
(20) Yu, G.; Sun, Z.; Peng, J.; Zhu, M.; Che, Q.; Zhang, G.; Zhu, T.;
Gu, Q.; Li, D. Secondary metabolites produced by combined culture
of Penicillium crustosum and a Xylaria sp. J. Nat. Prod. 2019, 82 (7),
2013−2017.
(21) Davies, M. W.; Maskell, L.; Shipman, M.; Slawin, A. M.; Vidot,
S. M.; Whatmore, J. L. Studies toward the synthesis of luminacin D:
assembly of simplified analogues devoid of the epoxide displaying
antiangiogenic activity. Org. Lett. 2004, 6 (22), 3909−3912.
(22) Walsh, C. T. Biological matching of chemical reactivity: pairing
indole nucleophilicity with electrophilic isoprenoids. ACS Chem. Biol.
2014, 9 (12), 2718−2728.
(23) Alkhalaf, L. M.; Ryan, K. S. Biosynthetic manipulation of
tryptophan in bacteria: Pathways and mechanisms. Chem. Biol. 2015,
22 (3), 317−328.
(24) Steinmetz, H.; Zander, W.; Shushni, M. A. M.; Jansen, R.;
Gerth, K.; Dehn, R.; Drag̈er, G.; Kirschning, A.; Müller, R. Precursor-
directed syntheses and biological evaluation of new elansolid
derivatives. ChemBioChem 2012, 13 (12), 1813−1817.
(25) Jansen, R.; Gerth, K.; Steinmetz, H.; Reinecke, S.; Kessler, W.;
Kirschning, A.; Müller, R. Elansolid A3, a unique p-quinone methide
antibiotic from Chitinophaga sancti. Chem. - Eur. J. 2011, 17 (28),
7739−7744.
(26) Dehn, R.; Katsuyama, Y.; Weber, A.; Gerth, K.; Jansen, R.;
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Scheme S1. Chemical synthesis of hydroxyclavatol.  
 
4-Methyl-6-acetylresorcinol was firstly synthesized by a Friedel-Craft acylation of 4-methylbenzene-1,3-diol 
(BLDpharm, Shanghai, China) as reported.1 Introducing the hydroxymethylene group onto 4-methyl-6-
acetylresorcinol was achieved by using a modified method reported for the synthesis of luminacin D.2 
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Figure S1. Examples of fungal clavatol-containing natural products.3-9 
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Figure S2. Structures of tested reactants with conversions between 10% – 55%. 
Products of reactants in green were further identified by NMR after isolation. Products of reactants in orange 
were only identified by LC-MS analysis. Products with two clavatol moieties were detected from reactants labled 
with *. Reaction mixtures (50 L) containing 0.4 mM hydroxyclavatol and 0.4 mM reactants were incubated at 
25 °C for 16 h before sent to LC-MS analysis. The conversion (%) was calculated by peak areas with UV 
detection. 
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Figure S3. Structures of tested reactants with conversions between 1% – 10% (A), and only detected by EIC of 
[M+H]+/[M-H]- ions (B). 
Reaction mixtures (50 L) containing 0.4 mM hydroxyclavatol and 0.4 mM reactants were incubated at 25 °C for 
16 h before sent to LC-MS analysis. Products of reactants in green were isolated from incubations at 95 °C for 30 
min. Products of reactants in orange were only identified by LC-MS analysis. Products with two clavatol moieties 
were detected from reactants labled with *. The conversion (%) was calculated by peak areas with UV detection. 
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Figure S4. Structures of tested reactants with no detectable product by EIC of [M+H]+/[M-H]- ions. 
Reaction mixtures (50 L) containing 0.4 mM hydroxyclavatol and 0.4 mM reactants were incubated at 25 °C for 
16 h before sent to LC-MS analysis. 
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Figure S5. LC-MS analysis of reaction mixtures of hydroxyclavatol with different reactants. 
HC: hydroxyclavatol, UV absorptions at 280 nm (black) are illustrated. EICs in blue or green refer [M+H]+ of 
products with one or two clavatol moieties with a tolerance range of ± 0.005. EICs refer [M-H]- of 17b, 17c, and 
18b.. 
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Figure S6. LC-MS analysis of reaction mixtures of hydroxyclavatol with different reactants. 
HC: Hydroxyclavatol, UV absorptions at 280 nm (black) are illustrated. EICs in blue or green refer [M+H]+ of 
products with one or two clavatol moieties with a tolerance range of ± 0.005. 
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Figure S7. LC-MS analysis of reaction mixtures of hydroxyclavatol with different reactants. 
HC: hydroxyclavatol, UV absorptions at 280 nm (black) are illustrated. EICs in blue or green refer [M+H]+ of 
products with one or two clavatol moieties with a tolerance range of ± 0.005. 
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Figure S8. LC-MS analysis of reaction mixtures of hydroxyclavatol with different reactants. 
HC: hydroxyclavatol, UV absorptions at 280 nm (black) are illustrated. EICs in blue or green refer [M+H]+ of 
products with one or two clavatol moieties with a tolerance range of ± 0.005.
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Figure S9. Conversions of hydroxyclavatol reactions with nitrogen-free reactants at 25 °C (left) or 95 °C (right). 
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Figure S10. Conversions of hydroxyclavatol reactions with nitrogen-containing reactants at 25 °C (left) or 95 °C 
(right). 
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Figure S11. Reaction mechanisms of different nucleophile additions to the ortho-quinone methide intermediate.  
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Figure S12. 1H NMR spectrum of 2b in DMSO-d6 (500 MHz). 
Figure S13. 13C{1H} NMR spectrum of 2b in DMSO-d6 (125 MHz).  
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Figure S14. HMBC spectrum of 2b in DMSO-d6. 
Figure S15. 1H NMR spectrum of 6b in DMSO-d6 (500 MHz).  
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Figure S16. 13C{1H} NMR spectrum of 6b in DMSO-d6 (125 MHz). 
Figure S17. HMBC spectrum of 6b in DMSO-d6. 
  
281
 
SUPPORTING INFORMATION          
S20 
 
Figure S18. 1H NMR spectrum of 6c in DMSO-d6 (500 MHz). 
Figure S19. 13C{1H} NMR spectrum of 6c in DMSO-d6 (125 MHz).  
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Figure S20. HMBC spectrum of 6c in DMSO-d6. 
Figure S21. 1H NMR spectrum of 14b in acetone-d6 (500 MHz).  
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Figure S22. 1H NMR spectrum of 14b in pyridine-d5 (500 MHz). 
Figure S23. 1H NMR spectrum of 14b in DMSO-d6 (500 MHz).
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Figure S24. 13C{1H} NMR spectrum of 14b in DMSO-d6 (125 MHz). 
Figure S25. HMBC spectrum of 14b in DMSO-d6.
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Figure S26. 1H NMR spectrum of 14c in acetone-d6 (500 MHz). 
Figure S27. 1H NMR spectrum of 17b in DMSO-d6 (500 MHz). 
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Figure S28. 13C{1H} NMR spectrum of 17b in DMSO-d6 (125 MHz). 
Figure S29. HMBC spectrum of 17b in DMSO-d6.  
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Figure S30. 1H NMR spectrum of 17b in acetone-d6 (500 MHz). 
Figure S31. 1H NMR spectrum of 17c in acetone-d6 (500 MHz).
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Figure S32. 1H NMR spectrum of 18b in DMSO-d6 (500 MHz). 
Figure S33. 13C{1H} NMR spectrum of 18b in DMSO-d6 (125 MHz).  
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Figure S34. HMBC spectrum of 18b in DMSO-d6. 
Figure S35. 1H NMR spectrum of 29b in CDCl3 (500 MHz).  
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Figure S36. 13C{1H} NMR spectrum of 29b in CDCl3 (125 MHz). 
Figure S37. HMBC spectrum of 29b in CDCl3.  
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Figure S38. 1H NMR spectrum of 35b in DMSO-d6 (500 MHz). 
Figure S39. 13C{1H} NMR spectrum of 35b in DMSO-d6 (125 MHz).  
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Figure S40. HMBC spectrum of 35b in DMSO-d6. 
 
Figure S41. 1H NMR spectrum of 41b in DMSO-d6 (500 MHz).  
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Figure S42. 13C{1H} NMR spectrum of 41b in DMSO-d6 (125 MHz). 
Figure S43. HMBC spectrum of 41b in DMSO-d6. 
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Figure S44. 1H NMR spectrum of 44b in DMSO-d6 (500 MHz). 
Figure S45. 13C{1H} NMR spectrum of 44b in DMSO-d6 (125 MHz).  
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Figure S46. HMBC spectrum of 44b in DMSO-d6. 
Figure S47. 1H NMR spectrum of 45b in acetone-d6 (500 MHz).  
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Figure S48. 1H NMR spectrum of 47b in DMSO-d6 (500 MHz). 
Figure S49. 13C{1H} NMR spectrum of 47b in DMSO-d6 (125 MHz).  
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Figure S50. HMBC spectrum of 47b in DMSO-d6. 
Figure S51. 1H NMR spectrum of 50b in acetone-d6 (500 MHz).  
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Figure S52. 1H NMR spectrum of 61b in DMSO-d6 (500 MHz). 
Figure S53. 13C{1H} NMR spectrum of 61b in DMSO-d6 (125 MHz).  
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Figure S54. 1H NMR spectrum of (±)-65b in acetone-d6 (500 MHz). 
Figure S55. 1H NMR spectrum of (±)-65c in DMSO-d6 (500 MHz).  
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Figure S56. 13C{1H} NMR spectrum of (±)-65c in DMSO-d6 (125 MHz). 
Figure S57. HMBC spectrum of (±)-65c in DMSO-d6.  
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Figure S58. HSQC spectrum of (±)-65c in DMSO-d6. 
Figure S59. 1H NMR spectrum of (±)-65c in acetone-d6 (500 MHz).  
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Figure S60. 1H NMR spectrum of 72b in CDCl3 (500 MHz). 
Figure S61. 1H NMR spectrum of 76b in CDCl3 (500 MHz).  
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Figure S62. 1H NMR spectrum of 77b in DMSO-d6 (500 MHz). 
Figure S63. 1H NMR spectrum of 79b in CDCl3 (500 MHz). 
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Figure S64. 1H NMR spectrum of 79b in DMSO-d6 (500 MHz). 
Figure S65. 13C{1H} NMR spectrum of 79b in DMSO-d6 (125 MHz).
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Figure S66. HMBC spectrum of 79b in DMSO-d6. 
Figure S67. 1H NMR spectrum of 79c in CDCl3 (500 MHz).  
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Figure S68. 1H NMR spectrum of 79d in CDCl3 (500 MHz). 
Figure S69. 1H NMR spectrum of 80b in acetone-d6 (500 MHz).  
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Figure S70. 13C{1H} NMR spectrum of 80b in acetone-d6 (125 MHz). 
Figure S71. HMBC spectrum of 80b in acetone-d6.
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Figure S72. 1H NMR spectrum of 80c in acetone-d6 (500 MHz). 
Figure S73. 1H NMR spectrum of 95b in DMSO-d6 (500 MHz).  
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Figure S74. 13C{1H} NMR spectrum of 95b in DMSO-d6 (125 MHz). 
 
Figure S75. HMBC spectrum of 95b in DMSO-d6. 
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Figure S76. 1H NMR spectrum of 98b in DMSO-d6 (500 MHz). 
Figure S77. 13C{1H} NMR spectrum of 98b in DMSO-d6 (125 MHz).  
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Figure S78. HMBC spectrum of 98b in DMSO-d6. 
Figure S79. 1H NMR spectrum of 101b in acetone-d6 (500 MHz).   
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Figure S80. 13C{1H} NMR spectrum of 101b in acetone-d6 (125 MHz). 
Figure S81. HMBC spectrum of 101b in acetone-d6. 
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Figure S82. 1H NMR spectrum of 101c in acetone-d6 (500 MHz). 
Figure S83. 1H NMR spectrum of 101d in acetone-d6 (500 MHz).  
Peaks labelled with * are signals belong to 101b.  
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Figure S84. 1H NMR spectrum of 102b in CD3OD (500 MHz). 
Figure S85. 13C{1H} NMR spectrum of 102b in CD3OD (125 MHz).
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Figure S86. HMBC spectrum of 102b in CD3OD. 
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5 Conclusions and future prospects 
In this thesis, the structural diversification of natural products was achieved by using either enzymes 
or reactive intermediates from the nature’s biosynthetic machinery. Enzymes involved in the 
biosynthesis of natural products catalyze an expansive array of chemical transformations for the 
construction or modification of secondary metabolites. Recent advances in chemoenzymatic synthesis 
proved it as a promising tool to access various chemical entities. In addition, reactive intermediates 
from the biosynthetic pathway of secondary metabolites often exhibit multipotent behavior and can be 
used as starting points in diversity-oriented semi-synthesis. Therefore, usage of biosynthetic 
intermediates can be considered as an alternative strategy to expand the structural diversity of natural 
products.  
An attempt of manipulating five DMAPP-specific PTs was achieved by large-to-small mutation of the 
gatekeeping residues for prenyl donor selectivity. The generated mutants, i.e. FtmPT1_M364G, 
BrePT_I337G, CdpC2PT_T351G, CdpNPT_M349G, and CdpC3PT_F335G showed an increased 
activity towards GPP compared to their corresponding wild-types. As a result, the generated mutants 
catalyzed the conversion of 15 tested CDPs to their geranylated derivatives with different geranylation 
patterns. In total, 42 geranylated derivatives were obtained from one-step chemoenzymatic reactions. 
Particularly, nine products carrying geranyl moieties at all seven possible positions of the indole ring 
were obtained from the incubation mixtures of cyclo-L-Trp-L-Trp with the mutants in the presence of 
GPP. This study has proven structure-based protein engineering as an efficient and effective way to 
enrich the structural library of geranylated CDPs.  
Over the course of searching reactive intermediates from biosynthetic pathway of natural products, 
we focused on an ortho-QM intermediate involved in the biosynthesis of peniphenone and 
penilactones in Penicillium crustosum PRB-2. The ortho-QM is formed by spontaneous water 
elimination of hydroxyclavatol, which was the oxidative product of clavatol by the nonheme FeII/2-
oxoglutarate dependent oxygenase ClaD. The reactivity of the ortho-QM was confirmed by proving 
the nonenzymatic 1,4-Michael addition between the ortho-QM and the -butyrolactones in aqueous 
system, which led to the formation of peniphenone D and penilactone A or penilactones D and B. In 
addition to peniphenone and penilactones, the frequent occurrence of clavatol-containing natural 
products in fungi also implied the involvement of the ortho-QM intermediate in their formation. 
Therefore, subsequent efforts were made for the application of the ortho-QM in facile synthesis of 
clavatol-containing compounds. The reactivity of the ortho-QM derived from hydroxyclavatol was 
tested with 102 natural products or natural product-like compounds ranging from different phenolic 
compounds to indole derivatives. Totally, 32 clavatol-containing products were obtained in this study 
by incorporation of one or two clavatol units onto the ortho- or para-positions of the phenolic hydroxyl 
groups at the benzene ring, as well as by connection between the methylene group of the clavatol unit 
and the C-2 position of indole skeletons. We thus succeeded in the generation of diverse clavatol-
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containing products by exploiting the reactivity of the ortho-QM intermediate derived from 
hydroxyclavatol. 
For future prospects, the following works can be performed: 
➢ In the project of protein engineering of PTs, the constructed mutants exhibited increased GPP 
acceptance but reduced regioselectivity. Therefore, further mutagenesis experiments are 
required to increase the desired regio- and stereoselectivity, which will facilitate the product 
isolation from one-step incubations. 
➢ Since the structural information of more and more PTs will be available in the future, it is 
possible to mutate additional available PTs at the corresponding positions. The structural 
spectrum of geranylated and farnesylated products can be further expanded by using more 
mutants and testing more aromatic substrates. 
➢ One of the prerequisites for the generation of the ortho-QM is the employment of the nonheme 
FeII/2-oxoglutarate dependent oxygenase ClaD for oxidation of clavatol to hydroxyclavatol. 
Incubating ClaD with more clavatol-like substrates may lead to the formation of more 
hydroxyclavatol-like benzylic alcohol products, which may also undergo spontaneous 
dehydration to yield various ortho-QM intermediates. By doing so, it is possible that not only 
clavatol-containing products but also other coupling products of clavatol-like molecules can be 
easily created. 
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